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ABSTRACT OF DISSERTATION

IN VIVO OXIDATIVE STRESS IN ALZHEIMER DISEASE BRAIN AND A MOUSE
MODEL THEREOF: EFFECTS OF LIPID ASYMMETRY AND THE SINGLE METHIONINE
RESIDUE OF AMYLOID-β PEPTIDE
Studies presented in this dissertation were conducted to gain more insight into the role of
phospholipid asymmetry and amyloid-β (Aβ)-induced oxidative stress in brain of subjects with
amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD). AD is a largely
sporadic, age-associated neurodegenerative disorder clinically characterized by the vast,
progressive loss of memory and cognition commonly in populations over the age of ~65 years,
with the exception of those with familial AD, which develop AD symptoms as early as ~30
years-old. Neuropathologically, both AD and FAD can be characterized by synapse and
neuronal cell loss in conjunction with accumulation of neurofibrillary tangles and senile plaques.
Elevated levels of oxidative stress and damage to brain proteins, lipids, and nucleic acids are
observed, as well. Likewise, aMCI, arguably the earliest form of AD, displays many of these
same clinical and pathological characteristics, with a few exceptions (e.g., no dementia) and to a
lesser extent.
Studies in this dissertation focused on the contributions of oxidative stress to the
exposure of phosphatidylserine (PtdSer) to the outer-leaflet of the lipid membrane, how and
when PtdSer asymmetric collapse contributes to the progression of aMCI, AD, and FAD, and the
role played by methionine-35 (Met-35) of Aβ in oxidative stress and damage, as measured in a
transgenic mouse model of Aβ pathology. Normally, the PtdSer is sequestered to the cytosolic,
inner-leaflet of the bilayer by the adenosine triphosphate (ATP)-dependent, membrane-bound
translocase, flippase, which unidirectionally transports PtdSer inward against its concentration
gradient. Oxidative stress-induced modification of flippase and/or PtdSer, however, leads to
prolonged extracellular exposure of PtdSer on the outer membrane leaflet, a known signal for
both early apoptosis and selective recognition and mononuclear phagocytosis of dying cells.
Within the inferior parietal lobule (IPL) of subjects with aMCI and AD, a significant collapse in
PtdSer asymmetry was found in association with increased levels of both pro- and anti-apoptotic
proteins, Bax, caspase-3, and Bcl-2. Moreover, a significant collapse in PtdSer asymmetry was
also found in whole brain of human double-mutant knock-in mouse models of Aβ pathology,
together with significantly reduced Mg2+ATPase activity, representing flippase activity, and
increased levels of pro-apoptotic caspase-3. Significant PtdSer externalization corresponded to
the age at which significant soluble Aβ(1-42) deposition occurs in this particular mouse model (9
months), and not of plaque deposition (12 months), suggesting that elevated levels of Aβ(1-42),

together with increasing oxidative stress and apoptosis, may contribute to altered PtdSer
membrane localization.
Also in this dissertation, transgenic mice carrying Swedish and Indiana mutations on the
human amyloid precursor protein (APPSw,In) and APPSw,In mice carrying a Met35Leu mutation on
Aβ were derived to investigate the role of Met-35 in Aβ(1-42)-induced oxidative stress in vivo.
Oxidative stress analyses revealed that Aβ-induced oxidative stress requires the presence of Met35, as all indices of oxidative damage (i.e., protein carbonylation, nitration, and protein-bound 4hydroxy-2-trans-nonenal [HNE]) in brain of Met35Leu mice were completely prevented.
Moreover, immunohistochemical analyses indicated that the Met35Leu mutation influences
plaque formation, as a clear reduction in Aβ-immunoreactive plaques in Met35Leu mice was
found in conjunction with a significant increase in microglial activation. In contrast, behavioral
analyses suggested that spatial learning and memory was independent of Met-35 of Aβ, as
Met35Leu mice demonstrated inferior water-maze performance compared to non-transgenic
mice.
Differential expression and redox proteomic analyses to pinpoint proteins significantly
altered by the APPSw,In and Met35Leu mutations was performed, as well. Expression proteomics
showed significant increases and decreases in APPSw,In and Met35Leu mouse brain, respectively,
in proteins involved in cell signaling, detoxification, structure, metabolism, molecular
chaperoning, protein degradation, mitochondrial function, etc. Redox proteomics found many of
these same proteins to be oxidatively modified (i.e., protein carbonylation and nitration) in both
APPSw,In and Met35Leu mouse brain, providing additional insights into the critical nature of
Met-35 of Aβ for in vivo oxidative stress in a mammalian species brain, and strongly suggesting
similar importance of Met-35 of Aβ(1-42) in brain of subjects with aMCI and AD. Taken
together, studies presented in this dissertation demonstrate the role of oxidative stress-induced
alteration of PtdSer asymmetry and Met-35 in Aβ-induced oxidative stress in aMCI, AD, and
FAD brain.

Keywords: Alzheimer disease (AD), amnestic mild cognitive impairment (aMCI), oxidative
stress, amyloid-β peptide (Aβ), phosphatidylserine (PtdSer), methionine 35 (Met-35)
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CHAPTER 1
INTRODUCTION
The studies presented in this dissertation were performed to gain greater insight into the
role of lipid peroxidation, phospholipid asymmetry, and amyloid-β (Aβ)-induced oxidative stress
in brain of subjects with amnestic mild cognitive impairment (aMCI), Alzheimer disease (AD),
and familial AD (FAD). These studies investigated the hypotheses that,
1) PtdSer asymmetry is significantly lost in synaptosomal membranes of the inferior
parietal lobule (IPL) of subjects with aMCI and AD, as well as lost as a function of
age and oligomeric Aβ(1-42) levels in synaptosomes isolated from brain of mouse
models of Aβ pathology commonly found in FAD brain.
2) The methionine 35 residue (Met-35) of the Aβ peptide is critical for in vivo oxidative
stress in brain of well-characterized PDAPP transgenic mouse models of Aβ
pathology commonly found in FAD brain.
As a largely sporadic, age-related neurodegenerative disorder, AD is pathologically
characterized by the appearance of neurofibrillary tangles, senile plaques, elevated oxidative
stress and damage to brain proteins, lipids, and nucleic acids, and the eventual loss of neurons
and synapses in populations over the age of ~65 years. In rare FAD cases, however, this
distinctive pathology begins as early as ~30 years of age (Citron et al., 1992; Scheuner et al.,
1996; Sturchler-Pierrat et al., 1997; Wisniewski et al., 1998). Unfortunately, the
neuropathological effects of this debilitating disease inevitably result in a significant decline in
cognitive function and eventual death, and are, to date, without a truly effective therapy.
Therefore, since aMCI is considered a possible transition point between normal cognitive aging
and probable AD (Petersen et al., 1999; Winblad et al., 2004) and displays similar pathology to
AD and FAD, results reported in this dissertation may not only identify possible biomarkers of
early AD pathology, but also elucidate unique characteristics of patients with aMCI that
eventually develop full-onset AD.
Oxidative stress, a hallmark of aMCI, AD, and FAD pathology, can be characterized as
an imbalance between the levels of antioxidants and oxidants within the cell, and can be
propagated by a variety of molecules, including reactive oxygen species (ROS), reactive nitrogen
species (RNS), and even Aβ(1-42), a major component of senile plaques. In particular, oxidative
stress and damage can induce protein oxidation, lipid peroxidation, and pro-apoptotic events in
aMCI, AD, and FAD brain, disrupting normal cellular homeostasis (Abdul et al., 2008;
Butterfield, 1997; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; 2006b; 2006d;
2007b; Castegna et al., 2004; Hensley et al., 1995; Keller et al., 2005; Lauderback et al., 2001;
Lyras et al., 1997; Markesbery, 1997; Mohmmad Abdul and Butterfield, 2005; Mohmmad Abdul
et al., 2006; Petersen et al., 1999; Smith et al., 1997; Varadarajan et al., 2000; Winblad et al.,
2004). Studies in this dissertation focused on the contributions of the lipid peroxidation product
4-hydroxy-2-trans-nonenal (HNE), apoptotic factor expression, and Aβ(1-42) to the exposure of
the aminophospholipid phosphatidylserine (PtdSer) to the outer-leaflet of the lipid membrane, as
well as the role played by methionine-35 (Met-35) of Aβ in oxidative stress and damage.
Normally, PtdSer is sequestered to the cytosolic, inner-leaflet of the lipid bilayer by the
adenosine triphosphate (ATP)-dependent, membrane-bound, aminophospholipid translocase,
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flippase, which unidirectionally transports PtdSer inward against its concentration gradient
(Bretscher, 1972; Daleke and Huestis, 1985; Daleke and Lyles, 2000; Op den Kamp, 1979;
Rothman and Lenard, 1977; Seigneuret and Devaux, 1984). Under oxidative stress conditions,
however, modification of flippase and/or PtdSer by HNE leads to prolonged extracellular
exposure of PtdSer onto the outer-leaflet of the cell membrane, a known signal for both early
apoptosis and selective recognition and mononuclear phagocytosis of dying cells (Castegna et
al., 2004; Fadok et al., 2001; 1992a; Kagan et al., 2003; Tyurina et al., 2004a; 2004b).
Apoptosis is typically modulated by both pro- and anti-apoptotic members, and plays a
crucial role in neuronal loss both in vitro and in vivo in AD (Cras et al., 1995; Honig and
Rosenberg, 2000; Ott et al., 2007). Unfortunately, however, little is known about apoptotic
pathways in aMCI to date. Oxidative stress and damage in aMCI, AD, and FAD brain can
initiate apoptosis by activation of pro-apoptotic proteins, disruption of the electron transport
chain, and subsequent release of cytochrome c from mitochondria (reviewed in Ott et al., 2007).
Specifically, increased anti-apoptotic Bcl-2 protein expression in AD blocks PtdSer exposure and
apoptotic cell death (Engidawork et al., 2001; Fabisiak et al., 1997; Kitamura et al., 1998b),
while increasing pro-apoptotic Bax and caspase-3 levels in AD brain promote PtdSer asymmetric
collapse and neuronal loss (Giannakopoulos et al., 1999; Nagy and Esiri, 1997; Su et al., 2001;
Tortosa et al., 1998). For example, PtdSer externalization and loss of flippase translocating
activity can be found downstream of caspases-3 activation in non-neuronal cell types under
oxidative stress conditions (Mandal et al., 2002; 2005; Martin et al., 1996; Vanags et al., 1996).
Furthermore, toxic Aβ(1-42) oligomers can also initiate lipid peroxidation and pro-apoptotic
signaling events during AD and FAD progression that contribute to PtdSer asymmetric collapse
(Abdul et al., 2008; Butterfield, 2002; Butterfield and Lauderback, 2002; Butterfield et al.,
2002b; 2007a; Lambert et al., 1998; Lauderback et al., 2001; Schubert et al., 1995; Selkoe,
2001b). This dissertation provides evidence that PtdSer asymmetric collapse is an early indicator
of neurodegenerative processes already well underway in AD brain, and may represent a
potential biomarker of those patients with aMCI that eventually develop full-onset AD.
In aMCI, AD, and FAD, it is the soluble, oligomeric form of the 42-mer, Aβ(1-42), that
is considered to be the toxic Aβ species (Demuro et al., 2005; Drake et al., 2003a; Selkoe, 2008;
Viola et al., 2008), as it can lead to elevated protein oxidation and lipid peroxidation, as indexed
by elevated levels of protein carbonyls, protein-resident 3-nitrotyrosine (3-NT), and proteinbound HNE (Ansari et al., 2006; Boyd-Kimball et al., 2004; Pappolla et al., 1999; Sultana et al.,
2005). The oxidative and neurotoxic properties of Aβ(1-42) are suggested to be dependent on
the formation of a sulfur (S)-centered, transient free radical on a single methionine residue at
position 35 that leads to a catalytic chain reaction in the lipid bilayer which amplifies production
of lipid peroxidation products, like HNE, as well as protein oxidation (Boyd-Kimball et al.,
2004; Butterfield and Boyd-Kimball, 2005; Kanski et al., 2002; Varadarajan et al., 2001; Yatin et
al., 1999). For example, in vitro substitution of the Met-35 S-atom with a norleucine (Nle) CH2
group in human Aβ(1–42) abrogates the oxidative and neurotoxic effects of the resulting Aβ(142) Met35Nle peptide, while maintaining similar length, hydrophobicity, and tendency to
aggregate as native Aβ(1-42) (Butterfield and Boyd-Kimball, 2005; Varadarajan et al., 2001;
Yatin et al., 1999). Moreover, in Caenorhabditis elegans AD models, a Met35Cys substitution
in human Aβ(1-42) prevents in vivo protein oxidation, while not affecting Aβ(1-42)
accumulation and plaque deposition (Drake et al., 2003a; Yatin et al., 1999). These results
suggest that those mechanisms of oxidative stress that involve Met-35 of Aβ(1-42) apply both in
vitro and in vivo. This dissertation also provides evidence that blocking oxidative damage
2

induced by Met-35 of Aβ in brain of subjects with aMCI, AD, and FAD offers a highly focused
therapeutic approach, in which to treat, slow progression of, or prevent aMCI, AD, and FAD.
In summary, this dissertation addresses the following questions:
1. Is PtdSer asymmetry significantly altered in the inferior parietal lobule (IPL)
of subjects with aMCI and AD, in association with the activation and upregulation of pro- and anti-apoptotic proteins, Bcl-2, Bax, and caspase-3,
respectively?
2. Is PtdSer asymmetry significantly altered in brain of human double-mutant
knock-in mouse models of Aβ pathology, and if so, at what age? Do agerelated changes in PtdSer leaflet localization correlate with age-related
increases in Aβ(1-42), activation and up-regulation of pro-apoptotic caspase3, and oxidative modification of Mg2+ATPase (i.e., flippase) enzymes?
3. Is Met-35 of the Aβ peptide critical for in vivo Aβ(1-42)-induced oxidative
stress and AD-related spatial memory deficits in APPSw,In (PDAPP)
transgenic mouse models of Aβ pathology carrying a Met35Leu substitution
on the Aβ peptide?
4. Which proteins are differentially expressed and/or oxidatively modified (i.e.,
protein carbonylation and nitration) in brain of PDAPP transgenic mouse
models of Aβ pathology?
5. Which proteins are differentially expressed and/or oxidatively modified (i.e.,
protein carbonylation and nitration) in brain of PDAPP transgenic mouse
models of Aβ pathology carrying a Met35Leu substitution on the Aβ
peptide?
6. Are there any commonalities and/or differences in protein expression and/or
oxidative modification between PDAPP transgenic mouse models of Aβ
pathology and PDAPP mice carrying a Met35Leu substitution on the Aβ
peptide? Can these commonalities/differences provide further insight into
the progression of AD?

Copyright © Miranda Lu Lange, 2010
3

CHAPTER 2
BACKGROUND
2.1 The Brain
2.1.1 Neurons
As part of the central nervous system (CNS), the brain is composed of nerve cells
(neurons) and support cells, called glia. In the brain, neurons are the basic structural elements
mainly responsible for cellular communication and signaling. A typical mammalian neuron is
composed of a cell body (soma or perikaryon) containing the nucleus, dendrites (neurites)
branching from the cell body, short processes which receive most neuronal input, and
unilaterally extending axons, long processes also projecting from the cell body which carry most
neuronal outputs (Fig. 2.1). Neurons also contain many intracellular organelles commonly
standard in most cells of the body, including microtubules, ribosomes, endoplasmic reticulum
(ER), Golgi, mitochondria, and neurofilaments, which are exclusive to neurons. Interestingly,
mitochondria can travel on microtubules to and from presynaptic terminals to aid in
neuromodulation and neurotransmission (section 2.1.3), with assistance of motor proteins,
kinesin and dynesin (Siegel et al., 2006). Most mammalian neurons are multi-polar, with several
dendrites and axons (Fig. 2.2). For example, bipolar neurons possess a single dendrite and axon
arising from the cell body; these neurons are typically sensory neurons, like those involved in
vision or olfaction [Fig. 2.2] (Blumenfeld, 2002).
Insulating the axons and their contents from the surrounding environment are specialized
glial cells that form a thick covering or “sheath” composed of the lipid molecule myelin (i.e.,
myelin sheath) [Fig. 2.3]; oligodendrocytes form myelin sheaths in the CNS (section 2.1.2),
while Schwann cells form this sheath in the periphery. The short, exposed segments of axon
between areas of oligodendrocyte-myelin sheath, called nodes of Ranvier, are concentrated with
voltage-gated ion channels, comprising the sites at which electrical conduction can be initiated.
For example, rapid inter-nodal conduction occurs via saltatory conduction (Blumenfeld, 2002).
Those areas of the CNS that contain primarily myelinated axons are called white matter, due to
their off-white color, while areas predominant with cell bodies are called gray matter, for their
gray color (Blumenfeld, 2002). In general, the majority of synaptic inter-neuronal
communication occurs in the gray matter, whereas axons within the white matter transmit signals
over greater distances (Blumenfeld, 2002).
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Figure 2.1

Figure 2.1 Basic structure of a neuron (image adapted from the Alzheimer's Disease
Education and Referral Center).
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Figure 2.2

Figure 2.2 Basic structures of different neuronal cells. A) & B) Most mammalian
neurons are multi-polar, with several dendrites and axons. C) Sensory neurons are
typically bipolar, with a single dendrite and axon arising from the cell body (adapted
from Lodish et al., 2000).
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Figure 2.3

Figure 2.3 Basic structure of an oligodendrocyte (adapted from Carlson, 2008).

2.1.2 Neuroglia
Neuroglia are some of the most abundant cell-types in the brain, including astrocytes,
oligodendrocytes, and microglia, among others. Astrocytes are unique, in that they possess
many more processes than other neuroglia and often resemble stars, from which their name
originates. These cells have numerous gap junctions, abundant glycogen granules, few
microtubules, and a smooth distribution of chromatin within the nucleolus (Blumenfeld, 2002).
There are two major types of astrocytes: protoplasmic (Fig. 2.4a), the typical gray matter
astrocytes co-localized to neuronal somata and dendritic processes; and fibrous (Fig. 2.4b), the
typical white matter astrocytes co-localized with axon bundles and arterioles (Blumenfeld,
2002). However, it should be noted that protoplasmic astrocytes can be found in white matter,
and fibrous astrocytes can also be found in gray matter. The abundant processes of astrocytes
form extensive, “knobby” contacts called end-feet with other astrocytes and neuroglia, neurons,
endothelial cells, and capillaries, which is crucial for cell signaling and nutrient delivery (Fig.
2.5). They are also known for being particularly rich in intermediate filaments, especially the
glial fibrillary acidic protein (GFAP), which is a marker of inflammation. Astrocytes are
extensively intertwined with neuronal cell bodies and processes, supporting structural integrity of
synapses and providing the structural framework for neuronal migration during development.
Like neurons, they also take up extracellular K+, take up and metabolize neurotransmitters such
as γ-aminobutyric acid (GABA), glutamate, and norepinephrine, and have receptors for many
extracellular ligands, including neurotrophins, cytokines, growth factors, etc. (Blumenfeld,
2002).
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Figure 2.4

Figure 2.4 Types of astrocytes.

Figure 2.5

Figure 2.5 Astrocyte end-feet. The abundant processes of astrocytes form extensive,
“knobby” contacts, called end-feet (yellow arrow), with other astrocytes and neuroglia,
neurons, endothelial cells, and capillaries (white arrow), which is crucial for cell
signaling and nutrient delivery (adapted from Simard et al., 2003).
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Unlike astrocytes, oligodendrocytes have round or oval nuclei, relatively few processes,
clumpy chromatin, no glycogen granules, few intermediate filaments, and an extensive
microtubule network (Blumenfeld, 2002). As mentioned above, the main function of
oligodendrocytes is to wrap neuronal axons with myelin sheaths to facilitate propagation of
action potentials (section 2.1.3) and saltatory conduction (Fig. 2.3). Other markers
distinguishing oligodendrocytes include myelin related proteins, such as myelin basic protein.
Microglia comprise roughly 20% of the brain‟s glia. These cells are rich in lysosomes,
have triangular nuclei, a fewer processes than astrocytes [Fig. 2.6] (Blumenfeld, 2002).
Microglia are considered the brain‟s immune cells, as they contain all the membrane features that
are characteristic of immune and inflammatory cells. For example, they express major
histocompatibility complex (MHC) proteins (e.g., HLA-DR, CD45, and CD64) and contain
receptors for many extracellular ligands, including neurotrophins, growth factors, cytokines, etc
(Blumenfeld, 2002). Reactive microglia, in particular, act as phagocytes, becoming activated by
phenotypic changes induced by various stimuli, such as inflammation, then clearing away
unnecessary or dead/dying cells. Interestingly, microglial activation increases with age.
Figure 2.6

Figure 2.6 Microglia (adapted from neuroscienceassociates.com).

2.1.3 Neurotransmission & Neuromodulation
In general, the neuron‟s primary function is to transmit and receive information through
nerve impulses generated by the sizeable influx of Na+ ions into the neuron; at rest, the neuron is
characterized by a higher intracellular concentration of K+ ions than Na+ ions (Siegel et al.,
2006). Thus, the neuronal resting potential (-70 mV) is maintained (and restored) primarily by
Na+/K+ATPase pumps, but also by various Ca2+ pumps, Na+/Ca2+ exchangers, and voltage-gated
ion channels that open or close in response to changes in the electrochemical gradient of the
neuron (Siegel et al., 2006). As the charge difference across the neuronal membrane approaches
zero, the membrane becomes depolarized, closing Na+ influx channels, opening K+ efflux
channels, and restoring the intracellular net negative charge difference (-70 mV) across the
membrane (Fig. 2.7).
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Figure 2.7

Figure 2.7 Overview of an action potential. Generation of an action potential begins with
the opening of Na+ ion channels allowing a large influx of Na+ ions into the neuron. As
the charge difference across the membrane approaches zero (becoming more positive),
the neuron becomes depolarized, closing Na+ influx channels and opening K+ efflux
channels. As neurons become hyperpolarized by the sizeable efflux of positive ions, K+
efflux channels close, and the neuron becomes re-polarized. Because cells are rarely at
equilibrium and permeable to several ions at once, the Goldman-Hodgkin-Katz voltage
equation (inset, above graph) can be used to calculate the steady-state potential across the
membrane (Eion), wherein the summation of permeant ion contributions is weighted
according to their relative permeabilities (Pi) using both the intracellular (i) and
extracellular (o) concentrations of that ion. R, universal gas constant (8.314 J∙K−1∙mol−1);
T, absolute temperature (K); F, Faraday constant (9.648×104 C∙mol−1).

Inter-neuronal communication, or neurotransmission, takes place at synapses, specialized
regions at the end of axons and dendrites that usually carry signals from axon terminals of one
neuron to dendrites of the next (Fig. 2.8). However, information can be transmitted in reverse,
from dendrites to axons, at axo-axonic and dendro-dendritic synapses (Blumenfeld, 2002). A
synapse consists of three parts: the pre-synaptic element of the transmitting neuron, the synaptic
cleft, and the post-synaptic region of the receptive neuron (Fig. 2.8). Owing to both the chemical
and electrical nature of the neuron, transient voltage changes, called an action potential, occur
when an electrochemical impulse rapidly travels through the axon and causes release of
neurotransmitter or neuromodulatory molecules from the presynaptic terminal into the synaptic
cleft (Blumenfeld, 2002). Action potentials can travel rapidly throughout the length of one
10

neuron, facilitated by the thick myelin sheath which insulates these electrical impulses from the
surrounding environment.
Figure 2.8

Figure 2.8 The synaptic cleft. After stimulation by the appropriate action potential,
synaptic vesicles fuse with the pre-synaptic (transmitting) neuronal membrane, and the
stored neurotransmitter molecules are released into the synaptic cleft. Upon release,
neurotransmitters diffuse to and bind receptors on the post-synaptic (receiving), or even
sometimes the pre-synaptic, neuron giving rise to another excitatory or inhibitory action
potential within the receiving neuron (adapted from Sadava et al., 2007).

Neurotransmitters are surrounded by synaptic vesicles within the pre-synaptic cleft,
which act as a reservoir of chemical stimuli. After stimulation by the appropriate electrical
impulse, the synaptic vesicle fuses with the cell membrane, with the help of specialized proteins,
and the neurotransmitter molecules are released into the synaptic cleft (Fig. 2.8). Upon release,
neurotransmitters diffuse to and bind receptors on the post-synaptic region of the receiving
neuron giving rise to another, either excitatory or inhibitory, action potential within the second
neuron, completing the process of neurotransmission. By and large, neurotransmitters either
mediate rapid inter-neuronal communication via excitatory post-synaptic potentials (EPSPs) and
inhibitory post-synaptic potentials (IPSPs), depending on the specific receptors present, or
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positively or negatively modulate neuronal signaling over a slower timescale [neuromodulation]
(Blumenfeld, 2002). Thus, the action of certain neurotransmitters may change at the same or at
different synapses when a mixture of receptor types are present (Blumenfeld, 2002).
Furthermore, often multiple neurotransmitter types are released into a single synapse. A brief
summary of a few important neurotransmitter and neuromodulator molecules, including
acetylcholine, glutamate, dopamine, serotonin, histamine, GABA, norepinephrine, and glycine
can be found in Table 2.1.
Table 2.1 Important neurotransmitter/neuromodulatory molecules.
Name
Receptor Subtypes
Main Action(s)
AMPA/kainate
Excitatory neurotransmission
Glutamate
NMDA
Modulation of synaptoplasticity
Metabotropic
Activation of second messenger systems
GABAA, GABAB
Inhibitory neurotransmission
GABA
GABAC
Inhibitory neurotransmission
Nicotinic
Muscle contraction and Autonomic
functions
Acetylcholine
Muscarinic
Parasympathetic functions
Muscarinic &
Neuromodulation
Nicotinic subtypes
Norepinephrine
α and β subtypes
Sympathetic system functions
Dopamine
D1-5
Neuromodulation
Serotonin
5-HTs
Neuromodulation
Histamine
H1-3
Mainly excitatory neuromodulation
Glycine
Inhibitory neurotransmission*
Glycine
MNDA
Neuromodulatory
Peptides
Numerous
Neuromodulation
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-methyl Daspartate; GABA, γ-aminobutyric acid; D, dopamine; 5-HT, 5-hydroxytryptamine; H,
histamine; MNDA, methyl D-aspartate [distinct from NMDA] (adapted from Blumenfeld,
2002).

2.2 The Cell Membrane
2.2.1 Overview: Structure, Function, & Composition
Like all cells, neurons are surrounded by a plasma membrane, which provides the cell
with an extensive framework within which cellular components are ordered for effective
interaction. The plasma membrane is a bimolecular layer of amphipathic lipids interspersed with
proteins, which thermodynamically favors an arrangement in which polar groups face the outer
aqueous environment, and hydrophobic fatty acyl chains face inward toward each other [Fig. 2.9]
(Karp, 2003). Thus, the plasma membrane is also referred to as a lipid bilayer, composed of two
continuous leaflets that face both extracellular and intracellular environs. This important
structure prevents unrestricted exchange of molecules, while also providing a means of
intercellular and inter-organelle communication since they contain proteins which transport
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substances from one side of the membrane to another, responding to external signals (i.e., signal
transduction) and facilitating energy transduction, especially in mitochondria (Karp, 2003).
Figure 2.9

Figure 2.9 The lipid bilayer. The plasma membrane, or lipid bilayer, is a bimolecular
layer of amphipathic lipids interspersed with proteins, which thermodynamically favors
an arrangement in which polar groups face the outer aqueous environment, and
hydrophobic fatty acyl chains face inward toward each other.

In general, the most abundant type of plasma membrane lipid is the phosphoglyceride or
phospholipid, which contains a polar phosphate head group and two nonpolar hydrocarbon tails.
What makes these diglycerides unique is the additional small, hydrophilic functional group
attached to the phosphate, comprising the head group. Typically, these groups are choline
(forming phosphatidylcholine, PtdCho), ethanolamine (forming phosphatidylethanolamine,
PtdEtn), serine (forming phosphatidylserine, PtdSer), or inositol (forming phosphatidylinositol,
PtdIns), among others; whereas a phospholipid without the additional substitution is called
phosphatidic acid (PtdOH), the precursor of all glycerolipids (Fig. 2.10). Other, less abundant
lipids within the membrane are sphingolipids and the sterol, cholesterol. Sphingolipids are
amphipathic sphingosine derivatives, in which the sphingosine is linked to a fatty acid through
its amino group, forming a ceramide (Fig. 2.11). The majority of sphingolipids within the
membrane have additional groups esterified to the terminal alcohol of the sphingosine moiety.
For example, sphingomyelin carries a phosphorylcholine substitution and is the only membrane
lipid without a glycerol backbone, whereas glycosphingolipids contain a carbohydrate
substitution (Fig. 2.11). Interestingly, glycolipids are particularly rich within the nervous
system; the myelin sheath contains a high content of the glycolipid galactocerebroside, formed
by addition of galactose to ceramide (Fig. 2.11), as well as PtdCho, PtdEtn, and ceramide (Karp,
2003; Siegel et al., 2006).
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Figure 2.10

Figure 2.10 Phospholipids.
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Figure 2.11

Figure 2.11 Sphingolipids.

In contrast, cholesterol is much smaller than other membrane lipids and less amphipathic.
These molecules orient themselves in each bilayer leaflet with the small, hydrophilic hydroxyl
groups facing the membrane surface, while the rest of the structure is embedded within the
bilayer (Fig. 2.12b). These rigid sterols are composed of flat, hydrophobic rings that interfere
with the movement of phospholipid hydrocarbon tails (Fig. 2.12a), adjusting the fluidity of each
membrane as necessary to cope with changing body temperatures and allowing membrane
proteins to assemble at particular sites within the membrane and form specialized structures,
such as intracellular junctions and synapses (Karp, 2003; Siegel et al., 2006).
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Figure 2.12

Figure 2.12 Cholesterol. A) Cholesterol structure. B) Orientation of cholesterol within
the bilayer.

2.2.2 Lipid Asymmetry
Of particular relevance to this dissertation is the highly asymmetrical distribution of
lipids within the inner- and outer-leaflets of the membrane bilayer. Though the bilayer leaflets of
different intracellular organelles tend to have markedly different lipid compositions, the cell
membrane typically confines PtdCho, sphingomyelin, and glycosphingolipid species to the
extracellular, outer-leaflet, while PtdSer, PtdEtn, and PtdIns are localized to the intracellular,
inner-leaflet, thus, conferring very different physical and chemical properties to each leaflet of
the bilayer. Most membrane lipids are synthesized entirely within the ER, with the exception
sphingomyelin, glycolipids, and some unique mitochondrial membrane lipids, and transported to
the Golgi and/or plasma membrane as part of the membrane that encompasses transport vesicles
(Karp, 2003). Lipid asymmetry is first established in the ER where lipids and proteins are
inserted into the two leaflets of the ER membrane, and is maintained as portions of this
membrane move throughout the cell by budding and fusion from one compartment to another
[Fig. 2.13] (Karp, 2003). Thus, those proteins and lipids originally situated on the inner, luminal
leaflet of the ER membrane are found on the luminal surface of transport vesicles and Golgi
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cisternae, but the extracellular leaflet of the plasma membrane [Fig. 2.13] (Karp, 2003).
Similarly, proteins and lipids situated on the outer, cytosolic leaflet of the ER membrane retain
their orientation and are ultimately found on the intracellular leaflet of the cell membrane [Fig.
2.13] (Karp, 2003).
Figure 2.13

Figure 2.13 Origination of lipid asymmetry. Lipid asymmetry of the plasma membrane
is first established in the endoplasmic reticulum (ER) bilayer, and is maintained as
portions of this membrane move throughout the cell by vesicular budding and fusion
(Karp, 2003). As a result, proteins and lipids originally situated on the inner, luminal
leaflet of the ER membrane (red circles) are found on the luminal surface of transport
vesicles and Golgi cisternae, but the extracellular leaflet of the plasma membrane.
Similarly, proteins and lipids situated on the outer, cytosolic leaflet of the ER membrane
(green circles) retain their orientation and are ultimately found on the intracellular leaflet
of the cell membrane (Karp, 2003).

Unfortunately, this manner of lipid integration into the cell membrane results in a
complete reversal of the proper asymmetrical distribution of lipids between leaflets that must be
corrected. Although phospholipids can diffuse laterally with relative ease, the transverse
diffusion between leaflets is thermodynamically unfavorable, and therefore, more or less
restricted (Karp, 2003). To bypass this problem, integral membrane proteins which actively
transport phospholipids inward and/or outward against their concentration gradients establish and
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maintain the appropriate asymmetrical distribution of phospholipids within the bilayer (section
2.2.3). While the purpose of lipid asymmetry beyond structural organization is not entirely
understood, it has been found that many membrane lipids act as receptors for certain ligands,
initiate intra- and extracellular signal transduction events, and are involved in cell regulation and
apoptosis. For example, the function of membrane phosphoinositides is among the most wellknown, as they are intimately involved in membrane trafficking, maintenance of the
cytoskeleton, cell death and survival, and regulation of ion channel activity (Karp, 2003; Siegel
et al., 2006). Cleavage of phosphoinositol-4,5-bisphosphate (PIP2) by phospholipases produces
the second messengers diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3), which
activate protein kinases and affect intracellular Ca2+ signaling (Karp, 2003; Siegel et al., 2006).
Therefore, the localization of membrane lipids to a specific bilayer leaflet is of utmost
importance to normal cell function.
Germaine to this dissertation, however, is the leaflet localization of the
aminophospholipid PtdSer. Typically, PtdSer is concentrated on the cytosolic leaflet of the
bilayer (Bretscher, 1972; Op den Kamp, 1979; Rothman and Lenard, 1977), due, in part, to its
small, negatively charged head group and overall conical shape, which fits seamlessly into the
inner-leaflet‟s negative radius of curvature [Fig. 2.14] (reviewed in Piomelli et al., 2007).
Although the functional properties of PtdSer on the inner-leaflet of the membrane are, as of yet,
unknown, it is thought that the net negative charge PtdSer carries at physiological pH makes it a
candidate for binding positively charged lysine and arginine residues located within the
membrane-spanning regions of integral membrane proteins (section 2.2.3). By contrast, the
appearance of PtdSer onto the outer-leaflet of the bilayer is better understood, as prolonged
exposure of PtdSer to the extracellular milieu has been found not only to induce blood
coagulation and signal the induction of early apoptosis (Fadok et al., 2001; 1992a; Kagan et al.,
2003; Tyurina et al., 2004a; 2004b), but is also crucial for membrane fusion events, such as
endo- and exocytosis and selective recognition and mononuclear phagocytosis of target cells by
macrophages and fibroblasts in the periphery or by microglia in the brain (Balasubramanian and
Schroit, 2003; Devaux, 2000; Farge et al., 1999; Zwaal and Schroit, 1997; Zwaal et al., 1998).
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Figure 2.14

Figure 2.14 Plasma membrane radius of curvature. Phosphatidylserine (PtdSer) is
normally concentrated on the cytosolic leaflet of the lipid bilayer, due, in part, to its
small, negatively charged head group and overall conical shape, which fits seamlessly
into the inner-leaflet‟s negative radius of curvature. In contrast, phosphatidylinositol
(PtdIns), is normally concentrated on the outer-leaflet of the lipid bilayer as a result of its
large head group and inverted conical shape, which fits well into the outer-leaflet‟s
positive radius of curvature (adapted from Piomelli et al., 2007).

2.2.3 Membrane-Associated Proteins
Plasma membranes typically contain hundreds of different proteins that are grouped by
their relationship to the membrane. Of these, the lipid-anchored and peripheral proteins are
located entirely outside of the membrane, on either the intra- or extracellular side, but are
associated with the bilayer in different ways; peripheral proteins associate with the membrane
surface by non-covalent bonds, while lipid-anchored proteins are covalently linked to a lipid
molecule situated within the bilayer [Fig. 2.15] (Karp, 2003). The third group of membraneassociated proteins is the integral or transmembrane proteins, which completely penetrate the
bilayer, passing entirely through both leaflets. Like the lipids that make up the bilayer, integral
membrane proteins are amphipathic, with nonpolar α-helical domains spanning the hydrophobic
intermembrane space. While some transmembrane proteins have only one membrane spanning
domain, others traverse the membrane multiple times.
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Figure 2.15

Figure 2.15 Membrane-associated proteins.

As previously mentioned, it is integral membrane proteins that are actively involved in
the maintenance of lipid asymmetry within the bilayer. These phospholipid transporters are
divided into three classes based on their direction of lipid transport: the non-energy dependent,
relatively non-specific, bidirectional „scramblases‟; the energy-dependent, unidirectional
„flippases‟ that move aminophospholipids to the inner-leaflet of the membrane; and the energydependent, unidirectional „floppases‟ that transport sphingolipid and choline-containing
phospholipids to the outer-leaflet of the bilayer. Specifically, flippases are of interest to this
dissertation due to their optimal specificity for PtdSer. Flippases are members of the multiple
membrane domain, Type 4 subfamily of P-type ATPases that unidirectionally transport one
PtdSer or, to a lesser extent, one PtdEtn, inward against their concentration gradient for every
one adenosine triphosphate (ATP) hydrolyzed by the enzyme (Beleznay et al., 1993; Daleke and
Huestis, 1985; Daleke and Lyles, 2000; Seigneuret and Devaux, 1984). PtdSer transport,
however, is dependent on a number of variables, namely the lipid head group and glycerol
backbone size and composition, enzyme sensitivity to Mg2+, and a critical cysteine residue of the
flippase primary structure.
Previous studies have shown that modification of the amine functional group of the
PtdSer head group (Fig. 2.10) significantly inhibits lipid transport (Daleke et al., 1995;
Drummond and Daleke, 1995; Morrot et al., 1989), with exception of N-methyl-PtdSer, which is
transported well (Daleke et al., 1995), indicating that flippase likely requires a protonatable
amine group. In contrast, modification of the serine carboxy moiety of the head group does not
appear to significantly affect transport, as evidenced by flippase‟s ability to transport both PtdSer
and PtdEtn (Fig. 2.10), although PtdEtn transport is 10-fold slower (Daleke and Lyles, 2000).
Flippase is also known to interact specifically with the DAG backbone [Fig. 2.10] (Morrot et al.,
1989), requiring acylation and proper stereochemistry of the glycerol backbone for effective
transport (Daleke and Huestis, 1985; Daleke et al., 1995; Hall and Huestis, 1994; Martin and
Pagano, 1987; Morrot et al., 1989). Interestingly, however, the composition of the lipid fatty
acyl chain does not appear to affect flippase translocation of PtdSer (Anzai et al., 1993; Daleke
and Huestis, 1985; 1989; Loh and Huestis, 1993; Morrot et al., 1989; Tilley et al., 1986).
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Flippase activity can be distinguished from other ATPases by its insensitivity to ionic
substrates and selective inhibitors of ion-motive ATPases. For example, flippase activity is
insensitive to intra- and extracellular [Na+] and [K+], as well as to the Na+K+ATPase inhibitor,
Ouabain (Seigneuret and Devaux, 1984), and is fully functional with selective depletion of
intracellular Ca2+ (Bitbol et al., 1987; Daleke and Huestis, 1985). However, flippase PtdSer
transport is reversibly inhibited with depletion of the divalent cation Mg2+, indicating that
flippase is a Mg2+ATPase (Bitbol et al., 1987; Daleke and Huestis, 1985). Furthermore, flippase
cannot be activated by extracellular ATP and is insensitive to externally applied proteases
(Connor and Schroit, 1989; Martin and Pagano, 1987), indicating that residue(s) responsible for
flippase activity are located within one of the transmembrane domains of this enzyme. In
particular, it is a cysteine residue of the primary structure of this enzyme that is most critical to
its conformational structure and translocating ability (Connor and Schroit, 1988; 1990).
2.3 Cellular Metabolism
2.3.1 Overview
In general, metabolism can be defined as a series of thermodynamically interdependent
chemical reactions that convert large molecules into smaller, more biologically useful forms.
Metabolic pathways are classified as either catabolic, those reactions that breakdown larger
molecules into smaller, more useful biomolecules, or anabolic, those reactions that require an
input of energy to synthesize complex molecules from simpler starting materials (Berg et al.,
2007; Karp, 2003). Extraction of energy from biofuels can be divided into three stages (Berg et
al., 2007). In the first stage, large food molecules are crudely degraded into smaller units by the
process of digestion. Proteins are broken down into their amino acids, carbohydrates into
hexoses and pentoses (e.g., glucose), and fats into fatty acids and glycerol. Digestion prepares
food for fatty acid, amino acid, or carbohydrate metabolism (i.e., glycolysis), in the second stage
of metabolic energy extraction. Although only a small amount of ATP (i.e., energy) is generated
in this stage, it is of utmost importance for membrane transporters, as well as other enzymes
located within the cytosol. The completion of the second phase of metabolism results in the
production of a common metabolite, acetyl coenzyme A (CoA) [Fig. 2.16], that is transported
into the mitochondria to begin the third and final phase of energy extraction. Within the
mitochondria ATP is produced from the complete oxidation of acetyl CoA, beginning with the
tricarboxylic acid (TCA) cycle (also called the citric acid or Kreb‟s cycle) and finishing with
oxidative phosphorylation.
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Figure 2.16

Figure 2.16 Structure of acetyl coenzyme A (CoA).

2.3.2 Glycolysis
The glycolytic break down of carbohydrates is common to virtually all cells, both
prokaryotic and eukaryotic (Berg et al., 2007). In eukaryotes, glycolysis occurs within the
cytosol in three stages, beginning with the conversion of glucose to fructose-1,6-bisphosphate
(Fig. 2.17). The main purpose behind this first stage is to trap glucose within the cell and from it
form a compound that is readily phosphorylated and cleaved into three-carbon units, which
occurs at the beginning of stage 2 (Fig. 2.17). The resultant three-carbon units are readily
interconvertible, and ultimately oxidized to a net total of two pyruvates with concomitant net
production of two ATP (Fig. 2.18) and two nicotinamide adenine dinucleotide (NADH)
molecules (Fig. 2.19). The entire process is completed in 10 linked anaerobic reactions within
the cytosol, and pyruvate converted to acetyl CoA (Fig. 2.16) under aerobic conditions within the
mitochondria (Berg et al., 2007). The production of pyruvate is physiologically important
because it can be converted into the amino acids alanine, valine, and leucine (Fig. 2.21), and is a
main source of acetyl CoA within the cell, over that produced by amino acid, fatty acid, and
glycerol metabolism.
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Figure 2.17

Figure 2.17 Glycolysis. In the stage one of glycolysis (steps 1-4), glucose is trapped in
the cell, readily phosphorylated, then cleaved into two glyceraldehyde-3-phoshate (GAP)
three-carbon units (only one shown). In stage two (step 5), GAP is reversibly converted
to dihydroxyacetone phosphate (DHAP) as needed by the cell. In the third and final
glycolytic stage (steps 6-10), one molecule of GAP is oxidized to one molecule of
pyruvate with concomitant net production of two adenosine triphosphate (ATP) and one
nicotinamide adenine dinucleotide (NADH) molecules. Because stage one actually
results in the production of two GAP molecules, stage three is completed twice (only
shown once) for every one molecule of glucose glycolytically metabolized. PGI,
phosphoglucose isomerase; PFK, phosphofructokinase; ADP, adenosine diphosphate;
TPI, triose phosphate isomerase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
PEP, phosphoenolpyruvate.
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Figure 2.18

Figure 2.18 Structure of adenosine triphosphate (ATP).

Figure 2.19

Figure 2.19 Structure of nicotinamide adenine dinucleotide (NAD+/NADH).

Interestingly, many studies have demonstrated that key glycolytic enzymes, such as
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate kinase, aldolase, enolase,
phosphoglycerate mutase, phosphoglycerate kinase, and hexokinase, are electrostatically bound
to cell and organelle membranes of various cell types (Kant and Steck, 1973; Rogalski et al.,
1989; Tsai et al., 1982; Xu and Becker, 1998; Xu et al., 1995). In fact, the glycolytic activity
many of these membrane-bound glycolytic enzymes is directly affected by their interaction with
these membranes (Galli et al., 1998; Kant and Steck, 1973; Rogalski et al., 1989; Tsai et al.,
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1982). Some studies suggest that, although neither glycolysis nor oxidative phosphorylation
alone is capable of sustaining cellular energy deficits, the primary source of ATP for membrane
ion pumps, such as the Na+/K+-ATPase and Ca2+-ATPase, is glycolytic (Kauppinen et al., 1988;
Mielke et al., 1996; Xu et al., 1995). Moreover, glycolytic ATP has been shown to be more
important for maintaining ER Ca2+ stores and inositol trisphosphate (IP3)-mediated Ca2+
signaling than ATP produced from the electron transport chain (ETC) (Kahlert and Reiser, 2000;
Kauppinen et al., 1988). These studies suggest that the close proximity of glycolytic enzymes to
other membrane-associated proteins would predispose the coupling of glycolysis to ion pump
activity (Kahlert and Reiser, 2000; Xu et al., 1995), as well as account for the cell‟s glycolytic
ATP preference (Weiss and Lamp, 1989; Xu et al., 1995).
Furthermore, inhibition of any glycolytic enzyme would cause the cell to shift its reliance
on glycolysis to the pentose phosphate shunt (section 2.3.5), which produces nicotinamide
adenine dinucleotide phosphate (NADPH) in lieu of NADH. This metabolic switch can be
beneficial as some antioxidant enzymes require NADPH to detoxify the cell. However, under
pathological conditions this shift is often permanent, producing a hypometabolic environment
that ultimately leads to cell death. Therefore, because the brain is one of the greatest consumers
of glucose, it is of utmost importance that glycolysis be maintained.
2.3.3 The Tricarboxylic Acid (TCA) Cycle
Following glycolysis, pyruvate is transported into the mitochondrial matrix and
oxidatively decarboxylated by the pyruvate dehydrogenase complex to form acetyl CoA and
NADH (Fig. 2.20), irreversibly linking glycolysis to the TCA cycle (Berg et al., 2007). The
acetyl units of acetyl CoA are then completely oxidized to CO2 in the TCA cycle (also called the
citric acid or Kreb‟s cycle). This cycle generates a net total of four high-energy electrons that are
eventually utilized for the synthesis of ATP in the ETC (section 2.3.4.2). The TCA cycle can be
considered a “central metabolic hub” within the cell, as it is “the gateway to the aerobic
metabolism of any molecule that can be transformed into an acetyl group or another component
of the TCA cycle,” and is an important source of amino acids, nucleotide bases, and porphyrin
(the organic component of hemes) [Fig. 2.21] (Berg et al., 2007).
Overall, the TCA cycle begins with the condensing of a two-carbon acetyl group with the
four-carbon oxoacetate to yield a six-carbon tricarboxylic acid (Fig. 2.21). Following two
successive oxidative decarboxylations, the six-carbon tricarboxylic acid releases two CO2
molecules that yield high-energy electrons in the form of reduced energy carriers, NADH and
flavin adenine dinucleotide (FADH2) [Fig. 2.22]. The four-carbon oxaloacetate is then
regenerated, and can initiate another round of the cycle (Fig. 2.21). Although the TCA cycle
does not generate a large amount of ATP, it does produce a net two molecules of guanosine
triphosphate (GTP) [Fig. 2.23], which are energetically equivalent to ATP, and two molecules
each of the reduced energy carriers, NADH and FADH2, which yield 2.5 and 1.5 ATP molecules
each, respectively, when oxidized by O2 in the ETC (Berg et al., 2007).

25

Figure 2.20

Figure 2.20 Conversion of pyruvate to acetyl coenzyme A (CoA).
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Figure 2.21
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Figure 2.21 The tricarboxylic acid (TCA) cycle and amino acid synthesis.

Figure 2.22

Figure 2.22 Structure of flavin adenine dinucleotide (FAD/FADH2).

Figure 2.23

Figure 2.23 Structure of guanosine triphosphate (GTP).
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2.3.4 Oxidative Phosphorylation
2.3.4.1 Mitochondrial Structure
Mitochondria are oval-shaped, semi-autonomous, intracellular organelles that contain
their own DNA and RNA, as well as the ETC, TCA cycle, and enzymes of fatty acid oxidation.
Interestingly, mitochondria are bounded by a double lipid membrane, where the outer membrane
bilayer is generally smooth and faces the intracellular milieu, and the inner-membrane bilayer is
folded into a series of internal ridges, called cristae (Berg et al., 2007). Although the outer
membrane is permeable to most small molecules and ions by way of multiple pore-forming
porins (i.e., voltage-dependent anion channels [VDAC]), the inner membrane is essentially
impermeable. Access to the mitochondrial matrix is attained through a large family of integral
membrane transporters, including the malate-aspartate and glycerol-3-phosphate shuttles,
situated within the inner membrane that shuttle metabolites such as NADH, ATP, pyruvate, and
citrate across the inner mitochondrial membrane (Berg et al., 2007).
As a result of the double membrane, mitochondria have two compartments, the
intermembrane space between the inner and outer bilayers, and the matrix, bounded solely by the
inner membrane. Compartmentalization of different molecules, proteins, and reactions allows
mitochondria to effectively carry out a variety of cellular functions simultaneously. For
example, conversion of pyruvate to acetyl CoA, the TCA cycle, and fatty acid oxidation take
place in the matrix, while oxidative phosphorylation takes place within the inner mitochondrial
membrane. Moreover, mitochondria are the major source of cellular ATP, since they possess the
entire ETC, and are considered the “power-house” of the cell.
2.3.4.2 The Electron Transport Chain (ETC)
Oxidative phosphorylation is the process that couples the oxidation of biofuels in fatty
acid, amino acid, and carbohydrate (i.e., glycolysis) metabolism and the TCA cycle to large-scale
ATP synthesis within the cell. ATP is formed from the transfer of electrons from NADH or
FADH2 to reduce molecular O2 to water by a series of electron carriers situated within the inner
mitochondrial membrane (Fig. 2.24). The reduced energy carriers NADH and FADH2 each
contain a pair of electrons with a high-energy transfer potential. Flow of these electrons through
the ETC liberates a large amount of free energy that leads to pumping of protons out of the
matrix and into the intermembrane space, against their concentration gradient (Berg et al., 2007).
Build-up of protons within the intermembrane space not only creates a pH gradient, but also a
transmembrane electrical potential, created by the net positive charge of the unequally
distributed protons (Berg et al., 2007). Flow of these protons back into the mitochondrial matrix
generates a proton-motive force that facilitates the synthesis ATP. Overall, oxidative
phosphorylation generates 26 of the 30 ATP molecules that are produced by the complete
breakdown of one molecule of glucose, assuming transport of cytosolic NADH into the
mitochondrial matrix is by the glycerol-3-phosphate shuttle.
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Figure 2.24

Figure 2.24 The electron transport chain (ETC). The ETC is located within the inner
mitochondrial membrane. As Complex I, III, and IV pump protons (H+) out of the
mitochondrial matrix and into the intermembrane space, Complex V pumps the
heightened concentration of intermembrane H+ back into the matrix to facilitate
production of adenosine triphosphate (ATP). NAD+/NADH, nicotinamide adenine
dinucleotide; FAD/FADH2, flavin adenine dinucleotide; Q, Coenzyme Q or ubiquinone;
CytC, cytochrome c; ADP, adenosine diphosphate; e-, electron; I, NADH-Q
oxidoreductase (Complex I); II, succinate-Q reductase (Complex II); III, Q-cytochrome c
oxidoreductase (Complex III); IV, cytochrome c oxidase (Complex IV); V, ATP synthase
[Complex V] (adapted from Kaplan, 2009).

The conversion of the electrons into the proton-motive force is carried out by the
electron-driven, transmembrane proton pumps of the ETC, NADH-Q oxidoreductase (Complex
I), Q-cytochrome c oxidoreductase (Complex III), and cytochrome c oxidase (Complex IV) [Fig.
2.24], which contain multiple oxidation–reduction centers, including quinines, flavins, ironsulfur clusters, hemes, and copper ions. Complex II (succinate-Q reductase), on the other hand,
does not pump electrons since it does not completely traverse the inner mitochondrial membrane,
but instead converts FADH2 to FAD by transferring its electrons to Complex III (Fig. 2.24).
Electrons are carried from Complex I and II to Complex III by the reduced form of coenzyme Q
(or ubiquinone) [Fig. 2.24], a hydrophobic quinone that diffuses rapidly within the inner
mitochondrial membrane (Fig. 2.25), while electrons from Complex III are carried to Complex
IV by cytochrome c, a small soluble protein (Fig. 2.24). The last of the proton pumping
assemblies, Complex IV, catalyzes the transfer of four electrons from cytochrome c to molecular
O2, the final electron acceptor of the ETC, which produces two molecules of water while
pumping four protons out of the matrix. Finally, ATP is synthesized by ATP synthase [or
Complex V (Berg et al., 2007)], an ATP synthesizing assembly that is driven by the flow of
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protons back into the mitochondrial matrix (i.e., the proton-motive force). Interestingly, the role
of the proton-motive force in ATP synthesis is not to form ATP but to facilitate its release from
the synthase complex, as ATP synthase has been shown to readily convert adenosine diphosphate
(ADP) to ATP in the absence of a proton gradient; proton flow through ATP synthase drives the
rotational release of ATP from the catalytic site of the synthase enzyme (Berg et al., 2007).
Figure 2.25

Figure 2.25 Reduction of ubiquinone (Q). Electrons are carried from Complex I and II to
Complex III in the electron transport chain by the reduced form of coenzyme Q (or
ubiquinone; Q), a hydrophobic quinone that diffuses rapidly within the inner
mitochondrial membrane. Q is a quinine derivative with a long hydrocarbon tail, whose
chain length depends on the Q species (e.g., the commonly known dietary supplement
CoQ10 has 10 hydrocarbon isoprene units). In the fully oxidized state, Q has two keto
groups. The addition of one electron (e-) and one proton (H+) results in the formation of a
.
semiquinone (QH ), while addition of a second e- and H+ forms reduced Q, ubiquinol
(QH2).

2.3.5 The Pentose Phosphate Pathway (PPP)
The PPP, or pentose phosphate shunt (PPS), provides an alternative pathway for the
degradation of glucose within the cytoplasm, in which oxidation of glucose generates NADPH,
the primary source of reductive biosynthesis within the cell (e.g., reduction of oxidized
glutathione; section 2.4.6.1). This pathway begins with the oxidative production of NADPH,
followed by the non-oxidative interconversion of three-, four-, five-, six-, and seven-carbon
phosphorylated sugars [Fig. 2.26] (Berg et al., 2007). The PPP is also employed by cells to
metabolize the dietary intake of five-carbon sugars, synthesize sugars required for nucleotide,
fatty acid, cholesterol, and neurotransmitter biosynthesis, and to catabolize and synthesize
typically uncommon four- and seven-carbon sugars (Berg et al., 2007). Overall, the PPP
generates 12 molecules of NADPH for each molecule of glucose-6-phosphate completely
oxidized to CO2.
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Figure 2.26

Figure 2.26 The pentose phosphate pathway (PPP). The PPP, or pentose phosphate
shunt, provides an alternative pathway for the degradation of glucose, since glucose can
be readily converted to glucose-6-phosphate when necessary. Phase one of this pathway
begins with production of nicotinamide adenine dinucleotide phosphate (NADPH),
followed by the formation of five-carbon sugars. In phase two, 5-carbon sugars are
interconverted to three-, four-, five-, six-, and seven-carbon sugars. Overall, the PPP
generates 12 molecules of NADPH for each molecule of glucose-6-phosphate completely
oxidized to CO2 (only one cycle shown).
G-6-P DH, glucose-6-phosphate
dehydrogenase; 6-PG DH, 6-phosphogluconate dehydrogenase.

As stated above (see section 2.3.2), inhibition of glycolysis would cause a metabolic shift
to the PPS, producing NADPH instead of NADH. In the short-term this shift would benefit
detoxification of the cell, however, a permanent shift would be detrimental considering the PPP
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does not directly produce ATP, nor can NADPH be exploited by the ETC to yield ATP.
Furthermore, although excess pentose sugars produced by the PPP can be converted into
glycolytic intermediates, their interconversion is not substantial enough for the cell to completely
bypass the glycolytic break-down of carbohydrates for prolonged periods of time.
2.4 Oxidative Stress
2.4.1 Overview
Oxidative stress can be characterized as an imbalance between the levels of antioxidants
and oxidants within the cell caused by age, environmental stressors, or diseases which lead to a
deficiency in endogenous antioxidants, the excess production of reactive oxygen (ROS) and/or
reactive nitrogen species (RNS), or the reduced clearance of damaged proteins within the cell
[Fig. 2.27] (Brown et al., 1997; Grune et al., 2004; Halliwell, 1991; 2006a; b; Harman, 1956; Liu
and Mori, 1993). In the brain, levels of oxidative stress have been shown to increase with age,
inducing protein and nucleic acid oxidation, lipid peroxidation, and apoptosis, leading to loss of
synapses and neurons, and declining cognition (Aruoma et al., 1991; Halliwell, 2006a; Halliwell
and Aruoma, 1991; Sastre et al., 2000; Stadtman, 2006). Oxidative modification of proteins and
lipids by ROS and/or RNS, in turn, results in either the diminished, complete loss of, or toxic
gain in protein function (Butterfield and Stadtman, 1997; Stadtman, 2006), thereby enhancing
age- and disease-related brain dysfunction.
Figure 2.27

Figure 2.27 Oxidative stress. Oxidative stress can be characterized as an imbalance
between the levels of antioxidants (AOX) and oxidants (reactive oxygen species
[ROS]/reactive nitrogen species [RNS]) within the cell caused by depletion of AOX,
excess production of ROS/RNS, or the reduced clearance of damaged proteins within the
cell.

2.4.2 Reactive Oxygen Species (ROS)
ROS are moderate to highly destructive molecules that contain oxygen, but possess a
higher reactivity than ground state O2; these molecules include both radical and non-radical
species (Table 2.2). In general, the majority of ROS found in the cell result from electron
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leakage from the ETC within the mitochondria, which leads to production of the superoxide
.
anion (O2 -) and hydrogen peroxide (H2O2) by partial reduction of molecular O2 (Adam-Vizi,
2005; Berg et al., 2007; Miquel et al., 1980). However, it should be noted that ROS can stem
from other sources, such as environmental toxins, metal-catalyzed reactions, the ER, as well as
many other enzymatic reactions and cellular processes [Fig. 2.28] (Adam-Vizi, 2005; Kamata
and Hirata, 1999; Santos et al., 2009; Thomas and Aust, 1986). Thus, because there is always a
basal level of oxidative stress and damage to intracellular contents (Halliwell and Whiteman,
2004), there are many systems and mechanisms the cell employs to scavenge ROS and protect
cellular homeostasis, which are briefly discussed in the following section (section 2.4.6). Yet,
even though ROS are very reactive and potentially damaging, they are not without benefit.
Extracellular secretion of pro-oxidants stimulates a variety of immune responses and recruits the
phagocytic ingestion of damaged cells, bacteria, viruses, and other pathogens (reviewed in
Martinon et al., 2009), while their intracellular secretion stimulates various cell signaling
systems (reviewed in Kamata and Hirata, 1999). Unfortunately, it is conditions which promote
the excess production of ROS and RNS, with subsequent oxidative stress and damage that are the
focus of this dissertation. Below is a discussion of some prominent ROS; a more complete list of
ROS can be found in Table 2.2.
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Table 2.2 List of different free radical and non-radical reactive species produced during
oxidative stress.
Free Radical Species
Non-Radical Species
.Hydrogen Peroxide (H2O2)
Superoxide (O2 )
.
Ozone (O3)
Hydroxyl radical ( OH)
.
ROS Ground-state Oxygen (O2)
Hydroperoxyl radical (HO2 )
.Organic peroxidases (ROOH)
ROS Carbonate radical anion (CO3 )
.Peroxomonocarbonate (HOOCO2-)
Carbon Dioxide radical anion (CO2 )
.
Hypochlorous acid (HOCl)
Peroxyl radical (RO2 )
.
Nitryl Chloride (NO2Cl)
Alkoxyl radical (RO )
RCS Chlorine gas (Cl2)
RCS Atomic Chlorine (Cl*)
Chlorine Dioxide (ClO2)
Bromine Chloride (BrCl)†
RBS Atomic Bromine (Br*)
Nitryl Chloride (NO2Cl)‡
.
Hypobromous acid (HOBr)
Nitric Oxide radical (NO )
RNS Nitrogen Dioxide radical (NO2.)
RBS Bromine gas (Br2)
.
Bromine Chloride (BrCl)†
Nitrate radical (NO3 )
Nitrous acid (HNO2)
Nitrosyl cation (NO+)
Nitroxyl anion (NO-)
Dinitrogen Tetroxide (N2O4)
Dinitrogen Trioxide (N2O3)
Peroxynitrite (ONOO-)
RNS Peroxynitrate (O2NOO-)
Peroxynitrous acid (ONOOH)
Nitronium cation (NO2+)
Alkyl Peroxynitrite (ROONO)
Alkyl Peroxynitrate (RO2ONO)
Nitryl Chloride (NO2Cl)‡
Peroxyacetyl Nitrate [CH3C(O)OONO2]
ROS, reactive oxygen species; RCS, reactive chlorine species; RBS, reactive bromine species; RNS,
reactive nitrogen species. †Considered both RCS and RBS; ‡Considered both RCS and RNS (adapted
from Halliwell, 2006a).

35

Figure 2.28

Figure 2.28 Overview of reactive oxygen species (ROS) production in the cell. COX,
cyclooxygenase; UV, ultraviolet; NOS, nitric oxide synthase; NADP+/NADPH,
nicotinamide adenine dinucleotide phosphate; NAD+/NADH, nicotinamide adenine
dinucleotide; SOD, superoxide dismutase; Q, ubiquinone or coenzyme Q; C, cytochrome
C, I, Complex I; II, Complex II; III, Complex III; IV, Complex IV; GPx, glutathione
peroxidase; GSH, glutathione; GSSG, oxidized glutathione; ATP, adenosine triphosphate
(adapted from Kamata and Hirata, 1999).
.

.

2.4.2.1 Superoxide (O2 -), Hydrogen Peroxide (H2O2), & Hydroxyl Radicals ( OH)
.

As stated above (see section 2.4.2), O2 - is a moderately reactive free radical species
produced from the transfer of a single electron to molecular O2 (reaction 1), primarily at, but not
limited to, Complexes I and IV of the ETC.
(reaction 1)
.

O2 - can also originate from other ETC complexes, the ER, and other enzymes, such as
NADPH oxidase, lipoxygenase, cyclooxygenase (COX), cytochrome P450, xanthine oxidase,
and UV-γ-irradiation, among others [Fig. 2.28] (Adam-Vizi, 2005; Kamata and Hirata, 1999;
.
Santos et al., 2009). Because O2 - is a free radical, it has an inherently short half-life, being able
.
to react with almost anything in close proximity. For example, O2 - can destroy the catalytic
function of various enzymes by attacking the iron-sulfur clusters (Flint et al., 1993), cause
protein oxidation and lipid peroxidation (sections 2.4.4 & 2.4.5), and create additional highly
reactive free radical species which serve to amplify conditions of oxidative stress. One
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mechanism in which the cell is able to scavenge this free radical is through the
.
disproportionation of O2 - by manganese superoxide dismutase (MnSOD) in the mitochondrial
matrix (Weisiger and Fridovich, 1973) or by Cu/ZnSOD in the mitochondrial intermembrane
space and/or the cytosol, to form molecular O2 and H2O2 [reaction 2] (Fridovich, 1989; McCord
and Fridovich, 1969).
(reaction 2)
Unfortunately, H2O2, is itself, a potent non-radical oxidizing agent that can react with
reduced metal ions, such as Cu2+ (reaction 3) and Fe2+ (reaction 4) [i.e., Fenton chemistry], to
.
form highly reactive hydroxyl radicals [ OH] (Butterfield and Stadtman, 1997) if not quickly
scavenged by other enzymes, such as peroxidases, reductases, and catalases, back into water
(reviewed in Gilgun-Sherki et al., 2001). Other significant sources of H2O2 in the cell are
NADPH oxidase, xanthine oxidase, lysosomes, and monoamine oxidase, among other enzymatic
processes [Fig. 2.28] (Kamata and Hirata, 1999; Santos et al., 2009), as well as from many other
radical-radical recombination reactions.
(reaction 3)
(reaction 4)
.

However, it is OH, produced from H2O2-induced Fenton chemistry and the reaction
.
between O2 - and H2O2 that is the most reactive ROS (reaction 5).
(reaction 5)
.

Hydroxyl free radicals ( OH) inflict severe oxidative damage by reacting with almost any
.
molecule it comes in contact with. For example, OH can cause protein oxidation and lipid
peroxidation through direct or indirect cleavage of the peptide backbone (section 2.4.4) and
polyunsaturated fatty acids (PUFAs) [section 2.4.5], β-scission of amino acid side-chains
(section 2.4.4), generation of protein-protein cross-linkages (sections 2.4.4 & 2.4.5), and
generation of RNS (Butterfield and Stadtman, 1997; Stadtman, 2006).
2.4.3 Reactive Nitrogen Species (RNS)
Like ROS, RNS are moderate to highly reactive compounds that contain nitrogen and
oxygen and include both radical and non-radical species (Table 2.2). RNS are typically derived
.
from nitric oxide (NO ), an abundant cell signaling molecule with both autocrine and paracrine
.
activities. In the CNS, NO production is associated with cognitive function, including the
induction and maintenance of synaptic plasticity, as well as control of the sleep-wake cycle,
appetite, body temperature, and neurosecretion (Guix et al., 2005; McCann, 1997; Rivier, 2001).
.
Excess production of NO , however, is toxic, especially to cells already consumed by oxidative
.
stress. Oxidation and/or reduction of NO by ROS, in turn, forms toxic RNS compounds that
further cultivate oxidative damage to cells, termed nitrosative stress (Ridnour et al., 2004). Thus,
as with ROS, there exist certain endogenous antioxidant defense systems within the cell to
scavenge RNS and protect cellular homeostasis, which are described below (section 2.4.6).
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Although RNS have different reactivities from one another, their half-lives are generally longer
.
.
than OH and O2 - (Balazy and Nigam, 2003). Below is a more detailed discussion of some of the
most common RNS, with a more complete list located in Table 2.2.
.

2.4.3.1 Nitric Oxide (NO )
.

As mentioned above, membrane-permeable NO is an abundant cell signaling molecule in
.
the CNS associated with cognitive function. However, the oxidation and/or reduction of NO by
ROS forms toxic RNS compounds that cultivate oxidative damage, during nitrosative stress.
.
Primarily, it is the NO synthase (NOS) family of enzymes that are responsible for synthesizing
.
NO , by catalyzing the conversion of L-arginine to L-citrulline with the cofactor NADPH and in
the presence of O2 (Fig. 2.29). This family of enzymes contains three isoforms, which can all be
found in the brain: constitutively expressed, Ca2+-dependent neuronal NOS (nNOS), abundant in
the cytoplasm of neurons, as well as astrocytes, cerebral blood vessels, and a few areas of the
periphery (Bredt et al., 1991; Dawson and Snyder, 1994; De Giorgio et al., 1994; Guix et al.,
2005; Magee et al., 1996; Rodrigo et al., 1994; Toda et al., 2005; Vincent and Kimura, 1992);
Ca2+-independent inducible NOS (iNOS), located in the cytosol of astrocytes and microglia
following inflammation, viral infection, or trauma (Bredt, 1999; Calabrese et al., 2006), as well
as in the periphery; and constitutively expressed, Ca2+-dependent endothelial NOS (eNOS),
located within the plasma membrane of cerebral and peripheral endothelial cells wherein it
regulates blood flow (Calabrese et al., 2006; Colasanti et al., 1998; Rajasekaran et al., 1998).
Figure 2.29

Figure 2.29 Formation of nitric oxide (NO.) from nitric oxide synthase (NOS).
NADP+/NADPH, nicotinamide adenine dinucleotide phosphate.
.

Interestingly, NO can be both neuroprotective and neurotoxic, depending on the
oxidative state of the cell. Because of their long half-lives, the reaction between NO. and other
free radicals (e.g., O2.- and .OH) “stabilizes” these radicals, essentially scavenging them from
.
solution (Halliwell et al., 1999). NO , via N2O3, S-nitrosylates (section 2.4.4.2) pro-apoptotic
caspase-3 and two subunits of the N-methyl-D-aspartate receptor (NMDAR), consequently,
inhibiting caspase-3 and glutamate-induced NMDAR Ca2+ influx activity and reducing the levels
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.

of cell death (reviewed in Calabrese et al., 2007a). NO also activates the neuroprotective cyclic
AMP-responsive element binding-protein (CREB) and Akt proteins via stimulation of the
soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP)-protein kinase G
.
(PKG) pathway (reviewed in Calabrese et al., 2007a). Furthermore, NO induces production of
biliveridin by heme oxygenase-1 (HO-1), which is a precursor to the powerful antioxidant and
anti-nitrosative molecule, bilirubin [Fig. 2.30] (Kitamura et al., 1998a; Mancuso et al., 2003;
Motterlini et al., 2002).
Figure 2.30
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.

Figure 2.30 Formation of bilirubin. NO induces production of biliveridin by heme
oxygenase-1 (HO-1), which is a precursor to the powerful antioxidant and anti-nitrosative
molecule, bilirubin. NADP+/NADPH, nicotinamide adenine dinucleotide phosphate.
.

NO typically does not elicit neurotoxic effects unless produced in excess or within a cell
in the pro-oxidant state, as is the case in many neurodegenerative disorders. In a majority of
these disorders, excess NO. is produced by iNOS as a result of a pro-inflammatory response, or
.
by nNOS due to excitotoxicity. Under these conditions, NO mediates the nitrosylation of
critical sulfur residues (i.e., S-nitrosylation) within proteins (section 2.4.4.2), inhibiting their
.
activity. For example, NO acutely and rapidly inhibits neuronal energy production in neurons as
it pertains to both mitochondrial oxidative phosphorylation and glycolysis by S-nitrosylating a
number of enzymes involved in both processes, including glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and enolase (Brorson et al., 1999; Calabrese et al., 2007a).
.
Additionally, NO activates COX enzymes, which generate free radicals and pro-inflammatory
prostaglandins (reviewed in Calabrese et al., 2007a). Antioxidant defense systems within the cell
scavenge RNS and their by-products, including GSH (section 2.4.6.1), redoxin enzymes, and
other various peroxidases and sulfoxide reductases (Fang et al., 2002; Halliwell, 2006a).
.

2.4.3.2 Peroxynitrite (ONOO-) & Nitrite Radicals (NO2 )
.

.

NO indirectly elicits its cytotoxic effects by reacting with O2 -, a by-product of NOS
activity, to form the potent RNS molecules, peroxynitrite (ONOO-) [reaction 6] and the nitrite
.
radical (NO2 ) [reaction 7] (Halliwell et al., 1999).
(reaction 7)
.

The interaction between ONOO- or NO2 and a variety of cellular components results in
destructive protein nitration and S-nitrosylation [section 2.4.4.2] (Guix et al., 2005; Halliwell et
al., 1999; Keszler et al., 2010). For example, nitration of either type of SOD disables their
ability to scavenge ROS, resulting in an excess of intracellular H2O2 and an overall increase
oxidative stress (Alvarez et al., 2004; Jackson et al., 1998). Furthermore, the reaction between
.
ONOO- and CO2 can also produce NO2 (reaction 8), as well as from many other radical-radical
recombination reactions.
(reaction 8)
.

NO2 can also be absorbed into the body through inhalation of indoor/outdoor air
pollutants, such as car emissions, fossil fuels, cigarette smoke, etc. (Persinger et al., 2002).
.
Studies have shown that even minimal exposure to NO2 can result in long-term morphological
changes resulting in inflammation and cellular injury (Moldeus, 1993), as this radical RNS, as
well as others, leads to an increase in lipid peroxidation, especially in lung tissue (Persinger et
.
al., 2002; Sagai et al., 1984). During inflammation, NO2 oxidation is mediated by peroxidases,
such as eosinophil peroxidase and myeloperoxidase (Byun et al., 1999; Dedon and Tannenbaum,
2004; Podrez et al., 1999; Wang et al., 1995a; Zhang et al., 2002).
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2.4.4 Protein Oxidation
As previously mentioned, increasing levels of oxidative stress in brain with age and/or
disease pathogenesis induce protein and oxidation and lipid peroxidation events, which
inevitably lead to neuronal cell death (Aruoma et al., 1991; Halliwell, 2006a; Halliwell and
Aruoma, 1991; Sastre et al., 2000; Stadtman, 2006). Post-translational oxidative modification of
proteins by ROS and RNS results in diminished and/or complete loss of protein function,
whereas oxidative modification of lipids results in the production of additional reactive
nucleophilic species, amplifying the neurotoxic effects of ROS and RNS (Butterfield and
Stadtman, 1997; Stadtman, 2006). Examples of oxidative modifications include
phosphorylation, glycosylation, carbonylation (section 2.4.4.1), nitration (section 2.4.4.2), and Snitrosylation (section 2.4.4.2).
2.4.4.1 Protein Carbonylation
Protein carbonylation of proteins is among the most common post-translational oxidative
modifications, resulting from β-scission of amino acid side-chains (Fig. 2.31) and direct or
indirect cleavage of the peptide backbone (Fig. 2.32) by ROS and RNS (Butterfield and
Stadtman, 1997; Stadtman, 2006). Although moderately carbonylated proteins can be degraded
by the proteasome, those proteins that are heavily carbonylated often accumulate to form highmolecular-weight aggregates that are resistant to proteolysis and can even inhibit proteasomal
activity (reviewed in Dalle-Donne et al., 2006). Interestingly, although this is the most abundant
and common form of post-translational oxidative modification, there appears to be a form of
selectivity to carbonylation, considering the relative amount of a protein does not dictate the
degree of carbonylation, and many studies have shown that some proteins are more susceptible
to carbonylation than others (Cabiscol et al., 2000; Choi et al., 2005; Dalle-Donne et al., 2006;
Jana et al., 2002). It has been proposed that such selectivity is likely due to protein structure
since the presence of a transition metal binding-site appears to be a key feature in predicting the
susceptibility of proteins to carbonylation (Stadtman, 1990; 2006). Because protein
carbonylation is an irreversible form of oxidative damage, immunochemical detection protein
carbonyls (described in Chapter 3) is the most widely recognized way in which to index levels of
global oxidative stress in a given tissue (Dalle-Donne et al., 2006; 2005; Levine et al., 1990).
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Figure 2.31

Figure 2.31 β-Scission of amino acid side-chains: Protein carbonyl formation (adapted
from Stadtman, 2006).
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Figure 2.32

Figure 2.32 Oxidative cleavage of the peptide backbone. I) α-Amidation. II) Diamide
formation (adapted from Stadtman, 2006).

2.4.4.2 Protein Nitration & S-Nitrosylation
As mentioned above, the interaction between RNS and a variety of cellular components
results in destructive protein nitration and S-nitrosylation (Greenacre and Ischiropoulos, 2001;
Guix et al., 2005; Halliwell et al., 1999). ONOO- can S-nitrosylate sulfur atoms on methionine
and cysteine residues [Fig. 2.33] (Broillet, 1999), as well as nitrate tryptophan and tyrosine
residues to form 3-nitrotyrosine (3-NT)-protein adducts (Fig. 2.34), which inhibit normal protein
function (Alvarez and Radi, 2003; Greenacre and Ischiropoulos, 2001; Halliwell et al., 1999).
Like protein carbonyls, immunochemical detection of 3-NT (described in Chapter 3) is a second
43

way in which to index the level of protein oxidation and overall oxidative stress in a given tissue
(Greenacre and Ischiropoulos, 2001; Ischiropoulos, 1998; Ohshima et al., 1990).
Figure 2.33

Figure 2.33 Overall reaction of S-nitrosylation of sulfur containing amino acids.

Figure 2.34

Figure 2.34 3-Nitrotyrosine (3-NT) formation.

2.4.5 Lipid Peroxidation
Within the brain, lipids are most vulnerable to oxidation since this organ is particularly
enriched with PUFAs. The majority of lipid peroxidation events within the cell occur as a result
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of free radical chain reactions, in which their allylic carbons are most susceptible, until quenched
[reactions 9-12] (reviewed in Spiteller, 2001).

(reactions 9 -12)

Moreover, oxidative modification of lipids results in the production of additional reactive
species, amplifying the neurotoxic effects of ROS and RNS (Butterfield and Stadtman, 1997;
Stadtman, 2006). Examples of lipid peroxidation products include malondialdehyde [MDA]
(Esterbauer and Cheeseman, 1990; Esterbauer et al., 1991), 4-hydroxy-2-trans-nonenal [HNE]
[section 2.4.5.1] (Esterbauer et al., 1991; Mattson et al., 1997; Waeg et al., 1996), conjugated
fatty acids (Esterbauer and Zollner, 1989; Jira et al., 1996), isoprostanes (Morrow and Roberts,
1997; Wang et al., 1995b), and products derived by addition of lipid peroxidation products to
DNA and/or proteins (Burcham, 1998; Waeg et al., 1996).
2.4.5.1 Protein-Bound 4-Hydroxy-2-Trans-Nonenal (HNE)
Arachidonic acid, linoleic acid, and decosahexanoic acid are the main PUFAs that
compose the hydrophobic, lipid phase of the neuronal plasma membrane. Because of their
extreme length, and therefore, high content of allylic carbons, oxidative cleavage of either PUFA
generates a wide variety of highly reactive peroxidation products. In particular, it is the βoxidation of the 11th carbon of arachidonic acid that is of interest in this dissertation, due to its
production of the highly reactive alkenal, HNE (Fig. 2.35). Increased levels of HNE can cause
disruption of Ca2+ homeostasis, membrane damage, and cell death by covalently modifying
amino acid residues, such as lysine, histidine, and cysteine [Fig. 2.36] (Esterbauer et al., 1991;
Schaur, 2003; Siems and Grune, 2003; Subramaniam et al., 1997). Immunochemical detection
of protein-bound HNE is a third way in which to index the level of protein oxidation and overall
oxidative stress in a given tissue (Waeg et al., 1996).
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Figure 2.35
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Figure 2.35 Formation of 4-hydroxy-2-trans-nonenal (HNE) from arachidonic acid.

Figure 2.36

Figure 2.36 Formation of 4-hydroxy-2-trans-nonenal (HNE) adducts. Increased levels of
HNE can cause protein oxidation and lipid peroxidation by covalently modifying
(Michael addition) amino acid residues, such as lysine, histidine, and cysteine.

2.4.6 Antioxidants
As previously mentioned, because there is always a basal level of oxidative damage to
intracellular contents (Halliwell and Whiteman, 2004), there are many endogenous antioxidant
defense systems and mechanisms the cell employs to scavenge ROS and RNS and protect
cellular homeostasis. Unfortunately, these antioxidant defense systems become impaired with
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age and neurodegenerative disease, since many antioxidant enzymes are redox sensitive and,
therefore, easily oxidized (Mates et al., 1999). Thus, recent surges in the research of exogenous
antioxidant compounds as a therapeutic strategy to combat increasing oxidative stress and
damage with age and disease progression has lead to increased dietary supplementation.
Beyond the endogenous antioxidant systems and enzymes mentioned above (see sections 2.4.2 &
2.4.3), this section will describe in detail the endogenous GSH system (section 2.4.6.1), as well
as the exogenous, non-enzymatic low-molecular-weight molecules, γ-glutamylcysteine ethyl
ester (GCEE) [section 2.4.6.2], vitamin E (section 2.4.6.3), vitamin C (section 2.4.6.4), α-lipoic
acid (LA) [section 2.4.6.5]. Other dietary antioxidants that have been investigated for their
neuroprotective effects in neurodegenerative disease include, but are not limited to, quercitin,
coenzyme Q10, polyphenolic flavonoids (e.g., resveratrol and quercitin), curcumin, ferulic acid
and ferulic acid ethyl ester (FAEE), and N-acetyl-L-cysteine (NAC).
2.4.6.1 The Glutathione (GSH) System
GSH is the most prevalent, endogenous, antioxidant in the brain as it can be found in
millimolar concentrations within cells. Thiol-containing GSH scavenges ROS and RNS, as well
as nucleophilic compounds, using its reduced thiol group [i.e., S-glutathionylation] (reviewed in
Dalle-Donne et al., 2009). By reacting with ROS and RNS (i.e., S-nitrosylation), GSH is
oxidized to produce GSSG by GSH peroxidase (GPx), then is recycled back to two GSH
molecules by GSH reductase and NADPH (from the PPP; see section 2.3.5), effectively
completing this detoxification cycle [Fig. 2.37] (Dalle-Donne et al., 2009; Keszler et al., 2010).
GSH S-transferase (GST) catalyzed S-glutathionylation of nucleophilic compounds, like the lipid
peroxidation product HNE, by GSH results in the production of GSH-S-protein conjugates that
are effluxed from the cell by the multidrug resistance protein-1 (MRP-1) [Fig. 2.38] (Renes et
al., 1999). Interestingly, S-glutathionylation not only scavenges ROS and RNS, but also protects
redox sensitive proteins, including glycolytic enzymes GAPDH and enolase (reviewed in DalleDonne et al., 2009), from oxidative modification since this type of post-translational
modification is reversed by the thiol transferase, glutaredoxin [Fig. 2.38] (Chrestensen et al.,
2000). Therefore, the ratio of GSSG to GSH is often used as a marker of redox thiol status and
overall oxidative stress in the cell. For example, a linear correlation between increased GSSG
levels and cognitive status using the Mini-Mental Status Examination (MMSE) has been
previously ascertained in Alzheimer disease patients (Lloret et al., 2009).
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Figure 2.37

Figure 2.37 Cycling of reduced and oxidized glutathione (GSH/GSSG). By reacting with
ROS and RNS, GSH is oxidized to GSSG by GSH peroxidase (GPx), then is recycled
back to two GSH molecules by GSH reductase and nicotinamide adenine dinucleotide
phosphate (NADPH/NADP+), effectively completing this detoxification cycle.
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Figure 2.38

Figure 2.38 Antioxidant cycling. NADP+/NADPH, nicotinamide adenine dinucleotide
.
phosphate; R, protein; LOH, lipid hydroxide; LOOH, lipid hydroperoxide; LOO , lipid
peroxyl radical; GSH, reduced glutathione; GSSG, oxidized glutathione; Vit C, vitamin
C; Vit E, vitamin E; S, sulfur; ATP, adenosine triphosphate; ADP, adenosine
diphosphate; Pi, inorganic phosphate; MRP-1, multi-drug resistance protein-1; GST,
glutathione-S-transferase; GPx, glutathione peroxidase; GR, glutathione reductase; GRx,
glutaredoxin; Gly, glycine; Cys, cysteine; GCL, -glutamylcysteine ligase; -Glu-Cys; glutamylcysteine; GCEE, -glutamylcysteine ethyl ester (adapted from Fang et al., 2002).

Unfortunately, the levels of GSH in the brain decrease as a function of age, as well as in a
number of neurodegenerative diseases (Higuchi, 2004; Liu and Mori, 1993; Liu and Choi, 2000).
Moreover, oxidative modification of GPx, GST, GSH reductase, and even MRP-1 often
increases with brain aging and disease, increasing the levels of oxidative stress (Sultana et al.,
2004). Thus, exogenous supplementation with GSH precursors in order to increase levels of
GSH may be an effective way to protect against oxidative stress. Although the glutamate and
glycine components of GSH are naturally abundant in the brain, cysteine residues are limited.
Therefore, much research has recently focused on increasing the levels of free cysteine for the
biosynthesis of GSH.
2.4.6.2 γ-Glutamylcysteine Ethyl Ester (GCEE)
One highly effective way to increase biosynthesis of GSH is supplementation with GCEE
[Fig. 2.39] (Anderson and Meister, 1983). Because -glutamylcysteine formation is the rate50

limiting step in GSH biosynthesis, due to the low level of free cysteines, supplementation with glutamylcysteine bypasses the feed-back inhibition loop of GSH on -glutamylcysteine ligase
(GCL) [Fig. 2.38], which produces -glutamylcysteine, while attaching an ethyl ester group to
the N–terminus of -glutamylcysteine allows this GSH precursor to readily traverse the bloodbrain barrier (BBB) and cell membranes (Drake et al., 2002; 2003b). GCEE has been shown to
increase brain and mitochondrial GSH levels, thereby protecting synaptosomes, neurons, and
mitochondria against ONOO- damage, protein oxidation and lipid peroxidation, and DNA
fragmentation (Drake et al., 2002; 2003b; Reed et al., 2009). In addition to increasing GSH
levels, GCEE may also protect cells from oxidative stress and damage by directly reacting with
ROS/RNS via its thiol-containing cysteine residue (Aluise et al., 2009; Hayashi et al., 1998).
Figure 2.39

Figure 2.39 Structure of γ-glutamylcysteine ethyl ester (GCEE).

2.4.6.3 Vitamin E
Vitamin E (i.e., tocopherol) [Fig. 2.40] is one of the most well-known phenolic
compounds known to scavenge free radicals with its phenolic hydrogen-atom and is recycled
through various pathways, including vitamin C, GSH, and theoredoxin [Fig. 2.38] (Kagan et al.,
1992). This lipophilic compound can insert itself within the lipid bilayer and protect PUFAs
from lipid peroxidation, as well as protect proteins from post-translational oxidative modification
and prevent free radical formation (Topinka et al., 1989). Vitamin E is a chain-breaking
antioxidant and, therefore, disrupts free radical chain reactions associated with lipid peroxidation
(reactions 9-12; see section 2.4.5). Vitamin E originates from various food sources, mainly plant
oils (e.g., corn and soybean), and consists of -, -, -, and -tocopherol isoforms. However,
vitamin E supplements often consist solely of -tocopherol, arguably the most biologically
potent form of vitamin E. Unfortunately, studies focused only on the use of -tocopherol to
prevent or slow cognitive decline and dementia have been inconsistent (Morris et al., 2005);
thus, combining different isoforms may produce more effective results. For instance, although
both -tocopherol and -tocopherol have been shown to independently reduce cerebral ischemiainduced brain damage when injected into rat brain (Mishima et al., 2003), -tocopherol displayed
greater anti-inflammatory properties (Jiang and Ames, 2003) and was a major RNS scavenger
(Morton et al., 2002; Williamson et al., 2002). Moreover, other studies have shown that dietary
supplementation with -tocopherol has been shown to decrease -tocopherol levels in plasma
(Handelman et al., 1985).
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Figure 2.40

Figure 2.40 Structure of vitamin E.

Vitamin E has been investigated for decades to determine its relationship to cognitive
decline, and many have shown that levels of this vitamin decrease with age and dementia,
correlating with memory loss (Butterfield et al., 2002a; Perkins et al., 1999). However, while
vitamin E supplementation does, in fact, increase vitamin E levels in the body and decrease
susceptibility of lipoproteins to oxidation (Kontush et al., 2001), it is unclear whether vitamin E
actually improves cognition. Many studies with vitamin E alone or in combination with other
vitamins and minerals have shown no association with dementia (Fillenbaum et al., 2005; Laurin
et al., 2004; Luchsinger et al., 2003), while others have noted a correlation with improved
cognitive performance (Chandra, 2001; Engelhart et al., 2002; Morris et al., 1998; Nourhashemi
et al., 2000; Zandi et al., 2004). A recent study by Lloret, et al. (2009) found that of Alzheimer‟s
patients on high-dose vitamin E, only half maintained or improved cognitive skill, while the
other half showed decreased cognition compared to controls (Lloret et al., 2009). Their findings
demonstrated that those patients displaying cognitive improvement on high-dose vitamin E had
decreased oxidative stress, as measured by GSSG/GSH ratio and MDA levels (Lloret et al.,
2009). It is possible that vitamin E is detrimental to individuals with already high levels of
oxidative stress and do not show improvement with supplementation, since oxidized vitamin E
can be reactive unless promptly recycled and reduced (Fig. 2.38). Thus, supplementation of
vitamin E in combination with other water-soluble antioxidant(s) capable of recycling vitamin E
and increasing redox thiol status, such as inducing GCEE up-regulation, may have more
consistent positive effects on cognition.
2.4.6.4 Vitamin C
Vitamin C (ascorbate) [Fig. 2.41] is a water-soluble molecule found in many citrus fruits,
which also has the ability to protect against intracellular oxidative stress and damage alone, or by
recycling vitamin E to its reduced form [Fig. 2.38] (Chan, 1993; Padh, 1990). Beyond being a
scavenger of ROS and RNS, vitamin C is necessary for normal brain functions as its oxidized
form, dehydroascorbate (Fig. 2.41), can undergo irreversible hydrolysis and decarboxylation to
produce certain components of the PPP (see section 2.3.5) or oxalic and threonic acid
(Grunewald, 1993; Schreiber and Trojan, 1991). In addition, vitamin C is thought to be involved
in catecholamine synthesis and release, may be a critical cofactor for the dopamine βhydroxylase enzyme, and release of is highly associated with glutamatergic neuron activity,
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primarily by glutamate-ascorbate heteroexchange across neuronal or glial membranes
(Grunewald, 1993; Schreiber and Trojan, 1991). Since humans cannot synthesize this vitamin
naturally, it must be obtained from the diet (Chatterjee et al., 1975). Vitamin C crosses the BBB
as dehydroascorbate and is retained in brain tissue as ascorbic acid at concentrations 10-fold
greater than that which is found in the plasma and serum (Agus et al., 1997; Frei et al., 1989;
Rose and Bode, 1993; Schreiber and Trojan, 1991). Thus, it is very likely that increasing the
concentration of ascorbic acid, and therefore, dehydroascorbate, in the blood by dietary
supplementation may also increase the concentration of vitamin C in the brain. However, recent
clinical trials investigating the use of vitamin C supplementation as a therapeutic strategy for
certain neurodegenerative disorders have reported a lack of efficacy when administered alone,
while supplementation in combination with vitamin E showed some benefit (reviewed in GilgunSherki et al., 2001). Moreover, a study by Lee, et al. (2001) demonstrated that high doses of
vitamin C mediate formation of genotoxins from lipid hydroperoxides and can cause DNA strand
breaks (Lee et al., 2001).
Figure 2.41

Figure 2.41 Structure of vitamin C and dehydroascorbate.
2.4.6.5 α-Lipoic Acid (LA)
LA (i.e., thioctic acid) plays many roles as an antioxidant in neurodegenerative diseases
and has been widely investigated for its neuroprotective effects. Being readily available from
dietary sources, LA is absorbed into the small intestines, and easily passes through the BBB
(Seaton et al., 1996). LA, as well as its reduced form, dihydrolipoic acid (DHLA), contains two
sulfur atoms that are responsible for its antioxidant, anti-inflammatory, and metal ion chelation
abilities [Fig. 2.42] (Packer et al., 1997). LA has also been shown to have diverse
pharmacological properties and is a cofactor in multi-enzyme complexes in the mitochondria,
such as pyruvate dehydrogenase and -ketoglutarate dehydrogenase (Packer et al., 1997). LA
also interacts with other antioxidants such as GSH, ubiquinol, thioredoxin, vitamin C, and
indirectly with vitamin E, regenerating their reduced forms [Fig. 2.43] (Kagan et al., 1992; Ou et
al., 1995; Sen et al., 1997). For example, dehydroascorbate is reactive if not readily reduced
back to ascorbic acid in the brain; LA can inhibit dehydroascorbate-induced production of H2O2
by Cu+ (Kagan et al., 1992).
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DHLA may also play a role as a cofactor for choline acetyl transferase (ChAT) or reduce
a vital cysteine residue that is required for enzyme activity, as it has been found to increase
ChAT activity, whereas LA did not (Haugaard and Levin, 2000). In mitochondria, the lipoamide
dehydrogenase enzyme catalyzes reduction of free LA to DHLA, using NADH as a cofactor,
whereas, in the cytosol, GSH reductase catalyzes this reduction, using NADPH as a cofactor
(reviewed in Biewenga et al., 1997). Therefore, when DHLA is derived from lipoamide
dehydrogenase reduction of LA, the cell is able to draw on its pool of NADH molecules to
promote antioxidant activity, in addition to its NADPH pools via GSH reductase, which are
usually consumed during oxidative stress (reviewed in Biewenga et al., 1997).
Figure 2.42

Figure 2.42 Structure of α-lipoic acid and dihydrolipoic acid (DHLA).

Figure 2.43

Figure 2.43 Cycling of α-lipoic acid. GSH, reduced glutathione; GSSG, oxidized
.
.
glutathione; LOO , lipid peroxyl radical; LOOH, lipid hydroperoxide; ROO , alkyl
peroxyl radical; ROOH, alkyl hydroperoxide (adapted from Butterfield et al., 2002a).

Several studies in aged rats and canines have shown that diets rich in antioxidants, such
as LA, have improved learning and reversed memory impairment, as well as decreased levels of
certain markers of oxidative stress (Bickford et al., 2000; Christie et al., 2009; Farr et al., 2003;
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Liu et al., 2002; Opii et al., 2008). Aged rats fed LA were able to increase activity of
mitochondrial enzymes isocitrate dehydrogenase, NADH dehydrogenase, succinate
dehydrogenase, -ketoglutarate dehydrogenase, and cytochrome c oxidase (Arivazhagan et al.,
2001). Other studies have shown that GSH levels and GCL activity decrease almost 50% with
age, due, in part, to a 50% reduction in total and nuclear levels of NF-E2-related factor-2 [Nrf2]
(Suh et al., 2004), which governs expression of GCL subunits through the antioxidant response
element in DNA. When aged rats were administered R-α-LA, levels of Nrf2 increased along
with an increase of GCL levels and activity (Suh et al., 2004). In addition, DHLA may aid GSH
biosynthesis by reduction of cystine to cysteine (Packer et al., 1997). Thus, demonstrating that
LA influences GSH levels through direct regeneration, increasing the GSH precursor cysteine
and transcription factors that regulate GSH synthesis. Furthermore, recent clinical studies of
Alzheimer disease patients demonstrated that administration of 600 mg/day of LA stabilized
cognitive function as assessed by the MMSE and Alzheimer Disease Assessment Scale
Cognitive Subscale scores (Hager et al., 2007). Patients with mild dementia showed
significantly delayed disease progression compared to untreated patients or patients on
acetylcholine esterase inhibitors (Hager et al., 2007).
2.5 Cell Death
2.5.1 Apoptosis
Apoptosis, or “programmed cell death,” is a process that removes cells that are no longer
required or damaged beyond repair, and can be characterized by the overall shrinkage of cell
volume, the loss of adhesion to neighboring cells, membrane blebbing, nuclear chromatin
condensation and fragmentation, mitochondrial changes, activation of pro-apoptotic proteins, and
exposure of PtdSer to the cell surface (see sections 2.2.2 & 2.5.2) followed by the rapid
phagocytic engulfment of the apoptotic cell [Fig. 2.44] (Karp, 2003). Apoptosis can be triggered
by both external and internal stimuli, both of which can be divided into three distinct phases:
initiation, when the cell responds to death stimuli; integration/decision, when the cell commits
itself to destruction by activating caspases and mitochondrial death effectors – considered “the
point of no return”; and execution/degradation, when the death sentence is carried out in full and
the cell is engulfed by phagocytosis (Karp, 2003; Kroemer et al., 2007).
Although apoptosis can be elicited in many ways, it is the extrinsic and intrinsic
pathways that are most prominent. The extrinsic pathway is stimulated by external stimuli,
which trigger the ligand-induced activation of transmembrane death receptors at the cell surface.
Thus, the extrinsic pathway of apoptosis is also known as the “death receptor pathway.”
Namely, one of the most well known death stimuli is the tumor necrosis factor (TNF), which
evokes an apoptotic response by binding the TNF death receptor, TNFR1(Karp, 2003; Kroemer
et al., 2007). Upon binding TNF, TNFR1undergoes a conformational change within its
cytoplasmic death domain, which recruits and induces oligomerization of adapter molecules,
such as the Fas-associated death domain-containing protein [FADD] (Karp, 2003; Kroemer et
al., 2007). Oligomerized FADD can then bind the initiator aspartate-specific cysteine proteases
(caspases) -8 and -10, causing their dimerization and activation (Debatin and Krammer, 2004),
which initiate intracellular apoptotic events by proteolytic cleavage and subsequent activation
and/or deactivation of downstream components (Karp, 2003; Kroemer et al., 2007).
The intrinsic pathway, on the other hand, is stimulated by any number of internal stimuli,
such as irreparable genetic damage, high concentrations of cytosolic Ca2+ (i.e., Ca2+
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excitotoxicity), or severe oxidative stress, which lead to the activation of pro-apoptotic
cytoplasmic factors and significant changes to mitochondria [Fig. 2.45] (Karp, 2003). The most
well-known apoptotic factors activated in this pathway are members of the B-cell lymphoma
type-2 (Bcl-2) family of pro- and anti-apoptotic proteins; examples of prominent pro-apoptotic
members include Bax, Bad, and Bid, while prominent anti-apoptotic members include Bcl-XL,
Bcl-W, and Bcl-2 (Karp, 2003). Activation of both anti- and pro-apoptotic factors by internal
death stimuli typically causes the translocation and insertion of these factors from the cytosol
into the outer mitochondrial membrane. At this point, several changes in mitochondrial structure
occur, including the increased production of ROS and RNS, K+ channel activation, significant
Ca2+ ion uptake, swelling, depolarization of membrane potential, increased membrane
permeability, and finally, the release of intermembrane and matrix-resident proteins, such as
cytochrome c, apoptosis inducing factor (AIF), Smac/DIABLO, Omi stress-regulated
endoprotease/high temperature requirement protein A2 (Omi/HtrA2), and at least two DNA
degrading enzymes (Kroemer et al., 2007; Siegel et al., 2006). Thus, the intrinsic pathway is
also called the “mitochondrial pathway” since apoptosis results from an intracellular cascade of
events in which mitochondrial permeabilization plays a crucial role (Scaffidi et al., 1998).
Figure 2.44

Figure 2.44 Overview of apoptosis. Apoptosis can be characterized by the overall
shrinkage of cell volume, the loss of adhesion to neighboring cells, membrane blebbing,
nuclear chromatin condensation and fragmentation, mitochondrial changes, apoptotic
body formation, and apoptotic body lysis if the apoptotic cell is not phagocytized first
(adapted from Yau, 2009).
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Figure 2.45

Figure 2.45 Intrinsic apoptosis. The intrinsic apoptotic pathway is stimulated by internal
stimuli, such as irreparable genetic damage, excitotoxicity, or severe oxidative stress.
Several changes in mitochondrial structure occur, creating three different pathways by
which to amplify the apoptotic pathway, beginning with increased mitochondrial
membrane permeability (MMP) and eventual release of intermembrane and matrixresident proteins, such as cytochrome c (CytC), apoptosis inducing factor (AIF),
Smac/DIABLO, Omi stress-regulated endoprotease/high temperature requirement protein
A2 (Omi/HtrA2), and the DNA degrading enzyme, endoprotease G (EndoG). In path I,
CytC promotes formation of the apoptosome with apoptosis protease activating factor 1
(Apaf-1) and adenosine triphosphate (ATP/dATP) which causes proteolytic cleavage and
subsequent activation of pro-caspase-9 (ProCas-9) to caspases-9 (Cas-9). Active Cas-9
catalyzes the proteolytic activation of the effector caspases, which translocate to the
nucleus contributing to DNA fragmentation and chromatin condensation. In path II,
caspase-independent death effectors, AIF and EndoG, translocate into the nucleus, also
contributing to DNA fragmentation and chromatin condensation.
In Path III,
Smac/DIABLO and Omi/HtrA2 indirectly promote apoptosis by antagonizing members
of the inhibitor of apoptosis protein (IAP) family. Binding of IAPs by Smac/DIABLO
and Omi/HtrA2 serves to promote apoptosis induced by activation of effector caspases
from paths I and II (adapted from Kroemer et al., 2007).
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Formation of permeability transition pores in the mitochondrial membrane (MPTP)
results from the association of voltage-dependent anion channels (VDAC), adenine nucleotide
translocators, cyclophilin D, peripheral benzodiazepine receptors, hexokinase, and creatine
kinase, which is promoted by attachment of pro-apoptotic Bcl-2 family members and prevented
by anti-apoptotic Bcl-2 proteins [Fig. 2.46] (Karp, 2003; Kroemer et al., 2007; Siegel et al.,
2006). Upon release, cytochrome c binds the cytosolic adapter molecule, apoptosis protease
activating factor-1 (Apaf-1), initiating formation of the multi-protein complex, called the
apoptosome, and caspase-dependent apoptosis, while Smac/DIABLO and Omi/HtrA2 bind and
neutralize cytosolic inhibitors of apoptosis proteins (IAPs), initiating caspase-independent
apoptosis [Fig. 2.45] (Kroemer et al., 2007; Siegel et al., 2006). Multimerization and activation
of initiator caspase-9 by the apoptosome, in turn, causes activation of executioner, or effector,
caspases-3, -6, and -7 (Fuentes-Prior and Salvesen, 2004), which mediate proteolytic cleavage of
specific substrates and complete the final phases of the cell‟s destruction. Although most
vertebrate cell death proceeds through the intrinsic apoptotic pathway (Green and Kroemer,
2004), both extrinsic and intrinsic pathways ultimately converge via activation of the same
executioner caspases (Karp, 2003). Moreover, previous studies have shown a certain amount of
cross-talk between these pathways (Krammer, 2000; Scaffidi et al., 1998).
Figure 2.46

Figure 2.46 The mitochondrial permeability transition pore (MPTP). The MPTP is
thought to be composed of multiple proteins, including the voltage-dependent anion
channel (VDAC), adenine nucleotide translocase (ANT), hexokinase (HK), creatine
kinase (CK), peripheral-type benzodiazepine receptor (PBR), and cyclophilin D (CypD).
Both anti-apoptotic Bcl-2 and pro-apoptotic Bax modulate activity of the MPTP, through
direct interactions with ANT and/or VDAC (adapted from Kroemer et al., 2007).

In normal cells, apoptosis is critically involved in the maintenance of tissue homeostasis,
and therefore, must be strictly controlled (Green and Kroemer, 2004). Dysfunction of even one
apoptotic event or protein could pathogenically disable apoptosis, contributing to oncogenesis
and cancer, or lead to unwarranted apoptosis, causing substantial cell loss and disease (Kroemer
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et al., 2007). Excessive apoptosis occurs in a majority of neurodegenerative diseases, as there is
a significant loss of neuronal tissue, especially in Alzheimer disease brain.
2.5.2 Phagocytosis
Completion of the apoptotic process is accomplished through phagocytic engulfment of
late-stage apoptotic cells (Fig. 2.47), which prevents further damage to the environment
surrounding the dying cell. However, before final clearance, apoptotic cells must first expose a
certain signal on their extracellular surface to attract phagocytes to the appropriate location. The
most well-known signal for apoptotic-cell clearance is the exposure of PtdSer onto the outerleaflet of the plasma membrane (see section 2.2.2), which is crucial for selective recognition and
mononuclear phagocytosis of target cells by macrophages and fibroblasts in the periphery, or
microglia in the brain (Fadok et al., 2001; 1992a; Kagan et al., 2003; Schroit et al., 1985).
Several phagocytic receptors have been implicated in the recognition of PtdSer, including the
lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), β2-glycoprotein I (β2GPI)
receptor, αvβ3-vitronectin receptor, Mer receptor tyrosine kinase, and the PtdSer receptor (PSR),
among others (Arur et al., 2003; Balasubramanian et al., 1997; Fadok et al., 2000; 1992b;
Hanayama et al., 2002; Li et al., 2003; Sambrano and Steinberg, 1995; Savill et al., 1990; Scott
et al., 2001).
Figure 2.47

Figure 2.47 Phagocytosis (image courtesy of the U.S. National Library of Medicine,
www.nlm.nih.gov).

Normally, the collapse of PtdSer asymmetry and subsequent phagocytosis is considered a
process balancing the rate of cell death and cell division, in order to maintain cellular
homeostasis. However, under conditions of oxidative stress, for example, an abnormal amount
of apoptosis and extracellular exposure of PtdSer is observed (Kagan et al., 2000; 2002; Martin
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et al., 1995; Tyurina et al., 2004a; 2004b), such as in the Alzheimer disease brain, which is
discussed in the following sections. Chapters 4 and 5 of this dissertation will focus on the
relationship between PtdSer exposure, apoptosis, and oxidative stress in Alzheimer disease brain.
2.6 Alzheimer Disease (AD)
AD is an age-associated, largely sporadic, neurodegenerative disorder clinically
diagnosed by the vast, progressive loss of memory and cognition commonly in subjects over the
age of 65 (Price et al., 1998). Neuropathologically, this dementing disorder can be characterized
by synapse and neuronal cell loss in conjunction with the appearance and accumulation of
neurofibrillary tangles (NFTs) and senile (or neuritic) plaques (SPs), whose composition consists
largely of amyloid-β peptide (1-42) [Aβ(1-42)] (section 2.6.2). A hallmark of AD is wide-spread
oxidative stress and damage to brain proteins, lipids, and nucleic acids [see section 2.4]
(Aksenov et al., 2001; Butterfield, 2002; Butterfield et al., 2007a; Castegna et al., 2003; 2002a;
Hensley et al., 1995; Lyras et al., 1997; Markesbery, 1999; Perluigi et al., 2009; Smith et al.,
1997; Sultana et al., 2006a; 2006b; Varadarajan et al., 2000), as well as increased production of
reactive aldehydes, like HNE, within the lipid bilayer [see section 2.4.2] (Butterfield, 2002;
Butterfield et al., 2002b; 2006c; Lauderback et al., 2001; Lovell et al., 2001; Markesbery and
Lovell, 1998; Perluigi et al., 2009; Williams et al., 2006). This dementing disorder was first
described in 1907 by Alois Alzheimer from a patient experiencing rapid memory loss and
disorientation. Following post-mortem autopsy of the patient‟s brain, Alzheimer found a
significant reduction in brain mass, especially the hippocampus, as well as a substantial amount
of what are now known as NFTs and SPs by histopathological analyses (Fig. 2.48). Because the
hippocampus is primarily responsible for memory function and processing, and is often the first
area of the brain to succumb to AD pathogenesis, it is not surprising that this disease affects
cognition to such a devastating degree.
Figure 2.48

Figure 2.48 Alzheimer disease (AD) brain histopathology. Silver stains of A) senile
plaques (SPs) and B) neurofibrillary tangles (NFTs).

NFTs are composed of paired helical filaments of the hyperphosphorylated microtubuleassociated protein (MAP), tau, which is almost exclusively expressed in the brain (Brandt and
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Lee, 1993). Microtubules play an important role in various cellular functions, including mitosis,
intracellular transport, and maintenance of cell shape. MAPs, such as tau, aid microtubule
assembly by nucleation. Tau is particularly enriched in axons (Binder et al., 1985; Brion et al.,
1988; Kowall and Kosik, 1987; Trojanowski et al., 1989) and plays a major role in the
development of axonal morphology (Caceres and Kosik, 1990; Caceres et al., 1991). Routine
phosphorylation of tau is necessary to its function in the control of microtubule assembly and
stability, as well as intracellular axonal transport (Brandt and Lee, 1993; Cleveland et al., 1977;
Weidemann et al., 1989); however, hyperphosphorylation of tau results in the formation and
intracellular accumulation of neurotoxic NFTs [Fig. 2.49] (Butterfield et al., 2006d; 1986a;
Grundke-Iqbal et al., 1986b; Iqbal et al., 2000; Roder et al., 1993).
Figure 2.49

Figure 2.49 Formation of neurofibrillary tangles (NFTs). NFTs are composed of paired
helical filaments of the hyperphosphorylated microtubule-associated protein, tau. In
Alzheimer disease brain, NFTs accumulate into neurotoxic “clumps” or tangles (image
courtesy of the Alzheimer's Disease Education and Referral Center).

In rare cases, AD pathology can begin as early as ~30 years of age due to autosomal
dominant missense mutations in the amyloid precursor protein (APP; chromosome 21) or
presenilin (PS) genes 1 (chromosome 14) and/or 2 [chromosome 1] (Citron et al., 1992;
Scheuner et al., 1996; Sturchler-Pierrat et al., 1997; Wisniewski et al., 1998), with a mutation in
PS-1 being more aggressive. APP is a transmembrane protein that functions in neuronal
plasticity, long term potentiation, and memory loss (Turner et al., 2003). However, APP is most
well-known for its role in pathologic production of the cleavage product, Aβ. Because
presenilins are involved in APP processing (Selkoe et al., 1996), mutations in APP and PS-1 or
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PS-2 result in the increased production of pathologic Aβ(1-40) and Aβ(1-42) [section 2.6.2]
(Borchelt et al., 1997; Cai et al., 1993; Oyama et al., 1998; Scheuner et al., 1996). Thus,
missense mutations in PS-1 or PS-2 are gain-of-function. Presenilins are a group of conserved
integral membrane proteins that have been shown to interact with and proteolytically cleave a
number of different proteins, including catenins (Georgakopoulos et al., 1999; Yu et al., 1998;
Zhou et al., 1997), cadherins (Georgakopoulos et al., 1999), Notch receptors (Baumeister et al.,
1997; De Strooper et al., 1999; Struhl and Greenwald, 1999), APP proteins (Xia et al., 1997;
1998), and γ-secretases. Interestingly, PS-1 is known to participate in the γ-secretase-associated
cleavage of APP into Aβ (section 2.6.2), either as part of a proteolytic complex with γ-secretase,
as a diaspartyl cofactor for γ-secretase, or actually is the γ-secretase which cleaves APP directly
(Naruse et al., 1998; Thinakaran et al., 1998; Wolfe et al., 1998; 1999a; 1999b; Xia et al., 1997).
Hence, presenilins (PS-1 in particular) may play a crucial role in the proteolytic turnover of the
transmembrane domains of a variety of single-pass integral membrane proteins, thus
participating in a variety signal transduction events and possibly even mediating apoptosis
(reviewed in Selkoe, 2001a).
2.6.1 Mild Cognitive Impairment (MCI)
MCI is considered a transition point between normal cognitive aging and probable AD
(Petersen et al., 1999; Winblad et al., 2004), as this disease displays similar pathology to AD at
its earliest stages, although to a much lesser extent. Diagnostic criteria include a lack of
dementia, but a slight cognitive deficit that has not significantly disturbed the subject‟s activities
of daily living (Petersen et al., 1999). There are two broad subtypes of MCI: amnestic MCI
(aMCI), in which subjects exhibit significant memory impairment as per the diagnostic criteria of
MCI; and non-amnestic MCI, in which subjects do not present a significant memory deficit
(Economou et al., 2007; Petersen, 2004; Portet et al., 2005). Hence, aMCI is arguably the
earliest form of AD, and is, therefore, the subtype of interest to this dissertation. Other brain
functions, such as language, attention, and viseospatial skills may also be impaired in either MCI
subtype.
Pathologically, MCI brain shows mild degradation of the hippocampus, entorhinal cortex,
sulci, and gyri, though not as pronounced as in AD brain [Fig. 2.50] (Barnes et al., 2007;
Devanand et al., 2007; Du et al., 2001; 2004; Jack et al., 1999; Mevel et al., 2006; Mori, 2005).
SPs and NFTs are significantly elevated in aMCI brain compared to normal age-matched control
individuals, but their levels are significantly lower when compared to AD brain (Markesbery et
al., 2006). Interestingly, the rate of aMCI patient conversion to full-onset AD is ~10-15% per
year (Maioli et al., 2007; Rozzini et al., 2007), although some aMCI individuals have been
shown to revert to a normal clinical phenotype (Petersen, 2000). Furthermore, aMCI brain has
also been reported to have elevated levels of oxidative stress (2006b; Butterfield et al., 2006c;
2007b; Keller et al., 2005; Lovell and Markesbery, 2007; Markesbery and Lovell, 2007;
Markesbery et al., 2005; Reed et al., 2008a; 2008b).
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Figure 2.50

Figure 2.50 Pathological effects of Alzheimer disease (AD) progression. Compared to a
A) normal brain, B) mild cognitive impairment (MCI) brain shows mild degradation of
the hippocampus, entorhinal cortex, sulci, and gyri, and moderate enlargement of the
ventricles; although these features are not as pronounced as those found in AD brain
(image adapted from the Alzheimer's Disease Education and Referral Center).
2.6.2 The Amyloid-β (Aβ) Peptide
As previously mentioned, Aβ is a proteolytic product of APP cleavage produced in large
quantities during the progression of AD, eventually accumulating as the main component of SPs.
In particular, cleavage of APP by both β-secretase (N-terminus) and γ-secretase (C-terminus)
enzymes results in the formation of Aβ(1-40) and/or Aβ(1-42) [Fig. 2.51]. In particular, it is the
longer, more hydrophobic Aβ(1-42) that is toxic in AD (Drake et al., 2003a; Lambert et al.,
1998; Mattson, 1997), as it is considerably more prone to oligomerization and subsequent fibril
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formation than the more abundantly produced Aβ(1-40) (Burdick et al., 1992; Jarrett et al.,
1993). Whereas Aβ(1-42) deposits as the main component of SPs, Aβ(1-40) deposits as the main
component of soluble diffuse plaques. Similar to ROS and RNS produced en masse in AD and
aMCI brain, Aβ(1-42) oligomers have been shown to initiate direct lipid peroxidation and
indirect protein oxidation events [Fig. 2.52] (Butterfield, 2002; Butterfield et al., 2007a; Lambert
et al., 1998; Lauderback et al., 2001; Schubert et al., 1995; Selkoe, 2001b) by integrating into the
membrane and/or binding to its surface (Hertel et al., 1997; Kayed et al., 2004; McLaurin and
Chakrabartty, 1997) and increasing bilayer permeability and conductance by altering its
dielectric structure (Arispe and Doh, 2002; Demuro et al., 2005; Kayed et al., 2004; Muller et al.,
1995; Sokolov et al., 2006).
Figure 2.51

Figure 2.51 Formation of the amyloid-β (Aβ) peptide. A) & B) Proteolytic cleavage of
the membrane-bound amyloid precursor protein (APP) by β- and γ-secretases results in
the production of Aβ. C) Aβ(1-40) is the main component of soluble, diffuse plaques,
while Aβ(1-42) is the main component of senile plaques. Both Aβ(1-40) and Aβ(1-42)
are produced in large quantities during the progression of Alzheimer disease (AD) [image
courtesy of the Alzheimer's Disease Education and Referral Center].
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Figure 2.52

Figure 2.52 The amyloid-β (Aβ)-induced oxidative stress hypothesis. Similar to reactive
oxygen species (ROS) and reactive nitrogen species (RNS) which are mass produced in
Alzheimer disease and amnestic mild cognitive impairment, Aβ(1-42) oligomers have
been shown to initiate direct lipid peroxidation and indirect protein oxidation events,
leading to neuronal cell death. APP, amyloid precursor protein (adapted from Butterfield
et al., 2010).
Aβ(1-42) readily inserts itself into the hydrophobic interior of the lipid bilayer by
adopting an α-helical formation. Previous studies from the Butterfield laboratory and others
have shown that in vitro and in vivo Aβ(1-42) results in elevated protein oxidation and lipid
peroxidation (Abdul et al., 2008; Boyd-Kimball et al., 2005b; Drake et al., 2003a; Mohmmad
Abdul et al., 2006; Resende et al., 2008; Zhu et al., 2008), which has been linked to a single
methionine residue at position 35 of Aβ (residue 631 of human APP) [Fig. 2.53]. Substitution of
the Met-35 sulfur (S)-atom with a norleucine (Nle) CH2 group in human Aβ(1–42) abrogates the
oxidative and neurotoxic effects of the resulting peptide in cultured neurons, while maintaining
similar length, hydrophobicity, and tendency to aggregate as native human Aβ(1-42) [Fig. 2.53]
(Boyd-Kimball et al., 2005b; Varadarajan et al., 2001; Yatin et al., 1999). In Caenorhabditis
elegans, substitution of the Met codon with a cysteine codon in DNA encoding human Aβ(1-42)
prevents in vivo protein oxidation, while not affecting Aβ(1-42) accumulation and plaque
deposition (Yatin et al., 1999).
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Figure 2.53

Figure 2.53 Amyloid-β (Aβ) amino acid sequence. Previous studies have shown that in
vitro and in vivo Aβ(1-42) results in elevated levels of oxidative stress due to a single
methionine residue at position 35 (Met-35; M) of Aβ. Substitution of the Met-35 sulfur
(S)-atom with a norleucine (Nle) CH2 group in human Aβ(1–42) abrogates the oxidative
and neurotoxic effects of the resulting peptide in cultured neurons, while maintaining
similar length, hydrophobicity, and tendency to aggregate as native human Aβ(1-42)
(Boyd-Kimball et al., 2005b; Varadarajan et al., 2001; Yatin et al., 1999). In
Caenorhabditis elegans, substitution of the Met-35 S-atom with a cysteine (C) thiol
group in human Aβ(1-42) prevents in vivo oxidative stress (Yatin et al., 1999).
It has been proposed that Aβ-induced oxidative stress is dependent on the formation of a
S-centered, transient free radical on Met-35 (Boyd-Kimball et al., 2004; Butterfield and BoydKimball, 2005; Kanski et al., 2002; Varadarajan et al., 2001; Yatin et al., 1999). According to
the "i+4" rule of α-helices, a lone-pair of oxygen electrons from the backbone carbonyl of
isoleucine 31 (Ile-31) is within Van Der Waals distance of the Met-35 S-atom (Fig. 2.54). This
has been confirmed by Nuclear Magnetic resonance [NMR] (Riek et al., 2001). The electronwithdrawing effect of the oxygen lone-pair redistributes the sulfur‟s electron-density (towards
the oxygen), making the Met-35 S-atom more susceptible to a one-electron oxidation event
which would create a sulfuranyl radical cation on Met-35 (Kanski et al., 2002). A small amount
of sulfuranyl radical on Aβ(1–42) can become greatly amplified by a series of chain reactions
within the hydrophobic intermembrane space of the bilayer, initiated by abstraction of an allylic
hydrogen (H)-atom from unsaturated fatty acyl chains of lipids by the sulfuranyl radical [Fig.
2.55] (Varadarajan et al., 2001). As long as allylic H-atoms are available, this Met-35-induced
radical chain reaction can continuously produce lipid peroxidation products, such as HNE (see
section 2.4.5.1), and oxidatively modify membrane proteins [Fig. 2.55b] (Lauderback et al.,
2001; Mark et al., 1997). Because this chain reaction inevitably regenerates the reduced form of
Met-35, which can again undergo one-electron oxidation, this process is considered catalytic
(Fig. 2.55). Consequently, oligomeric Aβ(1-42) could be a major contributor to the oxidative
stress and damage observed in AD and aMCI brain.
66

Figure 2.54

Figure 2.54 The interaction between isoleucine 31 (Ile-31) and methionine 35 (Met-35)
of the amyloid-β (Aβ) peptide. In order to integrate into the membrane, Aβ must be in an
α-helical conformation. Thus, according to the "i+4" rule of α-helices, a lone-pair of
oxygen (O) electrons from the backbone carbonyl of Ile-31 is within Van Der Waals
distance of the Met-35 sulfur (S)-atom. The electron-withdrawing effect of the oxygen
lone-pair redistributes the sulfur‟s electron-density (towards the oxygen), making the Satom more susceptible to a one-electron oxidation, which would create a sulfuranyl
radical cation on Met-35 (Kanski et al., 2002). Data were obtained from the RCSB
protein data bank as entry code 1Z0Q.pdb, DOI: 10.2210/pdb1z0q/pdb. This figure was
drawn using the DeepView Swiss-PDB viewer program, version 4.0.
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Figure 2.55

Figure 2.55 Proposed reaction mechanism of amyloid-β (Aβ)-induced oxidative stress.
A) Following “priming” of the methionine 35 (Met-35) sulfur (S)-atom by the backbone
carbonyl oxygen of isoleucine 31, the S-atom becomes susceptible to one-electron
oxidation by any number of oxidants to form a sulfuranyl radical cation. The sulfuranyl
radical quickly abstracts an allylic hydrogen (H)-atom from the unsaturated fatty acyl
chains of lipids within the bilayer. Following H-atom abstraction, the radical
.
protein/lipid product (R ) can B) proceed to react with other nearby proteins and lipids,
while the A) extremely acidic Met-35 cationic compound (pKa -5) readily reacts with any
base, including water, removing the acidic H-atom and reforming reduced Met-35
(Varadarajan et al., 2001). This process is catalytic since the newly reduced Met-35 can
again undergo a one-electron oxidation.
Copyright © Miranda Lu Lange, 2010
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CHAPTER 3
MATERIALS & METHODS
3.1 Control, Mild Cognitive Impairment (MCI), & Alzheimer Disease (AD) Brain
Frozen inferior parietal lobule (IPL) brain samples from subjects with amnestic mild
cognitive impairment (aMCI; n=5), late-stage Alzheimer disease (AD; n=5), and age-matched
controls (n=5) with post-mortem intervals (PMI) ranging from 2.8 h to 3.4 h were obtained from
the University of Kentucky Rapid Autopsy Program of the Alzheimer Disease Clinical Center
(UK ADC; Tables 3.1 & 3.2). All AD patients exhibiting significant cognitive decline met the
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer
Disease and Related Disorders Association (NINCDS-ARDA) Workgroup criteria for clinical
diagnosis of probable AD (McKhann et al., 1984) and also displayed progressive intellectual
decline (Table 3.2). All age-matched control subjects in both the aMCI and AD
phosphatidylserine (PtdSer) asymmetry studies were without a history of dementia or other
neurological disorders and underwent annual mental status testing and semi-annual physical and
neurological exams as part of the UK ADC normal volunteer longitudinal aging study, and had
test scores in the normal range (Tables 3.1 & 3.2). Brain tissue and demographics used for the
AD PtdSer asymmetry study were described previously (Butterfield et al., 2006c). Additional
demographic parameters of controls and subjects with aMCI and AD without personal identifiers
were made available by the UK ADC and are provided in Tables 3.1 and 3.2.
Table 3.1 Characteristics of control and amnestic mild cognitive
impairment (aMCI) patients available from medical records.
Parameters:
Control Subjects aMCI Subjects
Demographic Variables
Number of subjects
Gender (male/female)
Age at death (yrs)a
PMI (h)a
Brain Weight (g)a
Braak Stage
a

5
2/3
82 ± 2.6
2.87 ± 1.14
1260 ± 120
I-II

(mean ± S.D.); PMI, post-mortem interval.
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5
2/3
88 ± 1.5
3.125 ± 1.033
1120 ± 61
III-V

Table 3.2 Characteristics of control and Alzheimer disease (AD) patients available
from medical records.
Parameters:
Control Subjects
AD Subjects
Demographic Variables
Number of subjects

5

5

3/2

3/2

Age at death (yrs)a

87.0 ± 3.94

85.8 ± 6.02

PMI (h)a
MMSE; number of months
prior to death test takena
APOE genotype, if known (n)

2.9 ± 0.70

3.4 ± 1.4

28 ± 0.8; 6.6 ± 1.4

15.7 ± 2.6; 6.6 ± 1.4

3/3 (3) 3/4 (2)
surgery complications,
cardiac failure; COPD

ND
surgery complications,
cardiac failure; COPD

Gender (male/female)

Cause of death
a

(mean ± S.D.); AD, Alzheimer disease; PMI, post-mortem interval; MMSE, Mini-Mental
State Examination; APOE, apolipoprotein E; ND, not determined; n, number of
individuals; COPD, Chronic Obstructive Pulmonary disease (adapted from Sultana et al.,
2006b).

3.2 Animal Procedures
3.2.1 Post-Mortem Interval (PMI) Mice
All procedures using mice for PMI studies were approved by the University of Kentucky
Animal Care and Use Committee. Six male FBV/N mice (Harlan Laboratories Inc.,
Indianapolis, IN) were euthanized with CO2 in a chamber until death and quickly placed in a
Styrofoam™ box containing two 710 ml bottles of water at ~37 °C, in order to delay post-mortem
cooling of the brain and more closely approximate the human brain cooling curve (Geddes et al.,
1986; Schwab et al., 1994). After intervals of 2.8 h and 3.4 h, whole mouse brains, excluding
cerebellum, were isolated and frozen at −80 °C until use. These PMIs were chosen based on the
minimum and maximum human brain PMIs obtained from the UK ADC found in Tables 3.1 and
3.2. Three additional mice were euthanized with CO2 in a chamber until death, and whole brain
tissue was rapidly removed, excluding cerebellum, to represent a 0 h PMI (i.e., fresh samples).
Synaptosomes from fresh 0 h (n=3) and thawed 2.8 h (n=3) and 3.4 h (n=3) mouse brain were
processed simultaneously.
3.2.2 APP/PS-1 Knock-In Mice
The University of Kentucky Animal Care and Use Committee approved all procedures
using APP/PS-1 mice. All mice used in this study were male. APPNLh/APPNLh x PS-1P264L/PS1P264L human double mutant knock-in mice were generated using Cre-loc© knock-in technology
(Cephalon Inc., Frazer, PA) to humanize the mouse Aβ sequence (NLh), and create a presenilin-1
(PS-1) proline to leucine mutation on codon 264 [P264L] (Reaume et al., 1996; Siman et al.,
2000), thus, creating a mammalian model of amyloid-β (Aβ) pathology commonly found in
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familial AD (FAD) that yields proper cleavage of the amyloid precursor protein (APP) in order
to generate Aβ peptides (Flood et al., 2002). Gene expression produced by crossing APPNLh and
PS-1P264L knock-in mice is driven by endogenous promoters of both the APP and PS-1 genes.
Therefore, expression is limited by replacement of these genes and not by expression of multiple
transgenes (Anantharaman et al., 2006). APP/PS-1 mice were maintained on a CD-1/129
background. Five age-groups for both wild-type (WT) and APP/PS-1 mice were used (1, 3, 6, 9,
and 12 months-old) to examine Aβ pathology (n=5 for all age groups, except 1 month-old mice,
n=23) and PtdSer asymmetry (n=5 for all age groups, except 6 month-old mice, n=8) with age.
Whole brain tissue was isolated and frozen at -80 oC until use.
3.2.3 PDAPP Transgenic Mice
All studies using PDAPP transgenic mice were approved by the Institutional Animal Care
and Use Committee (IACUC) of the Buck Institute for Age Research (Novato, CA), and carried
out in the Buck Institute‟s Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC)-accredited vivarium. All mice used in this study were male. PDAPP(M631L)
mice were derived directly in the C57BL/6J genetic background using the same approach as
described previously (Galvan et al., 2006; Mucke et al., 2000). Briefly, a mutation was
introduced into the platelet-derived growth factor (PDGF) β-chain promoter-driven human APP
minigene, carrying the Swedish (K670N and M671L) and Indiana (V717F) familial AD (FAD)
mutations, that mutated methionine 631 (APP695 numbering) to leucine, generating
PDAPP(M631L) transgenic (Tg) mice by direct injection into C57BL/6J embryos. The PDGF βchain promoter-driven APPSw,In minigene and J20 line of PDAPP mice, without the M631L
substitution, were developed and provided by Professor Lennart Mucke at the University of
California (San Francisco, CA) as previously described (Mucke et al., 2000), and kept in their
original C57BL/6J background. Tg PDAPP(M631L) mice express the PDAPP(Sw,In,M631L)
transgenes to levels 12.5% higher than those of the PDAPP(Sw,In) transgene in the J20 line. All
Tg lines were maintained by heterozygous crosses with C57BL/6J breeders (Jackson
Laboratories, Bar Harbor, ME); thus, all Tg animals were heterozygous with respect to the
transgene. Non-transgenic (Non Tg) littermates from each Tg line, J20 and M631L, were used
as controls in all studies related to PDAPP mice.
Whole mouse brain tissue was extracted and frozen at -80 oC by the Bredesen laboratory
at the Buck Institute for Age Research (Novato, CA) and one-half on each brain sent to the
Butterfield laboratory at the University of Kentucky (Lexington, KY), where they remained at 80 oC until used. Experimental groups of animals were as follows: Tg PDAPP(J20) [n=10]; Tg
PDAPP(M631L) [n=10]; Non Tg PDAPP (n=5); Non Tg M631L (n=5).
3.3 Experimental Materials
For all PtdSer asymmetry studies in this dissertation, synaptosomes were prepared from
either whole mouse brain tissue or the IPL tissue from brain of subjects with AD and aMCI, as
described below (section 3.4.1). All other studies incorporated whole or half mouse brain tissue
homogenate. All chemicals, proteases, and antibodies used in all of the following experiments of
this chapter were purchased from Sigma-Aldrich (St. Louis, MO) unless noted otherwise. All
Criterion precast polyacrylamide gels (1D and 2D), Tris/Glycine/Sodium dodecyl sulfate (TGS)
and XT 2-(N-morpholino)ethanesulfonic acid (MES) electrophoresis running buffer,
ReadyStrip™ immobilized pH gradient (IPG) strips, mineral oil, Precision Plus Protein™
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standards, overlay agarose, SYPRO Ruby® Protein Stain, and nitrocellulose membranes (0.45
μm) were purchased from Bio-RAD (Hercules, CA).
3.4 Sample Preparation
3.4.1 Synaptosome Preparation
Synaptosomes are commonly used in studies of the brain as a complete model of a
functional synapse. This rather simplistic model system contains a continuous plasma membrane
with functional pumps and channels capable of ion exchange, readily responds to depolarization
in either a Ca2+-dependent or Ca2+–independent manner, and retains subcellular organelles such
as mitochondria. Furthermore, aminophospholipid translocase activity has been demonstrated
previously in synaptosomes (Zachowski and Gaudry-Talarmain, 1990). Therefore,
synaptosomes provide a reliable in vitro model of neuronal PtdSer asymmetry, among other
synaptic processes (Whittaker, 1993).
Synaptosome fractions from mouse and human brain were prepared as previously
described (Mohmmad Abdul and Butterfield, 2005; Whittaker, 1959; 1968), with exceptions.
Brain tissue was homogenized in a Wheaton glass homogenizer (~100 passes) and suspended in
isolation buffer (0.32 M sucrose, 0.2 mM PMSF, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 4
g/ml leupeptin, 4 g/ml pepstatin, 5 g/ml aprotinin, and 20 g/ml trypsin inhibitor; pH 7.4);
from this initial homogenate, a small aliquot was reserved for protein expression studies
described below (sections 3.7.1 & 3.8.1). The homogenate was then centrifuged at 4000 rpm
(1940 x g) in a Beckman J2-MI high-speed centrifuge (JA-20 rotor; Beckman-Coulter, Fullerton,
CA) for 10 min at 0 oC and the supernatant (S1) decanted. Due to the precious nature of human
brain tissue and the small sample size of human IPL provided, this first pellet (P1) was saved
during preparation of human synaptosomes, re-homogenized in isolation buffer, and again,
centrifuged at 4000 rpm (1940 x g) in a Beckman J2-MI high-speed centrifuge (JA-20 rotor;
Beckman-Coulter, Fullerton, CA) for 10 min at 0 oC in order to extract an optimal amount of
crude synaptosomes. Following centrifugation, this second pellet (P2) was discarded, while the
new supernatant (S2) was mixed with S1. It should be noted, however, that preservation of P1
was not necessary in preparation of mouse synaptosomes, as a larger sample size was available
(i.e., whole mouse brain) and a sufficient amount of crude synaptosomes was extracted after the
initial centrifugation.
In order to ultra-purify synaptosomes, the supernatant (S1, for mice; S1+S2, for human)
was centrifuged at 14,800 rpm (25,400 x g) for 12 min at 0 oC. The resulting pellet from both
tissue types was mixed with 1 ml of cold isolation buffer and layered onto cold discontinuous
sucrose gradients containing 10 ml each of 1.18 M (pH 8.5), 1.0 M (pH 8.0), and 0.85 M (pH
8.0) sucrose, as well as 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES. Gradients were
centrifuged in a Beckman Optima L-90K ultracentrifuge (SW-28 rotor; Beckman-Coulter,
Fullerton, CA) at 22,000 rpm (82,500 x g) for 1 h at 4 oC. The resulting ultra-purified
synaptosomes were removed from the 1.18/1.0 M sucrose interface and washed three times in
Locke‟s buffer (0.15 M NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 3 mM NaHCO3, 5 mM
glucose, 5 mM HEPES; pH 7.4) at 15,500 rpm (29,100 x g) for 12 min each at 0 oC in a Hettich
Mikro 22 R microcentrifuge (Hettich, Beverly, MA). Protein concentrations were determined
according to the Pierce BCA method described below (section 3.5).
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3.4.2 Whole & Half Brain Tissue Preparation
Whole or one-half mouse brain samples were homogenized using a Wheaton glass
homogenizer (~100 passes) in 1 ml of Media I buffer (0.32 M sucrose, 0.10 mM Tris-HCl [pH
8.0], 0.10 mM MgCl2, 0.08 mM EDTA, 10 g/ml leupeptin, 0.5 g/ml pepstatin, and 11.5 g/ml
aprotinin; pH 8.0). Homogenates were vortexed to equilibrate, aliquotted into Eppendorf
microcentrifuge tubes, and sonicated with a Fisher Scientific 550 Sonic Dismembrator (Fisher
Scientific, Pittsburgh, PA) for 10 s at 20% power. Protein concentrations were determined
according to the Pierce BCA method described below (section 3.5).
3.5 Bicinchoninic Acid (BCA) Protein Assay
All protein concentrations in this dissertation were determined using the Pierce
Bicinchoninic acid (BCA) Protein Assay (Pierce, Rockford, IL). This method combines the
Biuret reaction, used for detection of peptide bonds, with the colorimetric detection of the
cuprous cation (Cu+) by BCA (Smith et al., 1985). In this assay, proteins mediate the reduction
of Cu2+ to Cu+ through amino acids, such as cysteine or cystine, tryptophan, and tyrosine, and
peptide bonds in an alkaline environment (Smith et al., 1985; Wiechelman et al., 1988). The
reduced Cu+ subsequently forms a soluble chromophoric complex with two BCA molecules (Fig.
3.1), turning the solution purple and exhibiting strong linear absorbance at a wavelength of 562
nm (Smith et al., 1985). In this colorimetric assay, the intensity of the purple color is directly
proportional to the protein concentration; therefore, determination of the protein concentration
can be calculated with the Beer-Lambert law (A=εlc), using bovine serum albumin (BSA) to
develop a standard curve. Duplicate samples (2–5 μl) are diluted to 100 μl in a clear polystyrene
fluorescence assay plate (non-treated, non-sterile, flat-bottom; Evergreen Scientific, Los
Angeles, CA) with a 49:1 mix of Peirce BCA reagents A and B (Pierce, Rockford, IL),
respectively. After incubation at 37 oC for 10 min, sample absorbance is determined using a
BIO-TEK μ-Quant UV plate reader (562 nm) [BIO-TEK, Winooski, VT].
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Figure 3.1

Figure 3.1 Bicinchoninic acid (BCA) protein assay. Proteins mediate reduction of Cu2+
to Cu+ via amino acids and peptide bonds. Reduced Cu+ subsequently forms a purple
chromophoric complex with two BCA molecules, which exhibits strong absorbance at
562 nm. Color intensity is directly proportional to protein concentration using the BeerLambert law (A=εlc).

3.6 Phosphatidylserine (PtdSer) Asymmetry Assays
3.6.1 Annexin V (AV) Fluorescence
This assay was conducted as described previously (Castegna et al., 2004; Kuypers et al.,
1996) to directly study externalization of PtdSer, with exceptions. Synaptosome samples (200
g) from human and mouse brain were covered and incubated for 5 min at 37 oC in Annexin
binding buffer (ABB) [10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2; pH 7.4] and fluorescein
isothiocyanate (FITC)-labeled AV (Invitrogen Molecular Probes, Eugene, OR). Samples were
then washed twice with ABB at 14,000 rpm (23,700 x g) for 5 min at 4 oC in a Hettich Mikro 22
R microcentrifuge (Hettich, Beverly, MA), and resuspended in ABB (200 l). After
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resuspension, samples were loaded in duplicate onto a Costar black polystyrene fluorescence
assay plate (non-treated, non-sterile, flat-bottom; Corning Inc., Corning, NY) where residual
fluorescence was measured in a Molecular Devices SpectraMAX Gemini fluorescence plate
reader (Ex/Em: 494/518 nm) [Molecular Devices, Sunnyvale, CA]. Exposed PtdSer is detected
through its high binding affinity for AV, a phospholipid binding-protein coupled with a FITC
(Fig. 3.2) fluorescent tag, leading to increased fluorescence for samples in which the AV probe
has bound outer-leaflet exposed PtdSer.
Figure 3.2

Figure 3.2 Structure of the fluorescein isothiocyanate (FITC) fluorescent probe. FITC is
a basic fluorescein molecule functionalized with an isothiocyanate reactive group (–
N=C=S) at one of two hydrogen atoms on the bottom ring of the structure, and is reactive
towards primary amine groups on proteins, peptides, and other biomolecules. When
coupled with AV, this fluorophore provides the basis of PtdSer outer-leaflet detection in
the AV assay (λEx/Em: 494/518 nm).

3.6.2 NBD-PS Fluorescence
This assay was used to indirectly study externalization of the membrane phospholipid,
PtdSer. Synaptosome fractions (200 μg) from human and mouse brain were prepared for NBDPS [1-palmitoyl-2-[6(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl-sn-glycero-3phosphoserine] (Avanti Polar Lipids, Alabaster, AL) fluorescent assay as previously described
(Comfurius et al., 1996; McIntyre and Sleight, 1991), with exceptions. This particular probe was
chosen because flippase enzymes (which unidirectionally transport PtdSer inward against its
concentration gradient) are most sensitive to head group structure and relatively insensitive to
acyl chain composition (Daleke and Lyles, 2000); therefore, the fluorescent NBD group attached
to the fatty acyl tail would not interfere with the translocating activity of flippase enzymes and
maintain validity of results. Samples were covered and incubated for 1 h at 37 oC with NBD-PS
(2 μg/mg), a PtdSer with a fluorescent NBD group attached (Fig. 3.3a), then washed twice with
Locke‟s buffer (pH 7.4) at 14,000 rpm (23,700 x g) for 5 min at 4 oC in a Hettich Mikro 22 R
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microcentrifuge (Hettich, Beverly, MA). After resuspension in Locke‟s buffer (200 l), samples
were loaded in duplicate onto a Costar black polystyrene fluorescence assay plate (non-treated,
non-sterile, flat-bottom; Corning Inc., Corning, NY) and treated with 7.5 mM sodium dithionite
(Na2S2O4) to quench fluorescence by reduction of any exposed, NBD-labeled PtdSer (Fig. 3.3b).
Loss of residual fluorescence was measured in a Molecular Devices SpectraMAX Gemini
fluorescence plate reader (Ex/Em: 460/514 nm) [Molecular Devices, Sunnyvale, CA].
This assay leads to a decrease in measured fluorescence for samples in which the NBDPS probe has successfully integrated into the membrane bilayer and has been subsequently
exposed onto the outer leaflet, where membrane impermeable S2O42- can chemically convert the
fluorescent NBD group into a non-fluorescent, 7-amino derivative [Fig. 3.3b] (McIntyre and
Sleight, 1991). Extracellular exposure of NBD-PS is interpreted as a consequence of the cell‟s
inability to maintain PtdSer asymmetry, as PtdSer is preferentially sequestered onto the innerleaflet of the bilayer in non-apoptotic cells. This assay has the value-added characteristic of
addressing potential concerns related to AV-associated probe access to the inner leaflet of an
unstable system, possibly creating an incorrect interpretation of asymmetric collapse, since
highly ionic S2O42- does not readily diffuse through the bilayer (McIntyre and Sleight, 1991). On
the other hand, although this method has been extensively tested, it should be noted that, as with
all experimental techniques, the NBD-PS assay does have potential limitations. For example,
this assay is carried out under the assumption that exogenous NBD-PS acts relatively identical to
endogenous PtdSer. However, the ability of NBD-PS to efficiently integrate into the outer
membrane leaflet during the 1 h pre-incubation period can vary from sample to sample; the rate
at which NBD-PS integrates into the membrane may be faster in some cells and slower in others,
depending on the inherent fluidity of each cell membrane to begin with.
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Figure 3.3

Figure 3.3 NBD-PS fluorescence assay. A) NBD-PS structure. This NBD-PS probe was
chosen because flippase enzymes (which unidirectionally transport PtdSer inward against
its concentration gradient) are most sensitive to head group structure and relatively
insensitive to acyl chain composition (Daleke and Lyles, 2000); therefore, the fluorescent
NBD group attached to the fatty acyl tail would not interfere with the translocating
activity of flippase enzymes. B) Na2S2O4 quenching of NBD-PS. The highly
electronegative NO2 functional group of the NBD moiety delocalizes electrons located
within the conjugated ring system to which it is attached. Reduction of this NO2 group to
NH2 (electron-donating) by the dithionite ion (S2O42-) alters the electronic transitions of
this NBD-analogue, thereby altering its fluorescence properties in quenching existing
fluorescence [λEx/Em: 460/514 nm] (McIntyre and Sleight, 1991).
3.6.3 Mg2+ATPase Activity
Determination of Mg2+ATPase activity in human and mouse brain was employed to
indirectly represent the activity of the adenosine triphosphate (ATP)-dependent, membranebound enzyme flippase, as highly specific antibodies to flippase have not yet been obtained
(Auland et al., 1994). Although flippase is known to transport both PtdSer and
phosphatidylethanolamine (PtdEtn) [Fig. 2.10] inward against their concentration gradients,
PtdEtn transport is 10-fold slower (Daleke and Lyles, 2000). This assay was completed
77

according to previous procedures (Castegna et al., 2004; Sadrzadeh et al., 1993), with few
exceptions. Synaptosome samples (7.5 μg) suspended in ATPase assay buffer (18 mM Histidine,
18 mM Imidazole, 80 mM NaCl, 15 mM KCl, 3 mM MgCl2, 0.1 mM EGTA; pH 7.1) were
covered and incubated with 0.1 mM of the Na+/K+ATPase inhibitor Ouabain in a clear
polystyrene microtiter plate (non-treated, non-sterile, flat-bottom; Evergreen Scientific, Los
Angeles, CA) for 10 min at 37 oC (100 μl total volume). Next, 3 mM ATP was added to all
sample wells, and plates were incubated for another 60 min at 37 oC. The reaction was
terminated by addition of 5% SDS (5 μl) and 125 μl of color reagent containing 0.36 g of
ascorbic acid in 15 ml of molybdate acid solution (3.7 mM ammonium molybdate
[(NH4)6Mo7O24 ∙ 4 H2O] and 0.43 M H2SO4 [Fisher Scientific, Pittsburgh, PA]), turning the
solution blue in color. Mg2+ATPase activity was measured with a BIO-TEK μ-Quant UV plate
reader (810 nm) [BIO-TEK, Winooski, VT] as the net amount of inorganic phosphate (Pi)
produced by functional Mg2+ATPase enzymes following incubation with and subsequent
cleavage of ATP [Fig. 3.4] (Sadrzadeh et al., 1993). Like the BCA assay described above (see
section 3.5), the Mg2+ATPase assay for enzyme activity is colorimetric in nature, and therefore,
the intensity of the blue color is directly proportional to Mg2+ATPase activity.
Figure 3.4

Figure 3.4 Hydrolysis of adenosine triphosphate (ATP). Because Mg2+ATPase enzymes
(e.g. flippase) are ATP-dependent, their activity can be measured (810 nm) as the net
amount of inorganic phosphate (Pi) produced by hydrolyzing ATP to adenosine
diphosphate (ADP). Like the BCA assay (see section 3.5), the Mg2+ATPase assay is
colorimetric, and therefore, the intensity of the blue color (i.e., Pi produced) is directly
proportional to Mg2+ATPase activity (Sadrzadeh et al., 1993).
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3.7 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
3.7.1 One-Dimensional (1D)-Gel Electrophoresis
1D-PAGE is performed to separate proteins into bands based on size, shape, and
molecular weight. Prior to 1D-PAGE separation, brain homogenates of known concentration are
prepared by suspension in a sample loading buffer (0.5 M Tris [pH 6.8], 40% glycerol, 8% SDS,
20% β-mercaptoethanol, 0.01% bromophenol blue), then heated at 95 °C for 5-10 min to ensure
protein denaturation and quick-cooled on ice prior to gel loading. Precision Plus Protein™ All
Blue Standards (2.5 μl) are loaded in a separate lane to provide a reference marker for various
molecular weights. Although gel-type and running buffer vary by experiment, electrophoresis
typically begins at 80 V for ~10 min to ensure proper protein stacking, and finishes at 120 V for
~120 min in a Criterion Cell™ vertical electrophoresis buffer tank (Bio-RAD, Hercules, CA) at
room temperature (RT), unless indicated otherwise; electrophoretic run-time is given as an
approximation due to differences in voltage preference and/or gel composition and porosity.
3.7.1.1 Bcl-2, Bax, & Caspase-3 Expression
In human IPL studies of apoptotic protein expression levels, equal amounts of brain
homogenate (75 μg) were loaded and separated using 12.5% Tris-HCl polyacrylamide gels and a
1 X dilution of TGS running buffer. For APP/PS-1 mouse studies, however, equal amounts of
whole brain homogenate (75 μg) were loaded and separated using Criterion XT precast 4-12%
Bis-Tris linear gradient gels and a 1 X dilution of XT MES running buffer starting with 80 V for
~10 min to ensure proper protein stacking, and finishing with 140 V for ~110 min. Instead of
SYPRO Ruby® in-gel staining of proteins, gels were directly transferred onto Western blots as
described below (sections 3.8.1.1 & 3.8.1.2).
3.7.1.2 Pyruvate Kinase M2 (PK M2) & Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1)
Expression
These gels were run to experimentally verify selected PD-Quest-identified significantly
differentially expressed protein spots PK M2 and Pin-1 in PDAPP mouse brain. For PK M2
expression, equal amounts of half brain homogenates (75 μg) were loaded and separated with
Criterion precast 8-16% linear gradient Tris-HCl polyacrylamide gels and a 1 X dilution of TGS
running buffer at 80 V for ~10 min to ensure proper protein stacking, followed by a voltage
increase to 120 V for ~120 min for the duration of electrophoresis. Pin-1 expression gels were
run as described for PK M2, but using Criterion XT precast 12% Bis-Tris polyacrylamide gels in
a 1 X dilution of XT MES running buffer at 80 V for ~10 min and finishing at 140 V for ~110
min instead of SYPRO Ruby® in-gel staining of proteins, all gels were directly transferred onto
Western blots as described below (section 3.8.1.3).
3.7.1.3 Amyloid Precursor Protein (APP) Expression
PDAPP mouse brain APP expression studies were conducted by the Bredesen laboratory
at the Buck Institute for Age Research (Novato, CA). PDAPP mouse brain lysates (75 μg) were
added to NuPage sample buffer (Invitrogen, Carlsbad, CA) with β-mercaptoethanol and
separated with a 7% Tris-Acetate NuPage gel (Invitrogen, Carlsbad, CA) using Tris-Acetate
running buffer. Electrophoresis began at 80 V for ~10 min, and finished at 120 V for ~120 min.
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Instead of SYPRO Ruby® in-gel staining of proteins, gels were directly transferred onto Western
blots as described below (section 3.8.1.4).
3.7.2 Isoelectric Focusing (IEF)
IEF is a technique used to separate proteins according to their inherent isoelectric point
(pI) [Fig. 3.5a,b], and is the first-dimension of separation for proteins in a 2D-separation process
used for proteomic analyses. In preparation for this first dimension of electrophoresis, mouse
brain homogenates (200 μg) are first precipitated by addition of trichloroacetic acid (TCA) or
acetone, depending on the oxidative modification to be examined:
Figure 3.5

Figure 3.5 Overview of Isoelectric focusing (IEF) and 2D-polyacrylamide gel
electrophoresis (2D-PAGE). A) & B) IEF separates proteins according to their inherent
isoelectric point (pI), and is the first-dimension of separation for proteins in a 2Dseparation process used for proteomic analyses. C) 2D-PAGE separates individual
proteins into single detectable spots based on molecular migration rate (i.e., size/shape
and molecular weight) after they are separated by pI using IEF. MWM, molecular weight
marker; IPG, immobilized pH gradient.
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Protein Carbonyls: Samples to be analyzed for protein carbonylation are first
derivatized to 4 X the sample volume with 10 mM 2,4-dinitrophenylhydrazine (DNPH)
[Chemicon International, Temecula, CA] in 2 N HCl for 30 min at RT to form a protein-2,4dinitrophenylhydrazone (DNP) adduct wherever a free carbonyl group (excluding primary chain
peptide bond carbonyls) is located on a protein (Fig. 3.6), followed by the precipitation of
proteins by addition of ice-cold 100% TCA to obtain a final concentration of 15% TCA in
solution, and incubated on ice for 10 min.
Figure 3.6

Figure 3.6 2,4-Dinitrophenylhydrazine (DNPH) reaction mechanism.
Protein
carbonylation is a way in which to quantify levels of oxidative stress in a given sample.
Samples to be analyzed for protein carbonylation are first derivatized with DNPH,
forming a protein-2,4-dinitrophenylhydrazone (DNP) adduct wherever a free carbonyl
group (excluding primary chain peptide bond carbonyls) is located on a protein. This
condensation, or addition-elimination, reaction results in the nucleophilic addition of the
DNPH NH2 group to the carbonyl group of the protein, followed by removal of water.
The resulting protein-DNP adduct forms a dark orange-brown color in solution.
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Protein-Resident 3-Nitrotyrosine (3-NT): Samples to be analyzed for protein-resident
3-NT, however, do not undergo derivatization, nor are they TCA precipitated because the highly
acidic environment created by TCA could potentially remove the NO2 functional group from 3NT (Fig. 2.34) causing an incorrect interpretation of results. Therefore, these samples are
acetone precipitated, according to the Pierce Acetone Precipitation of Proteins procedure (Pierce,
Rockford, IL), with exceptions. Briefly, proteins are precipitated by addition of -20 oC, 100%
acetone to 4 X the sample volume and incubated for 60 min at -80 oC.
Samples are then centrifuged at 14,000 rpm (23,700 x g) for 5 min at 4 oC in a Hettich
Mikro 22 R microcentrifuge (Hettich, Beverly, MA). The pellet was then resuspended in Wash
buffer (1:1 [v/v] ethanol:ethyl acetate) and vortexed to equilibrate. Centrifugation and washing
of the pellet is repeated three additional times to ensure adequate removal of excess salts that
may interfere with proper IEF of proteins. After the final wash, the supernatant is removed and
pellets are allowed to dry at RT for ~10 min under a flow hood to evaporate any remaining
organic solvent. After sufficient drying, pellets are continuously vortexed and rehydrated for 2 h
at RT in 200 μl of Rehydration buffer (8 M urea [BioRAD, Hercules, CA], 2 M thiourea, 50 mM
dithiothreitol [DTT; Bio-RAD, Hercules, CA], 2.0% [w/v] CHAPS, 0.2% Biolytes [Bio-RAD,
Hercules, CA], bromophenol blue). Following rehydration, samples are sonicated in a Fisher
550 Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA) for 10 s at 20% power and applied
(200 μl) to an 11 cm ReadyStrip™ IPG strip (pH 3-10).
To begin the process of IEF, strips were actively rehydrated with and soaked in the
sample solution for 1 h at 20 oC in a Protean IEF Cell (Bio-RAD, Hercules, CA) to allow the
uptake of proteins into the gel portion of strips, then were covered with 2 ml of mineral oil to
prevent sample evaporation throughout the IEF process. Strips continued with active rehydration
for 16-18 h at 50 V and 20 oC, then began IEF at a constant temperature of 20 oC and a
progressively increasing voltage beginning at 300 V for 2 h linearly, 500 V for 2 h linearly, 1000
V for 2 h linearly, 8000 V for 2 h linearly, and finishing at 8000 V for 10 h rapidly. After
completion of IEF, strips were stored at -80 oC for no more than 3 weeks, until the second
dimension of electrophoresis was performed.
3.7.3 Two-Dimensional (2D)-Gel Electrophoresis
2D-PAGE is performed to separate individual proteins already separated by pI into single
detectable protein spots based on molecular migration rate (i.e., size/shape and molecular
weight) [Fig. 3.5c]. Subsequent to IEF, proteins (200 μg) contained within IPG strips were
thawed and equilibrated for 10 min in Equilibration buffer A (50 mM Tris-HCl [pH 6.8], 6 M
urea, 1% [w/v] SDS, 30% [v/v] glycerol, 0.5% DTT [Bio-RAD, Hercules, CA]) and then reequilibrated for 10 min in Equilibration buffer B (50 mM Tris-HCl [pH 6.8], 6 M urea, 1% [w/v]
SDS, 30% [v/v] glycerol, 4.5% IA [Bio-RAD, Hercules, CA]). All strips were rinsed in a 1 X
dilution of TGS running buffer before being placed into a Criterion precast 8-16% linear gradient
Tris-HCl linear gradient gels suitable for 11 cm IPG strips and a 1 X dilution of TGS running
buffer. Precision Plus Protein™ All Blue Standards (2.5 μl) are loaded in a separate single well
to provide a reference marker for various molecular weights. To ensure strips remain
immobilized and in contact with the gel during electrophoresis, ~1.5 ml of overlay agarose (0.5%
in 1 X TGS with bromophenol blue) was evenly distributed overtop the protein standard and IPG
strip wells and allowed to set. Lastly, electrophoresis is run at a constant 200 V for 65 min at RT
in a Criterion Cell™ vertical electrophoresis buffer tank (Bio-RAD, Hercules, CA).
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3.7.4 SYPRO Ruby® In-Gel Protein Staining
After 2D-PAGE, gels were either incubated in a fixing solution (7% [v/v] acetic acid,
10% [v/v] methanol) for 20 min at RT or directly transferred onto a nitrocellulose membrane
(0.45 μm) for Western blotting, as described below (section 3.8.2). To fixed gels, ~50 ml of
SYPRO Ruby® Protein Gel Stain was added to stain proteins overnight on a gently rocking
platform at RT to obtain linear and sensitive staining, then gels were de-stained overnight in ~50
ml deionized water at RT. Gels were scanned into Adobe Photoshop 6.0 with a Molecular
Dynamics STORM Phosphoimager (Ex/Em: 470/618 nm) [Molecular Dynamics, Sunnyvale,
CA] and analyzed via PD-Quest 2D-Analysis software (Bio-RAD, Hercules, CA), as described
below (section 3.9), and stored at 4 oC in deionized water until needed for in-gel trypsin
digestion.
3.8 Western Blotting
Western blotting is performed to detect either 1D- or 2D-PAGE-separated protein(s) of
interest immunochemically on a nitrocellulose membrane in order to quantitate either protein
expression levels and/or post-translational modifications (Fig. 3.7). Following 1D- or 2DPAGE, proteins are transferred to a nitrocellulose membrane (0.45 μm) using a Bio-RAD TransBlot Semi-dry Transfer Cell system (Bio-RAD, Hercules, CA) at 20 V for 2 h (Fig. 3.7).
Membranes are then incubated in a blocking solution to prevent non-specific binding of
antibodies used for immunochemical detection of protein(s) and/or modification(s) of interest,
incubated with primary and secondary antibodies, and then developed either colorimetrically
(Fig. 3.8a,b) or by chemifluorescence (Fig. 3.8a,c), as noted.
Figure 3.7
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Figure 3.7 Western blot protein transfer set-up. Following 1D- or 2D-polyacrylamide
gel electrophoresis (PAGE), proteins are transferred onto a nitrocellulose membrane
(0.45 μm) using a Semi-dry Transfer Cell system.

Figure 3.8
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Figure 3.8 (cont.)

Figure 3.8 Western blot detection of proteins. Western blotting is performed to detect
either 1D- or 2D-polyacrylamide gel electrophoresis (PAGE)-separated protein(s) of
interest immunochemically on a nitrocellulose membrane in order to quantitate either
protein expression levels and/or post-translational modifications. A) Overview of
detection process. A primary antibody binds the protein of interest on the membrane and
is detected using a colorimetric or chemifluorescent probe attached to a secondary
antibody. B) Colorimetric development: BCIP/NBT. In this procedure, 5-Bromo-4chloro-3-indolyl phosphate dipotassium (BCIP) is hydrolyzed by the secondary antibody,
alkaline phosphatase (ALP), forming a blue intermediate. The intermediate is then
oxidized by Nitrotetrazolium Blue chloride (NBT) to produce an insoluble dimer that
exhibits an intense purple color wherever an ALP-linked protein is located on the
nitrocellulose membrane. C) Chemifluorescent development: Lumigen PS-3. In this
detection procedure, Lumigen PS-3 (i.e., luminol) is oxidized by a horseradish peroxidase
(HRP)-linked secondary antibody in the presence of acridan to form an acridinium ester
intermediate. Interaction of this intermediate with a buffer peroxide creates an excited
radical product that fluoresces at λEx/Em: 470/618 nm, wherever a HRP-linked protein is
located on the nitrocellulose membrane.
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3.8.1 Protein Expression Levels
3.8.1.1 Bcl-2, Bax, & Caspase-3 Expression in Human Inferior Parietal Lobule (IPL)
Membranes analyzed in human IPL studies were blocked with 5% non-fat dried milk in
Wash Blot (a phosphate-buffered saline [PBS] solution containing 0.01% [w/v] NaN3, 0.04%
[v/v] Tween-20, and 0.10 M NaCl) at 4 oC for 1 h. After blocking, blots were incubated in their
respective blocking solutions for 2 h at RT on a rocking platform with either mouse monoclonal
anti-Bcl-2 (1:1000) [Stressgen Biotech, Ann Arbor, MI], rabbit polyclonal anti-Bax (1:1000)
[Calbiochem, La Jolla, CA], or rabbit polyclonal anti-caspase-3 (1:2000) [Calbiochem, La Jolla,
CA] primary antibodies using the mouse polyclonal anti-β-tubulin (1:8000) primary antibody as
a loading control. Blots were then rinsed three times at RT for 5 min each in Wash Blot and
incubated with anti-mouse and anti-rabbit IgG alkaline phosphatase (1:3000) secondary
antibodies in Wash Blot for 1 h at RT on a rocking platform. Subsequent to secondary
incubation, blots were rinsed again in Wash Blot three times for 10 min each at RT, then
colorimetrically developed with a solution of 5-Bromo-4-chloro-3-indolyl phosphate dipotassium
combined with Nitrotetrazolium Blue chloride (BCIP/NBT) in ALP buffer (0.1 M Tris [BioRAD, Hercules, CA], 0.1 M NaCl, 5 mM MgCl2 ∙ 6 H2O; pH 9.5) [Fig. 3.8a,b]. After, blots
were dried at RT overnight between KIMTECH Kimwipes (Kimberly-Clark, Roswell, GA),
scanned with a Hewlett Packard ScanJet 3300C into Adobe Photoshop 6.0, and quantified using
Scion Image software (PC version of Macintosh-compatible NIH Image software).
3.8.1.2 Caspase-3 Expression in APP/PS-1 Mouse Brain
Membranes analyzed in APP/PS-1 mouse studies were blocked with 3% BSA in Wash
Blot, without NaN3, for 2 h at RT on a rocking platform. Blots were then incubated in their
respective blocking solutions with both rabbit polyclonal anti-caspase-3 (1:5000) [Calbiochem,
La Jolla, CA] and mouse polyclonal anti-α-tubulin (1:8000) primary antibodies for 2 h at RT on
a rocking platform; anti-α-tubulin was used as the loading control from which to normalize
caspase-3 immunoreactivity. It should be noted that both anti-caspase-3 and anti-α-tubulin
primary antibodies were added simultaneously since each antibody was raised in a distinct
animal host and is specific for a particular protein(s) whose molecular weight(s) do not overlap.
Blots were then rinsed three times for 5 min each in Wash Blot at RT, without NaN3, and
incubated for 1 h with Amersham ECL anti-mouse and anti-rabbit IgG horseradish peroxidase
(HRP)-linked (1:8000) [GE Healthcare, Pittsburgh, PA] secondary antibodies at RT on a rocking
platform. Again, both secondary antibodies were added simultaneously as there is minimal
cross-reactivity between mouse- and rabbit-specific antibodies, and the molecular weights of
active and latent forms of caspase-3 and α-tubulin do not overlap. Following incubation with
secondary, blots were rinsed in Wash Blot, without NaN3, three times for 10 min each at RT on a
rocking platform and developed chemifluorescently through addition of a 40:1 dilution of
Amersham ECL-Plus Western blotting detection reagents A and B (GE Healthcare, Pittsburgh,
PA), respectively (Fig. 3.8a,c). After allowing blots to develop while covered for 5 min at RT,
they were scanned on a Molecular Dynamics STORM Phosphoimager (Ex/Em: 470/618 nm)
[Molecular Dynamics, Sunnyvale, CA] and quantified using the 1D-component of GE
ImageQuant TL software (GE Healthcare, Pittsburgh, PA).

86

3.8.1.3 Pyruvate Kinase M2 (PK M2) & Peptidyl-Prolyl Cis-Trans Isomerase 1(Pin-1)
Expression in PDAPP Mouse Brain
All blots used in PDAPP PD-Quest verification studies were blocked with 3% BSA in
Wash Blot, without NaN3, for 2 h at RT on a rocking platform. Blots were then incubated for 2 h
at RT in their respective blocking solutions with either rabbit polyclonal anti-PK M2 (N-term)
[1:2000] (Abgent, San Diego, CA) or rabbit anti-Pin-1 (H-123) [1:2000] (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) primary antibodies, and rabbit polyclonal anti-actin
(1:8000) primary antibody as the loading control for all blots, on a rocking platform. It should
be noted that, both the protein of interest and actin primary antibodies were added
simultaneously as each antibody was either raised in a distinct animal host, and/or specific for
particular proteins whose molecular weights did not overlap. Blots were then rinsed three times
for 5 min each at RT in Wash Blot, without NaN3, with subsequent incubation in a secondary
antibody for 1 h at RT on a rocking platform.
Secondary antibody incubation was conducted as follows: PK M2 blots were incubated
with only anti-rabbit IgG alkaline phosphatase (1:3000) secondary antibody; Pin-1 blots were
incubated with only Amersham ECL anti-rabbit IgG HRP-linked (1:8000) [GE Healthcare,
Pittsburgh, PA] secondary antibody. Unbound, excess secondary antibody was rinsed from blots
three times for 10 min each at RT with Wash Blot, without NaN3, on a rocking platform before
development. PK M2 blots were developed colorimetrically (Fig. 3.8a,b) as described above for
human IPL (see section 3.8.1.1). However, these blots were scanned into Adobe Photoshop 6.0
with a Canon CanoScan 8800F scanner. Pin-1 blots were developed chemifluorescently (Fig.
3.8a,c) as described above for PDAPP mouse brain (see section 3.8.1.3). Both PK M2 and Pin-1
blots were quantified using the 1D-component of GE ImageQuant TL software (GE Healthcare,
Pittsburgh, PA).
3.8.1.4 Amyloid Precursor Protein (APP) Expression in PDAPP Mouse Brain
PDAPP mouse brain APP Western blot analysis was conducted by the Bredesen
laboratory at the Buck Institute for Age Research (Novato, CA). Membranes analyzed in
PDAPP mouse studies were transferred to polyvinylidene difluoride (PVDF) membranes
(Schleicher & Schuell, Dassel, Germany) and initially stained with SYPRO Ruby® (Invitrogen,
Carlsbad, CA) to verify transfer and equal loading. Immunochemical detection of APP was
completed as follows: PDVF membranes were blocked with 5% non-fat milk at 4 °C overnight.
The following day, membranes were first incubated with rabbit anti-APP (CT15) primary
antibody (Soriano et al., 2001) in blocking solution for 1-2 h at RT on a rocking platform, rinsed
with Wash Blot, without NaN3, then incubated with HRP-conjugated donkey anti-rabbit
secondary antibodies (GE Healthcare, Pittsburgh, PA) for 1-2 h at RT on a rocking platform.
Blots were developed chemifluorescently (Fig. 3.8a,c) as described above for APP/PS-1 studies
(see section 3.8.1.2).
3.8.2 Post-Translational Oxidative Modification (Redox Proteomics)
Membranes analyzed for protein carbonylation or protein-resident 3-NT, two indices of
oxidative stress, were blocked with 3% BSA in Wash Blot, without NaN3, for 2 h at RT,
followed by a 2 h incubation with either a rabbit anti-DNP (1:150) [Millipore, Temecula, CA] or
rabbit polyclonal anti-Nitrotyrosine (1:2000) primary antibody in their respective blocking
solutions at RT on a rocking platform. Blots were rinsed three times for 5 min each at RT in
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Wash Blot, without NaN3, followed by a 1 h incubation with an anti-rabbit IgG alkaline
phosphatase (1:3000) [Chemicon International, Temecula, CA] secondary antibody in Wash
Blot, without NaN3, at RT on a rocking platform. Blots were again washed in Wash Blot,
without NaN3, five times for 5, 15, 15, 15, and 5 min each at RT on a rocking platform and
developed colorimetrically with BCIP/NBT in ALP buffer (Fig. 3.8a,b) as described above for
human IPL (see section 3.8.1.1). After drying overnight between KIMTECH Kimwipes
(Kimberly-Clark, Roswell, GA), blots were scanned into Adobe Photoshop 6.0 with a Canon
CanoScan 8800F scanner and analyzed via PD-Quest 2D-Image Analysis Software 7.2.0 (BioRAD, Hercules, CA), as described below (section 3.9).
3.9 PD-Quest 7.2.0 Image & Statistical Analysis
3.9.1 Differential Expression Proteomics
Spot intensities from SYPRO Ruby®-stained 2D-gel images were quantified
densitometrically after selecting a “master” gel from which to compare and normalize spots from
all other gels [Tg and Non Tg or Tg PDAPP(J20) and Tg PDAPP(M631L)] according to the total
spot density (Fig. 3.9). Differential expression analysis between gels begins with manual
matching of common spots that could be visualized among all gels, until a significant number of
matched spots are obtained (≥20 spots). Then, the PD-Quest software launches an automated
matching analysis to define spot centers for each gel based on user-defined detection parameters
of the “master” gel which identify a faint spot, the smallest spot, and the largest spot cluster. If
automated matching should fail to identify spots that are obvious to the naked-eye, those spot
centers can be manually assigned.
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Figure 3.9

Figure 3.9 Overview of the proteomics process. After homogenization of tissue, a known
concentration of sample is subjected to isoelectric focusing (IEF), to separate proteins
based on isoelectric point (pI), followed by 2D-polyacrylamide gel electrophoresis
(PAGE) separation of proteins based on molecular migration rate. Western blotting is
performed to identify samples with post-translational oxidative modifications, such as
protein carbonyls or protein-resident 3-nitrotyrosine (3-NT). After PD-Quest analysis,
proteins of interest are excised from 2D-gels and subjected to trypsin digestion. The final
phase of this process is mass spectrometry and computational analysis of tryptic peptides
for identification.

In order to identify a significant difference in protein expression levels between Tg and
Non Tg or Tg PDAPP(J20) and Tg PDAPP(M631L) gels, three analysis sets were created using
the Analysis Set Manger software integrated into PD-Quest to calculate the number of pixels per
protein spot. Only those spots with significantly increased or decreased pixelation (i.e., levels of
protein expression) between Tg and Non Tg or Tg PDAPP(J20) and Tg PDAPP(M631L) groups
are considered for mass spectrometry identification. Of these analysis sets, the Quantitative
Analysis Set recognizes matched spots with 1.5-fold increases or decreases, while the Statistical
Analysis Set compares matched spots using a Student‟s t-test at 95% confidence, with P<0.05
considered significant. Finally, those spots identified by the Boolean Analysis Set as
overlapping spots from the Quantitative and Statistical sets, were selected for in-gel trypsin
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digestion (section 3.10) and subsequent mass spectrometric analysis (section 3.11) described
below.
3.9.2 Redox Proteomics
The immunoreactivity of carbonyl and 3-NT post-translational oxidative modifications
on Western blot images was also quantified densitometrically, as blot spot intensity is
normalized to the actual protein content as measured by the spot intensity of untransferred,
SYPRO Ruby®-stained, 2D-expression gels [Fig. 3.9] (Desiderio et al., 2006). Like 2Dexpression gels, carbonyl and 3-NT blots were first quantified densitometrically by selecting a
“master” blot from which to compare and normalize spots from all other blots [Tg and Non Tg or
Tg PDAPP(J20) and Tg PDAPP(M631L)] according to spot density. After selection of a
“master” blot for each oxidative modification group, differential carbonyl and 3-NT analysis of
blots by PD-Quest software is identical to that described above (see section 3.9.1).
However, because significantly modified protein spots on nitrocellulose membranes
cannot be excised for mass spectrometric analysis, blots require an additional PD-Quest
comparison to 2D-expression gels, which also ensures immunochemistry results are not due to
differences in protein expression levels. To make this comparison, a “High-Match Set” is
created between the “master” gel and each “master” blot, and PD-Quest analysis between these
matched sets is completed as described above (see section 3.9.1), with exceptions. Instead of
creating analysis sets, raw spot intensity values summarized in a Quantity Table Report are
exported to a Microsoft Excel spreadsheet where the average intensity for a particular spot on
each blot is normalized to the average intensity of the same spot on each gel to determine the
specific protein carbonyl or 3-NT level for that spot. Those spots with statistically significant
increases or decreases in protein carbonyl or protein-resident 3-NT levels as calculated by a
Student‟s t-test at 95% confidence (P<0.05 considered significant) were selected for in-gel
trypsin digestion (section 3.10) and subsequent mass spectrometric analysis (section 3.11)
described below.
3.10 In-Gel Protein Digestion
In-gel trypsin digestion of selected gel spots was performed as previously described
(Thongboonkerd et al., 2002). Protein spots identified as significantly changed from controls
were excised from SYPRO Ruby®-stained 2D-gels with a clean, sterilized blade and transferred
to Eppendorf microcentrifuge tubes. Gel plugs were then washed with 0.1 M NH4HCO3 at RT
for 15 min, followed by incubation with 100% acetonitrile at RT for 15 min. After solvent
removal, gel plugs were dried in their respective Eppendorf tubes under a flow hood at RT.
Plugs were then incubated with for 45 min in 20 μl of 20 mM DTT (Bio-RAD, Hercules, CA) in
0.1 M NH4HCO3 at 56 oC. The DTT/NH4HCO3 solution was then removed and replaced with 20
μl of 55 mM IA (Bio-RAD, Hercules, CA) in 0.1 M NH4HCO3, tubes covered with foil, and
incubated with gentle agitation at RT for 30 min. The excess IA solution was then removed and
plugs incubated for 15 min with 200 μl of 50 mM NH4HCO3 at RT. To the previous solution,
200 μL of 100% acetonitrile was added and tubes incubated for 15 min at RT. Subsequent to
incubation, the solvent was removed, and the gel plugs dried for 30 min at RT under a flow
hood. Plugs were rehydrated with 20 ng/μl of modified trypsin (Promega, Madison, WI) in 50
mM NH4HCO3 with the minimal volume to cover the gel plugs and placed in a shaking incubator
overnight at 37 oC.
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3.11 Mass Spectrometry (MS)
Following in-gel digestion of protein spots of interest, salts and contaminants were
removed from tryptic peptide solutions using C18 ZipTips (Sigma-Aldrich, St. Louis, MO),
reconstituted to a volume of ~15 µL in a 50:50 water:acetonitrile solution containing 0.1%
formic acid. In the event sample volumes became greater than ~15 μl, excess solvent was
removed using a rotary evaporator (Roto-Vap) set to 37 oC. Tryptic peptide solutions were then
analyzed with an automated NanoMate electrospray ionization (ESI) [Advion Biosciences,
Ithaca, NY] Orbitrap XL MS platform (ThermoScientific, Waltham, MA) [Fig. 3.10] at the
University of Kentucky-Louisville (Louisville, KY). The Orbitrap MS was operated in a datadependent mode whereby the eight most intense parent ions measured in the Fourier transform
(FT) at 60,000 resolution were selected for ion trap fragmentation with the following conditions:
injection time 50 ms, 35% collision energy, MS/MS spectra were measured in the FT at 7500
resolution, and dynamic exclusion was set for 120 s. Each sample was acquired for a total of
~2.5 min. MS/MS spectra were searched against the International Protein Index (IPI) database
using SEQUEST and results were filtered with the following criteria: Xcorr > 1.5, 2.0, 2.5, 3.0
for +1, +2, +3, and +4 charge states, respectively, Delta CN > 0.1, and P-value (protein and
peptide) < 0.01. IPI accession numbers were cross-correlated with SwissProt accession numbers
for final protein identification. It should be noted that proteins identified with a single peptide
were kept for further analyses if multiple spectral counts (SC, number of observed MS/MS
spectra) were observed in a single analysis or if the peptide was identified in a separate analysis
and workup of the same protein spot.
Figure 3.10

Figure 3.10 Schematic diagram of Orbitrap XL mass spectrometer. ESI, Electrospray
Ionization; HCD, High-energy C-trap Dissociation (adapted from thermo.com).

3.12 Immunoprecipitation
Protein samples (250 μg) were first incubated with a Lysing buffer (5 N NaCl, 1 M TrisHCl [pH 7.6], 0.5% NP-40, 4 g/ml leupeptin, 4 g/ml pepstatin, 5 g/ml aprotinin) for 30 min
at 4 oC while continuously agitated, then pre-cleared for 1 h at 4 oC while continuously agitated
with Protein G PLUS/Protein A agarose beads (Calbiochem, La Jolla, CA). Prior to pre-clearing,
agarose beads were pre-washed three times with Lysing buffer in a Hettich Mikro 22 R
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microcentrifuge (Hettich, Beverly, MA) at 3000 rpm for 5 min each at 4 oC to remove any
possible contaminants that would cause non-specific binding of antibodies used for Western blot
analysis. Following a 5 min centrifugation in a Hettich Mikro 22 R microcentrifuge (Hettich,
Beverly, MA) at 3000 rpm, supernatants were transferred to clean Eppendorf microcentrifuge
tubes, and incubated overnight at 4 oC in rabbit anti-Pin-1 (H-123) antibody (1:2000) [Santa
Cruz Biotechnology Inc., Santa Cruz, CA] with continuous agitation. The next day (~18 hrs),
samples were incubated again for 1 h at 4 oC while continuously agitated with Protein G
PLUS/Protein A agarose beads (Calbiochem, La Jolla, CA) that had been pre-washed three times
with Lysing buffer in a Hettich Mikro 22 R microcentrifuge (Hettich, Beverly, MA) at 3000 rpm
for 5 min each at 4 oC to remove any contaminants. Subsequent to incubation, protein-associated
agarose beads were washed five times in RIA buffer (5 N NaCl, 1 M Tris-HCl [pH 7.6], 1% NP40) in a Hettich Mikro 22 R microcentrifuge (Hettich, Beverly, MA) at 3000 rpm for 5 min each
at 4 oC. Following the final wash, beads were prepared for 1D-PAGE separation on Criterion
XT precast 12% Bis-Tris polyacrylamide gels in a 1 X dilution of XT MES running buffer and
Western blotted, as described above (see sections 3.7.1 & 3.8.2), using rabbit polyclonal antiNitrotyrosine (1:2000) primary and Amersham ECL anti- rabbit IgG HRP-linked (1:8000) [GE
Healthcare, Pittsburgh, PA] secondary antibodies, and developed chemifluorescently (Fig.
3.8a,c; see section 3.8.1.2). Blots were scanned on a Molecular Dynamics STORM
Phosphoimager (Ex/Em: 470/618 nm) [Molecular Dynamics, Sunnyvale, CA], and quantified
using the 1D-component of GE ImageQuant TL software (GE Healthcare, Pittsburgh, PA).
3.13 Slot-Blot Analysis Oxidative Stress (Oxyblotting)
3.13.1 Protein Carbonyls (PCO)
Protein carbonyls are a marker of protein oxidation (see section 3.4.4.1) and were
determined as previously described (Butterfield and Stadtman, 1997), with exceptions. Mouse
brain samples (5 μl) were derivatized at RT for 20 min in 5 μl of 12% SDS and 10 μl 10 mM
DNPH [Chemicon International, Temecula, CA] in 2 N HCl to denature proteins and form a
protein-DNP adduct wherever a free carbonyl group is located on a protein (excluding primary
chain peptide bond carbonyls) [Fig. 3.6]. Samples were then neutralized with 7.5 μl of
neutralization solution (2 M Tris in 30% [v/v] glycerol; Millipore, Temecula, CA), and
derivatized samples (250 ng/well) were loaded in duplicate onto a nitrocellulose membrane (0.45
μm) under vacuum pressure using a Bio-RAD slot-blot apparatus (Bio-RAD, Hercules, CA).
Membranes were blocked with 3% BSA in Wash Blot, without NaN3, for 1.5 h at RT and
incubated with a 1:100 dilution of rabbit polyclonal anti-DNP primary antibody (Chemicon
International, Temecula, CA) in blocking solution for 2 h at RT on a rocking platform. After
primary incubation, blots were rinsed three times for 5 min each at RT in Wash Blot, without
NaN3, and subsequently incubated with anti-rabbit IgG alkaline phosphatase secondary antibody
(1:8000) in Wash Blot, without NaN3, for 1 h at RT on a rocking platform. Blots were then
washed three times for 5 min each at RT in Wash Blot, without NaN3, on a rocking platform and
developed colorimetrically (Figs. 3.8a,b; 3.11a) as described for Western blotting above (see
section 3.8). Finally, blots were dried overnight at RT between KIMTECH Kimwipes
(Kimberly-Clark, Roswell, GA), scanned with a Hewlett Packard ScanJet 3300C into Adobe
Photoshop 6.0, and quantified using Scion Image software (PC version of Macintosh-compatible
NIH Image software). In order to create a negative control which demonstrates the specificity of
the anti-DNPH primary antibody for carbonyl groups, derivatization of samples was done with a
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25 mM solution of sodium borohydride (NaBH4) in 80% methanol for 30 min at RT in order to
reduce protein carbonyls to alcohols in lieu of DNPH. Negative control blots were blotted and
developed the same as positive control, (i.e., DNPH-derivatized) blots; however, no anti-DNPH
primary antibody was added to control the specificity of protein carbonyl immunoreactivity
localization.
Figure 3.11

Figure 3.11 Representative slot-blot membranes. A) Anti-dinitrophenylhydrazone
(DNP) probed blot for detection of protein carbonyls (PCO). B) Anti-3-nitrotyrosine (3NT) probed blot for detection of protein-resident 3-NT. C) Anti-protein-bound-4hydroxy-2-trans-nonenal (HNE) probed blot for detection of protein-bound HNE. A)-C)
All samples loaded in duplicate, horizontally.

3.13.2 Protein-Resident 3-Nitrotyroine (3-NT)
Protein-resident 3-NT levels are used as another marker of oxidative damage (see section
2.4.4.2), and were determined as previously described (Butterfield and Stadtman, 1997;
Butterfield et al., 2007b), with few exceptions. Mouse brain samples (5 μl) were incubated at RT
for 20 min in 5 μl of 12% SDS and 10 μl of Laemmli buffer (0.125 M Tryzma base [pH 6.8], 4%
[v/v] SDS, 20% [v/v] glycerol) and diluted with 7.5 μl PBS. Samples (250 ng) were blotted in
duplicate, developed colorimetrically (Figs. 3.8a,b; 3.11b) using rabbit polyclonal anti-3Nitrotyrosine primary (1:2000) and anti-rabbit IgG alkaline phosphatase secondary (1:8000)
antibodies, and quantified as described for protein carbonyl blots above (see section 3.13.1). In
order to create a negative control which demonstrates the specificity of the anti-3-NT primary
antibody for nitrated proteins, samples were pretreated with sodium dithionite (Na2S2O4) in order
to reduce 3-NT residues to amines. Negative control blots were developed the same as
untreated, positive control blots.
3.13.3 Protein-Bound 4-Hydroxy-2-Trans-Nonenal (HNE)
Levels of protein-bound HNE are used as a marker of lipid peroxidation (see section
2.4.5.1) and were determined as previously described (Lauderback et al., 2001), with exceptions.
Mouse brain samples (5 μl) were incubated at RT for 20 min in 5 μl of 12% SDS and 10 μl of
Laemmli buffer then diluted with 7.5 μl PBS. Samples (250 ng) were blotted in duplicate,
developed colorimetrically (Figs. 3.8a,b; 3.11c) using rabbit polyclonal anti-HNE primary
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(1:2000) [Alpha Diagnostic International Inc., San Antonio, TX] and anti-rabbit IgG alkaline
phosphatase secondary (1:8000) antibodies, and quantified as described for protein carbonyl
blots above (see section 3.13.1). In order to create a negative control which demonstrates the
specificity of the anti-HNE primary antibody for protein-bound HNE, blots were developed with
an anti-HNE primary antibody that was pre-absorbed with HNE.
3.14 Two-Site (Sandwich) Enzyme-Linked Immunosorbant Assay (ELISA)
The principle behind both ELISA assays used in this dissertation was to quantitate the
amount of target protein in a given tissue sample using a standard double antibody approach
combined with colorimetric detection at a wavelength of 450 nm. A monoclonal antibody to the
amino (NH2)-terminus of each Aβ sequence (the capture antibody) is pre-coated onto the wells of
the microtiter strips to which brain homogenate is added, followed by incubation with a second
monoclonal antibody specific for the carboxy (COOH)-terminus of each Aβ sequence (detection
antibody). Addition of an HRP-linked secondary antibody and a substrate solution produces a
color change whose intensity is directly proportional to the concentration of monoclonal Aβ
antibody present in the original specimen (Fig. 3.12).
Figure 3.12

Figure 3.12 Two-site enzyme-linked immunosorbant assay (ELISA). ELISA is performed
to quantify the amount of amyloid-β (Aβ) peptides, Aβ(1-40) and Aβ(1-42), using a
standard double antibody approach combined with colorimetric detection at 450 nm. The
capture antibody is pre-absorbed to the microtiter plate and is specific for the NH2terminus of Aβ, while the detection antibody is added to detect the COOH-terminus of
Aβ. Following incubation with a horseradish peroxidase (HRP)-linked antibody, addition
of a tetramethylbenzidine (TMB) substrate solution produces a color change whose
intensity is directly proportional to the concentration of Aβ present.
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3.14.1 Amyloid-β (Aβ) Peptide Levels in APP/PS-1 Mouse Brain
In collaboration with Dr. M. Paul Murphy at the University of Kentucky Sanders-Brown
Center on Aging and Department of Molecular and Cellular Biochemistry (Lexington, KY), the
solubility of Aβ was measured by a standard three-step serial extraction of Aβ followed by twosite (sandwich) ELISA, as described previously (Das et al., 2003; Gravina et al., 1995;
McGowan et al., 2005; Murphy et al., 2007; Suzuki et al., 1994). This ELISA procedure has
been demonstrated to quantitatively extract Aβ from brain tissue, and an estimate of this value
can be determined by adding the amount of the Aβ(1-40) and Aβ(1-42) in all extracts (Das et al.,
2003; Levites et al., 2006; McGowan et al., 2005; Murphy et al., 2007; Roher et al., 1986; 1993).
APP/PS-1 mouse brain tissue was homogenized with a Polytron homogenizer in DEA buffer (50
mM NaCl, 0.2% diethylamine; 150 mg/ml wet tissue weight) including a complete protease
inhibitor cocktail. Samples were centrifuged at 14,000 × g for 30 min at 4 °C, and the
supernatant collected, while the pellet was re-extracted by sonication (10 × 0.5 s microtip pulses
at 100 W) with a Fisher Model 500 Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA) in
2% SDS. After a second centrifugation at 14,000 × g for 30 min at RT, the supernatant was
again collected and the remaining pellet extracted by sonication in 70% formic acid (FA). The
final extract was then centrifuged at 100,000 × g for 1 h in a Beckman OptimaMAX tabletop
ultracentrifuge (TLA55 rotor; Beckman-Coulter, Fullerton, CA). All sample extracts were stored
at −80 °C until the time of ELISA assay.
Thawed SDS-soluble fractions were diluted in AC buffer (0.02 M sodium phosphate
buffer [pH 7.0], 0.4 M NaCl, 2 mM EDTA, 0.4% Block Ace [AbD Serotec, Raleigh, NC], 0.2%
BSA, 0.05% CHAPS, 0.05% NaN3), while FA fractions were diluted (at least 1:1) in AC buffer
following neutralization by 1:20 dilution in TP buffer (1 M Tris base, 0.5 M Na2HPO4). Pilot
studies were completed to empirically determine final sample dilutions. Standard curves were
prepared in the same buffer as APP/PS-1 samples using known concentrations of synthetic Aβ(140) and Aβ(1-42); all standards and samples were performed at least in duplicate. ELISA was
completed with monoclonal Ab9 [specific for human Aβ(1–16)], monoclonal 13.1.1 [endspecific for human Aβ40; anti-Aβ(35-40)], and monoclonal 21.3.1 [end-specific for human
Aβ42; anti-Aβ(35-42)] antibodies. Nunc MaxiSorp ELISA antibody coated plates (1 μg/well in
PBS) [Thermo Fisher Scientific, Rochester, NY] were blocked with a solution of 2% Block Ace
(AbD Serotec, Raleigh, NC) and 1% BSA in PBS overnight. COOH-terminal antibodies were
used for capture, to avoid an excess of one Aβ peptide from competing away the other, while
HRP-conjugated Ab9 antibody was used as a detection antibody. The lower limit of detection
was approximately 5 pM, with a linear range of about two orders of magnitude (~20–2000 pM).
After development with tetramethylbenzidine (TMB) reagent (Kirkegaard and Perry
Laboratories; Gaithersburg, MD), plates were stopped with 6% o-phosphoric acid and read at
450 nm using a Bio-TEK multi-well plate reader (Bio-TEK, Winooski, VT). Aβ concentrations
(pmol/g wet tissue) were calculated using Softmax software (Molecular Devices, Menlo Park,
CA) by comparing APP/PS-1 sample absorbance with respective Aβ(1-40) and Aβ(1-42)
standard curves.
3.14.2 Amyloid-β (Aβ) Peptide Levels in PDAPP Mouse Brain
The unused half of PDAPP mouse brains was used to measure the levels of Aβ(1–40) and
Aβ(1–42) by two-site, solid-phase sandwich ELISA at the Bredesen laboratory of the Buck
Institute for Age research (Novato, CA), similar to the procedure described for APP/PS-1
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samples above, with exceptions; Aβ(1–40) and Aβ(1–42) were determined according to the
manufacturer‟s protocol (Invitrogen, Carlsbad, CA). Briefly, frozen PDAPP mouse hemi-brains
were weighed and homogenized in 8 X the samples mass with cold 50 mM Tris (pH 8.0)
containing 5 M guanidine to achieve 100 mg brain/ml buffer. Hemi-brain samples were kept on
ice and sonicated several times until homogeneous in solution, as the buffer was added in stages.
Homogenates were then rotated at RT for 3-5 h and stored at -20 oC until used for ELISA assay.
For ELISA, homogenate samples were diluted 1:50 in the provided Diluent buffer (15
mM NaN3) [Invitrogen, Carlsbad, CA] and that same amount of guanidine was also included in
the standard curve. ELISA was completed with plates pre-coated with a rabbit monoclonal antiAβ(1-40) or Aβ(1-42) antibody [specific for the NH2-terminus of Aβ(1-40) or Aβ(1-42)]
(Invitrogen, Carlsbad, CA), incubation with the rabbit monoclonal anti-Aβ(1-40) or anti-Aβ(142) detection antibody [specific for the COOH-terminus of Aβ(1-40) or Aβ(1-42)] (Invitrogen,
Carlsbad, CA), and incubation with the rabbit anti-IgG HRP secondary antibody (Invitrogen,
Carlsbad, CA). After removal of excess HRP-conjugated secondary antibody, a Stabilized
Chromagen (TMB) substrate solution was added (Invitrogen, Carlsbad, CA), which is acted upon
by the bound HRP-enzyme to produce a color change. Microtiter plate absorbance was read at a
wavelength of 450 nm using a Bio-TEK multi-well plate reader (Bio-TEK, Winooski, VT). Aβ
concentrations (pmol/g wet tissue) were calculated using Softmax software (Molecular Devices,
Menlo Park, CA) by comparing PDAPP sample absorbance with respective Aβ(1-40) and Aβ(142) standard curves.
3.15 Immunohistochemistry
Immunohistochemical staining of PDAPP mouse brains was carried out by the Bredesen
laboratory at the Buck Institute for Age Research (Novato, CA) to fluorescently label Aβ and
microglia. Amyloid plaques, comprised mainly of Aβ proteins and microglia, were labeled and
plaques counted in Non Tg PDAPP (n=6) and Tg PDAPP(M631L) mice (n=6) at 8 months of
age. Mice were anesthetized, perfused with saline, and a sagittal hemi-brain from each mouse
was submersion-fixed in 2% paraformaldehyde. The fixed brains were processed into paraffin
and 10 μm coronal sections cut from the area where the hippocampus is readily apparent (bregma
−2.18) and mounted on charged glass slides (Platinum line; Mercedes Medical, Sarasota, FL).
Two slides were used for each antibody label for each individual mouse, two sections per slide.
Both the anti-Aβ (6E10) and the anti-ionized Ca2+ binding protein-1 (Iba-1) antibodies require
that antigen retrieval be performed in 10 mM sodium citrate (pH 6.0) for 5 min at 98 °C. For
mouse monoclonal 6E10, endogenous mouse IgG was blocked with chicken anti-mouse (Vector)
at 1:200 for 1 h in TBST (20 mM Tris base, 137 mM NaCl [pH 7.8], 0.05% Tween-20).
Blocking of nonspecific antibody binding and all antibody incubations were done in 5% normal
donkey serum in TBST; and all washes were done in TBST. Both primary antibodies were
diluted to 1:500 and incubated overnight at 4 °C. The secondary antibodies were anti-mouse and
anti-rabbit AlexaFluor 488 raised in donkey (Invitrogen, Carlsbad, CA). Labeled sections were
viewed and imaged at 20 X and 40 X on a Nikon Eclipse E800 fluorescence microscope (Nikon
Instruments Inc, Melville, NY) using the FITC filter and Nikon Act 1 software (Nikon
Instruments Inc, Melville, NY). Plaques were counted only from the molecular layer of the
hippocampus within the granular cell layer of the CA regions and above the dentate gyrus.
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3.16 Behavioral Analysis of PDAPP Mice
Behavioral analysis of PDAPP mice was carried out the Bredesen laboratory at the Buck
Institute for Age Research (Novato, CA), using the Morris water-maze procedure to test spatial
memory (Morris, 1984). According to this procedure, mice are placed into a large circular pool
of water containing a platform hidden just beneath the surface of the water. In addition, the
water is opacified with a non-toxic agent to render the platform virtually invisible to mice,
eliminating any local cues that would guide animal escape. Animals are then forced to search for
an escape from the water (i.e., the platform) by swimming in random search paths throughout the
pool; cognitively normal mice quickly learn to swim directly towards the platform from any
starting position around the entire circumference of the pool using spatial memory relative to
distal cues. Cognitively impaired mice, however, have degenerate spatial awareness and,
therefore, take much longer to locate the platform, as they continue to search at random.
All PDAPP animals had normal motor and visual skills as determined by sensorimotor
tasks performed before testing. All groups were assessed for swimming ability with a straight
water alley (15 cm x 200 cm) containing a submerged (1 cm) 12×12 cm platform 2 days before
water-maze testing. All water-maze cognitive tests were performed in a 100 cm diameter tank
filled with water opacified by the addition of non-toxic paint. The water was kept at 24 ± 1 °C
and surrounded by dark walls containing geometric designs that served as distal visual cues.
During acquisition, each animal was subjected to 3-4 trials per day for 3 days, with a maximum
of 60 s to find the submerged platform, with 10 min inter-trial intervals. After 60 s, mice that did
not find the escape platform were physically guided to it and allowed to remain on the platform
for 30 s. A probe trial was performed at the end of training, in which the platform was
inaccessible. The time taken by each mouse to locate the platform (latency), their path lengths
and patterns, the percentage time spent floating and percentage time spent engaged in
thigmotactic swim (swimming at a distance of ≤10 cm from the tank wall) were monitored.
Animals were monitored daily and weights recorded weekly. Performance in all tasks (latency
to platform, distance swum, swim velocity, time spent in target quadrant, passes through target,
and thigmotaxis) was recorded by a computer-based video tracking system (HVS Image Analysis
VP-200, HVS Image, Hampton, UK). Data were analyzed offline by using HVS Image software
(HVS Image, Hampton, UK) and processed with Microsoft Excel.

Copyright © Miranda Lu Lange, 2010
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CHAPTER 4
LOSS OF PHOSPHOLIPID ASYMMETRY & ELEVATED BRAIN APOPTOTIC
PROTEIN LEVELS IN SUBJECTS WITH AMNESTIC MILD COGNITIVE
IMPAIRMENT & ALZHEIMER DISEASE
4.1 Overview
Normally, the aminophospholipid phosphatidylserine (PtdSer) is asymmetrically
distributed on the cytosolic, inner-leaflet of the lipid bilayer of all cells, including neurons.
However, during oxidative stress, PtdSer is exposed onto the extracellular, outer-leaflet,
initiating the first stages of an apoptotic process. PtdSer asymmetry is actively maintained by the
adenosine triphosphate (ATP)-dependent, membrane-bound translocase flippase, whose function
is inhibited if covalently bound by lipid peroxidation products, such as 4-hydroxy-2-transnonenal (HNE) and 2-propen-1-al (acrolein), within the bilayer. In addition, pro-apoptotic
proteins Bax and caspase-3 have been implicated in the oxidative modification of flippase and/or
PtdSer, resulting in PtdSer asymmetric collapse, while anti-apoptotic protein Bcl-2 has been
found to prevent this process. The present dissertation study investigated loss of PtdSer
asymmetry in synaptosomes from brain of subjects with Alzheimer disease (AD) and amnestic
mild cognitive impairment (aMCI), as well as levels of apoptotic factors Bcl-2, Bax, and
caspase-3. NBD-PS fluorescence and Western blot analysis suggest that PtdSer outer-leaflet
exposure is significantly increased in aMCI and AD brain, contributing to the early elevation of
pro- and anti-apoptotic proteins, and subsequent neuronal cell loss. Verifying these results were
not simply due to post-mortem interval (PMI) or freeze-thawing, NBD-PS fluorescence and
Mg2+ATPase (i.e., flippase) activity assays performed on synaptosomes isolated from normal
mice demonstrated no significant difference in PtdSer exposure as a function of PMI or freezethawing. Since aMCI is considered a possible transition point between normal cognitive aging
and probable AD, and is reported to have increased levels of tissue oxidation, results of this
dissertation study could mark the progression of patients with aMCI into AD. This study also
contributes to a model of apoptosis-specific oxidation of phospholipids consistent with the notion
that PtdSer exposure is required for apoptotic-cell death.
4.2 Introduction
Beyond basic structural integrity, phospholipid asymmetry influences the activity of
membrane receptors and transport proteins (reviewed in Paulusma and Oude Elferink, 2005),
intra- and extra-cellular signal transduction pathways (Verkleij and Post, 2000), and cellular
morphology via lipid-protein and protein-protein interactions (Balasubramanian and Schroit,
2003; Lubin et al., 1981; Schlegel et al., 1985; Wali et al., 1987; Zwaal and Schroit, 1997).
Therefore, the asymmetric distribution and localization of phospholipids in the cell membrane is
of physiologic importance and must be actively maintained. Because phospholipids that
necessitate equilibration between the two bilayer leaflets do so at slow rates, active transport by
integral membrane proteins, and, to some extent, vesicle fusion and pinching between
membranes, is a means by which living cells accelerate this process (reviewed in Sprong et al.,
2001). In particular, the aminophospholipid PtdSer (Fig. 2.10) is typically sequestered to the
cytosolic, inner-leaflet of the cell membrane (Bretscher, 1972; Op den Kamp, 1979; Rothman
98

and Lenard, 1977), a distribution that is actively regulated by the ATP-dependent, membrane
bound, aminophospholipid translocase, flippase, which unidirectionally transports PtdSer, and to
a much lesser extent, phosphatidylethanolamine (PtdEtn), inward against its concentration
gradient (Daleke and Huestis, 1985; Daleke and Lyles, 2000; Seigneuret and Devaux, 1984). In
the course of asymmetric collapse, however, PtdSer is exposed to the outer-leaflet of the
membrane, which signals induction of early apoptosis, and is crucial for selective recognition
and mononuclear phagocytosis of target cells by macrophages and fibroblasts in the periphery, or
microglia in the brain [see section 2.5.2] (Castegna et al., 2004; Fadok et al., 2001; 1992a; Kagan
et al., 2003; Tyurina et al., 2004a; 2004b).
Under normal conditions, collapse of PtdSer asymmetry and subsequent phagocytosis is
considered a process balancing the rate of cell death to that of cell division, in order to maintain
cellular homeostasis. However, previous studies have found an abnormal levels of
aminophospholipids in AD brain (Prasad et al., 1998), likely due to oxidative stress and damage
that is inherent to this devastating disease (Aksenov et al., 2001; Butterfield and Lauderback,
2002; Butterfield et al., 2007a; Castegna et al., 2003; 2002a; Hensley et al., 1995; Lyras et al.,
1997; Markesbery, 1999; Perluigi et al., 2009; Smith et al., 1997; Sultana et al., 2006a; 2006b;
Varadarajan et al., 2000). Oxidative stress can lead to an increased production of lipid
peroxidation products, HNE (Fig. 2.35) and acrolein, within the bilayer [see section 2.4.5]
(Butterfield and Lauderback, 2002; Butterfield et al., 2002b; 2006c; Lauderback et al., 2001;
Lovell et al., 2001; Markesbery and Lovell, 1998; Perluigi et al., 2009; Williams et al., 2006)
that can diffuse from their formation sites and react via Michael addition with flippase,
covalently binding a critical cysteine residue of its primary structure (Fig. 2.36), thereby causing
irreversible PtdSer asymmetric collapse (Butterfield and Stadtman, 1997; Castegna et al., 2004;
Daleke, 2003; Daleke and Lyles, 2000; Paulusma and Oude Elferink, 2005; Tyurina et al.,
2004b). Moreover, oxidative modification of flippase and/or PtdSer by these reactive alkenals is
also greatly elevated in the early apoptotic phenotype of mouse models of Aβ pathology
(Butterfield and Lauderback, 2002; Castegna et al., 2004; Fadok et al., 1992a; Herrmann and
Devaux, 1990; Kagan et al., 2000; 2003; Markesbery and Lovell, 1998; Mohmmad Abdul and
Butterfield, 2005).
Oxidative stress and damage in AD can also initiate apoptosis by disruption of the
electron transport chain and subsequent release of cytochrome c from mitochondria [see sections
2.3.4 & 2.5.1] (Ott et al., 2007), both known to play important in vitro and in vivo roles in AD
neuronal loss (Cras et al., 1995; Honig and Rosenberg, 2000). Apoptosis is typically modulated
by both pro- and anti-apoptotic members of the B-cell lymphoma-2 (Bcl-2) family (Pellegrini
and Strasser, 1999). Specifically, anti-apoptotic Bcl-2 protein expression has been found
significantly increased in AD temporal and frontal cortex, blocking PtdSer oxidation and
apoptotic cell death, while promoting neuronal survival (Engidawork et al., 2001; Fabisiak et al.,
1997; Kitamura et al., 1998b); further indication that PtdSer is essential to the apoptotic process,
as well as neuronal life and death. A second Bcl-2 family member is the pro-apoptotic Bcl-2associated X protein (Bax), known to compete with Bcl-2, as both proteins can be found
constitutively expressed in neurons of the central and peripheral nervous systems (Castren et al.,
1994; Oltvai et al., 1993). Previous studies have shown that in many regions of AD brain such
as the hippocampus, entorhinal cortex, and frontal and temporal cortices, Bax immunoreactivity
is increased with the exception of dentate granule hippocampal cells (Giannakopoulos et al.,
1999; Nagy and Esiri, 1997; Tortosa et al., 1998). Thus, similar to Bcl-2, Bax may also
indirectly affect PtdSer asymmetry.
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In addition, other apoptotic factors, such as the aspartate-specific cysteine proteases
(caspases), which function in both cell disassembly (effectors) and in initiating disassembly in
response to pro-apoptotic signals [initiators; see section 2.5.1] (Wolf and Green, 1999), may also
serve to affect PtdSer asymmetry, as activated caspase-3 has been shown to be elevated in
neurons and astrocytes in AD brain (Su et al., 2001). Interestingly, PtdSer externalization can be
found downstream of caspase-3 activation in some cell types under oxidative stress conditions
(Mandal et al., 2002; Martin et al., 1996; Vanags et al., 1996); in non-neuronal cells, caspase-3
activation is associated with loss of flippase translocase activity (Mandal et al., 2005).
Unfortunately, not much is known about PtdSer asymmetry and apoptotic processes with
respect to aMCI, arguably the earliest form of AD and considered a transition point between
normal cognitive aging and probable AD (Petersen et al., 1999; Winblad et al., 2004). Like AD,
oxidative stress-induced protein and nucleic acid oxidation, lipid peroxidation, and apoptosis,
leading to loss of synapses and neurons and declining brain function is prominent in aMCI
(2006b; Butterfield et al., 2006c; 2007b; Keller et al., 2005; Lovell and Markesbery, 2007;
Markesbery and Lovell, 2007; Markesbery et al., 2005; Reed et al., 2008a; 2008b). Moreover,
effector caspase-6 has been shown to be intimately linked to pathological hallmarks of AD in the
hippocampus of persons with all stages of AD, including MCI and NCI [severely aged, but
cognitively normal] (Albrecht et al., 2007). Therefore, the purpose of this study was to
investigate the hypothesis that PtdSer asymmetry is significantly lost in synaptosomal
membranes of the inferior parietal lobule (IPL) of subjects with aMCI and AD, due, in part, to
increased oxidative modification by lipid peroxidation products. A sequela of this hypothesis is
that outer-leaflet exposure of PtdSer may also be due to activation of pro-apoptotic proteins in
aMCI and AD.
4.3 Experimental Procedures
All materials and methods used in this study are described in Chapter 3 of this
dissertation. Specifically, sections 3.1, 3.2.1, 3.3, 3.4.1, 3.5, 3.6, 3.7.1.1, and 3.8.1.1.
4.3.1 Statistical Analysis
All data presented as mean ± standard deviation (S.D.). All statistical analyses were
performed using a two-tailed Student's t-test, where P<0.05 was considered significantly
different from controls.
4.4 Results
4.4.1 Detection of Phospholipid Asymmetry in Synaptosomes of Subjects with Amnestic
Mild Cognitive Impairment (aMCI) & Alzheimer Disease (AD) by NBD-PS Assay
NBD-PS fluorescence is an indirect method in which to study PtdSer asymmetric
collapse in AD and aMCI synaptosomes compared to non-diseased, control individuals. This
method results in a fluorescence decrease for those samples in which the NBD-PS probe has
successfully integrated into the bilayer, and has been subsequently exposed onto the outer-leaflet
where the fluorescent NBD-moiety is quenched by membrane-impermeable sodium dithionite
(Na2S2O4) [Fig. 3.3]. This technique has a value-added characteristic of addressing potential
concerns with fluorescent probe access to the inner-leaflet of an unstable system, which would
create an incorrect interpretation of asymmetric collapse, as highly ionic S 2O42- does not readily
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diffuse through the membrane (McIntyre and Sleight, 1991). These results suggest significant
PtdSer exposure in brain of subjects with aMCI (Fig. 4.1, **P<0.00001) and AD (Fig. 4.1,
*P<0.0001) compared to respective controls.
Figure 4.1

Figure 4.1 NBD-PS assay in synaptosomes isolated from the inferior parietal lobule
(IPL) of subjects with amnestic mild cognitive impairment (aMCI) and Alzheimer disease
(AD). Phosphatidylserine (PtdSer) outer-leaflet exposure is measured as the percent
decrease in fluorescence following Na2S2O4 quenching. Results show a significant
decrease in NBD-PS fluorescence in both aMCI and AD brain compared to controls,
suggesting significant loss of PtdSer asymmetry in both diseases. The control value was
set to 100%, to which experimental values were compared. These data, in arbitrary units
on the ordinate axis, are presented as mean ± S.D.; AD, n=5, *P<0.0001; aMCI, n=5,
**P<0.00001.

4.4.2 Post-Mortem Interval (PMI) Studies in FVB/N Mouse Synaptosomes
Post-mortem autopsy of patients from the University of Kentucky Rapid Autopsy
Program of the Alzheimer Disease Clinical Center (UK ADC) usually occurs no more than four
hours after death in order to preserve brain tissue from further oxidation and degradation (Tables
3.1 & 3.2). However, in the short time between death and tissue extraction, it is possible that
significant alteration of tissue could occur influencing the present AD and aMCI IPL results.
Moreover, during the freeze-thawing process of samples post-mortem, freeze-fracturing of the
cell membrane could conceivably occur, potentially causing a significant collapse in PtdSer
asymmetry that would artifactually alter fluorescence results. Because PMI studies were focused
on the effects of post-mortem intervals, in addition to freeze-thawing, 2.8 h and 3.5 h samples
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obtained from normal FBV/N mice held at ~37 °C post-mortem were compared to fresh (0 h)
samples as a control.
4.4.2.1 NBD-PS Fluorescence in FBV/N Mouse Synaptosomes as a Function of PostMortem Interval (PMI)
NBD-PS fluorescence was conducted as described above for human AD and aMCI IPL
(see section 4.4.1). However, mouse synaptosomal NBD-PS data were not analyzed and
presented as a percentage of control; rather, the average fluorescence signal of each sample set
was measured, in arbitrary units, and compared to the average 0 h fluorescence signal. NBD-PS
results from these mouse synaptosomes suggest no significant PtdSer exposure difference
between 0 h, 2.8 h, and 3.5 h samples (Fig. 4.2). It should be noted, however, that during
synaptosome preparation, one sample of the 2.8 h PMI was irretrievably lost, reducing the
sample number to n=2 for that PMI. Thus, these results suggest that significant changes
observed in aMCI and AD synaptosomes were likely due to oxidative processes inherent in
aMCI and AD pathology, and are not artifactual in nature.
Figure 4.2

Figure 4.2 Post-mortem interval (PMI) NBD-PS assay in synaptosomes isolated from
brain of normal FVB/N mice. Outer-leaflet exposure of phosphatidylserine (PtdSer) was
measured as a decrease in NBD-PS fluorescence signal, compared to 0 h, after quenching
with Na2S2O4. Since samples were not compared as a percentage of control, negative
values are not seen, but graphical interpretation is relatively the same. Results show no
significant difference in NBD-PS fluorescence from 0 h to 2.8 h and 3.5 h, suggesting
results obtained from amnestic mild cognitive impairment (aMCI) and Alzheimer disease
(AD) NBD-PS assay were resultant from disease progression and not PMI. A
fluorescence decrease, compared to 0 h, would denote an increased amount of PtdSer
exposure. Data shown in arbitrary fluorescence units on the ordinate axis as mean ±
S.D.; 0 h, n=3; 2.8 h, n=2; 3.5 h, n=3.
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4.4.2.2 Mg2+ATPase Activity in FBV/N Mouse Synaptosomes as a Function of PostMortem Interval (PMI)
Mg2+ATPase activity was used as an indirect assessment of ATP-dependent, membranebound flippase activity, as highly specific antibodies to flippase have not yet been obtained
(Auland et al., 1994). Mg2+ATPase activity was performed by measurement of the net amount of
inorganic phosphate (Pi) formed by functioning Mg2+ATPase enzymes within the membrane
following the hydrolysis of exogenous ATP [Fig. 3.4] (Sadrzadeh et al., 1993). Present results
show decreased UV-absorbance (810 nm) in 2.8 h and 3.4 h PMI sample sets compared to 0 h
PMI samples, denoting an overall decrease in membrane Mg2+ATPase activity with PMI that
was not significant (Fig. 4.3). This suggests that, although PMI does appear to affect
Mg2+ATPase (i.e., flippase) activity, significant PtdSer asymmetric collapse as measured by
NBD-PS fluorescence in aMCI and AD brains of PMIs up to 3.4 h was not merely a function of
PMI, but of disease progression.
Figure 4.3

Figure 4.3 Mg2+ATPase activity assay in synaptosomes isolated from brain of normal
FVB/N mice. Mg2+ATPase activity was measured to represent flippase activity. Results
only show a significant decrease in enzyme activity from 0 h to 2.8 h, but not from 0 h to
3.5 h, also suggesting that results obtained from amnestic mild cognitive impairment
(aMCI) and Alzheimer disease (AD) NBD-PS assay were resultant from disease
progression and not post-mortem interval (PMI). Decreased ultraviolet (UV)-absorbance
(810 nm) compared to 0 h denotes decreased Mg2+ATPase activity. Data shown in
arbitrary absorbance units on the ordinate axis as mean ± S.D.; 0 h, n=3; 2.8 h, n=2,
*P<0.04; 3.5 h, n=3.
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4.4.3 Apoptosis-Related Proteins in Amnestic Mild Cognitive Impairment (aMCI) &
Alzheimer Disease (AD) Brain
The following Western blot analyses were conducted in order to investigate the
relationship between outer-leaflet exposure of PtdSer and activation and/or up-regulation of proapoptotic proteins in aMCI and AD brain. All apoptosis-related protein data were obtained in
collaboration with visiting Ph.D. student, Giovanna Cenini (University of Kentucky, Lexington,
KY).
4.4.3.1 Bcl-2 levels in Amnestic Mild Cognitive Impairment (aMCI) & Alzheimer
Disease (AD) Inferior Parietal Lobule (IPL)
Expression of anti-apoptotic Bcl-2 (26 kDa) was measured by Western blot analysis in
aMCI and AD IPL compared to non-diseased control subjects, using β-tubulin (50 kDa) as a
loading control to normalize the amount of protein loaded in each well of the gel (Fig. 4.4a).
Quantification of band intensities on Western blots showed Bcl-2 protein levels were
significantly increased in both aMCI (Fig. 4.4b, *P<0.006) and AD (Fig. 4.4c, *P<0.04) brain,
illustrating a dramatic increase in neuronal apoptotic activity, as early as aMCI, that the brain is
attempting to combat with increasing levels of anti-apoptotic proteins, such as Bcl-2.
Figure 4.4
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Figure 4.4 Bcl-2 levels in brain from subjects with amnestic mild cognitive impairment
(aMCI) and Alzheimer disease (AD). Bcl-2 levels were measured by 1Dpolyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western
blot analysis. A) Increased band intensity after normalization with β-tubulin represents
an increase in the amount of Bcl-2 present. B) & C) Graphical analysis of control (C),
aMCI (M), and AD band intensities, respectively. Results demonstrate a significant
increase in Bcl-2 expression levels in both aMCI and AD, suggesting initiation of an
apoptotic process as early as aMCI. The control value was set to 100%, to which
experimental values were compared. Data are shown in arbitrary units on the ordinate
axis as mean ± S.D.; aMCI, n=3, *P<0.006; AD, n=3, *P<0.04. Data obtained in
collaboration with visiting Ph.D. student, Giovanna Cenini (University of Kentucky,
Lexington, KY).

4.4.3.2 Bax levels in Amnestic Mild Cognitive Impairment (aMCI) & Alzheimer
Disease (AD) Inferior Parietal Lobule (IPL)
Expression of pro-apoptotic Bax (21 kDa) in IPL was measured by Western blot analysis
in brain of subjects with aMCI and AD compared to non-diseased control subjects, using βtubulin (50 kDa) as a loading control to normalize the amount of protein loaded in each well of
the gel (Fig. 4.5a). Western blot analysis shows Bax protein levels to be significantly increased
in aMCI brain compared to controls (Fig. 4.5b, *P<0.03), but significantly decreased in AD (Fig.
4.5c, *P<0.005). In addition, the ratios of Bax to Bcl-2 in aMCI and AD were 2.38 and 0.23,
respectively. Like the Bcl-2 assay, these results also suggest a dramatic increase in neuronal
apoptotic activity, beginning early in disease progression with aMCI. Interestingly, however,
Bax levels in AD brain do not follow this trend, in that decreased Bax levels, as well as Bax/Bcl2 ratios, suggest an increase in neuronal resistance to apoptosis with disease progression.
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Figure 4.5

Figure 4.5 Bax levels in brain from subjects with amnestic mild cognitive impairment
(aMCI) and Alzheimer disease (AD). Bax levels were measured by 1D-polyacrylamide
gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot analysis. A)
Increased band intensity after normalization with β-tubulin represents an increase in the
amount of Bax present. B) & C) Graphical analysis of control (C), aMCI (M), and AD
band intensities, respectively. Results demonstrate a significant increase in Bax
expression levels in aMCI and a significant decrease in AD, suggesting initiation of an
apoptotic process as early as aMCI. The control value was set to 100%, to which
experimental values were compared. Data are shown in arbitrary units on the ordinate
axis as mean ± S.D.; aMCI, n=3, *P<0.03; AD, n=3, *P<0.005. Data obtained in
collaboration with visiting Ph.D. student, Giovanna Cenini (University of Kentucky,
Lexington, KY).
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4.4.3.3 Caspase-3 Levels in Amnestic Mild Cognitive Impairment (aMCI) &
Alzheimer Disease (AD) Inferior Parietal Lobule (IPL)
Pro-apoptotic caspase-3 is synthesized as an inactive, cytosolic precursor (36 kDa),
which upon receiving an apoptotic signal, is activated and subsequently cleaved into two active
subunits, p18 (20 kDa; amino acids 29-175) and p12 (18 kDa; amino acids 176-277). The anticaspase-3 primary antibody was used to recognize and probe both inactive precursor and
activated caspase-3 fragments on Western blots, while β-tubulin (50 kDa) was used to normalize
(Fig. 4.6a). Interestingly, only the band relative to the inactive caspase-3 precursor was
recognized, while bands relative to either activated fragment were not detected (Fig. 4.6a).
Quantification of procaspase-3 immunoreactivity on blots revealed a significant increase in the
levels of this precursor in both aMCI (Fig 4.6b, *P<0.02) and AD (Fig. 4.6c, *P<0.04) compared
to non-diseased control subjects, confirming both Bcl-2 and Bax results, which demonstrate
escalating levels of neuronal apoptosis in aMCI and AD brain.
Figure 4.6

Figure 4.6 Caspase-3 levels in brain from subjects with amnestic mild cognitive
impairment (aMCI) and Alzheimer disease (AD). Caspase-3 levels were measured by
1D-polyacrylamide gel electrophoresis (1D-PAGE) [75 μg/lane] and subsequent
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Western blot analysis. A) Increased band intensity after normalization with β-tubulin
represents an increase in the amount of procaspase-3 present. B) & C) Graphical
analysis of control (C), aMCI (M), and AD band intensities, respectively. Results
demonstrate a significant increase in procaspase-3 expression levels in both aMCI and
AD, suggesting initiation of an apoptotic process as early as aMCI. The control value
was set to 100%, to which experimental values were compared. Data are shown in
arbitrary units on the ordinate axis as mean ± S.D.; aMCI, n=3, *P<0.02; AD, n=3,
*P<0.04. Data obtained in collaboration with visiting Ph.D. student, Giovanna Cenini
(University of Kentucky, Lexington, KY).

4.5 Discussion
The present dissertation study investigated synaptosomal PtdSer asymmetry and its
relation to apoptotic protein expression levels by fluorescent assay and immunoblotting, in order
to determine the role of apoptosis-specific oxidation of PtdSer and/or flippase in the progression
of aMCI into AD. Results obtained from the NBD-PS assay demonstrated a significant decrease
in fluorescence in both aMCI and AD IPL brain samples compared to non-diseased control
subjects (Fig. 4.1), which suggests that PtdSer outer-leaflet externalization may be an important
contributor to neurodegeneration found in AD brain and, notably, a potential link to those
patients with aMCI that eventually develop AD.
An investigation into elevated exposure of PtdSer to the outer-leaflet of the membrane
bilayer in aMCI and AD brain begins with oxidative stress and damage, predominant in the
progression of both aMCI and AD disease states (Aksenov et al., 2001; Butterfield and
Lauderback, 2002; Butterfield et al., 2002b; 2007a; 2006b; 2006c; 2007b; Castegna et al., 2003;
2002a; Hensley et al., 1995; Keller et al., 2005; Lauderback et al., 2001; Lovell and Markesbery,
2007; Lovell et al., 2001; Lyras et al., 1997; Markesbery, 1999; Markesbery and Lovell, 1998;
2007; Markesbery et al., 2005; Perluigi et al., 2009; Reed et al., 2008a; 2008b; Smith et al.,
1997; Sultana et al., 2006a; 2006b; Varadarajan et al., 2000; Williams et al., 2006). Oxidative
stress contributes to the production of lipid peroxidation products, HNE (Fig. 2.35) and acrolein,
within the bilayer of apoptotic cells that can interfere with PtdSer asymmetry by eliciting protein
oxidation and lipid peroxidation via free radical mechanisms of their own (Butterfield and
Lauderback, 2002; Butterfield et al., 2002b; 2006c; Castegna et al., 2004; Lauderback et al.,
2001; Lovell et al., 2001; Markesbery and Lovell, 1998; Mohmmad Abdul and Butterfield, 2005;
Perluigi et al., 2009; Prasad et al., 1998; Williams et al., 2006). In particular, these neurotoxic
alkenals likely affect PtdSer asymmetry by diffusing from their formation sites and forming
Michael adducts with the translocase flippase, covalently binding a critical cysteine residue of
this transporter‟s primary structure [Fig. 2.36] (Butterfield and Stadtman, 1997; Castegna et al.,
2004; Daleke, 2003; Daleke and Lyles, 2000; Paulusma and Oude Elferink, 2005; Tyurina et al.,
2004b), establishing a definite relationship between asymmetric collapse and lipid peroxidation
in AD.
In addition, oxidative stress is also known to initiate apoptosis, which plays an important
role in neuronal loss both in vitro and in vivo in AD (Cotman and Anderson, 1995; Cras et al.,
1995; Honig and Rosenberg, 2000; MacGibbon et al., 1997; Smale et al., 1995). Unfortunately,
however, not much is known about apoptotic pathways in aMCI to date. Several previous
studies have demonstrated increased anti-apoptotic Bcl-2 expression in the hippocampus and
entorhinal cortex of AD brains (Satou et al., 1995; Su et al., 1996). Congruent with these
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studies, present Western blot results conducted in human IPL illustrate basal Bcl-2 levels to be
significantly increased in AD (Fig. 4.4a,c), and for the first time, in aMCI brain (Fig. 4.4a,b).
This up-regulation of anti-apoptotic Bcl-2 can be interpreted as a compensatory response elicited
by neurons in an attempt to resist increasing apoptotic activity and eventual cell death in aMCI
and AD brain. Moreover, because apoptotic PtdSer externalization is reportedly blocked by Bcl2 (Fabisiak et al., 1997), it is likely this neuroprotective response is an attempt to prevent the
oxidative modification of PtdSer and/or flippase and subsequent apoptotic-cell phagocytosis.
Like Bcl-2, pro-apoptotic Bax protein levels are also significantly increased in aMCI
brain (Fig. 4.5a,b), confirming a dramatic increase in apoptotic activity that neurons are actively
trying to moderate. In contrast, however, the present study demonstrated a significant decrease
in Bax levels in AD IPL (Fig. 4.5a,c), although previous studies have shown increased Bax
immunoreactivity in many regions of AD brain, such as the hippocampus, entorhinal cortex, and
frontal and temporal cortices, with the exception of dentate granule hippocampal cells
(Giannakopoulos et al., 1999; Nagy and Esiri, 1997; Tortosa et al., 1998). It is possible that
present results in human IPL suggest a dynamic involvement of Bax in the earliest stages of AD
in this particular brain region that is attenuated later in disease progression due to a relative
neuronal resistance to apoptosis. For instance, pro-apoptotic Bax is known to compete with Bcl2 as increased levels of Bax can induce cell death, while increased levels of Bcl-2 prevent it
(Oltvai et al., 1993). Evidence supporting the notion that the pro-apoptotic system in AD IPL is
progressively neutralized by the anti-apoptotic system is demonstrated by the higher levels of
Bcl-2 found in AD IPL compared to aMCI IPL (Figs. 4.4; 4.5).
Additionally, latent and active caspase-3 immunoreactivity was investigated in this
dissertation study because of their critical involvement in PtdSer externalization and apoptosis
(Mandal et al., 2002; Nicholson, 1999). While the antibody used in this study should have
recognized both precursor and active fragments of caspase-3 if present in aMCI and/or AD IPL,
only a signal correlating to increased procaspase-3 levels was detected by Western blot in both
aMCI and AD samples (Fig. 4.6). Although activated caspase-3 fragments, p18 and p12, are
found only in cells undergoing apoptosis (Nicholson et al., 1995), present results do not
necessarily indicate a lack of apoptosis in either aMCI or AD IPL brain, but rather they suggest
that levels of key components of the apoptotic system are altered and may be the initial cause of
neuronal loss. Unfortunately, the relative contribution of apoptosis to neuronal cell loss in AD
brain is difficult to assess due to the chronic nature of the process. While some neurons exhibit
morphological features of apoptosis, many degenerating neurons do not, indicating apoptosis is
not the only mechanism of neurodegeneration in AD (Su et al., 1994), or even aMCI. Detection
of increased procaspase-3 in the current study is congruent with previous studies showing loss of
flippase translocase activity and subsequent PtdSer externalization downstream of caspase-3 upregulation and activation under oxidative stress conditions (Mandal et al., 2002; 2005; Martin et
al., 1996; Nicholson, 1999; Vanags et al., 1996). These studies demonstrate that excessive outerleaflet exposure of PtdSer in erythrocytes, as well as loss of flippase activity, can be blocked by
pretreatment with a caspase-3 inhibitor prior to oxidation (Mandal et al., 2002). Such findings
imply PtdSer oxidation and subsequent exposure is an intrinsic feature of the apoptotic process
due to flippase inactivation (Kagan et al., 2002).
Apart from the factors described above, other considerations could conceivably
contribute to the loss of PtdSer asymmetry observed in aMCI and AD IPL in the current study.
For example, flippase has a known sensitivity to the cellular influx of Ca2+, in that its
translocating activity is significantly affected at [Ca2+]i of 0.2 μM or higher (Bitbol et al., 1987;
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Daleke, 2003). Furthermore, HNE and acrolein can also disrupt Ca2+ homeostasis, again
interfering with PtdSer asymmetry by eliciting protein oxidation and lipid peroxidation on their
own (Castegna et al., 2004; Mohmmad Abdul and Butterfield, 2005). However, it is unlikely
that elevated Ca2+ is the chief contributor to asymmetric collapse as previous studies indicate that
in the presence of BAPTA AM (a Ca2+ chelator), acrolein can still induce significant loss of
flippase activity and PtdSer externalization (Castegna et al., 2004). In addition to intracellular
Ca2+ levels, PtdSer asymmetry can also be affected by oxidative stress-induced changes in
membrane cholesterol, elevated levels of amyloid-β peptide (Aβ), and aging (Lopez-Revuelta et
al., 2007; Wood et al., 2003; 2002).
Cholesterol is a physiochemical modulator of the lipid bilayer (Fig. 2.12) that affects
multiple membrane functions (see section 2.2), including its susceptibility to oxidative stress
(Lopez-Revuelta et al., 2007), control of Aβ synthesis, and interactions between Aβ and neuronal
membranes (Eckert et al., 2003). A previous study by Lopez-Revuelta et al. (2007) suggests that
cholesterol depletion promotes oxidative stress-induced externalization of PtdSer associated with
significant inhibition of flippase activity and increased uptake of altered cells by macrophages in
the periphery (Lopez-Revuelta et al., 2007). Moreover, diminishing membrane cholesterol levels
could contribute to oxidative stress and neurodegeneration induced by increased production of
small, soluble aggregates of Aβ(1-42) that elicit their neurotoxic effects by inserting into the
bilayer [Fig. 2.52] (Butterfield et al., 2007a; Drake et al., 2003a; Kanski et al., 2002; Klein,
2006; Lambert et al., 1998; Schubert et al., 1995; Selkoe, 2001b). PtdSer asymmetric collapse
has been reported to be caused by Aβ(1-42), a process that can be inhibited by antioxidants [see
section 2.2.4.6] (Mohmmad Abdul and Butterfield, 2005). Thus, cholesterol asymmetry and
Aβ(1-42)-induced oxidative stress could also contribute to the loss of PtdSer asymmetry
observed in aMCI and AD brain in the present study. However, it is important to note that
although many different parameters may contribute to PtdSer asymmetric collapse in AD and
aMCI brain, all studies converge on the notion that oxidative-inactivation of flippase is a central
cause.
Results reported in this dissertation study represent the first investigation of aMCI PtdSer
asymmetry and its relation to apoptotic-factor expression to date, and are consistent with the
concept that oxidative modification of PtdSer and/or flippase occurred in the IPL of subjects with
aMCI and AD causing the collapse of PtdSer inner-leaflet asymmetry and eventual neuronal cell
death. These findings also suggest that oxidative stress not only increases the production of lipid
peroxidation products, HNE and acrolein in the bilayer, but also levels of pro- and anti-apoptotic
proteins that affect PtdSer asymmetry, thereby causing neuronal death as early as aMCI. By
looking at both disease stages, we can conclude that PtdSer outer-leaflet exposure is an important
link to those patients with aMCI that eventually develop full-onset AD, in accordance with the
model of apoptosis-specific oxidation of phospholipids that confirms PtdSer exposure is required
for apoptotic-cell phagocytosis in aMCI and AD brain. Furthermore, it is crucial that flippase
activity be highly maintained in order to prevent premature PtdSer exposure, early apoptosis, and
subsequent neurodegeneration. Once flippase-specific antibodies become available, we will be
able to directly examine this particular translocase apart from similar integral membrane
transporters, as well as its response to oxidation phenomena apart from PtdSer.

Copyright © Miranda Lu Lange, 2010
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CHAPTER 5
AGE-RELATED LOSS OF PHOSPHOLIPID ASYMMETRY IN APPNLh/APPNLh x PS1P264L/PS-1P264L HUMAN DOUBLE KNOCK-IN MICE: RELEVANCE TO ALZHEIMER
DISEASE
5.1 Overview
Using brain from APPNLh/APPNLh x PS-1P246L/PS-1P246L human double knock-in (APP/PS1) mice, this dissertation study examined whether phosphatidylserine (PtdSer) asymmetry is
significantly altered in an age-dependent manner due to oxidative stress, toxic amyloid-β peptide
(1-42) [Aβ(1-42)] oligomer production, and/or apoptosis. Annexin V (AV) and NBD-PS
fluorescent assays examined PtdSer exposure with age in synaptosomes of wild-type (WT) and
APP/PS-1 mice, while Mg2+ATPase activity was determined in order to correlate PtdSer
asymmetry changes with activity of flippase, the adenosine triphosphate (ATP)-dependent,
membrane-bound PtdSer translocase. AV and NBD-PS assays both demonstrated significant
PtdSer exposure beginning at 9 months of age compared to 1 month-old WT controls, a trend
that was augmented in APP/PS-1 synaptosomes. Decreasing Mg2+ATPase activity confirmed
that the age-related exposure of PtdSer to the outer-leaflet of the lipid membrane is likely due to
declining flippase activity, which is more prominent in APP/PS-1 brain. Two-site (sandwich)
enzyme-linked immunosorbant assay (ELISA) on sodium dodecyl sulfate (SDS)- and formic
acid (FA)-soluble APP/PS-1 brain fractions was completed in order to compare levels of soluble
and insoluble Aβ(1-40) and Aβ(1-42) with age-related trends exhibited in AV, NBD-PS, and
Mg2+ATPase assays. ELISA assay revealed a significant increase in both SDS- and FA-soluble
Aβ(1-40) and Aβ(1-42) with age, consistent with PtdSer and flippase assay trends. Finally, the
levels of both latent and active forms of caspase-3 were measured by Western blot to further
examine the relationship between PtdSer exposure and pro-apoptotic factor expression, as PtdSer
exposure is known to be affected by caspase-3. Western blot analysis revealed an increase in
both active fragments of caspase-3 with age, while levels of procaspase-3 gradually decreased.
These results are discussed with relevance to loss of PtdSer asymmetry and consequent
neurotoxicity in Alzheimer disease (AD) brain.
5.2 Introduction
AD is a largely sporadic, age-associated neurodegenerative disorder that can be
pathologically characterized by the appearance of neurofibrillary tangles and neuritic plaques,
elevated oxidative stress and damage to brain proteins, lipids, and nucleic acids, and eventual
synapse and neuronal cell loss, all of which culminate into progressive cognitive decline (see
section 2.6). However, in rare cases this disease can be inherited as familial AD (FAD), which is
caused by autosomal dominant mutations in the amyloid precursor protein [APP] (Goate et al.,
1991) or presenilin (PS) genes 1 and/or 2 (Citron et al., 1992; Cruts et al., 1998; Scheuner et al.,
1996; Sturchler-Pierrat et al., 1997), a mutation in PS-1 being more aggressive. FAD produces
the same clinical and pathological consequences as sporadic forms of AD, but at a much earlier
age of onset [~30 years old] (Citron et al., 1992; Scheuner et al., 1996; Sturchler-Pierrat et al.,
1997; Wisniewski et al., 1998). Because presenilins are involved in APP processing (Selkoe et
al., 1996), mutations in APP and PS-1 or PS-2 result in the increased production of pathologic
111

amyloid-β peptides (1-40) [Aβ(1-40)] and (1-42) [Aβ(1-42)] (Figs. 2.51; 2.53) (Borchelt et al.,
1997; Cai et al., 1993; Oyama et al., 1998; Scheuner et al., 1996). In particular, it is the longer,
more hydrophobic Aβ(1-42) that is toxic in AD (Drake et al., 2003a; Lambert et al., 1998;
Mattson, 1997), as it is considerably more prone to oligomerization and subsequent fibril
formation than the more abundantly produced Aβ(1-40) (Burdick et al., 1992; Jarrett et al.,
1993), and represents the main component of neuritic plaques [see section 2.6.2] (Selkoe, 2001b;
Wirths et al., 2006).
Oxidative stress-induced lipid peroxidation in AD and FAD disrupts cellular homeostasis
by interfering with a variety of processes (Butterfield and Lauderback, 2002; Lauderback et al.,
2001), such as phospholipid asymmetry in the cell membrane (Castegna et al., 2004; Mohmmad
Abdul and Butterfield, 2005). In particular, the aminophospholipid PtdSer (Fig. 2.10) is
normally sequestered to the cytosolic, inner-leaflet of the lipid bilayer (Bretscher, 1972; Op den
Kamp, 1979; Rothman and Lenard, 1977) by the ATP-dependent, membrane bound,
aminophospholipid translocase, flippase, which unidirectionally transports PtdSer, and to a lesser
extent, phosphatidylethanolamine (PtdEtn), inward against its concentration gradient (Daleke
and Huestis, 1985; Daleke and Lyles, 2000; Seigneuret and Devaux, 1984). However, collapse
of PtdSer asymmetry can be induced by lipid peroxidation products, 4-hydroxy-2-trans-nonenal
(HNE) [Fig. 2.36] and/or 2-propen-1-al [acrolein] (Butterfield et al., 2006c; Lauderback et al.,
2001; Lovell et al., 2001; Markesbery and Lovell, 1998), within the bilayer that expose PtdSer to
the outer-leaflet, signaling the first stages of an apoptotic process and for selective recognition
and mononuclear phagocytosis of dying cells [see section 2.5] (Castegna et al., 2004; Fadok et
al., 2001; 1992a; Kagan et al., 2003; Tyurina et al., 2004a; 2004b).
In the same way, toxic Aβ(1-42) oligomers can also initiate lipid peroxidation events
during AD and FAD progression (Butterfield et al., 2007a; Kanski et al., 2002; Lambert et al.,
1998; Schubert et al., 1995; Selkoe, 2001b; Wirths et al., 2006) by integrating into the membrane
and/or binding to its surface (Hertel et al., 1997; Kayed et al., 2004; McLaurin and Chakrabartty,
1997) and being stabilized by the very phospholipids that comprise the majority of the membrane
itself [Fig. 2.52] (Johansson et al., 2007b; Martins et al., 2008). For example, Aβ(1-42)-induced
lipid peroxidation can disrupt phosphatidylinositol-4,5-bisphosphate metabolism (Berman et al.,
2008), increase bilayer conductance by altering its dielectric structure (Sokolov et al., 2006), and
increase bilayer permeability (Arispe and Doh, 2002; Demuro et al., 2005; Kayed et al., 2004;
Muller et al., 1995). Consequently, oligomeric Aβ(1-42) could be a major contributor to the
oxidative stress and damage observed in AD and FAD by augmenting lipid peroxidation events,
indexed by elevated levels of HNE and acrolein, and disrupting PtdSer distribution (Figs. 2.52;
2.54; 2.55).
Aβ(1-42)-induced oxidative stress can also elevate the levels of apoptosis and neuronal
cell death by increasing pro-apoptotic factor expression, including the aspartate-specific cysteine
protease, caspase-3. Specifically, elevated levels of activated caspase-3 immunoreactivity have
been found in neurons and astrocytes of subjects with AD (Su et al., 2001). In addition, PtdSer
outer-leaflet externalization and loss of flippase translocating activity has been found to occur
downstream of caspase-3 activation in erythrocytes undergoing oxidative stress (Mandal et al.,
2002; 2005; Martin et al., 1996; Vanags et al., 1996). Thus, it can be concluded that PtdSer
extracellular exposure could be the result of one or more factors in AD and FAD brain either
working alone or in concert to negatively affect cellular homeostasis.
The present dissertation study investigated PtdSer asymmetry in brain of APPNLh/APPNLh
P246L
x PS-1
/PS-1P246L human double mutant knock-in mice (APP/PS-1) that are known to deposit
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Aβ(1-42) in an age-dependent manner beginning at 9 months, with neuritic plaques developing at
12 months (Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000). Synaptosomes
prepared from brain isolated from wild-type (WT) and APP/PS-1 mice were examined in an agedependent manner using AV and NBD-PS fluorescent assays to test the hypothesis that PtdSer
asymmetry is significantly altered in the brain of this mouse model of Aβ pathology, together
with age-related increases in Aβ(1-42). Two-site sandwich ELISA on SDS- and FA-soluble
brain fractions of APP/PS-1 mice was conducted in order to correlate soluble and insoluble
Aβ(1-40) and Aβ(1-42) levels with possible age-related trends ascertained from AV and NBDPS fluorescent assays. In addition, Mg2+ATPase activity was determined to compare any
changes observed in PtdSer asymmetry with flippase activity, while Western blotting was
employed to investigate how PtdSer asymmetry and flippase activity are affected by the levels of
latent and active forms of pro-apoptotic caspase-3.
5.3 Experimental Procedures
All materials and methods used in this study are described in Chapter 3 of this
dissertation. Specifically, sections 3.2.2, 3.3-3.6, 3.7.1.1, 3.8.1.2, and 3.14.1.
5.3.1 Statistical Analysis
All data in this dissertation study are presented as mean ± standard error of the means
(S.E.M.) and analyzed via GraphPad Prism 5.0 software for Windows (San Diego, CA). In onevariable experiments, one-way analysis of the variants (ANOVA) was used to determine the
effect(s) of WT mouse age on PtdSer asymmetry, Mg2+ATPase activity, and caspase-3 levels
followed by a Tukey post-hoc analysis to evaluate the significance of differences between group
means. In two-variable experiments, two-way ANOVA was used to determine the effect(s) of
age and WT or APP/PS-1 genotype on PtdSer asymmetry, Mg2+ATPase activity, and caspase-3
levels followed by Bonferroni's post-hoc analysis to evaluate the significance of differences
between group means. P<0.05 was considered significant for all studies.
5.4 Results
5.4.1 Sodium Dodecyl Sulfate (SDS)-Soluble Aβ(1-40) & Aβ(1-42) Levels as a Function
of Age in APP/PS-1 Mouse Brain
Two-site sandwich ELISA analysis of SDS-soluble Aβ(1-40) and Aβ(1-42) levels was
obtained in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington, KY).
Brain from 3, 6, 9, and 12 month-old APP/PS-1 mice were compared to brains from 1 month-old
APP/PS-1 mice as a control, as these APP/PS-1 mice are known to have significantly more
Aβ(1-40) and Aβ(1-42) than WT mice at all ages (Anantharaman et al., 2006; Murphy et al.,
2007; Reaume et al., 1996; Siman et al., 2000). Current results demonstrate a significant agedependent increase in both SDS-soluble Aβ(1-40) and Aβ(1-42) that begins at 1 month-old,
although values are masked by y-axis scaling (Fig. 5.1). The age-related increase in Aβ(1-40)
and Aβ(1-42) levels can be observed to begin at 3 months of age, although not significant, (Fig.
5.1), and continues to rise 500-fold in Aβ(1-40) and 300-fold in Aβ(1-42) at 12 months of age
relative to 1 month-old mice [Fig. 5.1a, Aβ(1-40), ***P<0.001; Fig. 5.1b, Aβ(1-42),
***P<0.001]. Moreover, the levels of Aβ(1-40) are slightly higher than Aβ(1-42) at all ages,
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consistent with the fact that Aβ(1-40) is produced in greater abundance (Burdick et al., 1992;
Jarrett et al., 1993).
Figure 5.1

Figure 5.1 Soluble amyloid-β (Aβ) load in sodium dodecyl sulfate (SDS)-fractions of
aging APP/PS-1 mouse brain. Soluble Aβ(1-40) and Aβ(1-42) levels in brain from 1, 3,
6, 9, and 12 month-old APP/PS-1 mice were quantified (pmol/g wet tissue) by enzymelinked immunosorbant assay (ELISA). Results demonstrate a significant age-dependent
increase in soluble A) Aβ(1-40) and B) Aβ(1-42) compared to respective 1 month-old
APP/PS-1 controls, which suggests soluble, toxic Aβ species induce early oxidative stress
and subsequent PtdSer outer-leaflet exposure. A) & B) Data are presented as mean ±
S.E.M. and significance assessed by one-way ANOVA followed by a Tukey post-hoc
analysis; ***P<0.001. 1 month-old, n=23; 3, 6, 9, and 12 months-old, n=5. Data
obtained in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington,
KY).
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5.4.2 Formic Acid (FA)-Soluble Aβ(1-40) & Aβ(1-42) Levels as a Function of Age in
APP/PS-1 Mouse Brain
Two-site sandwich ELISA analysis of FA-soluble Aβ(1-40) and Aβ(1-42) levels was
obtained in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington, KY).
Brain from 3, 6, 9, and 12 month-old APP/PS-1 mice were compared to brains from 1 month-old
APP/PS-1 mice as a control, as WT mice do not produce significant amounts of insoluble Aβ(140) or Aβ(1-42) at any age (Anantharaman et al., 2006; Murphy et al., 2007; Reaume et al.,
1996; Siman et al., 2000). These results demonstrate an age-dependent increase in FA-soluble
Aβ(1-40) and Aβ(1-42) [Fig. 5.2] compared to 1 month-old APP/PS-1 control mice, that begins
at 3 months-old for Aβ(1-42) [Fig. 5.2b], although not significantly. Levels of insoluble Aβ(142) continue to rise significantly 100-fold at 12 months of age (Fig. 5.2b, **P<0.01), while
insoluble Aβ(1-40) levels do not begin this age-related increase until 6 months of age (Fig. 5.2a).
Most notably, the amount of FA-soluble Aβ(1-42) is at all ages greater than that of Aβ(1-40),
which can be attributed to Aβ(1-42) being considerably more prone to and faster at
oligomerization and subsequent fibril formation than the more abundantly produced Aβ(1-40)
(Burdick et al., 1992; Jarrett et al., 1993).
Figure 5.2
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Figure 5.2 Insoluble amyloid-β (Aβ) load in formic acid (FA)-fractions of aging APP/PS1 mouse brain. Insoluble Aβ(1-40) and Aβ(1-42) levels in brain from 1, 3, 6, 9, and 12
month-old APP/PS-1 mice were quantified (pmol/g wet tissue) by enzyme-linked
immunosorbant assay (ELISA). Results demonstrate a significant age-dependent
increase in insoluble A) Aβ(1-40) and B) Aβ(1-42) compared to respective 1 month-old
APP/PS-1 controls, suggesting that soluble Aβ is most likely associated with the
observed age-dependent collapse in phosphatidylserine (PtdSer) asymmetry, and not the
insoluble, plaque-deposited species. A) & B) Data are presented as mean ± S.E.M. and
significance assessed by one-way ANOVA followed by a Tukey post-hoc analysis;
*P<0.05, **P<0.01. 1 month-old, n=23; 3, 6, 9, and 12 months-old, n=5. Data obtained
in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington, KY).

5.4.3 Annexin V (AV) Fluorescence in Synaptosomes from Brain of Wild-Type (WT) &
APP/PS-1 Mice
In order to assess the effects of normal brain aging on PtdSer outer-leaflet exposure,
synaptosomes extracted from whole brain of 1 month-old WT mice were used as a control to
compare synaptosomes isolated from whole brain of 6, 9, and 12 month-old WT mice. Present
results demonstrate a significant age-related increase in AV fluorescence beginning at 6 monthsold (Fig. 5.3a, *P<0.05), an increase that remains significant as mice age to 9 and 12 months-old
(Fig. 5.3a, 9 months-old, ***P<0.001; 12 months-old, **P<0.01) and are consistent with the
well-known increase in brain oxidative stress with age that leads to neuronal cell death
(Butterfield and Stadtman, 1997; Harman, 1956).
To assess effects of normal brain aging and genotype, AV-associated fluorescence in
synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1 mice was analyzed relative to that
of 1 month-old WT mice as a control (Fig. 5.3b). AV fluorescence was found to be significantly
increased at 9 and 12 months of age in brain of APP/PS-1 mice compared to 1 month-old WT
controls (Fig. 5.3b, 9 & 12 months-old, ***P<0.001). Additionally, there was a significant
increase in 9 and 12 month-old APP/PS-1 AV fluorescence compared to their respective 9 and
12 month-old, age-matched WT mice (Fig. 5.3b, 9 month-old, §§P<0.01; 12 month-old,
§§§
P<0.001), demonstrating that the APP/PS-1 knock-in genotype affects PtdSer exposure
significantly more than normal aging alone at these ages. Interestingly, both WT and APP/PS-1
mice exhibited an age-related AV fluorescence increase from 6 to 9 months-old, which was
significantly more prominent in APP/PS-1 mice (Fig. 5.3a, §P<0.05; Fig. 5.3b, §§§P<0.001),
directly correlating with significant Aβ(1-42) aggregation reported to begin at 9 months of age in
this particular mouse model of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996;
Siman et al., 2000).
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Figure 5.3

Figure 5.3 Annexin V (AV) binding assay in synaptosomes from wild-type (WT) and
APP/PS-1 mice. Synaptosomes isolated from 1, 6, 9, and 12 month-old WT and APP/PS1 mice were treated with the Annexin V FITC (AV). A) Phosphatidylserine (PtdSer)
outer-leaflet exposure for each WT age-group is presented as a percentage of 1 month-old
WT control. Results demonstrate a significant increase in AV fluorescence beginning at
6 months that continues to increase with age. Percent control values are presented as
mean ± S.E.M. and significance assessed by one-way ANOVA followed by a Tukey
post-hoc analysis; §,*P<0.05, **P<0.01, ***P<0.001. 1, 9, and 12 month age groups,
n=5; 6 month-old, n=8. B) PtdSer outer-leaflet exposure for each WT and APP/PS-1
age-group is presented as a percentage of 1 month-old WT control. Results demonstrate
a dramatic age-dependent increase in AV fluorescence in both WT and APP/PS-1 mice
from 6 to 9 months that continues to increase with age. However, this increase is more
prominent in APP/PS-1 mice, suggesting that increasing oxidative stress, Aβ load, and/or
apoptosis may cause significantly more PtdSer exposure than normal brain aging. A) &
B) Percent control values are presented as mean ± S.E.M. and significance assessed by
two-way ANOVA followed by Bonferroni's post-hoc analysis; §,*P<0.05, §§,**P<0.01,
§§§,
***P<0.001. 1, 9, and 12 month age groups, n=5; 6 month-old, n=8.
117

5.4.4 NBD-PS Fluorescence in Synaptosomes from Brain of Wild-Type (WT) &
APP/PS-1 Mice
In order to assess the effects of normal brain aging on PtdSer outer-leaflet exposure,
synaptosomes extracted from whole brain of 1 month-old WT mice were used as a control to
compare synaptosomes isolated from whole brain of 6, 9, and 12 month-old WT mice. NBD-PS
fluorescence was a second method employed to examine the effect of age on PtdSer asymmetry
in synaptosomes and confirm results obtained from AV assay. Loss of NBD-PS fluorescence is
observed if the exogenous NBD-PS probe has successfully integrated into the membrane and has
been exposed onto the outer bilayer leaflet where membrane-impermeable sodium dithionite
(Na2S2O4) chemically quenches fluorescence [Fig. 3.3] (McIntyre and Sleight, 1991). The value
of this technique is that it addresses potential concerns with fluorescent probe access to the innerleaflet of an unstable system, creating incorrect interpretation of asymmetric collapse, since
highly ionic S2O42- does not readily diffuse through the bilayer (McIntyre and Sleight, 1991). In
order to avoid graphical results showing negative, downward-facing bar graphs, data were
analyzed as a percentage of control values set to 100%, yielding a graphical presentation more
familiar to biochemical assays. Like AV studies, results show a significant decrease in NBD-PS
fluorescence beginning at 9 months (Fig. 5.4a, ***P<0.001) that remains significant to 12
months of age (Fig. 5.4a, ***P<0.001), again consistent with the well-known increase in brain
oxidative stress with age that can lead to neuronal cell death (Butterfield and Stadtman, 1997;
Harman, 1956).
To assess the effects of normal brain aging and genotype in WT and APP/PS-1 mice,
NBD-PS fluorescence in synaptosomes isolated from brain of 1, 6, 9, and 12 month-old WT and
APP/PS-1 mice was analyzed relative to that of 1 month-old WT mice as a control (Fig. 5.4b).
NBD-PS fluorescence was significantly lost at 9 and 12 months-old in brain from APP/PS-1
mice compared to 1month-old WT control brain (Fig. 5.4b, 9 & 12 months-old, ***P<0.001).
Additionally, there was a significant decrease in 12 month-old APP/PS-1 fluorescence compared
to age-matched, 12 month-old WT mice (Fig. 5.4b, §§P<0.01), which also illustrates that the
APP/PS-1 knock-in genotype has a significantly greater affect on PtdSer externalization than
normal aging alone at these ages.
Also confirming results obtained from AV fluorescence assay described above, both WT
and APP/PS-1 mice exhibited a significant age-related decrease in NBD-PS fluorescence from 6
to 9 months of age (Fig. 5.4a,b, WT & APP/PS-1, §§§P<0.001) that is more prominent in
APP/PS-1 mice. These results directly correlate with significant Aβ(1-42) aggregation that is
reported to begin at 9 months of age in this particular mouse model of Aβ pathology
(Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000). Moreover, there was
significantly greater maintenance of PtdSer asymmetry in brain from 1 and 6 month-old APP/PS1 mice compared to 1 month-old WT controls (Fig. 5.4b, 1 month-old, †††P<0.001; 6 months-old,
†
P<0.05), suggesting that the APP/PS-1 mouse brain attempts to counter elevated oxidative stress
associated with Aβ(1-42) that develops at these early ages (Abdul et al., 2008).
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Figure 5.4

Figure 5.4 NBD-PS assay in synaptosomes from wild-type (WT) and APP/PS-1 mice.
Synaptosomes isolated from 1, 6, 9, and 12 month-old WT and APP/PS-1 mice were
treated with the fluorescent phospholipid NBD-PS and quenched with Na2S2O4. A)
Phosphatidylserine (PtdSer) outer-leaflet exposure for each WT age-group is presented as
a percentage of 1 month-old WT mice as a control. Results demonstrate a significant
decrease in NBD-PS fluorescence from 6 to 9 months that continues to decrease with age.
Percent control values are presented as mean ± S.E.M. and significance assessed by oneway ANOVA followed by a Tukey post-hoc analysis; §§§,***P<0.001. 1, 9, and 12
month age groups, n=5; 6 month-old, n=8. B) PtdSer outer-leaflet exposure for each WT
and APP/PS-1 age-group is presented as a percentage of 1 month-old WT control.
Results demonstrate an age-dependent decrease in NBD-PS fluorescence in both WT and
APP/PS-1 mice from 6 to 9 months-old. However, this decrease is more prominent in
APP/PS-1 mice, suggesting that increasing oxidative stress, Aβ load, and/or apoptosis
may cause significantly more PtdSer exposure than normal brain aging. Conversely, at 1
and 6 months of age there was a significant increase in APP/PS-1 NBD-PS fluorescence,
suggesting less PtdSer exposure at these ages compared to age-matched WT controls. A)
& B) Percent control values are presented as mean ± S.E.M. and significance assessed by
two-way ANOVA followed by Bonferroni's post-hoc analysis; Significant decrease:
119

P<0.01, §§§,***P<0.001; Significant increase: †P<0.05,
age groups, n=5; 6 month-old, n=8.
§§

†††

P<0.001. 1, 9, and 12 month

5.4.5 Mg2+ATPase Activity in Synaptosomes from Brain of Wild-Type (WT) &
APP/PS-1 Mice
Mg2+ATPase activity was measured as an indirect representation of the activity of the
ATP-dependent, membrane-bound PtdSer translocase, flippase, as highly specific antibodies to
flippase have not yet been obtained (Auland et al., 1994). Mg2+ATPase activity was measured
by UV-absorbance (810 nm) as the net amount of inorganic phosphate (Pi) formed by
functioning Mg2+ATPase enzymes within the membrane (Sadrzadeh et al., 1993). The effect of
normal brain aging on Mg2+ATPase activity was assessed by comparison of 6, 9, and 12 monthold whole brain-extracted synaptosomes to those isolated from 1 month-old WT mice as a
control. These results demonstrate a significant age-dependent decrease in enzyme activity
beginning at 9 months-old (Fig. 5.6a, *P<0.05), a decrease that becomes even more significant at
12 months of age (Fig. 5.5a, **P<0.01) compared to 1 month-old WT controls. Together with
AV and NBD-PS studies described above, Mg2+ATPase results are also congruent with previous
reports of increasing oxidative stress in brain due to normal aging processes (Butterfield and
Stadtman, 1997; Harman, 1956).
The effect of normal brain aging with respect to genotype in WT and APP/PS-1 mice on
2+
Mg ATPase activity was assessed by comparison of synaptosomes extracted from 1, 6, 9, and
12 month-old WT and APP/PS-1 mice to that of 1 month-old WT mice as a control (Fig. 5.5b).
Similar to WT aging trends, APP/PS-1 mice show a significant decrease in Mg2+ATPase activity
starting at 9 months-old (Fig. 5.5a, **P<0.01) that becomes even more significant at 12 months
of age (Fig. 5.5b, ***P<0.001) compared to 1 month-old WT controls. Additionally, there was a
significant decrease in 12 month-old APP/PS-1 mouse enzyme activity compared to 12 monthold WT mice (Fig. 5.5b, §§§P<0.001), illustrating that the APP/PS-1 genotype significantly
affects the activity of all Mg2+ATPase enzymes, including flippase, to a greater extent than
normal aging alone.
Notably, APP/PS-1 mice exhibit a significant age-related decrease in Mg2+ATPase
activity from 6 to 9 months and 9 to 12 months-old (Fig. 5.5b, 6 to 9 months-old, §§§P<0.001; 9
to 12 months-old, §§P<0.01) that is absent in WT mice (Fig. 5.5a), which directly correlates to
the significant aggregation of Aβ(1-42) that is reported to begin at 9 months of age in this mouse
model of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).
However, this trend is contrasted by either greater maintenance or enrichment of Mg2+ATPases
in the lipid bilayer from 1 to 6 months-old in APP/PS-1 mice (Fig. 5.5b, †P<0.05), a trend that is
also significant between 6 month-old WT and age-matched 6 month-old APP/PS-1 mice (Fig.
5.5b, †††P<0.001). Consistent with both AV and NBD-PS fluorescence, this particular trend
reinforces the notion that young APP/PS-1 mouse brain is attempting to protect itself from an
increasingly oxidative environment associated with Aβ(1-42) (Abdul et al., 2008).
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Figure 5.5

Figure 5.5 Mg2+ATPase activity in synaptosomes from wild-type (WT) and APP/PS-1
mice. Mg2+ATPase activity from 1, 6, 9, and 12 month-old WT and APP/PS-1 mice was
measured to represent flippase activity. Decreased UV-absorbance (810 nm) denotes
decreased Mg2+ATPase (i.e., flippase) activity. A) Mg2+ATPase activity for each WT
age-group is presented as a percentage of 1 month-old WT mice as a control. Results
demonstrate a significant decrease in Mg2+ATPase activity beginning at 9 months that
continues to decrease with age. Percent control values are presented as mean ± S.E.M.
and significance assessed by one-way ANOVA followed by a Tukey post-hoc analysis;
§,
*P<0.05, **P<0.01. 1, 9, and 12 month age groups, n=5; 6 month-old, n=8. B)
Mg2+ATPase activity for each WT and APP/PS-1 age-group is presented as a percentage
of 1 month-old WT mice as a control. Results demonstrate an age-dependent decrease in
Mg2+ATPase activity in both WT and APP/PS-1 mice from 6 to 9 months-old. However,
this decrease is more prominent in APP/PS-1 mice at 12 months-old, suggesting that
increasing oxidative stress, amyloid-β (Aβ) load, and/or apoptosis may cause
significantly more damage to transmembrane proteins, thus affecting PtdSer asymmetry.
Conversely, from 1 to 6 months-old there was a significant increase enzyme activity in
APP/PS-1 brain, suggesting significant protection or up-regulation of Mg2+ATPases at
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these ages compared to age-matched WT mice. A) & B) Percent control values are
presented as mean ± S.E.M. and significance assessed by two-way ANOVA followed by
Bonferroni's post-hoc analysis; Significant decrease: *P<0.05, §§,**P<0.01,
§§§,
***P<0.001; Significant increase: †P<0.05, †††P<0.001. 1, 9, and 12 month age
groups, n=5; 6 month-old, n=8.

5.4.6 Caspase-3 Levels in Brain of Wild-Type (WT) & APP/PS-1 Mice
Pro-apoptotic caspase-3 is synthesized as an inactive, cytosolic precursor (36 kDa), that is
cleaved into two active fragments, p18 (20 kDa; amino acids 29-175) and p12 (18 kDa; amino
acids 176-277) upon activation by apoptotic stimuli. The anti-caspase-3 primary antibody used
in this study was chosen for its ability to recognize all three forms of caspase-3 on Western blots,
while α-tubulin (50 kDa) was used as a loading control to normalize the amount of protein
loaded in each well of the gel and transferred to blots (Figs. 5.6a; 5.7a; 5.8a). In order to
examine the effect of normal aging on the levels of latent and active forms of casepase-3, whole
brain homogenate from 6, 9, and 12 month-old WT mice was blotted and analyzed with respect
to 1 month-old WT mice as a control (Figs. 5.6-5.8). Results demonstrate that procaspase-3
levels steadily decrease with age (Fig. 5.6a,b), becoming significant at 12 months-old (Fig. 5.6b,
*P<0.05) compared to 1 month-old WT controls. This age-related decrease in procaspase-3
levels was mirrored in brain from 1, 6, 9, and 12 month-old APP/PS-1 mice compared to 1
month-old WT controls, emulating trends detected with NBD-PS fluorescence, in that, there is a
large increase in 6 month-old APP/PS-1 procaspase-3 levels, although not significant, followed
by steadily decreasing procaspase-3 levels with age (Fig. 5.6c).
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Figure 5.6

Figure 5.6 Procaspase-3 levels in brain from wild-type (WT) and APP/PS-1 mice.
Procaspase-3 levels were measured by 1D-polyacrylamide gel electrophoresis (1DPAGE; 75 μg/lane) and subsequent Western blot analysis in 1, 6, 9, and 12 month-old
WT and APP/PS-1 (HO) mice to correlate decreasing flippase activity with levels of proapoptotic factor expression. A) Increased band intensity after normalization with αtubulin represents an increase in the amount of procaspase-3 present. n=5 for all agegroups, however only representative bands from n=3 independent samples are shown. B)
Graphical analysis of WT mouse band intensities at each age compared to 1 month-old
WT mice as a control demonstrates a gradual decrease in procaspase-3 levels with age
that becomes significant at 12 months-old. Percent control values are presented as mean
± S.E.M. and significance assessed by one-way ANOVA followed by a Tukey post-hoc
analysis; *P<0.05; n=5 for all age-groups. C) Graphical analysis of WT and APP/PS-1
band intensities at each age compared to 1 month-old WT controls show that APP/PS-1
mice also present a decrease in procaspase-3 levels, becoming significant at 12 monthsold. However, like NBD-PS & Mg2+ATPase data, there is an obvious increase in 6
month-old APP/PS-1 procaspase-3 levels, although not significant, suggesting a possible
increase in apoptotic processes at this early age compared to WT mice. Percent control
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values are presented as mean ± S.E.M. and significance assessed by two-way ANOVA
followed by Bonferroni's post-hoc analysis; *P<0.05, §§,**P<0.01; n=5 for all age-groups.

In contrast, immunoblot analysis of the active-fragment p18 in 6, 9, and 12 month-old
WT mice compared to 1 month-old WT controls shows a tendency for levels of this fragment to
increase with age, becoming significant at 9 months-old (Fig. 5.7b, **P<0.01). This age-related
trend is also reflected in brain of 1, 6, 9, and 12 month-old APP/PS-1 mice compared to 1 monthold WT animals as a control, where a significant increase in p18 levels appear at 9 months-old
(Fig. 5.7c, ***P<0.001) and remaining significantly increased through 12 months of age (Fig.
5.7c, ***P<0.001). Moreover, there was a significant increase in both 9 and 12 month-old
APP/PS-1 p18 levels compared to respective age-matched, 9 and 12 month WT brain (Fig. 5.7c,
9 & 12 months-old, §P<0.05), suggesting that the APP/PS-1 knock-in genotype causes
significantly more neuronal apoptosis than normal aging alone in this particular mouse model of
Aβ pathology. Finally, the significant increase in p18 levels from 6 to 9 months-old in brain of
APP/PS-1 mice (Fig. 5.7c, §P<0.05) correlates with significant aggregation of Aβ(1-42) that is
reported to begin at 9 months-old in this APP/PS-1 mouse (Anantharaman et al., 2006; Reaume
et al., 1996; Siman et al., 2000).
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Figure 5.7

Figure 5.7 Active p18 fragment caspase-3 levels in brain from wild-type (WT) and
APP/PS-1 mice. Active caspase-3 fragment p18 (20 kDa) levels were measured by 1Dpolyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot
analysis in 1, 6, 9, and 12 month-old WT and APP/PS-1 (HO) mice to correlate
decreasing flippase activity with levels of pro-apoptotic factor expression. A) Increased
band intensity after normalization with α-tubulin represents an increase in the amount of
the p18 caspase-3 fragment present. n=5 for all age-groups, however only representative
bands from n=3 independent samples are shown. B) Graphical analysis of WT mouse
band intensities at each age compared to 1 month-old WT mice as a control demonstrates
a gradual increase in p18 levels with age that becomes significant at 9 months. Percent
control values are presented as mean ± S.E.M. and significance assessed by one-way
ANOVA followed by a Tukey post-hoc analysis; **P<0.01; n=5 for all age-groups. C)
Graphical analysis of WT and APP/PS-1 band intensities at each age compared to 1
month-old WT controls shows that levels of p18 in APP/PS-1 brain also significantly
increase from 6 to 9 months-old. However, this age-related increase is more prominent in
APP/PS-1 mice, suggesting that increasing oxidative stress and/or amyloid-β (Aβ) load
may cause significantly more apoptosis than normal brain aging. Percent control values
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are presented as mean ± S.EM. and significance assessed by two-way ANOVA followed
by Bonferroni's post-hoc analysis; §,*P<0.05, **P<0.01, ***P<0.001; n=5 for all agegroups.

Interestingly, the p12 active fragment of caspase-3 appears to follow a remarkably
different expression trend altogether, in that there is not an observable age-related increase or
decrease in p12 levels in either WT or APP/PS-1 mice (Fig. 5.8). Instead, both WT and APP/PS1 mice demonstrate a significant increase in p12 levels at 9 months of age (Fig. 5.8b, WT,
**P<0.01; Fig. 5.8c, APP/PS-1, *P<0.05) compared to 1 month-old WT controls that disappears
as WT and APP/PS-1 mice age from 9 to 12 months-old (Fig. 5.8b, WT, §§§P<0.001; Fig. 5.8c,
APP/PS-1, §P,0.05). However, it is of note that the present results do show a significant increase
in pro-apoptotic p12 levels at the age when significant aggregation of Aβ(1-42) is reported to
occur (i.e., 9 months) in brain of this particular mouse model of Aβ pathology (Anantharaman et
al., 2006; Reaume et al., 1996; Siman et al., 2000).
Figure 5.8
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Figure 5.8 Active p12 fragment caspase-3 levels in brain from wild-type (WT) and
APP/PS-1 mice. Active caspase-3 fragment, p12 (18 kDa) levels were measured by 1Dpolyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot
analysis in 1, 6, 9, and 12 month-old WT and APP/PS-1 (HO) mice to correlate
decreasing flippase activity with levels of pro-apoptotic factor expression. A) Increased
band intensity after normalization with α-tubulin represents an increase in the amount of
the p12 caspase-3 fragment present. n=5 for all age-groups, however only representative
bands from n=3 independent samples are shown. B) Graphical analysis of WT mouse
band intensities at each age compared to 1 month-old WT mice as a control demonstrates
a gradual increase in p12 levels with age that becomes significant at 9 months-old.
Percent control values are presented as mean ± S.E.M. and significance assessed by oneway ANOVA followed by a Tukey post-hoc analysis; **P<0.01, §§§P<0.001; n=5 for all
age-groups. C) Graphical analysis of WT and APP/PS-1 band intensities at each age
compared to 1 month-old WT controls shows that levels of p12 in APP/PS-1 brain also
significantly increase from 6 to 9 months-old. However, this age-related increase is more
prominent in APP/PS-1 mice, suggesting that increasing oxidative stress and/or amyloidβ (Aβ) load may cause significantly more apoptosis than normal brain aging. Percent
control values are presented as mean ± S.E.M. and significance assessed by two-way
ANOVA followed by Bonferroni's post-hoc analysis; §,*P<0.05, **P<0.01, ***P<0.001;
n=5 for all age-groups.

5.5 Discussion
AV and NBD-PS fluorescence analyses of synaptosomes from age-matched WT and
APP/PS-1 mice confirm the hypothesis that PtdSer asymmetry is significantly altered in brain of
this mouse model of Aβ pathology beginning at 9 months, in parallel with significant Aβ(1-42)
aggregation and oxidative stress (Abdul et al., 2008; Anantharaman et al., 2006; Mohmmad
Abdul et al., 2006; Reaume et al., 1996; Siman et al., 2000). Both WT and APP/PS-1 mice
follow a similar age-dependent trend in PtdSer outer-leaflet exposure, which suggests a
significant collapse in PtdSer asymmetry as a function of age (Figs. 5.3; 5.4). However, the key
difference between the loss of PtdSer asymmetry found in WT mice and APP/PS-1 mice is the
trend from 6 to 12 months of age, where the age-related increase in AV fluorescence, and
decrease in NBD-PS fluorescence, from 6 to 12 months-old is greater in APP/PS-1 mice (Figs.
5.3; 5.4), demonstrating that even though outer-leaflet exposure of PtdSer becomes increasingly
apparent with age, the degree of exposure is augmented in APP/PS-1 brain.
Furthermore, results from AV, NBD-PS, and ELISA assays illustrate that significant
PtdSer externalization corresponds to the age at which significant Aβ aggregation occurs (9
months; Figs. 5.1; 5.3; 5.4), and not of plaque deposition (12 months; Figs. 5.2-5.4). This
finding, along with previous studies of Aβ levels in APP/PS-1 mice (Anantharaman et al., 2006;
Mohmmad Abdul et al., 2006; Murphy et al., 2007; Siman et al., 2000), suggests that elevated
levels of SDS-soluble, oligomeric Aβ(1-42), together with increasing oxidative stress and
damage (Abdul et al., 2008; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; Kanski
et al., 2002; LaFontaine et al., 2002), in APP/PS-1 brain may contribute to altered PtdSer plasma
membrane localization beyond the effects of normal brain aging.
It is apparent from the significant rise in NBD-PS fluorescence in 1 and 6 month-old
APP/PS-1 mice (Fig. 5.4) that PtdSer externalization is an important dynamic in the ongoing
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neurodegeneration found in AD and FAD brain prior to significant Aβ aggregation or plaque
deposition, possibly representing a stage of toxic Aβ(1-42) oligomer formation. Consistent with
this notion, previous studies of 6 month-old Tg2576 mice expressing APP mutations similar to
this study (Hsiao et al., 1996) reveal that neuropathological changes and memory impairment
occur long before Aβ plaque deposition, correlating with levels of various soluble Aβ oligomers
(Hsia et al., 1999; Lesne et al., 2006; Mucke et al., 2000; Westerman et al., 2002). Moreover,
APP/PS-1 mice have been shown to have accumulated soluble Aβ as early as 1 day-old
(Mohmmad Abdul et al., 2006), while current ELISA results demonstrate a visible increase in
SDS-soluble Aβ(1-42) from 1 to 3 months-old that continues to escalate significantly with age
(Fig. 5.1b), in parallel to increasing oxidative stress levels previously measured in this same
APP/PS-1 mouse (Abdul et al., 2008). At these young ages, it is reasonable to speculate that the
APP/PS-1 mouse brain has up-regulated various neuroprotective systems (see section 2.4.6) that
have yet to be overcome by oxidative stress and damage induced, in part, by toxic Aβ(1-42)
oligomers. Such an up-regulation of a cellular stress response is a well-known course of action
which can be employed by neuronal cells to combat damage (Calabrese et al., 2007b; Poon et al.,
2004), and is consistent with the enrichment of PtdSer to the inner-leaflet of the plasma
membrane from 1 to 6 months-old (Fig. 5.4).
Initiation of a cell stress response involves the up-regulation of antioxidants and various
proteins that may be involved in maintenance of PtdSer asymmetry, including flippase, which is
represented by increasing Mg2+ATPase activity at 6 months of age in APP/PS-1 mouse brain
(Fig. 5.5). Current results suggest that during both WT and APP/PS-1 mouse brain aging,
oxidative stress intensifies beyond the capacity of the stress response (Abdul et al., 2008),
damaging flippase‟s translocating ability, and resulting in the age-dependent collapse in PtdSer
asymmetry, from 6 to 12 months-old (Figs. 5.3-5.5). Flippase activity is dependent on a critical
cysteine residue within its primary structure (Daleke, 2003; Daleke and Lyles, 2000; Paulusma
and Oude Elferink, 2005). Oxidative stress induces production of reactive alkenals, HNE (Fig.
2.35) and acrolein, within the bilayer that diffuse rapidly from their formation sites (Butterfield
and Stadtman, 1997; Butterfield et al., 2006c; Lovell et al., 2001; Markesbery and Lovell, 1998)
and form Michael adducts with cysteine residues, inhibiting flippase activity [Fig. 2.36] (Abdul
et al., 2008; Castegna et al., 2004; Daleke, 2003; Daleke and Lyles, 2000; Lauderback et al.,
2001; Paulusma and Oude Elferink, 2005; Tyurina et al., 2004a).
In addition to HNE and acrolein, Aβ(1-42) oligomers that continually form throughout
AD and FAD progression can also initiate lipid peroxidation events [see section 2.6.2]
(Butterfield, 2002; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; Kanski et al.,
2002; Schubert et al., 1995), either by penetrating the lipid membrane and/or binding to its
surface (Fig. 2.52). Either interaction is possible since Aβ(1-42) peptides are both hydrophobic
and inherently attracted to negatively charged phospholipid head-groups, such as PtdSer [Fig.
2.10] (McLaurin and Chakrabartty, 1997). Depending on the avenue of association, oligomers
can have a Ca2+ mobilizing effect through direct interaction with membrane receptors (Demuro
et al., 2005; Snyder et al., 2005), destabilize membrane structure by increasing its permeability
and fluidity (Demuro et al., 2005; Kayed et al., 2004; Muller et al., 1995; Sokolov et al., 2006),
and induce oxidative stress leading to dysregulation of mitochondria and subsequent apoptosis
[Figs. 2.52; 2.54; 2.55] (Butterfield, 2002; Butterfield and Lauderback, 2002; Butterfield et al.,
2007a; Drake et al., 2003a; Kanski et al., 2002; Lambert et al., 1998; Mattson, 2004; Schubert et
al., 1995). Thus, extensive oxidative stress, in addition to mounting Aβ(1-42) levels with age in
brains of APP/PS-1 mice, could be significant enough to overwhelm initial neuroprotective stress
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responses by 9 months-old and cause significant loss of PtdSer asymmetry beyond that of the
normal aged brain (Figs. 5.1; 5.3-5.5).
Ca2+ mobilization, whether Aβ(1-42)- and/or alkenal-induced, is noteworthy since
flippase possesses a known sensitivity towards the influx of Ca2+ at concentrations of 0.2 μM and
higher (Bitbol et al., 1987; Castegna et al., 2004; Daleke, 2003; Mohmmad Abdul and
Butterfield, 2005). However, prior studies with both in vitro and in vivo systems demonstrate
that Ca2+ dysregulation is not the chief contributor to PtdSer asymmetric collapse, but rather, a
secondary effect of oxidation events or other membrane alterations that lead to a detrimental
influx of Ca2+ influx (Castegna et al., 2004; Mohmmad Abdul and Butterfield, 2005). Therefore,
plasma membrane structural integrity with respect to cholesterol is also considered important.
The stability and structural integrity of the lipid membrane is generally attributed to
cholesterol, whose rigid structure allows it to integrate between phospholipid head-groups and
modulate membrane fluidity (Fig. 2.12). This physiochemical membrane modulator can affect
many bilayer functions (see section 2.2), including its susceptibility to oxidative stress (LopezRevuelta et al., 2007), control of Aβ synthesis, and interactions between Aβ and neuronal
membranes (Eckert et al., 2003). For example, previous studies with APP/PS-1 mice indicate
that brain Aβ(1-42) levels correlate inversely with declining membrane cholesterol levels
(George et al., 2004; Wirths et al., 2006). Another study by Arispe and Doh (2002)
demonstrated that enrichment of PC12 cells with exogenous cholesterol (i.e. reducing fluidity)
made them resistant to the cytotoxic action of soluble Aβ peptides, while reducing membrane
cholesterol (i.e. increasing fluidity) made cells more vulnerable (Arispe and Doh, 2002).
Furthermore, cholesterol depletion can stimulate an increase in lipid peroxidation (LopezRevuelta et al., 2005), resulting in significant PtdSer externalization associated with significantly
decreased flippase activity and increased uptake of altered cells by macrophages in the periphery
(Lopez-Revuelta et al., 2007). Taken en masse, this research suggests increased membrane
fluidity due to cholesterol reduction would provide soluble Aβ(1-42) oligomers the opportunity
to adversely affect PtdSer leaflet distribution and integral membrane protein (e.g. flippase)
function.
A third way in which soluble oligomers can lead to the age-related loss of synaptosomal
PtdSer asymmetry in APP/PS-1 mice is by inducing the up-regulation of pro-apoptotic factor
expression, as outer-leaflet exposure of PtdSer is a well-known signal of the initial stages of
apoptosis [see section 2.5] (Fadok et al., 1992a; Kagan et al., 2003; Paulusma and Oude Elferink,
2005; Tyurina et al., 2004a). Most notably, PtdSer externalization is reported downstream of
caspase-3 activation under oxidative stress conditions in some cell types (Mandal et al., 2002;
Martin et al., 1996; Nicholson, 1999; Vanags et al., 1996); in studies of erythrocytes, caspase-3
activation is also associated with loss of flippase PtdSer translocase activity (Mandal et al.,
2005). Current Western blot analysis of both precursor and active caspase-3 levels confirm that
apoptosis is an ongoing process in brain of APP/PS-1 mice as early as 1 month-old, as indicated
by the presence of the p18 and p12 active fragments of caspase-3 (Figs. 5.7; 5.8), found only in
apoptotic cells (Nicholson et al., 1995). Furthermore, the increasing p18 and p12
immunoreactivity beginning at 9 months is also consistent with AV, NBD-PS, and Mg2+ATPase
assay results, which all show significant changes occurring between the ages of 6 and 9 monthsold, emphasizing the importance of this time point in disease progression in brain of this
genotypic mouse model of Aβ pathology. It is interesting to note, however, that procaspase-3
levels steadily decrease as both WT and APP/PS-1 mice age, though more significantly in
APP/PS-1 brain (Fig. 5.6). Considering the steady increase in oxidative stress, Aβ(1-42)
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pathology, and apoptosis in APP/PS-1 mouse brain, the observed inverse relationship is most
likely due to the increased activation and cleavage of procaspase-3 into p18 and p12 active
fragments with disease progression.
Lastly, it should be noted that among other enzymes that could conceivably affect PtdSer
asymmetry, phospholipase A2 (PLA2), known to be altered in AD (Chalbot et al., 2009; Moses et
al., 2006), could contribute to exposure of PtdSer to the external leaflet in synaptosomes from
APP/PS-1 mice. However, previous studies of PLA2 from snake venom do not lead to
significant exposure of PtdSer in synaptosomal membranes (Ghassemi and Rosenberg, 1992).
Hence, though PLA2 may play a role in what we observed in this study, the likelihood of such a
role is small.
The current dissertation results are consistent with the notion that PtdSer exposure to the
outer bilayer leaflet indicates not only mounting oxidative stress and Aβ pathology in FAD and
AD, but also apoptosis at its earliest stages. Results reported in Chapter 4 of this dissertation
observing loss of PtdSer asymmetry in brain from subjects with aMCI and AD associated with
increased caspase-3 levels, along with a previous study in collaboration with the Butterfield
laboratory reporting a significant increase in oxidative stress beginning at 1 month-old in this
same APP/PS-1 mouse model (Abdul et al., 2008) support this notion. The significant innerleaflet enrichment of PtdSer at 1 and 6 months-old perhaps signifies an already well-advanced
cell stress response, while the diminution of inner-leaflet PtdSer levels from 6 to 9 months
suggests the elicited stress response was effectively overcome by harsh conditions generated
during disease progression in this mouse model of Aβ pathology. In summary, this study
represents the first age-dependent investigation of PtdSer asymmetry in a mouse model of Aβ
pathology by addressing how loss of PtdSer asymmetry may relate to pro-apoptotic factor
expression and toxic Aβ(1-42) accumulation.

Copyright © Miranda Lu Lange, 2010
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CHAPTER 6
IN VIVO OXIDATIVE STRESS IN BRAIN OF ALZHEIMER DISEASE TRANSGENIC
MICE: REQUIREMENT FOR METHIONINE 35 IN AMYLOID-β PEPTIDE OF APP
6.1 Overview
Numerous studies have demonstrated oxidative damage in the central nervous system in
both subjects with and animal models of Alzheimer disease (AD) amyoid-β (Aβ) pathology. In
this dissertation study, PDAPP transgenic (Tg) mice carrying Swedish and Indiana mutations in
the human amyloid precursor protein (APP) [Tg PDAPP(J20)] were used as an in vivo Aβ
pathology commonly found in familial AD (FAD) brain. In addition, genetically and agematched PDAPP mice carrying a methionine to leucine substitution at residue 35 (Met35Leu) on
the Aβ peptide (residue 631 in human APP numbering) [Tg PDAPP(M631L)] were created to
investigate the in vivo role of Met-35 in Aβ-induced oxidative stress. Slot-blot measures of
oxidative stress, indexed by levels of protein carbonyls, protein-resident 3-nitrotyrosine (3-NT),
and protein-bound 4-hydroxy-2-trans-nonenal (HNE), demonstrate that Aβ-induced oxidative
stress requires the presence of Met-35, as all indices of oxidative damage in brain of Tg
PDAPP(M631L) mice were completely prevented. Two-site enzyme-linked immunosorbant
assay (ELISA) demonstrated no significant differences in the levels of APP, Aβ(1–42), and
Aβ(1–40), or the ratio Aβ(1–42)/Aβ(1–40), suggesting that the loss of oxidative stress in vivo in
the brain of Tg PDAPP(M631L) mice was solely due to the Met35Leu (i.e., M631L)
substitution. However, immunohistochemical analysis showed a marked reduction in Aβimmunoreactive plaques in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, but a
significant increase in small punctuate areas of non-plaque immunoreactivity and microglial
activation. Contrasting slot-blot results, which suggested the requirement of Met-35 for
oxidative damage, behavioral analysis demonstrated no significant improvement in spatial
learning and memory in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice. This is
the first in vivo study to demonstrate the requirement for Met-35 of Aβ for oxidative stress in
brain of a mammalian model of Aβ pathology. However, in this specific Tg mouse model,
oxidative stress is neither required nor sufficient for memory abnormalities.
6.2 Introduction
Previous studies have demonstrated elevated levels of oxidative stress and damage in
brain of subjects with AD and amnestic mild cognitive impairment (aMCI), arguably the earliest
form of AD (Butterfield, 1997; Butterfield et al., 2007a; 2006b; 2006c; 2007b; Hensley et al.,
1995; Keller et al., 2005; Lyras et al., 1997; Markesbery, 1997; Petersen et al., 1999; Smith et al.,
1997; Varadarajan et al., 2000; Winblad et al., 2004). Proteomic analyses of human AD and
aMCI brain have identified numerous dysfunctional, oxidatively modified proteins consistent
with known biochemical, pathological, and clinical alterations in both conditions [see section
2.6] (Butterfield et al., 2007a; 2006b; Reed et al., 2008a; 2008b; Sultana et al., 2007a; 2007b;
2006b; 2006c).
In brain of subjects with AD and aMCI, it is the soluble, oligomeric 42-mer of the Aβ
peptide [Aβ(1-42)] that is considered to be the toxic Aβ species [see section 2.6.2] (Demuro et
al., 2005; Drake et al., 2003a; Viola et al., 2008), leading to a dramatic decline in learning and
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memory (Selkoe, 2008; Walsh et al., 2002). Previous studies have shown that the addition of
exogenous Aβ(1-42) to neurons in vitro results in elevated protein oxidation and lipid
peroxidation, as indexed by elevated levels of protein carbonyls (see section 2.4.4.1; Figs. 2.31;
2.32), protein-resident 3-NT (see section 2.4.4.2; Fig. 2.34), and protein-bound HNE (see section
2.4.5.1; Figs. 2.35; 2.36), each of which is blocked by antioxidants [see section 2.4.6] (Ansari et
al., 2006; Boyd-Kimball et al., 2004; Pappolla et al., 1999; Sultana et al., 2005). Moreover,
previous in vivo studies demonstrated that human Aβ(1-42) in Caenorhabditis elegans [C.
elegans] (Drake et al., 2003a) or in rodent brain (Abdul et al., 2008; Boyd-Kimball et al., 2005b;
Mohmmad Abdul et al., 2006; Resende et al., 2008; Zhu et al., 2008) also leads to oxidative
stress and damage.
Both Aβ(1-42) and Aβ(1-40) contain a single methionine residue at position 35
(corresponding to residue 631 of human APP) [Fig. 2.53] that has been linked to the oxidative
stress-inducing and neurotoxic properties of this peptide (Fig. 2.52). The Butterfield laboratory
has suggested that oxidative stress associated with toxic Aβ(1-42) is dependent on the formation
of a sulfur (S)-centered, transient free radical on Met-35 that leads to both protein oxidation and
lipid peroxidation in neurons [Figs. 2.54; 2.55] (Boyd-Kimball et al., 2004; Butterfield and
Boyd-Kimball, 2005; Kanski et al., 2002; Varadarajan et al., 2001; Yatin et al., 1999). For
example, substitution of norleucine (Nle) for Met (replacing the Met S-atom with a CH2 group;
Fig. 2.53) in human Aβ(1–42) abrogates the oxidative and neurotoxic effects of the resulting
Aβ(1-42) M35Nle peptide in cultured neurons, while maintaining similar length, hydrophobicity,
and tendency to aggregate as native human Aβ(1-42), even though this substitution does not
prevent fibril formation (Butterfield and Boyd-Kimball, 2005; Varadarajan et al., 2001; Yatin et
al., 1999). Likewise, in C. elegans, the expression of human Aβ(1-42) is also associated with
oxidative stress and damage (Drake et al., 2003a; Yatin et al., 1999); however, substitution of the
Met codon with a cysteine (Cys) codon (Fig. 2.53) in DNA encoding human Aβ(1-42) prevents
in vivo protein oxidation, while not affecting Aβ(1-42) accumulation or plaque deposition (Yatin
et al., 1999). These results suggest that those mechanisms of oxidative stress that involve Met35 of Aβ(1-42) apply both in vitro and in vivo, but do not involve deposition of the peptide.
The present dissertation study investigated the hypothesis that Met-35 of Aβ(1-42) is
critical for in vivo Aβ(1-42)-induced oxidative stress and in AD-related spatial memory deficits
in a well-characterized transgenic mouse model of Aβ pathology. Transgenic (Tg) mice carrying
human APP mutations corresponding to the Swedish and Indiana (APPSw,In) familial forms of
AD [Tg PDAPP(J20)] were derived, which show Aβ accumulation, plaque formation, and
memory deficits (Galvan et al., 2006; Hsia et al., 1999; Mucke et al., 2000). In addition,
genetically and age-matched Tg PDAPP mice carrying an additional M631L mutation
substituting a Leu for Met at residue 35 of Aβ [Tg PDAPP(M631L)] were also created to test the
hypothesis. Since Nle does not have a naturally occurring codon, Leu [-CH(CH3)2] was chosen
for its similar length and hydrophobicity to Met (Fig. 2.53). We then compared the degree of
oxidative damage in brain of Tg PDAPP(J20) mouse models of Aβ pathology with Tg
PDAPP(M631L) mice, as well as age-matched wild-type (WT) controls.
6.3 Experimental Procedures
All materials and methods used in this study are described in Chapter 3 of this
dissertation. Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, 3.7.1.3, 3.8.1.4, 3.13, 3.14.2, 3.15, and
3.16.
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6.3.1 Statistical Analysis
All slot-blot (Oxyblot) and ELISA analyses in this dissertation study are presented as
mean ± standard error of the means (S.E.M.) using a two-tailed Student‟s t-test, where P<0.05
was considered significantly different. All ELISA, 1D-polyacrylamide gel electrophoresis (1DPAGE), immunohistochemical, and behavioral analyses were performed by our collaborators at
the Buck Institute for Age Research (Novato, CA) using GraphPad Prism software (San Diego,
CA). In two-variable experiments, as when scoring performance of different genotypes across
several days of training, repeated measures, two-way analysis of the variants (ANOVA) followed
by Bonferroni‟s post-hoc tests were used to evaluate the significance of differences between
group means. When analyzing one-variable experiments with more than two groups, as when
scoring retention across genotypes in probe trials, significance of differences between means was
evaluated using one-way ANOVA followed by Dunnet‟s multiple comparison post-hoc test
using the Non Tg PDAPP and Tg PDAPP(M631L) as control groups in separate analyses. The
significance of differences in means between two different groups were further evaluated with
Student‟s t-test, where P<0.05 was considered significant. Pearson correlation coefficients
between variables were calculated with regression analyses using GraphPad Prism software (San
Diego, CA).
6.4 Results
PDAPP mice were created in collaboration with Professor Lennart Mucke at the
University of California (San Francisco, CA), while M631L mice were created by our
collaborators at the Buck Institute for Age Research (Novato, CA). Many lines of
PDAPP(M631L) were produced (>10) to derive two with high-level APP expression similar to
that of Tg PDAPP(J20) mice, in order to form an accurate comparison. Measures of Aβ(1–40)
and Aβ(1–42) are shown for the two highest expressing lines, A1058 and A1059. However,
because the A1058 line was closest to Tg PDAPP(J20) mice in APP expression, it was used for
all other studies reported in this study.
6.4.1 Indices of Oxidative Stress
Compared to Non Tg PDAPP littermates, brains isolated from Tg PDAPP(J20) mice
displayed elevated indices of oxidative stress (Fig. 6.1). Oxyblot (slot-blot) results demonstrate a
significant increase in protein carbonyls (Fig. 6.1a, *P<0.003), protein-resident 3-NT (Fig. 6.1b,
*P<0.002), and protein-bound HNE (Fig. 6.1c, *P<0.02) in brain from Tg PDAPP(J20) mice
compared to age-matched Non Tg PDAPP littermates. In addition, pre-treatment of Tg
PDAPP(J20) brain samples with NaBH4, to determine the specificity of the marker for protein
carbonyls by reducing carbonyls the alcohols preventing covalent attachment of 2,4dinitrophenylhydrazine (DNPH) [see section 3.13.1], prevented staining by the antidinitrophenylhydrazone (DNP) primary antibody (Fig. 6.2), in marked contrast to Tg
PDAPP(J20) samples derivatized with DNPH. This result confirms previous reports from the
Butterfield laboratory of the same finding (Aksenov et al., 2001; Sultana et al., 2006b). In
contrast, the Met35Leu substitution in brain of Tg PDAPP(M631L) completely abrogated the
elevation in all three parameters of oxidative stress compared to Tg PDAPP(J20) mice (Fig. 6.1).
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Figure 6.1

Figure 6.1 Oxidative modification of brain in transgenic (Tg) and non-transgenic (Non
Tg) mice: Role of Met-35 of amyloid-β (Aβ). A) Protein oxidation as indexed by protein
carbonylation. Results show a significant increase in the levels of protein carbonyls in
Tg PDAPP(J20) mice (n=10) compared to age-matched Non Tg PDAPP controls (n=5).
Tg PDAPP(M631L) mice (n=10) did not show a significant increase in protein carbonyls
compared to respective Non Tg M631L controls (n=5), but did, however, have
significantly reduced protein carbonyl levels compared to age-matched Tg PDAPP(J20)
mice. Non Tg control values were set to 100% to which Tg values were compared. Data
are presented as mean ± S.E.M. *P<0.003; **P<0.0004. B) Lipid peroxidation as
indexed by protein-bound 4-hydroxy-2-trans-nonenal (HNE). Results show a significant
increase in the levels of protein-bound HNE in Tg PDAPP(J20) mice (n=10) compared to
age-matched Non Tg PDAPP controls (n=5). Tg PDAPP(M631L) mice (n=10),
however, did not show a significant change in protein-bound HNE compared to Non Tg
M631L controls (n=5). Moreover, there were significantly reduced levels of proteinbound HNE in Tg PDAPP(M631L) mice compared to age-matched Tg PDAPP(J20)
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mice. Non Tg control values were set to 100%, to which Tg values were compared. Data
are presented as mean ± S.E.M. *P<0.02; **P<0.04. C) Protein oxidation as indexed by
protein-resident 3-nitrotyrosine (3-NT). In agreement with both protein carbonyl and
protein-bound HNE blots, a significant increase in Tg PDAPP(J20) [n=10] 3-NT levels
was found compared to age-matched Non Tg PDAPP controls (n=5), while Tg
PDAPP(M631L) [n=10] 3-NT levels did not significantly change compared to Non Tg
M631L controls (n=5).
However, there was a significant reduction in Tg
PDAPP(M631L) 3-NT levels compared to age-matched Tg PDAPP(J20) mice. Non Tg
control values were set to 100%, to which Tg values were compared. Data are presented
as mean ± S.E.M. *P<0.002; **P<0.0001.

Figure 6.2

Figure 6.2 Specificity assay for protein carbonyls. Duplicate brain samples from Tg
PDAPP(J20) mice (n=2) were subjected to Oxyblot analysis of protein carbonyls with
(right) and without (left) NaBH4 pre-treatment, a strong reducing agent that reduces
carbonyls to alcohols (Aksenov et al., 2001; Sultana et al., 2006b). Results clearly show
that pre-treatment with NaBH4 abrogates binding and subsequent staining with the antidinitrophenylhydrazone (DNP) primary antibody, demonstrating this assay‟s specificity
for protein carbonyls.

6.4.2 Amyloid Precursor Protein (APP) Expression, Amyoid-β (Aβ) production, & the
Aβ(1-42)/Aβ(1-40) Ratio
To ensure that Oxyblot results were not due to a difference in APP expression or
accumulation of Aβ(1–42) or Aβ(1–40), our collaborators at the Buck Institute for Age Research
(Novato, CA) compared the levels of APP by Western blot, while levels of both Aβ peptides
were determined by two-site sandwich ELISA. Western blot analysis of APP expression
demonstrated that the A1058 line of Tg PDAPP(M631L) mice expressed APP to similar levels as
Tg PDAPP(J20) mice (Fig. 6.3a), and therefore, the A1058 line of mice were chosen for all
analyses described in this dissertation study. ELISA assay demonstrated no significant
differences in production of either Aβ(1–40) or Aβ(1–42) in brains of Tg PDAPP(M631L) mice
compared to Tg PDAPP(J20) mice (Fig. 6.3b,c), whereas the ratio of Aβ(1–42) to Aβ(1–40) was
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slightly elevated, although not significantly, in the brains of the Tg PDAPP(M631L) mice
compared to Tg PDAPP(J20) mice (Fig. 6.3d). As no significant differences were found in APP
expression, Aβ(1–40) or Aβ(1–42) production, or the ratio of Aβ(1–42)/Aβ(1–40) between Tg
PDAPP(J20) and Tg PDAPP(M631L)A1058 mice, it was concluded that Oxyblot results were
solely a consequence of the Met35Leu transgene, and not a difference in APP expression or
accumulation of Aβ(1–42) or Aβ(1–40).
Figure 6.3

Figure 6.3 Amyloid precursor protein (APP) expression and amyloid-β (Aβ) production.
Many lines of PDAPP(M631L) were produced to derive two with a high-level of APP
expression similar to that of Tg PDAPP(J20) mice, to form an accurate comparison.
Western blot and enzyme-linked immunosorbant assay (ELISA) analyses demonstrate
that the PDAPP(M631L)A1058 line of mice A) express APP and B) produce Aβ(1-40)
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and C) Aβ (1-42) to similar levels as PDAPP(J20) mice. Therefore, A1058 Tg mice were
used for all other studies reported. D) The ratio of Aβ(1–42)/Aβ(1–40) between Tg
PDAPP(J20) and Tg PDAPP(M631L)A1058 mice. B)-D) Data are presented as mean ±
S.E.M. Data obtained by our collaborators at the Buck Institute for Age Research
(Novato, CA).

6.4.3 Immunohistochemistry
Plaque load in PDAPP mice was determined by our collaborators at the Buck Institute for
Age Research (Novato, CA) by anti-Aβ (6E10) immunohistochemistry, while microglial
activation was determined by anti-ionized Ca2+ binding-protein-1 (Iba-1) immunostaining. In the
molecular layer of the hippocampus, just superior to the dentate gyrus, anti-Aβ (6E10) staining
showed marked reduction in the size and abundance of Aβ-immunoreactive plaques in Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice (Fig. 6.4a,b). However, there was a
clear increase in punctate 6E10 labeling in Tg PDAPP(M631L) mice associated with increased
Iba-1 staining for microglial activation, not observed in Tg PDAPP(J20) mice (Fig. 6.4c,d).
Instead, Tg PDAPP(J20) mice showed amoeboid phagocytic microglia surrounding plaques.
Punctate labeling in Tg PDAPP(M631L) mice was even more marked in the corpus callosum and
white matter tracts lateral to the hippocampus and surrounding the thalamus, associated with a
proportionately greater microglial response (Fig. 6.4e,g). Tg PDAPP(J20) mice, again, did not
exhibit punctate staining, but instead showed phagocytic microglia surrounding plaques (Fig.
6.4f,h). Thus, these results suggest that Met-35 may be involved in Aβ plaque formation, as well
as oxidative stress.
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Figure 6.4
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Figure 6.4 Immunohistochemical staining of amyloid plaques and microglia. Coronal,
paraformaldehyde-fixed, paraffin-embedded brain sections were labeled with antiamyloid-β (Aβ) [6E10] and ionized Ca2+ binding-protein-1 (Iba-1), a marker for
microglia, antibodies. In the molecular layer of the hippocampus, just superior to the
dentate gyrus, 6E10 staining showed marked reduction in the size and abundance of Aβimmunoreactive plaques in A) Tg PDAPP(M631L) mice vs. B) Tg PDAPP(J20) mice.
A) & B) 6E10 images at 10 X original magnification. However, there was an increase in
punctate 6E10 labeling in C) Tg PDAPP(M631L) mice associated with increased Iba-1
staining for microglial activation, not observed in D) Tg PDAPP(J20) mice. Instead, Tg
PDAPP(J20) mice showed amoeboid phagocytic microglia surrounding plaques. E)
Punctate labeling in Tg PDAPP(M631L) mice was even more marked in the corpus
callosum and G) white matter tracts lateral to the hippocampus and surrounding the
thalamus, associated with a proportionately greater microglial response. F) Tg
PDAPP(J20) mice, again, did not exhibit punctate staining, but instead H) showed
phagocytic microglia surrounding plaques. C)-H) Iba-1 images at 20 X original
magnification. Data obtained by our collaborators at the Buck Institute for Age Research
(Novato, CA).

6.4.4 Behavioral Measures
Before beginning behavioral analyses, our collaborators at the Buck Institute for Age
Research (Novato, CA) evaluated PDAPP mice to ensure that their visual and somatic motor
systems were intact and that they were capable of swimming. None of the mice evaluated in this
study displayed any problems completing these preliminary tests.
In the Morris water-maze behavioral analyses (Morris, 1984), two indices were
examined: the latency index, which reflects the time necessary to find a hidden escape platform
and is a measure of visuospatial learning; and the number of passes mice made over the original
position of the platform after it was removed, which measures memory retention. The latency
index is characteristically abnormal in AD Tg mouse models, as well as other mice with
hippocampal dysfunction. The M631L mutation in Tg PDAPP(M631L) mice showed no
improvement over Tg PDAPP(J20) mice in latency index, as their performances were
indistinguishable from one another (Fig. 6.5a). However, both Tg PDAPP(J20) and Tg
PDAPP(M631L) mouse performance was significantly impaired with respect to Non Tg PDAPP
mice as a control [Fig. 6.5a, Tg PDAPP(J20), #P<0.01; Tg PDAPP(M631L), *P<0.01; Non Tg
M631L, ^P<0.05]. Tg PDAPP(M631L) mice also showed significantly increased floating
behavior with respect to all other groups (which were not significantly different from each other)
that may reflect helplessness associated with memory dysfunction [Fig. 6.5b, *P<0.001,
#
P<0.01, and ^P<0.001, with respect to Non Tg PDAPP, Non Tg M631L, and Tg PDAPP(J20)
mice, respectively]. Interestingly, the percentage of time spent floating increased significantly as
a function of day number during training for Tg PDAPP(J20), Tg PDAPP(M631L), and Non Tg
M631L mice compared to Non Tg PDAPP controls, as well [Fig. 6.5b, *P<0.0001 for all
groups].
As described previously (Galvan et al., 2008; 2006; Saganich et al., 2006), Tg
PDAPP(J20) mice showed a significant reduction in the number of passes over the former
platform position (target) compared to Non Tg littermates (Fig. 6.5c, *P<0.05). Similar to the
latency index, Tg PDAPP(M631L) mice showed no significant difference between Tg
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PDAPP(J20) and Non Tg M631L mice, suggesting that the M631L mutation did not improve
memory retention (Fig. 6.5c).
Figure 6.5

Figure 6.5 Morris water-maze behavioral assessment of PDAPP mice: Effect of the
M631L mutation. A) Latency index spatial training. Mean latencies to reach a hidden
platform were significantly different for Tg PDAPP(J20) [n=10, #P<0.01], Tg
PDAPP(M631L) [n=10, *P<0.01], and Non Tg M631L [n=5, ^P<0.05] groups with
respect to Non Tg PDAPP mice (n=5) as a control. Data are presented as mean ± S.E.M.
Data calculated by two-way ANOVA with Bonferroni's post-hoc test applied to a
significant effect of genotype F(3,78)=7.05, P=0.0013. B) Floating. Percentage time
spent floating increased significantly as a function of day number during training
[***P<0.0001 for all groups; F(3,78)=40.14]. Tg PDAPP(M631L) mice (n=10) spent a
significantly larger percentage of trial time floating than all other groups (which were not
significantly different from each other) [*P<0.001, #P<0.01, and ^P<0.001 with respect to
Non Tg PDAPP (n=5), Non Tg M631L (n=5), and Tg PDAPP(J20) mice (n=10),
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respectively]. Data are presented as mean ± S.E.M. Data calculated by two-way
ANOVA with Bonferroni's post-hoc test applied to a significant effect of genotype
F(3,78)=9.22, P=0.0003. “Floaters” were excluded from all other analyses. C) Probe
trial. Retention of the former platform site was impaired in Tg PDAPP(J20) mice with
respect to the Non Tg PDAPP littermates [*P<0.05; Dunnet's multiple comparison test
applied to a significant effect of genotype P=0.03; one-way ANOVA]. No significant
difference was observed for the comparison between Non Tg M631L or Tg PDAPP(J20)
mice and Tg PDAPP(M631L). Data are presented as mean ± S.E.M. Data obtained by
our collaborators at the Buck Institute for Age Research (Novato, CA).

6.5 Discussion
This dissertation study represents the first in vivo study to demonstrate the requirement of
the Met-35 residue of human Aβ for AD-associated oxidative stress in brain of a mammalian
model of Aβ pathology. Substitution of Met with Leu at residue 631 of human mutant APPSw,In
(corresponding to residue 35 of Aβ peptide) was shown to completely abrogate oxidative stress
induced by Aβ(1-42) when Met-35 was present (Fig. 6.1). Furthermore, differential expression
of APP, as well as ELISA-analyzed levels of Aβ(1-40) and Aβ(1-42), was shown not to be the
cause of diminished oxidative stress indices in brains of Tg PDAPP(M631L) mice (Fig. 6.4).
However, the Met35Leu mutation was shown to influence plaque formation, as Tg
PDAPP(M631L) mice displayed a reduction in 6E10 immunoreactive plaques (Fig. 6.5), and an
increase in non-plaque, punctate staining accompanied by a microglial response (Iba-1 staining)
[Fig. 6.5]. These findings suggest that Met-35 may be involved in the Aβ plaque formation
characteristic of Aβ, and are consistent with the notion that any non-specific or compensatory
changes secondary to the presence of a human transgene are unlikely to be responsible for the
lack of oxidative stress in brain isolated from Tg PDAPP(M631L) mice.
In general, methionine has important cellular functions, such as shielding the active sites
of enzymes against oxidation (Stadtman, 2004), promotion of α-helical secondary structure of
proteins (Vogt, 1995), aiding activity of certain repair or chaperone proteins (Bose-Basu et al.,
2004), and participation in the maintenance of redox status of cells (Schoneich, 2002). Within
the Aβ peptide, current studies indicate that Met-35 plays a crucial role in the oxidative stress
and damage associated with AD. In a study by Varadarajan, et al., (2001), it was suggested that
Aβ(1–42)-induced oxidative stress in neurons is carried out via catalytic processes [see section
2.6.2] (Varadarajan et al., 2001). They demonstrated that a small amount of Met-S-centered free
radical on Aβ(1–42) can be greatly amplified, as a chain reaction produced in the lipid phase of
the cell membrane initiated by abstraction of allylic hydrogen (H)-atoms from unsaturated acyl
chains of lipids by the S-centered radical cation (i.e., sulfuranyl radical) on Met-35 [Figs. 2.54;
2.55] (Varadarajan et al., 2001). This chain reaction can continue as long as there are allylic Hatoms available and continuously produce lipid peroxidation products, such as HNE [Fig. 2.35]
(Lauderback et al., 2001; Mark et al., 1997). This lipid peroxidation product can, in turn, react
via Michael addition with Cys, histidine (His), and lysine (Lys) residues of proteins causing
dramatic changes in structure [Fig. 2.36] (Subramaniam et al., 1997) and function (Esterbauer et
al., 1991; Lauderback et al., 2001; Sayre et al., 1997). When the sulfuranyl radical formed on
Met-35 of Aβ(1–42) abstracts an allylic H-atom from an unsaturated fatty acyl chain, it forms an
extremely acidic compound with a pKa of −5 (Fig. 2.55). Hence, any base, including water, can
remove the H+-atom from this acid, reforming the reduced S-atom on Met-35. Because the
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newly reduced Met-35 can, again, undergo a one-electron oxidation to form a sulfuranyl free
radical, this process is considered to be catalytic (Fig. 2.55).
The notion proposed by the Butterfield laboratory, that a one-electron oxidation of Met35 of Aβ(1–42) forms a sulfuranyl free radical that leads to lipid peroxidation and protein
oxidation in neurons in the brain of subjects with AD and aMCI (Butterfield and Boyd-Kimball,
2005; Kanski et al., 2002; Varadarajan et al., 2001), has been supported by other laboratories
(Crouch et al., 2006; Gomez-Balderas et al., 2005; Kadlcik et al., 2004). Recently, however, a
study by Maiti, et al. (2010) found a different result, demonstrating that substitution of Met-35
with a valine (Val) actually increases the toxicity of the resulting Aβ(M35V) peptide (Maiti et
al., 2010). However, it should be noted that this study was conducted with synthetic Aβ
peptides, using an amino acid that is slightly longer than Met, which could alter the reactive
properties of the resultant Aβ(Met35Val) peptide. On the other hand, considering the
aggregation properties of Aβ are strongly related to its toxicity, the current study has yet to
investigate the effects of the Met35Leu substitution on Aβ aggregation.
In agreement with the notion proposed by the Butterfield group, pulse radiolysis studies
conducted by Kadlcik, et al. (2004) revealed a S-centered free radical on Aβ(1–40), but not on
the peptide with the non-toxic, reverse sequence, Aβ(40–1) (Kadlcik et al., 2004). Moreover,
studies conducted by the Butterfield laboratory showing a lack of neurotoxicity, protein
oxidation, and lipid peroxidation in brain cells exposed to Aβ(1–42) when Met-35 was
substituted with Nle (Varadarajan et al., 2001; Yatin et al., 1999) or Cys [Fig. 2.53] (Yatin et al.,
1999) have also been confirmed by others (Clementi et al., 2006; Dai et al., 2007; Murray et al.,
2005). These studies suggested that Cu2+ was weakly bound to Met-35 of Aβ(1–42), consistent
with an earlier hypothesis proposed by the Butterfield laboratory (Butterfield and Boyd-Kimball,
2005), and with the results of studies with the divalent cation chelator clioquinol (Cherny et al.,
2001; Huang et al., 1999).
Figure 6.6

Figure 6.6 Structure of the divalent cation chelator, Clioquinol.

Clioquinol has been shown to dissolve plaques from Tg mice containing human mutant
APP (Cherny et al., 2001), even though the dissociation constant (KD) of Cu2+ for clioquinol
reportedly was nine orders of magnitude greater than that for Aβ(1–42) (Huang et al., 1999).
Hence, Butterfield and Boyd-Kimball (2005) suggested that a weakly bound Cu2+ ion on Met-35
of Aβ(1-42) could account for the one-electron oxidation of the Met-35, together with
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simultaneous reduction of Cu2+ to Cu+, which is capable of undergoing Fenton-type chemistry to
produce highly reactive free radicals (see section 2.4.3.1; reaction 3), and the data showing
weakly bound Cu2+ could be easily removed from Met-35 by cliquinol; whereas it is unlikely
that clioquinol could remove Cu2+ bound to His-6, -13, and -14 of Aβ(1–42) with a KD in the
attomolar range (Butterfield and Boyd-Kimball, 2005).
Indeed, oxidative stress has been demonstrated in the brain of another transgenic mouse
model of AD Aβ pathology (Smith et al., 1997), as well as a double knock-in mouse model of
Aβ pathology (Abdul et al., 2008). Although some have questioned the relevance of oxidative
stress associated with Aβ(1–42) in vivo (Nunomura et al., 2007), it is clear from the present
dissertation study that Aβ(1–42)-induced oxidative stress does not occur in mouse brain in vivo if
Met-35 of Aβ(1–42) is absent. The importance of the current dissertation study is that results
establish unequivocally the critical nature of Met-35 of Aβ(1-42) for in vivo oxidative stress in a
mammalian species brain, strongly suggesting similar importance of Met-35 of Aβ(1-42) in brain
of subjects with aMCI and AD. Although genetic manipulation of Met-35 of Aβ(1-42) in
humans is currently not possible, our results point to clinical translational possibilities for
therapy to potentially treat, slow progression of, or prevent aMCI and AD. Specifically,
blocking oxidative damage dependent on Met-35 of Aβ(1-42) in brain of subjects with aMCI and
AD offers a highly focused therapeutic approach, and studies to test this notion are in progress.
In contrast to the clear role of Met-35 of Aβ(1–42) in oxidative damage demonstrated
above, spatial learning and memory in Tg PDAPP(M631L) mice did not show a dependence on
Met-35 of Aβ. In behavioral analyses employing the Morris water-maze, neither the latency
period nor the number of times Tg PDAPP(M631L) mice swam over the platform site differed
significantly from that of the Tg PDAPP(J20) mice (Fig. 6.5). Thus, it can be concluded that
Met-35 and its associated oxidative damage are not required for the spatial memory loss that is
characteristic of this particular mouse model of Aβ pathology and human AD. However, it
should be noted that it is possible that we have, to date, missed a behavioral effect of the M631L
substitution, since mice were only analyzed for behavior and indices of oxidative stress at 9
months-old, meaning that at earlier or later stages of life, differences in behavior, if present,
would have been missed by the present studies. The notion that later behavioral deficits might
be mollified by the M631L substitution is compatible with recently published studies showing
that Tg PDAPP(D664A) mice begin to show Morris water-maze abnormalities at 13 months-old
that are not present at earlier ages (Galvan et al., 2008). Although it is not clear that this
behavioral trend is a result of oxidative damage, Tg PDAPP(D664A) mice do indeed show such
damage (Galvan et al., 2008). Thus further studies are needed to assess Tg mice with both the
D664A and M631L substitutions, to determine whether they resist the trend toward deterioration
in Morris water-maze performance with age.
Finally, 6E10 immunoreactive Aβ deposits in the brains of Tg PDAPP(M631L) mice
revealed marked differences from the frank plaque deposits found in Tg PDAPP(J20) mice (Fig.
6.4). Moreover, there is evidence of microglial activation in Tg PDAPP(M631L) mice (Fig. 6.4).
Therefore, it is conceivable that increased microglial activation in Tg PDAPP(M631L) mice
influenced behavior, potentially contributing to the lack of behavioral improvement relative to
Tg PDAPP(J20) mice.
In contrast to memory deficits apparently unaffected by the M631L substitution, the
Met35Cys substitution in Aβ(1–42) in AD models (Fig. 2.53), in which human Aβ(1–42) was
expressed in muscle [as opposed to full-length APP in neurons], abrogated this worm‟s paralytic
phenotype without changing deposition of the modified peptide (Yatin et al., 1999).
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Additionally, another study of aged beagle dogs (whose Aβ sequence is identical to that of
humans) fed a high antioxidant diet and given a program of behavioral enrichment showed
decreased oxidative stress in brain, improved learning and memory, and decreased levels of
Aβ(1–42) (Opii et al., 2008). Although the fundamental differences of these previous studies
make direct comparisons to the current studies difficult (e.g., the comparison of mutant APP
expression in mouse brain to Aβ expression in nematode muscle may, in fact, prove to be futile),
such comparisons may nonetheless offer some clues into AD pathogenesis and strategies for
future studies. For example, the M631L mouse model employed full-length APP with familial
AD-associated mutations, whereas the nematode model only expressed the Aβ peptide. Thus,
the lack of improvement in the mouse model may have been due to other, non-Aβ peptides
derived from APP, such as sAPPβ, Jcasp, and C31, all of which have been implicated in aspects
of the AD phenotype (Galvan et al., 2006; Lu et al., 2000; Madeira et al., 2005; Nikolaev et al.,
2009). Moreover, mouse, dog, and nematode data are all compatible with the notion that
multiple mechanisms are involved in AD pathogenesis, such that the threshold mechanism is
likely to differ from model to model. If this proves to be the case, then results obtained from
these different systems argue that it will be critical to test potential new therapeutics in more than
one system, and ultimately it will be crucial to determine which model or combination of models
provides the greatest predictive value for human AD.

Copyright © Miranda Lu Lange, 2010
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CHAPTER 7
DIFFERENTIAL EXPRESSION & REDOX PROTEOMICS ANALYSES OF AN
ALZHEIMER DISEASE TRANSGENIC MOUSE MODEL: EFFECTS OF AMYLOID-β
PEPTIDE OF APP
7.1 Overview
Amyloid-β peptide (Aβ)-induced oxidative stress has been demonstrated to play a key
pathological role in brain from subjects with and animal models of Alzheimer disease (AD) Aβ
pathology. Results from Chapter 6 of this dissertation report elevated levels of oxidative damage
in brain of PDAPP transgenic (Tg) mice carrying Swedish and Indiana mutations in the human
amyloid precursor protein (APP) [Tg PDAPP(J20)], as indicated by increased levels of protein
carbonyls, protein-resident 3-nitrotyrosine (3-NT), and protein-bound 4-hydroxy-2-trans-nonenal
(HNE) compared to non-transgenic (Non Tg) littermate control mice. This oxidative damage
was found to be dependent upon the methionine 35 residue (Met-35) of the Aβ peptide. Because
further insight into the molecular pathways affected in this in vivo Tg model of familial AD
(FAD) Aβ pathology may be gained by proteomics-based studies, 2D-gel expression proteomics
was performed to compare any differences in brain protein levels of Tg PDAPP(J20) mice with
Non Tg PDAPP littermate controls. Based on these studies, eight proteins were identified as
significantly up-regulated in Tg PDAPP(J20) mice relative to Non Tg PDAPP controls, many, of
which, have been previously identified as differentially expressed in in vitro and in vivo models
of Aβ pathology and subjects with AD and amnestic mild cognititve impairment (aMCI):
calcineurin subunit B type 1,  GDP-dissociation inhibitor 1, F-actin capping protein subunit β,
T-complex protein 1 subunit  A (TCP-1A), -enolase, peptidyl-prolyl cis-trans isomerase 1
(Pin-1), ATP synthase, subunit  (mitochondrial), and peroxiredoxin-1. Redox proteomics
analyses identified three significantly oxidatively-modified proteins: dihydropyrimidinaserelated protein 2 (Drp-2) with significantly increased levels of protein carbonylation and
phosphatidylethanolamine-binding protein 1 (PEBP-1) and Pin-1 with significantly decreased
levels of 3-NT in Tg PDAPP(J20) mice relative to Non Tg PDAPP controls. In addition,
Western blotting and immunoprecipitation analyses were used to validate spots identified as
significantly differentially expressed or oxidatively modified by PD-Quest image analysis.
7.2 Introduction
AD is an age-related neurodegenerative disorder that is pathologically manifested by
deposition of senile plaques (SPs), accumulation of neurofibrillary tangles (NFTs), and
subsequent synapse and neuronal cell loss (see section 2.6). Familial cases of AD have been
linked primarily to autosomal dominant mutations in APP (Goate et al., 1991), presenilin-1 (PS1) and/or presenilin-2 (PS-2) genes (Citron et al., 1992; Cruts et al., 1998; Scheuner et al., 1996;
Sturchler-Pierrat et al., 1997). Additionally, oxidative stress has been implicated in the
pathogenesis of AD (Butterfield and Lauderback, 2002; Butterfield et al., 2006c; Good et al.,
1996; Markesbery, 1997; Smith et al., 1997; 1994). SPs are largely composed of the Aβ(1-42)
peptide, generated by β- and -secretase cleavage of the APP protein (see section 2.6.2; Fig.
2.51). Although APP is known to produce Aβ(1-40) in higher abundance (Burdick et al., 1992;
Jarrett et al., 1993), it is Aβ(1-42) that is considered to be the more toxic peptide in model
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systems of AD (Boyd-Kimball et al., 2005a; 2005b; 2005c; Butterfield and Boyd-Kimball, 2004;
Drake et al., 2003a; Lambert et al., 1998; Mattson, 1997; Mohmmad Abdul et al., 2004; 2006).
In FAD, mutations close to the β- and γ-secretase cleavage sites are thought to lead to increased
levels of Aβ. Although Aβ peptides can exist as monomers, oligomers, fibrils, or aggregates, it
is the soluble, oligomeric form of Aβ(1-42) that is believed to be the most toxic Aβ species in
AD brain (Demuro et al., 2005; Drake et al., 2003a; Selkoe, 2008; Viola et al., 2008). The major
consequences of this toxicity are the observed cognitive losses in learning and memory (Selkoe,
2008; Walsh et al., 2002). The Butterfield laboratory, as well as others, have provided
considerable evidence that Aβ(1-42) induces oxidative stress in AD and various AD model
systems (Abdul et al., 2008; Ansari et al., 2006; Boyd-Kimball et al., 2004; 2005b; Drake et al.,
2003a; Mohmmad Abdul et al., 2006; Pappolla et al., 1999; Resende et al., 2008; Sultana et al.,
2005; Zhu et al., 2008).
In Chapter 6 of this dissertation, increased levels of three indices of oxidative stress (i.e.,
protein carbonyls, protein-resident 3-NT, and protein-bound HNE) in brain Tg PDAPP(J20)
were reported compared to that of Non Tg PDAPP control mice. Tg PDAPP(J20) mice carry
mutations in human APP corresponding to the Swedish (K670N and M671L) and Indiana
(V717F) familial forms of AD (APPSw,In), which are expressed behind a platelet-derived growth
factor (PDGF) β-chain promoter (Galvan et al., 2006; Mucke et al., 2000). Tg PDAPP(J20) mice
display many aspects of AD pathology, such as Aβ accumulation, neuritic plaque (i.e., SP)
formation, and memory deficits (Galvan et al., 2006; Mucke et al., 2000), but not NFTs.
Therefore, the oxidative stress and damage found in Tg PDAPP(J20) mice can be directly
correlated with these pathological hallmarks.
This dissertation study iinvestigated the hypothesis that specific biochemical pathways
are altered in Tg PDAPP(J20) mouse models of Aβ pathology. Alterations of brain proteins
from brain of Tg PDAPP(J20) mice in comparison to Non Tg PDAPP littermate controls were
identified following 2D-polyacrylamide gel electrophoresis (2D-PAGE) separation and
employing mass spectrometry (MS) and database searching techniques. Redox proteomic
experiments also were performed to identify brain proteins with significant differences in
oxidative modification in Tg PDAPP(J20) mice as measured by protein carbonyls and 3-NT.
SEQUEST and PD-Quest image analysis results were validated using 1D-Western blotting and
immunoprecipitation analyses of Pin-1. Overall, the findings from these proteomics studies
enhance the understanding of altered pathways in AD and provide potential targets for AD
prevention and treatment that warrant further investigation.
7.3 Experimental Procedures
All materials and methods used in this study are described in Chapter 3 of this
dissertation. Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, and 3.7-3.12.
7.3.1 Statistical Analysis
All data are presented as mean ± standard deviation (S.D.) or mean ± standard error of
the means (S.E.M.), as noted. Statistical analyses were performed using a two-tailed Student‟s ttest, wherein P<0.05 was considered significant for differential expression fold-change values
and oxidative modification levels. Protein and peptide identifications obtained with the
SEQUEST search algorithm with a P-value<0.01 were considered statistically significant. To
further validate PD-Quest and SEQUEST identifications of significantly different spots, the
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location of protein spots on the 2D-gels were manually checked to ensure they were near the
expected molecular weight (MW) and isoelectric point (pI) values based on SwissProt database
information.
7.4 Results
7.4.1 Differential Expression Proteomics
Differential expression proteomics analysis of proteins isolated from brains of Tg
PDAPP(J20) and Non Tg PDAPP control mice using a 2D-PAGE approach was conducted.
Effects inherently present in Tg PDAPP(J20) mouse brain as a result of the APPSw,In transgene
can be realized through this analysis. A total of eight protein spots were identified as being
significantly up-regulated in Tg PDAPP(J20) mice compared to Non Tg PDAPP controls.
Examples of 2D-gel images from these analyses can be found in Figure 7.1. Tryptic digestion
and MS analysis was completed on excised protein spots; Table 7.1 provides a list of the
corresponding protein spot identifications, the number of peptide sequences and spectral counts
(SC; the number of MS/MS events observed that meet SEQUEST filter criteria), MW, pI, foldchange levels, and P-values associated with each protein identified. Half of the proteins were
identified with more than one single peptide and several SC (Table 7.1); for proteins identified
with only a single peptide, more than one SC was observed and/or the protein was identified in
other MS experiments of that protein spot. I am confident in the identification of these proteins
based on the low P-values associated with the SEQUEST identifications (i.e., P2.00e-04). In
addition, the location of protein spots visually align with their anticipated MW and pI values on
the 2D-gels.
Figure 7.1
A) Non Tg PDAPP
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Figure 7.1 (cont.)
B) Tg PDAPP(J20)

Figure 7.1 Representative 2D-gel images of proteins isolated from Tg PDAPP(J20) and
Non Tg PDAPP mouse brain. Significantly up-regulated protein spots in A) Non Tg
PDAPP and B) Tg PDAPP(J20) mouse brain are labeled with protein identifications
obtained from nanospray electrospray ionization (ESI)-MS/MS analyses. TCP-1α, Tcomplex protein 1 subunit  A; GDP,  GDP-dissociation inhibitor 1; F-actin, F-actin
capping protein, subunit β; Pin-1, peptidyl-prolyl cis-trans isomerase 1; ATP, adenosine
triphosphate.
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Table 7.1 List of proteins with differential levels in Tg PDAPP(J20) mice relative to
Non Tg PDAPP controls.
SwissProt
MW
Peptides
FoldProtein
Accession
pI
pb
P-valued
a
(kDa)
(SC)
Changec
No.
F-actin capping protein,
P47757 30.61 5.62 1(2) 5.00e-06 49.6 ↑ 0.0064
subunit β
T-complex protein 1,
P11984 60.30 5.70 1(2) 2.00e-07 47.9 ↑ 0.00069
subunit α A (TCP-1αA)
Peroxiredoxin-1
P35700 22.16 8.20 1(2) 2.00e-04 30.4 ↑ 0.0023
ATP synthase, subunit α,
Q03265 59.72 9.53 5(10) 8.00e-07 12.2 ↑ 5.1e-06
mitohondrial
Peptidyl-prolyl cis-trans
P17742 18.30 7.97 1(3) 1.00e-05 3.09 ↑ 0.0047
isomerase 1 (Pin-1)
ρ GDP-dissociation
Q99PT1 23.39 4.96 3(13) 5.00e-09 2.62 ↑
0.033
inhibitor 1
Calcineurin, subunit B,
Q63810 19.29 4.49 3(10) 3.00e-10 2.47 ↑
0.014
Type 1
α-Enolase
P17182 47.11 6.38 5(9) 8.00e-13 1.88 ↑
0.039
a

The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.
The total number of MS/MS spectral counts (SC) is indicated in ( ).
b
The probability of an incorrect identification associated with each protein identification
using the SEQUEST search alogorithm.
c
The fold-change in spot density from Tg PDAPP(J20) mice compared to Non Tg PDAPP
controls. The arrow indicates the direction of change.
d
The P-value associated with fold-changec calculated using a Student‟s t-test. n=10 for Tg
PDAPP(J20), n=5 for Non Tg PDAPP.
pI, isoelectric point; MW, molecular weight.

Half of the brain proteins detected as significantly up-regulated in Tg PDAPP(J20) mice
had fold-change levels greater than 10-fold compared to Non Tg PDAPP mice (Table 7.1),
including F-actin capping protein, subunit β (49.6-fold, *P<0.006), TCP-1A (48-fold,
*P<0.0007), peroxiredoxin-1 (30.4-fold, *P<0.002), and ATP synthase, subunit ,
mitochondrial (12.2-fold, *P<5.09e-06). Other significantly up-regulated proteins in Tg
PDAPP(J20) mice are Pin-1 (3.09-fold, *P<0.005),  GDP-dissociation inhibitor 1 (2.62-fold,
*P<0.032), calcineurin, subunit B, Type 1 (2.47-fold, *P<0.013), and -enolase (1.88-fold,
*P<0.038) [Table 7.1].
7.4.2 Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1) Western Blot Spot Validation
Western blot analysis shows that the lanes corresponding to Pin-1 (18 kDa) and the loading
control, actin (42 kDa; used as a loading control to normalize the amount of protein loaded in
each well of the gel), levels agree with their expected positions based on MW (Fig. 7.2a). The
histogram based on lane intensity shows a ~15% significant increase (*P<0.04) in the level of
Pin-1 levels in the brains of Tg PDAPP(J20) mice relative to Non Tg PDAPP littermate controls
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(Fig. 7.2b). These results are consistent with the expression proteomics analyses described
above, though not duplicating the magnitude, in Tg PDAPP(J20) mice.
Figure 7.2

Figure 7.2 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) levels in brain of transgenic
(Tg) and non-transgenic (Non Tg) mice. Pin-1 and actin levels were measured by 1Dpolyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot
analysis in 9 month-old Tg PDAPP(J20) [Tg] and Non Tg PDAPP [NTg] control mice.
A) Increased band intensity after normalization with actin represents an increase in the
amount of Pin-1 present. n=5 for both Tg and NTg groups, however only representative
bands from n=3 independent samples are shown. B) Graphical representation of data
shown in A) demonstrates a significant increase in the levels of Pin-1 in Tg PDAPP(J20)
mice compared to Non Tg PDAPP littermate controls. Percent control values are
presented as mean ± S.E.M.; *P<0.04.

7.4.3 Redox Proteomics
Utilizing previously established redox proteomics approaches for the detection of protein
carbonyls and 3-NT (Butterfield and Sultana, 2008; Sultana et al., 2006b), three proteins were
identified to be significantly carbonylated or nitrated in brain of Tg PDAPP(J20) mice relative to
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Non Tg PDAPP controls (Table 7.2). A significant increase in Drp-2 protein carbonylation was
found in brain of Tg PDAPP(J20) mice in comparison to Non Tg PDAPP controls (*P<0.046;
Fig. 7.3), while a significant decrease in protein-resident 3-NT was found for PEBP-1
(*P<0.022; Fig. 7.4) and Pin-1 (*P<0.049; Fig. 7.5) in Tg PDAPP(J20) mice relative to their Non
Tg PDAPP littermates (Table 7.2). These results, as well as the aforementioned expression
proteomics results, will be discussed in detail below (section 7.5) with respect to protein
function(s) and how the detected changes may be implicated in AD etiology.
Table 7.2 List of oxidatively modified proteins in Tg PDAPP(J20) mice relative to Non
Tg PDAPP controls.
SwissProt
%
MW
Peptides
b
Protein
Accession
pI
p
Control P-valued
(kDa)
(SC)a
No.
(NTg)c
Protein Carbonyls:
Dihydropyrimidinaserelated protein-2
O08553 62.24 5.93 6(17) 4.00e-11 6510 ↑ 0.046
(Drp-2)
3-NT:
PhosphatidylethanolamineP70296 20.82 5.07 2(4) 3.00e-07 27.4 ↓ 0.023
binding protein 1 (PEBP-1)
Peptidyl-prolyl cis-trans
P17742 18.30 7.97 1(6) 3.00e-04 19.1 ↓ 0.049
isomerase 1 (Pin-1)
a

The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides. The
total number of MS/MS spectral counts (SC) is indicated in ( ).
b
The probability of an incorrect identification associated with each protein identification using the
SEQUEST search alogorithm.
c
Percent oxidation in Tg PDAPP(J20) mice compared to Non Tg (NTg) PDAPP controls (oxidative
level arbitrarily set to 100%).
d
The P-value associated with % Control (NTg)c calculated using a Student‟s t-test. n=10 for Tg
PDAPP(J20); n=5 for Non Tg PDAPP.
pI, isoelectric point; MW, molecular weight.

Figure 7.3
A) Non Tg PDAPP

B) Tg PDAPP(J20)
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Figure 7.3 Representative 2D-Western blot image corresponding to carbonylated
dihydropyrimidinase-related protein 2 (Drp-2). These images show a clear increase in
protein carbonylated Drp-2 in B) Tg PDAPP(J20) mice compared to A) Non Tg PDAPP
controls [images have been zoomed in to this spot]. Proteins were probed with an antidinitrophenylhydrazone (DNP) antibody, as described in Chapter 3.

Figure 7.4
A) Non Tg PDAPP

B) Tg PDAPP(J20)

Figure 7.4 Representative 2D-Western blot image corresponding to nitrated
phosphatidylethanolamine-binding protein 1 (PEBP-1). These images show a clear
decrease in 3-nitrotyrosine (3-NT)-modified PEBP-1 in B) Tg PDAPP(J20) mice
compared to A) Non Tg PDAPP controls [images have been zoomed in to this spot].
Proteins were probed with an anti-3-NT antibody, as described in Chapter 3.

Figure 7.5
A) Non Tg PDAPP

B) Tg PDAPP(J20)

Figure 7.5 Representative 2D-Western blot image corresponding to nitrated peptidylprolyl cis-trans isomerase 1 (Pin-1). These images show a clear decrease in 3nitrotyrosine (3-NT)-modified Pin-1 in B) Tg PDAPP(J20) mice compared to A) Non Tg
PDAPP controls [images have been zoomed in to this spot]. Proteins were probed with
an anti-3-NT antibody, as described in Chapter 3.
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7.4.4 Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1) Immunoprecipitation
Immunoprecipitation validation was performed for Pin-1 as a representative confirmation
of those brain proteins identified as significantly oxidatively modified by SEQUEST and PDQuest image analyses. Western blot analysis shows that lanes corresponding to Pin-1 (18 kDa)
are indeed nitrated (Fig. 7.6a), while the histogram representing the average lane intensity for
both Tg and Non Tg mice shows a significant decrease in the level of nitrated Pin-1 in Tg
PDAPP(J20) mice compared to Non Tg PDAPP controls (*P<0.02; Fig. 7.6b). These results are
consistent with the redox proteomics analyses described above, in which Pin-1 was identified as
being significantly less nitrated in Tg PDAPP(J20) mice compared to Non Tg PDAPP controls
(19.1%; Table 7.2).
Figure 7.6

Figure 7.6 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) nitration levels in brain of Tg
PDAPP(J20) and Non Tg PDAPP mice. Following immunoprecipitation, Pin-1 nitration
was measured by 1D-polyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and
Western blot analysis of 9 month-old Tg PDAPP(J20) [Tg] and Non Tg PDAPP [NTg]
control mice. A) Increased band intensity represents an increase in the amount of 3nitrotyrosine (3-NT)-modified Pin-1 present. n=5 for both Tg and NTg groups, however
only representative bands from n=3 independent samples are shown. B) Graphical
representation of data shown in A) demonstrates a significant decrease in Pin-1 nitration
levels in Tg PDAPP(J20) mice compared to Non Tg PDAPP littermate controls. Percent
control values are presented as mean ± S.E.M.; *P<0.02.
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7.5 Discussion
The J20 line of PDAPP mice used in the current dissertation study was 9 months-old,
corresponding to the age at which pathological and behavioral characteristics that mimic those
encountered in subjects with AD occur. Previous studies have demonstrated that Tg
PDAPP(J20) mice have age-related progressive accumulation of Aβ, SP formation, and cognitive
decline associated with AD disease progression (Galvan et al., 2006; Hsia et al., 1999; Mucke et
al., 2000). Current studies measured changes in the brain proteomes of Tg PDAPP(J20) mice
compared to Non Tg PDAPP littermate control mice using 2D-PAGE and MS/MS techniques.
Eight proteins were found to be significantly up-regulated in Tg PDAPP(J20) mice relative to
Non Tg PDAPP controls, including calcineurin, subunit B, Type 1,  GDP-dissociation inhibitor
1, F-actin-capping protein, subunit β, TCP-1A, -enolase, Pin-1, ATP synthase, subunit 
(mitochondrial), and peroxiredoxin-1 (Table 7.1). In accordance with results reported in Chapter
6 of this dissertation, which show significant changes in the global levels of protein oxidation
and lipid peroxidation in Tg PDAPP(J20) mice compared to Non Tg PDAPP controls, current
redox proteomics results show a significant increase in Drp-2 carbonylation, and a significant
decrease in PEBP-1 and Pin-1 nitration in Tg PDAPP(J20) mice compared to Non Tg PDAPP
controls (Table 7.2). The biochemical functions of proteins identified with altered levels or
oxidative modification include energy dysfunction, metabolism alterations, calcium signaling,
antioxidant defense, neuritic/structural abnormalities, cell-cycle/signaling, lipid abnormalities,
and cholinergic dysfunction. The relevance of increased levels of and/or differential oxidative
modification of these proteins in Tg PDAPP(J20) mice is discussed below with regards to
specific biochemical pathways and their significance in AD.
Table 7.3 List of proteins with differential levels and oxidative modifications in Tg
PDAPP(J20) mice relative to Non Tg PDAPP mice and their cellular functions.
Current
Protein
Cellular Function(s)
Alteration
↑ Expression α-Enolase
Energy Metabolism
↑ Expression

ATP synthase, subunit α, mitochondrial

↑ Expression

Peroxiredoxin-1

↑ Expression

T-complex protein 1, subunit α A (TCP-1αA)

↑ Expression
↑ Carbonylation
↑ Expression
↑ Expression;
↓ Nitration

F-actin capping protein, subunit β
Dihydropyrimidinase-related protein 2 (Drp-2)
ρ GDP-dissociation inhibitor 1

↓ Nitration
↑ Expression

Peptidyl-prolyl cis-trans isomerase (Pin-1)
Phosphatidylethanolamine-binding protein 1
(PEBP-1)
Calcineurin, subunit B, Type 1
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Energy Metabolism
Antioxidant
Molecular Chaperone;
Structural Integrity
Structural Protein
Structural Protein
Cell Signaling
Cell Signaling; Cell-Cycle
Cell Signaling,
Proliferation, & Migration;
Cholinergic System
Ca2+ Signaling &
Regulation

7.5.1 Energy Dysfunction & Metabolic Alterations
Cellular metabolism, particularly cerebral glucose uptake, is known to be altered in the
brains of patients with AD and amnestic mild cognititve impairment (aMCI) [Fig. 7.7] (Watson
and Craft, 2004). In this study, a significant increase in the levels of α-enolase and ATP
synthase, subunit α (mitochondrial), in Tg PDAPP(J20) mice was observed. α-Enolase is a
glycolytic enzyme responsible for catalyzing the conversion of 2-phosphoglycerate into
phosphoenolpyruvate in the final stages of glycolysis (Table 7.3; see section 2.3.2; Fig. 2.17).
The up-regulation of α-enolase in brain of Tg PDAPP(J20) mice suggests an increased need for
adenosine triphosphate (ATP; i.e., energy) production, in which the catabolic breakdown of
glucose is of utmost importance, congruent with previous reports indicating hypometabolism to
be a predominant pathological feature in AD brain (Mielke et al., 1996). Hypometabolism has
been associated with the oxidative-inactivation of several glycolytic enzymes, including enolase
(Butterfield et al., 2006b; Castegna et al., 2002a; Sultana et al., 2007b). Because the brain is one
of the greatest consumers of glucose, hypometabolism can cause the up-regulation of glycolytic
enzymes in an effort to combat the mounting energy deficit (Mielke et al., 1996). Furthermore,
key glycolytic enzymes, including enolase, have been shown to be electrostatically bound to cell
and organelle membranes (Kant and Steck, 1973; Rogalski et al., 1989; Tsai et al., 1982; Xu and
Becker, 1998; Xu et al., 1995), making glycolytically produced ATP the primary energy source
for membrane ion pumps, such as the Na+/K+-ATPase and Ca2+-ATPase [see section 2.3.2]
(Kauppinen et al., 1988; Mielke et al., 1996; Xu et al., 1995).
Figure 7.7

Figure 7.7 Cerebral glucose uptake. Positron Emission Tomography (PET) scans of
altered glucose metabolism in normal, mild cognitive impairment (MCI), and Alzheimer
disease (AD) brains. Altered cellular metabolism, particularly cerebral glucose uptake, is
altered as early as MCI, and becomes significantly decreased in AD brain (image
courtesy of the Alzheimer's Disease Education and Referral Center).

Although the glycolytic function of enolase does not directly produce ATP or the reduced
energy carrier nicotinamide adenine dinucleotide (NADH), up-regulation of -enolase in the
brain of Tg PDAPP(J20) mice suggests there may be an increased need for glycolytic ATP
production. Increased levels of -enolase have also been reported in proteomic studies of brain
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from subjects with AD and MCI, arguably the earliest form of AD [see section 2.6.1] (Castegna
et al., 2002a; Sultana et al., 2007b). Also, increased oxidative modification of -enolase as
indexed by protein carbonyls, 3-NT, and HNE has been reported in the brains of subjects with
AD and AD model systems (Castegna et al., 2003; 2002a; 2002b). Because oxidative
modification of proteins generally leads to a loss of function (Butterfield and Stadtman, 1997),
-enolase modification may result in impaired ATP production. Current results are consistent
with Positron Emission Tomography (PET) studies in AD and MCI brains that show altered
glucose metabolism (Watson and Craft, 2004). Moreover, α-enolase has other pro-survival
functions, including activation of ERK 1/2 and induction of plasmin (via plasminogen), a
degradation product, of which, is Aβ (Ledesma et al., 2000; Tucker et al., 2000a; 2000b; Van
Nostrand and Porter, 1999). Hence, conceivably up-regulation of α-enolase may be an attempt
by the brain of Tg PDAPP(J20) mice to evoke enolase-related pro-survival pathways in view of
induced Aβ(1-42) and subsequent oxidative stress observed.
ATP synthase, subunit  (mitochondrial), is a part of the ATP synthase complex, an inner
mitochondrial membrane integrated enzyme involved in the production of ATP during oxidative
phosphorylation (Table 7.3; see section 2.3.4). Mitochondrial dysfunction has been linked to AD
pathogenesis (Blass et al., 2002; Bubber et al., 2005). In advanced stages of AD, ATP synthase
activity is reportedly decreased in AD brain (Schagger and Ohm, 1995), in addition to being
oxidatively modified. As noted, the age of Tg PDAPP(J20) mice used in these studies was 9
months, an age at which significant Aβ accumulation and plaque deposition is present in the
brains (Galvan et al., 2006; Mucke et al., 2000; Shankar et al., 2009). Thus, both -enolase and
ATP synthase, subunit α (mitochondrial), up-regulation may represent an early attempt to
prevent lowered levels of ATP production that will inevitably occur with increased Aβ
accumulation and SP formation, signatures of advanced stages of AD.
7.5.2 Calcium Signaling
Dysregulation of Ca2+ homeostasis has been linked to brain aging (Foster et al., 2001)
and to AD (Mattson and Chan, 2001). Calcineurin is a highly expressed, heterodimeric
Ca2+/calmodulin-dependent serine (Ser)/threonine (Thr) protein phosphatase (also known as
PP2B) important in Ca2+ signaling in the brain [Table 7.3] (Goto et al., 1986; Klee et al., 1998).
Calcineurin consists of both a calmodulin binding subunit, calcineurin A (61 kDa), and a Ca2+
binding subunit, calcineurin B [19 kDa] (Aitken et al., 1984; Hemenway and Heitman, 1999;
Merat and Cheung, 1987). Unfortunately, studies of calcineurin expression and activity in AD
brain and various AD models to date have been somewhat contradictory. For example, one
study reported that calcineurin had reduced basal activity in AD frontal cortex (Lian et al., 2001),
while studies of cortical cells treated with exogenous Aβ(25-35) and Aβ(1-40) showed an
increase in calcineurin activity with protein levels being unaffected (Agostinho et al., 2008).
However, in a study of primary neuronal cultures treated with exogenous Aβ, the levels of
calcineurin were reduced (Celsi et al., 2007). It is possible that previous studies vary drastically
due to experimental design, in that in vitro systems do not necessarily always replicate what is
observed in vivo. Moreover, consistency may be found if each calcineurin subunit were
investigated individually.
For example, a study by Hata, et al. (2001) showed that the calcineurin subunit B is one
of the most up-regulated genes in AD hippocampus (Hata et al., 2001). Furthermore, the current
dissertation study observed an increased level of calcineurin, subunit B, Type 1, in vivo in brain
of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls. Consistent with this
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observation, a study by Norris, et al. (2005) reported significant over-expression of calcineurin in
hypertrophic astrocytes that surround SP in the brains of APP/PS-1 double transgenic mice
(Norris et al., 2005), which has also been reported in the hippocampus of patients with MCI and
AD (Abdul et al., 2009). Overall, increased levels of calcineurin in the present PDAPP mouse
model of Aβ pathology are consistent with alterations in glutamate release, neuroinflammation,
synaptic plasticity, cell survival, and cognitively related changes in behavior.
7.5.3 Antioxidant Defense
Peroxiredoxin-1 is an antioxidant enzyme (Table 7.3) that catalyzes the reduction of
peroxynitrite (ONOO-), hydrogen peroxide (H2O2), and alkyl hydroperoxides (ROOH) [see
sections 2.4.2 & 2.4.3] (Peshenko and Shichi, 2001). Thus, this enzyme is important to the cell‟s
defense against reactive oxygen (ROS) and nitrogen (RNS) species. Peroxiredoxin-1 is an
abundant intracellular protein shown to be significantly up-regulated in brain of Tg PDAPP(J20)
mice, relative to Non Tg PDAPP control mice, in the current dissertation study. Such an
increase in the levels of this antioxidant enzyme may represent a response to Aβ accumulation
and plaque deposition and subsequent increases in ROS and RNS in the mouse brain. In AD,
peroxiredoxins, including peroxiredoxin-2 and -6, have been found oxidatively modified, which
likely results in an increase in the levels of protein nitration (Reed et al., 2008b; Sultana et al.,
2006a). In the present J20 mouse model of Aβ pathology, it appears that prior to SP formation
(i.e., at 9 months) there are increased attempts at brain detoxification, considering Chapter 6 of
this dissertation reports increased indices of oxidative stress (i.e., protein carbonyls, 3-NT, and
HNE). This notion is consistent with proteomic studies that report increased levels of
peroxiredoxin-1 in the brains of AD subjects (Kim et al., 2001).
7.5.4 Neuritic Abnormalities & Structural Integrity
Cell structural integrity is known to be altered in AD, especially considering the widespread loss of synaptic plasticity and neurons found in AD brain (Butterfield et al., 2006c). The
current study found the F-actin-capping protein, subunit β, to be significantly up-regulated in
brains of Tg PDAPP(J20) mice. This particular protein is highly involved in cellular structural
integrity, as it binds to the end of filamentous actin polymers, regulating filament number and
length [Table 7.3] (Weeds and Maciver, 1993). Actin is also involved in cytoskeletal network
integrity and intracellular locomotion (Weeds and Maciver, 1993). Increased levels of F-actin
capping protein, subunit β, are consistent with the notion of increased intracellular
molecule/organelle movement, which may be evidence for the cell‟s increased effort to maintain
structural integrity and locomotion in the presence of Aβ accumulation and plaque deposition
that could be affecting these pathways in brain of Tg PDAPP(J20) mice.
TCP-1A is a part of the TCP-1 family that is involved in molecular chaperoning, is an
initiator of microtubule growth (Brown et al., 1996), and is necessary for maintaining normal
actin and tubulin function [Table 7.3] (Chen et al., 1994; Gupta, 1995; Ursic et al., 1994).
Because actin and tubulin are major TCP-1 substrates, an increase in TCP-1A would require an
increase in actin and actin-related proteins, like the F-acting-capping protein. The TCP-1 ε unit
was reported as having decreased levels in the parietal cortex and brains of subjects with AD
(Schuller et al., 2001; Yoo et al., 2001). The significant increase in TCP-1A levels that was
found in the present investigation further supports the notion that in the presence of Aβ deposits
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and oxidative stress at 9 months of age, cytoskeletal structural integrity is not yet compromised
in this particular Tg mouse model of Aβ pathology.
Consistent with reports of oxidative modification of Drp-2 in AD brain (Castegna et al.,
2002a; Sultana et al., 2006b), the current study also demonstrates an increase in Drp-2 protein
carbonylation in brains of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls. Drp-2 is
involved in axonal and dendritic outgrowth, through regulation of the protein collapsing, and in
neuronal repair (Hamajima et al., 1996; Kato et al., 1998). Thus, Drp-2 is important for
maintaining synaptic plasticity in the brain (Table 7.3). Oxidative modification of Drp-2 in Tg
PDAPP(J20) mice could lead to shortened neuritic connections, such as observed in AD
(Coleman and Flood, 1987), and is consistent with the substantial loss of learning and memory
endemic in this dementing disorder. Significant Drp-2 oxidative modification and consequent
dysfunction is consistent with behavioral changes in Tg PDAPP(J20) mice, which demonstrate
significant memory deficits (Galvan et al., 2006; Hsia et al., 1999; Mucke et al., 2000).
7.5.5 Lipid Abnormalities & Cholinergic Dysfunction
PEBP-1 is a precursor of the hippocampal cholinergic neurostimulating peptide (HCNP),
a signaling transduction peptide which regulates choline acetyltransferase (ChAT) function
(Table 7.3). Alterations to ChAT lead to reduced levels of acetylcholine, a neurotransmitter that
is necessary for regulating normal neurotransmission [see section 2.1.3; Table 2.1] (Ojika, 1998).
The present study reports a significant decrease in 3-NT levels associated with PEBP-1 in brains
of Tg PDAPP(J20) mice relative to Non Tg PDAPP controls. This result is somewhat
unexpected as PEBP-1 (also known as neuropolypeptide h3 and Raf-kinase inhibitor protein
[RIP]) has been previously reported as being significantly nitrated and HNE-modified (Castegna
et al., 2003; Reed et al., 2008a; 2008b), together with a decrease in PEBP-1 mRNA expression in
AD brain (Maki et al., 2002). In addition, PEBP-1 has been previously shown to have 20%
greater expression in the hippocampus of subjects with AD (Chen et al., 2006) and is believed to
be a potential calpain substrate leading to proteasome dysfunction. Furthermore, because PEBP1 is known to bind the inner-leaflet sequestered, membrane lipid, phosphatidylethanolamine, an
increase in PEBP-1 nitration in AD brain may contribute to disruption of lipid asymmetry in AD
and aMCI (see Chapters 4 & 5), leading to increased levels of apoptosis and poor
neurotransmission due to reduced acetylcholine levels.
Conversely, lower levels of 3-NT-modified PEBP-1 that were found in the current study
may indicate that acetylcholine levels and lipid asymmetry are not yet significantly disturbed at
this stage of AD/FAD pathology (i.e., 9 months-old) in these animals. Hence, under this
scenario, altered acetylcholine levels and lipid abnormalities could be a result of more advanced
plaque formation that occurs in later stages of AD and FAD. Finally, current results suggest that
Tg PDAPP(J20) mice at 9 months of age may not yet have experienced significant (if any)
proteasomal dysfunction. Taken together, it appears that specific biochemical changes observed
in AD and FAD may occur later in disease progression in Tg PDAPP(J20) mice despite the
presence of significant Aβ(1-42) accumulation, plaque deposition, and oxidative stress.
7.5.6 Cell Signaling, Cell-Cycle, Tau Phosphorylation, & Amyloid-β (Aβ) Production
Pin-1 belongs to the family of peptidyl-prolyl isomerase enzymes (PPIases) and acts as a
regulatory protein by binding to and isomerizing a proline residue on the C-terminal side of a
phosphorylated Ser/Thr moiety (pSer/pThr) from the cis to trans conformation, thereby
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regulating the activity of the target protein (Butterfield et al., 2006d). Pin-1‟s functions are
diverse and include regulation of pathways such as the cell-cycle, transcription, apoptosis, the
DNA damage response, and even acts as a cytokine [Table 7.3] (Butterfield et al., 2006d). In the
last decade, Pin-1 has been heavily implicated in AD pathogenesis via its regulation of the
phosphorylation state of the microtubule-associated protein tau [see section 2.6] (Lee and Tsai,
2003; Lu et al., 2003), as well as the production of Aβ through binding APP (Pastorino et al.,
2006). Pin-1 has been shown to be significantly oxidatively modified and has lowered
expression and activity in the hippocampus of human AD and MCI brain (Sultana et al., 2006c).
By contrast, the current study reported that Pin-1 levels were increased and nitration was
decreased in vivo in the brains of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls; it
should be noted, however, that in the present study, one-half of the mouse brain was
homogenized (see section 3.4.2) and thus regional comparison to AD was not possible.
Increased Pin-1 levels may indicate early response strategies that would maintain low levels of
Aβ and subsequent SP formation in brain. Furthermore, increased Pin-1 levels may keep postmitotic neurons from entering the cell-cycle, maintain normal transcriptional regulation of key
proteins, and allow the brain to respond to DNA damage that may be occurring in Tg
PDAPP(J20) mouse brain as a result of Aβ accumulation and plaque deposition and oxidative
stress.
Additionally, the levels of the cell signaling protein,  GDP-dissociation inhibitor 1, were
found to be increased in brains of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls.
This inhibitor belongs to the  guanosine triphosphatase (GTPase) family of enzymes, which
regulate membrane trafficking and recycling of GTPases (Wu et al., 1996), as well as APP
processing [Table 7.3] (Maillet et al., 2003). In the brain,  GDP proteins are involved in
neurotransmitter release (Maillet et al., 2003). A recent study involving the SN56 line of cells
showed that exogenous exposure of cells to Aβ(1-42) leads to reduced phosphorylation levels of
 GDP-dissociation inhibitor (Joerchel et al., 2008). In studies of concanavalin A-associated
proteins, the  GDP-dissociation inhibitor is reported as decreased in the hippocampus of
subjects with AD (Owen et al., 2009). Thus, increased levels of  GDP-dissociation inhibitor 1
and Pin-1 in Tg PDAPP(J20) mice suggests that normal neurotransmission may still be occurring
at 9 months-old in this mouse model of Aβ pathology, despite significant Aβ accumulation and
plaque deposition.
7.5.7 Conclusions
The changes in the levels of and oxidative modification of proteins observed in this
dissertation study of Tg PDAPP(J20) mouse brain support the notion that biochemical pathways
are altered in AD and FAD. Alterations in brain proteins in this mouse model of Aβ pathology
are consistent with previous reports of AD pathology, involving altered proteins associated with
calcium signaling and neuritic abnormalities. Interestingly, it appears that the central nervous
system of these mice may be responding to increased Aβ accumulation and/or SP deposition in
an attempt to maintain normal ATP levels, cytoskeletal structural integrity, and cell signaling
pathways. Moreover, there also appears to be a possible antioxidant defense response that Tg
PDAPP(J20) neurons are attempting to up-regulate against ROS and RNS, shown to be
significantly increased in brain of Tg PDAPP(J20) mice at this age (Chapter 6). Future studies
of Tg PDAPP(J20) mice will involve continued investigation of the downstream effects of Aβ(142)-induced oxidative stress, accumulation, and plaque deposition, in an attempt to gain more
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insight into Aβ(1-42)-associated mechanisms of Met-35-mediated oxidation via genetic
modification of the Tg PDAPP(J20) in vivo model of Aβ pathology.
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CHAPTER 8
IN VIVO EFFECTS ON THE PROTEOME OF AN ALZHEIMER DISEASE HUMAN
MUTANT TRANSGENIC MOUSE MODEL WITH AN ADDITIONAL MET631LEU
SUBSTITUTION ON APP
8.1 Overview
A single methionine residue at position 35 (Met-35) of the amyloid-β peptide (Aβ) has
been highly implicated in A-induced oxidative stress and neurotoxicity in Alzheimer disease
(AD) brain. Results reported in Chapters 6 and 7 of this dissertation demonstrated elevated
levels of oxidative stress in vivo in brain of PDAPP transgenic (Tg) mice carrying Swedish and
Indiana mutations on the human amyloid precursor protein (APP) [Tg PDAPP(J20)]. Chapter 6,
however, shows that substitution of Met-35 of Aβ with a leucine (Leu; corresponding to residue
631 of the human amyloid precursor protein [APP]) abrogated all indices of oxidative stress (i.e.,
protein carbonyls, protein-resident 3-nitrotyrosine [3-NT], and protein-bound 4-hydroxy-2-transnonenal [HNE]), thereby supporting the notion that Met-35 mediates the majority of A-induced
oxidative stress in AD brain. In the current dissertation study, differential expression proteomics
analysis of Tg PDAPP(J20) mice relative to PDAPP mice carrying a Met631Leu substitution on
APP [Tg PDAPP(M631L)] was conducted to gain a better understanding of specific protein
pathways that may be altered as a result of maintaining low levels of oxidative stress in the
absence of Met-35 of Aβ. 2D-gel expression studies identified 21 proteins as being significantly
down-regulated in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice. These
proteins are involved in pathways such as cell signaling, migration, and proliferation, the cellcycle, structural integrity, energy and metabolism, antioxidant/detoxification activity,
proteasomal degradation, and pH regulation. In addition, three proteins were found to be
significantly differentially expressed in brain of Tg PDAPP(M631L) mice relative to nontransgenic (Non Tg) M631L littermate mice. 1D-Western blot analysis used to validate spots
identified as significantly differentially expressed by SEQUEST and PD-Quest image analyses
confirmed the significant down-regulation of pyruvate kinase M2 (PK M2) in brain of Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice. Overall, these results suggest that in
addition to the role of Met-35-associated oxidative stress and neurotoxicity, this Aβ residue also
causes numerous downstream effects, which lead to differential expression of relevant protein
pathways in AD.
8.2 Introduction
Autosomal dominant mutations in APP and presenilins-1 or -2 lead to a familial form of
AD [FAD] (Citron et al., 1992; Cruts et al., 1998; Goate et al., 1991; Scheuner et al., 1996;
Sturchler-Pierrat et al., 1997), which is clinically diagnosed by the age-related decline in
cognition, in the same way as sporadic AD, but at an earlier age of onset [~30 years-old] (Citron
et al., 1992; Price et al., 1998; Scheuner et al., 1996; Sturchler-Pierrat et al., 1997; Wisniewski et
al., 1998). Major histopathological hallmarks of AD include the accumulation and deposition of
senile plaques (SPs) and neurofibrillary tangles (NFTs), synapse and neuronal cell loss, and
oxidative stress (Butterfield and Lauderback, 2002; Good et al., 1996; Markesbery, 1997;
Mohmmad Abdul et al., 2006; Smith et al., 1997; 1994). As a major component of SPs, Aβ(1161

42) is considered to be the more toxic form of Aβ produced in AD brain, especially in its soluble,
oligomeric form (Boyd-Kimball et al., 2005a; 2005b; 2005c; Demuro et al., 2005; Drake et al.,
2003a; Mohmmad Abdul et al., 2004; 2006; Selkoe, 1996; 2008; Viola et al., 2008). The
concept of Aβ-induced oxidative stress in AD has been extensively supported through various
studies of AD model systems and subjects with AD (Abdul et al., 2008; Ansari et al., 2006;
Boyd-Kimball et al., 2004; 2005b; Drake et al., 2003a; Mohmmad Abdul et al., 2006; Pappolla et
al., 1999; Resende et al., 2008; Sultana et al., 2005; Zhu et al., 2008).
Many of studies suggest the Met-35 residue of Aβ to be the main contributor to Aβinduced oxidative stress and damage. For example, in vitro studies substituting norleucine (Nle)
for Met (replacing the Met sulfur [S]-atom with a CH2 group; Fig. 2.53) at position 35 in human
Aβ(1–42) demonstrated an almost complete abrogation of the oxidative and neurotoxic effects of
the resulting Aβ(1-42) Met35Nle peptide in cultured neurons, while maintaining similar length,
hydrophobicity, and tendency to aggregate as native human Aβ(1-42) (Butterfield and BoydKimball, 2005; Varadarajan et al., 2001; Yatin et al., 1999). In addition, studies of
Caenorhabditis elegans (C. elegans) demonstrate that substitution of Met-35 with a cysteine
(Cys) [Fig. 2.53] in DNA encoding human Aβ(1-42) prevents in vivo protein oxidation and
worm paralysis (Fay et al., 1998; Yatin et al., 1999). Furthermore, results from Chapter 6 of this
dissertation show that Tg PDAPP mouse models of Aβ pathology with an A Met35Leu
substitution [Tg PDAPP(M631L)] have a significant decrease in protein oxidation and lipid
peroxidation relative to Tg PDAPP(J20) mice carrying the Swedish (K670N and M671L) and
Indiana (V717F) familial forms of AD (APPSw,In), which are expressed behind a platelet-derived
growth factor (PDGF) β-chain promoter (Galvan et al., 2006; Mucke et al., 2000). Additionally,
the A Met35Leu mutation results in animals with lessened SP formation (Galvan et al., 2006;
Mucke et al., 2000; Chapter 6).
It has been proposed by the Butterfield laboratory that oxidative stress associated with
toxic Aβ(1-42) is dependent on the formation of a S-centered, transient free radical on Met-35
(Boyd-Kimball et al., 2004; Butterfield and Boyd-Kimball, 2005; Kanski et al., 2002;
Varadarajan et al., 2001; Yatin et al., 1999). Free radical initiated one-electron oxidation of the
Met-35 S-atom makes it more susceptible to attack by reactive oxygen species (ROS), leading to
.
sulfuranyl or hydroxysulfuranyl radical cations, which may react with superoxide (O2 -) or
paramagnetic oxygen species. Thus, Met-35 can undergo a reversible oxidation leading to the
formation of methionine sulfoxide or it can undergo a two-electron oxidation leading to the
irreversible formation of methionine sulfone (Fig. 8.1). When Met-35 is not oxidized,
hydrophobic A(1-42) can insert into the lipid bilayer and therein form a S-centered, transient
free radical cation on Met-35 that can remove allylic hydrogen (H)-atoms from the acyl chains of
membrane lipids, leading to the formation of lipid peroxidation products (Butterfield and Bush,
2004; Butterfield and Boyd-Kimball, 2005). The hydrophilicity of Met-35, however, increases
when it is oxidized to methionine sulfoxide (Chao et al., 1997), making it less likely to insert into
the lipid bilayer of neurons and lead to further oxidation.
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Figure 8.1

Figure 8.1 Reversible oxidation of methionine (Met). Met can undergo a reversible
oxidation leading to the formation of methionine sulfoxide or it can undergo a twoelectron oxidation leading to the irreversible formation of methionine sulfone.
Other proposed mechanisms of Met-35-associated neurotoxicity of Aβ involve Met being
.
a source of electrons for metals such as copper or zinc, which could generate O2 - and highly
.
reactive hydroxyl radicals [ OH] (i.e., Fenton chemistry; see section 2.4.2.1; reaction 3) and
increase A deposition (Bush et al., 1994; Pogocki, 2004; Varadarajan et al., 2000; 2001). Met35 is also important in AD pathology because its redox status directly correlates with amyloid
fibril formation; when Met-35 is oxidized to methionine sulfoxide, the rate of fibril formation
with A(1-42) is lowered and protofibrils are not formed (Bitan et al., 2003; Hou et al., 2002;
Johansson et al., 2007a). Moreover, oxidized Met-35 is reported to be in high abundance in SPs
analyzed from subjects with AD (Kuo et al., 2001; Naslund et al., 1994). This accumulation may
be related to reduced activity of methionine sulfoxide reductase, an enzyme that cycles oxidized
Met back to its reduced form, in AD brain (Gabbita et al., 1999).
Met oxidation may be involved in regulatory signaling pathways and in antioxidant
defense (Butterfield and Kanski, 2002), by becoming oxidized in order to protect amino acids in
the active sites of various enzymes from oxidative insult (Stadtman, 2004). Met may also
influence the activity of repair or chaperone proteins (Bose-Basu et al., 2004) and helps to
regulate cellular redox state (Schoneich, 2002). Further insight into the exact mechanisms by
which Met-35 redox status contributes to or even prevents A-induced oxidative stress and AD
pathology can be realized by global proteome investigations. To-date, there are no reports
involving changes in the proteomes of AD or in vivo models of Aβ pathology as a function of the
redox state of Met-35.
The present dissertation study examined the hypothesis that the levels of specific brain
proteins isolated from Tg PDAPP(M631L) mice may be significantly altered relative to Tg
PDAPP(J20) mouse models of Aβ pathology, as well as Non Tg M631L mice. 2Dpolyacrylamide gel electrophoresis (2D-PAGE) coupled with mass spectrometry (MS) identified
alterations in the expression of 21 proteins isolated from brain of Tg PDAPP(M631L) mice in
comparison to Tg PDAPP(J20) mice, which are known to be involved in cell signaling,
migration, and proliferation, the cell-cycle, structural integrity, energy and metabolism,
antioxidant/detoxification activity, proteasomal degradation, and pH regulation. Additionally,
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three proteins were found to be significantly differentially expressed in brain of Tg
PDAPP(M631L) mice relative to Non Tg M631L littermates. 1D-Western blot analysis used to
validate spots identified as significantly differentially expressed by SEQUEST and PD-Quest
image analyses confirmed the significant down-regulation of PK M2 in brain of Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice. Results reported in this chapter will
be discussed with regard to the implications of the differentially expressed proteins as a result of
Met-35 redox state in AD.
8.3 Experimental Procedures
All materials and methods used in this study are described in Chapter 3 of this
dissertation. Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, 3.7, 3.8.1.2, 3.9.1, 3.10, and 3.11.
8.3.1 Statistical Analysis
All data are presented as mean ± standard deviation (S.D.) or mean ± standard error of
the means (S.E.M.), as noted. Statistical analyses were performed using a two-tailed Student‟s ttest, wherein P<0.05 was considered significant for differential expression fold-change values
and oxidative modification levels. Protein and peptide identifications obtained with the
SEQUEST search algorithm with a P-value<0.01 were considered statistically significant. To
further validate PD-Quest and SEQUEST identifications of significantly different spots, the
location of protein spots on 2D-gels were manually checked to ensure they were near the
expected molecular weight (MW) and isoelectric point (pI) values based on SwissProt database
information.
8.4 Results
PDAPP mice were created in collaboration with Professor Lennart Mucke at the
University of California (San Francisco, CA), while M631L mice were created by our
collaborators at the Buck Institute for Age Research (Novato, CA). Many lines of
PDAPP(M631L) were produced (>10) to derive two with high-level APP expression similar to
that of Tg PDAPP(J20) mice, in order to form an accurate comparison. Therefore, because the
A1058 line of Tg PDAPP(M631L) mice was closest to Tg PDAPP(J20) mice in APP expression,
it was used for all studies reported here. 2D-gel-based proteomics analyses were performed on
proteins extracted from the brains of Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L
mice, resulting in two comparisons: Tg PDAPP(M631L) mice relative to Tg PDAPP(J20) mice
and Tg PDAPP(M631L) mice relative to Non Tg M631L mice.
8.4.1 Tg PDAPP(M631L) Mice Compared to Non Tg M631L Mice
Effects inherently present in Tg PDAPP(M631L) mice as a result of the M631L
transgene can be realized through comparisons with their Non Tg M631L littermates as a
control. Three spots were observed to have significant differences in protein levels based on an
image analysis of spot densities in Tg PDAPP(M631L) mice compared to Non Tg M631L mice.
Examples of 2D-gel images from these analyses can be found in Figure 8.2. Table 8.1 lists the
number of peptide sequences, spectral counts (SC), MW, pI, fold-change levels, and P-values
associated with each protein identified in Tg PDAPP(M631L) relative to Non Tg M631L mice.
In order to increase confidence in proteins identified with only a single peptide sequence, more
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than one SC was observed and/or the protein was identified in other MS/MS experiments of that
protein spot. I am confident in the identification of these proteins based on the low P-values
associated with the SEQUEST identifications (i.e., P3.00e-04). In addition, the location of
protein spots visually align with their anticipated MW and pI values on the 2D-gels. It is
important to note that in some cases, there appears to be a shift in the observed MW and pI from
the predicted locations, presumably due to factors such as post-translational modification, which
influences the net charge of proteins and degradation products. Following MS/MS analysis of
in-gel tryptic digests, these spots were identified as dynamin-1, heat shock protein 90 B1 (Hsp90
B1), and proteasome, subunit , Type 2. As listed in Table 8.1, both dynamin-1 (5.98-fold,
*P<0.013) and Hsp90 B1 (2.28, *P<0.035) are up-regulated in Tg PDAPP(M631L) brain
relative to that of Non Tg M631L mice, whereas proteasome, subunit , Type 2 (1.65,
*P<0.019) is down-regulated.
Figure 8.2
A) Non Tg M631L
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Figure 8.2 (cont.)
B) Tg PDAPP(M631L)

Figure 8.2 Representative 2D-gel images of proteins isolated from brain of Tg
PDAPP(M631L) and Non Tg M631L mice. Protein spots identified as significantly
differentially expressed after PD-Quest and SEQUEST analyses of A) Non Tg M631L
and B) Tg PDAPP (M631L) 2D–gels are labeled. Hsp90 B1, heat shock protein 90 B1.
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Table 8.1 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to
Non Tg M631L controls.
SwissProt
MW
Peptides
FoldProtein
Accession
pI
pb
P-valued
a
(kDa)
(SC)
Changec
No.
Dynamin-1
P39053 97.74 7.62
1(3) 6.00e-09 5.99 ↑
0.013
Heat-shock protein 90, B1
P08113 92.42 4.59
4(8) 5.00e-06 2.28 ↑
0.035
(Hsp90 B1)
Proteasome, subunit β,
Q9R1P3 22.89 6.61
1(2) 3.00e-04 1.65 ↓
0.019
Type 2
a

The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides. The
total number of MS/MS spectral counts (SC) is indicated in ( ).
b
The probability of an incorrect identification associated with each protein identification using the
SEQUEST search alogorithm.
c
The fold-change in spot density from Tg PDAPP(M631L) mice compared to Non Tg M631L
controls. The arrow indicates the direction of change.
d
The P-value associated with fold-changec calculated using a Student‟s t-test. n=10 for Tg
PDAPP(M631L), n=5 for Non Tg M631L.
pI, isoelectric point; MW, molecular weight.

8.4.2 Tg PDAPP(M631L) Mice Compared to Tg PDAPP(J20) Mice
21 spots were observed to have a significant differential levels based on an image
analysis of spot densities in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, used
as a positive control of Aβ-related AD pathology. Examples of 2D-gel images from these
analyses can be found in Figure 8.3. Table 8.2 lists the number of peptide sequences, SC, MW,
pI, fold-change levels, and P-values associated with each protein identified in Tg
PDAPP(M631L) relative to Tg PDAPP(J20) mice. Interestingly, each of these proteins is downregulated in brain of Tg PDAPP(M631L) mice. In order to increase confidence in proteins
identified with only a single peptide sequence, more than one SC was observed and/or the
protein was identified in other MS/MS experiments of that protein spot. I am confident in the
identification of these proteins based on the low P-values associated with the SEQUEST
identifications (i.e., P3.00e-04). In addition, the location of protein spots visually align with
their anticipated MW and pI values on the 2D-gels. Again, it is important to note that in some
cases, there appears to be a shift in the observed MW and pI from the predicted locations,
presumably due to factors such as post-translational modification, which influences the net
charge of proteins and degradation products. The proteomic investigation into Tg PDAPP(J20)
mice relative to Non Tg PDAPP littermates reported in Chapter 7 of this dissertation will also be
used in this chapter to allow direct proteome comparisons based on the redox status of Met-35.

167

Figure 8.3
A) Tg PDAPP(M631L)

A) Tg PDAPP(M631L) [cont.]
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Figure 8.3 (cont.)
B) Tg PDAPP(J20)

B) Tg PDAPP(J20) [cont.]

Figure 8.3 Representative 2D-gel images of proteins isolated from brain of Tg
PDAPP(M631L) and Tg PDAPP(J20) mice. Protein spots identified as significantly
differentially expressed after PD-Quest and SEQUEST analyses of A) Tg
PDAPP(M631L) and B) Tg PDAPP(J20) 2D–gels are labeled.
Drp-2,
dihydropyrimidinase-related protein 2; FBA-C, fructose bisphosphate aldolase C; MDH,
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malate dehydrogenase, cytoplasmic; CA-2, carbonic anhydrase 1; TPI, triose phosphate
isomerase; NADH DH, nicotinamide adenine dinucleotide (NADH) dehydrogenase
[ubiquinone] flavoprotein 2; PEBP-1, phosphatidylethanolamine-binding protein 1; PRX2, peroxiredoxin-2; PRX-1, peroxiredoxin-1; Pin-1, peptidyl-prolyl cis-trans isomerase 1;
VDAC-1, voltage-dependent anion channel 1; MnSOD, superoxide dismutase [Mn],
mitochondrial; PK M1/M2, pyruvate kinase M1/M2; PGM 1, phosphoglycerate mutase 1;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Table 8.2 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) mice.
SwissProt
MW
Peptides
FoldProtein
Accession
pI
pb
P-valued
(kDa)
(SC)a
Changec
No.
Acot7, isoform B of cytosolic acyl
Q91V12 42.51 8.77 2(5) 3.00e-07 2.10 ↓ 0.024
coenzyme A, thioester 7
Q03265 59.72 9.53 5(10) 8.00e-07 4.21 ↓ 2.55e-05
ATP synthase subunit α,
mitochondrial *
Q03265 59.72 9.53 11(37) 1.00e-10 2.25 ↓ 0.0001
Carbonic anhydrase 2 (CA-2)
P00920 29.01 6.54 2(6) 1.00e-10 2.08 ↓ 0.0004
Dihydropyrimidinase-related
O08553 62.24 5.93 3(10) 2.00e-11 3.81 ↓ 0.019
protein 2 (Drp-2)
P05063 39.37 6.74 3 (6) 9.00e-08 3.86 ↓ 0.028
Fructose bisphosphate aldolase C *
P05063 39.37 6.74 1(3) 2.00e-08 1.70 ↓ 0.0014
P16858 35.81 8.33 4(11) 9.00e-11 3.23 ↓ 0.019
Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) *
P16858 35.81 8.33 4(11) 2.00e-07 1.58 ↓ 0.0002
Malate dehydrogenase,
P14152 36.49 6.16 2(4) 2.00e-05 2.33 ↓ 0.007
cytoplasmic
NADH dehydrogenase
Q9D6J6 27.27 7.15 3(7) 5.00e-07 2.15 ↓ 0.0097
[ubiquinone] flavoprotein 2
P17742 18.30 7.97 1(3) 3.00e-05 5.86 ↓ 0.0017
Peptidyl-prolyl cis-trans
P17742 18.30 7.97 1(3) 1.00e-05 2.24 ↓ 0.0015
isomerase (Pin-1) *
P17742 18.30 7.97 1(6) 2.00e-04 1.80 ↓ 0.00087
Peroxiredoxin-1
P35700 22.16 8.2
1(2) 2.00e-04 6.02 ↓ 0.004
Peroxiredoxin-2
Q61171 21.77 5.08 2(2) 4.00e-09 5.31 ↓ 0.037
PhosphatidylethanolamineP70296 20.82 5.07 3(11) 1.00e-07 5.51↓
0.010
binding protein 1 (PEBP-1)
Phosphoglycerate mutase 1
Q9DBJ1 28.81 6.79 3(7) 4.00e-08 1.81 ↓ 0.00074
Proteasome, subunit β, Type 3
Q9R1P1 22.95 6.15 1(3) 9.00e-09 2.45 ↓ 0.027
Pyruvate kinase isozymes M1/M2 P52480 57.95 6.73 1(2) 3.00e-04 33.3 ↓ 0.0063
(PK M1/M2) *
P52480 57.95 6.73 8(25) 1.00e-08 2.53 ↓ 0.0049
Serum Albumin
P07724 68.65 5.69 1(4) 6.00e-09 5.39 ↓ 0.0026
Superoxide dismutase [Mn],
P09671 24.59 8.80 1(3) 4.00e-05 2.09 ↓ 0.019
mitochondrial (MnSOD)
Transgelin-3
Q9R1Q8 22.46 7.16 1(5) 1.00e-04 2.37 ↓ 0.028
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Table 8.2 (Cont.)
Protein

SwissProt
MW
Peptides
Accession
pI
(kDa)
(SC)a
No.

pb

FoldP-valued
Changec

P17751 26.69 7.07 1(1) 4.00e-06 4.86 ↓ 0.022
Triose phosphate isomerase
(TPI) *
P17751 26.69 7.07 6(12) 2.00e-07 2.31 ↓ 9.97e-05
Voltage-dependent anionselective channel protein 1
Q60932 32.33 8.66 2(3) 3.00e-07 1.56 ↓ 0.029
(VDAC-1)
V-type proton ATPase, subunit F Q9D1K2 13.36 5.45 1(5) 2.00e-13 2.08 ↓ 0.045
a
The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides. The total
number of MS/MS spectral counts (SC) is indicated in ( ).
b
The probability of an incorrect identification associated with each protein identification using the
SEQUEST search alogorithm.
c
The fold-change in spot density from Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.
The arrow indicates the direction of change.
d
The P-value associated with fold-changec calculated using a Student‟s t-test. n=10 for Tg
PDAPP(M631L), n=10 for Tg PDAPP(J20).
*These proteins were detected at multiple spot locations, as shown in Figure 8.3
pI, isoelectric point; MW, molecular weight.

8.4.3 Pyruvate Kinase M2 (PK M2) Western Blot Spot Validation
Western blot validation was performed for the PK M2 protein as a representative
confirmation of those brain proteins identified as significantly differentially expressed by PDQuest and SEQUEST analyses. This data was obtained in collaboration with Dr. Rena Sowell
Robinson (University of Pittsburgh, Pittsburgh, PA). Western blot analysis showed that the lanes
corresponding to PK M2 (~58 kDa) and the loading control, actin (42 kDa; used as a loading
control to normalize the amount of protein loaded in each well of the gel), levels agree with their
expected positions based on MW (Fig. 8.4a). The histogram based on lane intensity shows a
~30% decrease in the level of PK M2 in the brains of Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) mice (Fig. 8.4b; P<0.06). The P-value for this change was near the level of
significance (i.e., *P<0.05), therefore, these results are in agreement with the down-regulation
observed in 2D-PAGE expression proteomics analyses described above.
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Figure 8.4

Figure 8.4 Pyruvate kinase M2 (PK M2) levels in brain of Tg PDAPP(M631L) and Tg
PDAPP(J20) mice. PK M2 and actin levels were measured by 1D-polyacrylamide gel
electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot analysis in 9
month-old Tg PDAPP(M631L) [lanes 2, 4, 6, 8, 10, and 12] and Tg PDAPP(J20) mice
(lanes 1, 3, 5, 7, 9, and 11). A) Increased band intensity after normalization with actin
represents an increase in the amount of PK M2 present.
n=6 for both Tg
PDAPP(M631L) and Tg PDAPP(J20) groups. B) Graphical representation of data shown
in A) demonstrates a ~30% decrease in the levels of PK M2 in Tg PDAPP(M631L) mice
compared to Tg PDAPP(J20) mice. Percent control values are presented as mean ±
S.E.M.; P<0.06. Data obtained in collaboration with Dr. Rena Sowell Robinson
(University of Pittsburgh, Pittsburgh, PA).

8.5 Discussion
Met-35 has been shown to have significant relevance to AD pathology, as evidenced by
its critical role in A(1-42)-induced oxidative stress. Changes to the redox status of Met-35 can
influence levels of oxidative stress and A-associated fibril and aggregate formation (Butterfield
and Bush, 2004; Butterfield and Boyd-Kimball, 2005). Supporting this notion are results
reported in Chapter 6 of this dissertation, where it was shown that the levels of oxidative stress in
Tg PDAPP(J20) mice increase significantly compared to Non Tg PDAPP littermates, as indexed
by protein carbonyls, protein-resident 3-NT, and protein-bound HNE. In vivo substitution of
Met-35 with Leu in Tg PDAPP(M631L) mice effectively returned oxidative stress levels in brain
to levels similar to that observed in Non Tg PDAPP and Non Tg M631L littermate control mice.
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Therefore, in order to gain further insight into the biochemical pathways altered as a result of the
Met35Leu substitution, differential expression proteomics analyses of Tg PDAPP(M631L), Non
Tg M631L littermates, and Tg PDAPP(J20) mice were conducted.
In the current study, 2D-PAGE analyses identified dynamin-1, Hsp90 B1, and
proteasome subunit , Type 3, to be significantly up-regulated in Tg PDAPP(M631L) mice
relative to Non Tg M631L mice (Table 8.1). Previous studies have demonstrated altered levels
of Hsp90 in AD hippocampus (Owen et al., 2009) and have indicated that both α and β subunits
of the proteasome are oxidatively modified in a C. elegans model of AD (Boyd-Kimball et al.,
2006). Moreover, studies have shown an Aβ-induced decrease in dynamin-1, resulting from
calpain-mediated cleavage of dynamin-1 protein, in addition to potential down-regulation of
dynamin-1 gene expression (Kelly et al., 2005; Sinjoanu et al., 2008). The observed alteration in
these proteins‟ levels in Tg PDAPP(M631L) mice may reflect introduction of the APPSw,In
transgene with a Met35Leu substitution. Dynamin-1 is a phosphatidylinositol 3-kinase inhibitor
and may be associated with synaptic vesicle recycling and endocytosis (Yao et al., 2003). Thus,
the up-regulation of dynamin-1 may reflect an increase in synaptic recycling, since synapse loss
was not shown to be compromised in brain of Tg PDAPP(M631L) mice in Chapter 6. Similar to
dynamin-1, up-regulation of the molecular chaperone, Hsp90 B1, suggests that Tg
PDAPP(M631L) mice have heightened cellular defense responses as compared to Non Tg
M631L mice. Down-regulation of proteasome, subunit , Type 2, in brain of Tg
PDAPP(M631L) mice relative to Non Tg M631L mice may be indicative of alterations in
proteasomal machinery caused by other pathways not directly related to A(1-42)-induced
oxidative stress. Since a decrease in proteasome subunit levels would deter the cells ability to
remove oxidatively or otherwise damaged proteins, it is reasonable to believe the cell employs an
equal but opposite response, which causes up-regulation of potentially protective proteins, like
dynamin-1 and Hsp90 B1, to compensate.
However, the primary goal of the current research was to determine differences in protein
levels between Tg PDAPP(M631L) and Tg PDAPP(J20) mice. In Chapter 7 of this dissertation,
the alteration of several proteins in brain of Tg PDAPP(J20) mice relative to Non Tg PDAPP
littermates was reported, possibly as a result of increased A oligomerization, deposition, and
oxidative stress (Galvan et al., 2006; Mucke et al., 2000). Moreover, AD pathology, including
SPs and oxidative stress, were shown to be significantly reduced in brain of Tg PDAPP(M631L)
mice compared to Tg PDAPP(J20) mice in Chapter 6, supporting the involvement of Met-35 in
A(1-42)-induced oxidative stress. In the current study, 21 proteins were identified as being
significantly down-regulated in Tg PDAPP(M631L) brain relative to that of Tg PDAPP(J20)
mice; below is a brief discussion of the overall functions associated with these proteins and their
implications to AD pathology.
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Table 8.3 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) and Non Tg M631L mice and their cellular functions.
Current
Protein
Cellular Function(s)
Alteration
Tg PDAPP(M631L) vs. Tg PDAPP(J20)
Acot7, isoform B of cytosolic acyl coenzyme
↓ Expression
A, thioester 7
↓ Expression ATP synthase, subunit α, mitochondrial

Energy Metabolism; Lipid
Synthesis
Energy Metabolism

↓ Expression Fructose bisphosphate aldolase C
Energy Metabolism
Glyceraldehyde-3-phosphate dehydrogenase
↓ Expression
Energy Metabolism
(GAPDH)
↓ Expression Malate dehydrogenase, cytoplasmic
Energy Metabolism
NADH dehydrogenase [ubiquinone]
↓ Expression
Energy Metabolism
flavoprotein 2
↓ Expression Phosphoglycerate mutase 1
Energy Metabolism
Pyruvate kinase isozymes M1/M2
↓ Expression
Energy Metabolism
(PK M1/M2)
↓ Expression Triose phosphate isomerase (TPI)
Energy Metabolism
↓ Expression V-type proton ATPase, subunit F
Energy Metabolism
Voltage-dependent anion-selective channel
↓ Expression
Mitochondrial Permeability
protein 1 (VDAC-1)
↓ Expression Peroxiredoxin-1
Antioxidant
↓ Expression Peroxiredoxin-2
Antioxidant
Superoxide dismutase [Mn], mitochondrial
↓ Expression
Antioxidant
(MnSOD)
↓ Expression Transgelin-3
Structural Protein
↓ Expression Dihydropyrimidinase-related protein 2 (Drp-2)
Structural Protein
↓ Expression Peptidyl-prolyl cis-trans isomerase (Pin-1)
Cell Signaling; Cell-Cycle
Cell Signaling, Proliferation,
Phosphatidylethanolamine-binding protein 1
↓ Expression
& Migration; Cholinergic
(PEBP-1)
System
↓ Expression Carbonic anhydrase 2 (CA-2)
pH Regulation
↓ Expression Proteasome, subunit β, Type 3
Protein Degradation
Oncotic Pressure; Transport
↓ Expression Serum Albumin
Protein
Tg PDAPP(M631L) vs. Non Tg M631L
Structural Protein;
↑ Expression Dynamin-1
Receptor-Mediated
Endocytosis
↑ Expression Heat-shock protein 90, B1 (Hsp90 B1)
Molecular Chaperone
↓ Expression Proteasome, subunit β, Type 2
Protein Degradation
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8.5.1 Energy Dysfunction, Metabolism, & Mitochondrial Alterations
Down-regulation of proteins involved in energy metabolism and mitochondrial function
observed in these studies (Table 8.3) are consistent with known alterations in the brain of
subjects with AD (Blass et al., 2002; Bubber et al., 2005; Watson and Craft, 2004), especially
since a majority of the identified proteins have previously been found oxidatively modified in
subjects with and animal models of AD (reviewed in Sultana et al., 2009). Cellular metabolism,
particularly cerebral glucose uptake, is known to be altered in the brains of patients with AD and
mild cognitive impairment (MCI) [Fig. 7.7] (Watson and Craft, 2004). Proteins identified to be
significantly up-regulated in brain of Tg PDAPP(J20) mouse models of Aβ pathology in Chapter
7, including α-enolase and ATP synthase, subunit α, support this notion. The significant
decrease in proteins associated with glucose metabolism in this current study serve to reaffirm
previous findings, suggesting that glucose metabolism, and hence, adenosine triphosphate
(ATP)-based energy production is reduced following substitution of Met-35 with Leu. This
down-regulation of energy- and metabolic-related proteins suggests that Tg PDAPP(M631L)
brain is not under a substantial amount of oxidative stress, which would initiate the increased
production of key glycolytic proteins (Mielke et al., 1996), compared to Tg PDAPP(J20) brain.
Likewise, down-regulation of voltage-dependent anion channel protein-1(VDAC-1), a major
component of the mitochondrial permeability transition pore (see section 2.5.1), also suggests
that Tg PDAPP(M631L) mouse brain is not exposed to a substantial amount of oxidative stress
relative to brain of Tg PDAPP(J20) mice.
8.5.2 Antioxidant & Cellular Defense
Peroxiredoxins-1 and -2 and superoxide dismutase [Mn], mitochondrial (MnSOD or
SOD2) are antioxidant enzymes (Table 8.3) which help the cell defend itself against ROS and
reactive nitrogen species (RNS). Peroxiredoxins catalyze the reduction of peroxynitrite (ONOO), hydrogen peroxide (H2O2), and alkyl hydroperoxides (ROOH) [see sections 2.4.2 & 2.4.3]
(Peshenko and Shichi, 2001). Peroxiredoxin-1 is up-regulated in the brain of subjects with AD
(Kim et al., 2001), as well as in brain of Tg PDAPP(J20) mouse models of Aβ pathology
.
(Chapter 7). MnSOD, an antioxidant enzyme that catalyzes the dismutation of O2 - into
molecular oxygen and H2O2 (see section 2.4.2.1), has previously been found to be oxidatively
modified in brain of subjects with AD, and is also down-regulated in the current study. The
down-regulation of peroxiredoxins-1, -2, and/or MnSOD in brain of Tg PDAPP(M631L) mice is
consistent with the notion that the Met35Leu substitution substantially reduces the amount of
ROS and RNS produced in neuronal cells, likely by Aβ, suspending the need for a greater
surplus of antioxidant enzymes. This notion is supported by results observed in Chapter 6, in
which Tg PDAPP(M631L) mice had significantly lower levels of oxidative stress relative to Tg
PDAPP(J20) mice.
8.5.3 Neuritic Abnormalities & Structural Integrity
Cellular structural integrity is another known alteration in AD brain (Mohmmad Abdul et
al., 2006; Sultana et al., 2009). Transgelin-3 and dihydropyrimidinase-related protein 2 (Drp-2)
are two structural proteins found to be down-regulated in the present study (Table 8.3).
Transgelin-3, also known as neuronal protein 25, is an F-actin binding protein whose cellular
functions are not completely understood (Mori et al., 2004). In brain of Tg PDAPP(J20) mice,
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an increase in the levels of F-actin capping protein, subunit β, was observed relative to Non Tg
PDAPP controls (Chapter 7). Although further investigation into the function(s) of transgelin-3
are necessary, it can be speculated that current results suggest that the Met35Leu mutation
reduces the need to maintain structural integrity and locomotion, compared to Tg PDAPP(J20)
brain. Likewise, Drp-2 is associated with axonal outgrowth and maintenance of neuronal
plasticity (Hamajima et al., 1996; Kato et al., 1998). Although a significant alteration in Drp-2
levels was not observed in brain of Tg PDAPP(J20) mice, this protein was found to be
significantly carbonylated in brain of Tg PDAPP(J20) mice (Chapter 7), as well as in brain of
subjects with AD (Boyd-Kimball et al., 2005c; Casserly and Topol, 2004; Castegna et al.,
2002a). Therefore, down-regulation of Drp-2 in Tg PDAPP(M631L) mouse brain may signify
the ability of neurons to maintain structural integrity.
8.5.4 pH Regulation
Carbonic anhydrase 2 (CA-2) is involved in the maintenance of cellular pH levels (Table
8.3) through catalysis of carbon dioxide (CO2) into bicarbonate (HCO3-) and protons, as well as
regulating CO2 and HCO3- transport, and maintaining H2O and electrolyte balance (Sly and Hu,
1995). In addition, CA-2 is also involved in the production of cerebral spinal fluid and the
synthesis of glucose and some lipids (Frey et al., 1998; Markesbery, 1997). The ability of the
cell to maintain the proper pH is necessary for optimal efficiency of mitochondrial and glycolytic
enzymes involved in ATP production, as well as preventing the formation of protein aggregates.
CA-2 has also previously been found to be oxidatively modified in brain of AD patients (Sultana
et al., 2006b). A decrease in CA-2 levels in Tg PDAPP(M631L) brain relative to that of Tg
PDAPP(J20) mice suggests that pH maintenance is properly regulated in the brains of Tg
PDAPP(M631L) mice.
8.5.5 Lipid Abnormalities, Cholinergic Dysfunction, & Proteasome Degradation
Phosphatidylethanolamine-binding protein 1 (PEBP-1; also known as neuropolypeptide
h3 and Raf-kinase inhibitor protein [RIP]), a precursor of the hippocampal cholinergic
neurostimulating peptide (HCNP), is involved in the regulation of choline acetyltransferase
(ChAT), which influences the levels of the neurotransmitter, acetylcholine [Table 8.3] (Ojika,
1998). Elevated levels of PEBP-1 was previously reported in AD brain (Chen et al., 2006) and
in brain of Tg PDAPP(J20) mice (Chapter 7), as well as oxidatively modified in brain of subjects
with AD (Castegna et al., 2003; Reed et al., 2008a; 2008b). Increased PEBP-1 levels would be
indicative of a disruption in acetylcholine neurotransmission and lipid asymmetry; however, the
significant decrease in PEBP-1 levels in brain of Tg PDAPP(M631L) mice suggests that
cholinergic neurotransmission is still quite adequate and, thus, ChAT up-regulation via PEBP-1
is not necessary. This notion is, again, consistent with the concept that oxidative stress disrupts
cholinergic neurotransmission, as Met-35 contributes to reduced acetylcholine levels and poor
neurotransmission in subjects with AD and Tg PDAPP(J20) mouse models of Aβ pathology.
Moreover, PEBP-1 is believed to be a potential calpain substrate leading to proteasome
dysfunction (Chen et al., 2006). Defects in proteasomal machinery in AD brain would lead to an
accumulation of oxidatively and otherwise modified proteins that require degradation. It appears
intuitive that an increase in the levels of proteasome subunits would suggest that additional
proteasome machinery is necessary to handle an overabundance of potential degradable proteins
(i.e., aggregated or oxidized proteins). In brain of Tg PDAPP(M631L) mice, however, it appears
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that the Met35Leu substitution circumvents accumulation of degradation products and
proteasomal dysfunction; therefore, excess production of proteasome-related proteins, such as
proteasome subunit β, Type 3, is unnecessary, and subsequently reduced relative to that of Tg
PDAPP(J20) brain.
8.5.6 Cell Signaling, the Cell-Cycle, Tau Phosphorylation, & Amyloid-β (Aβ)
Production
Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) is a regulatory protein that belongs to the
family of peptidyl-prolyl isomerase enzymes (PPIases), and acts as a regulatory protein by
binding to and isomerizing a proline residue on the C-terminal side of a phosphorylated Ser/Thr
moiety (pSer/pThr) from the cis to trans conformation, thereby regulating the activity of the
target protein (Butterfield et al., 2006d). Pin-1‟s functions are associated with cell-cycle
regulation, transcription, cytokines, apoptosis, and the DNA damage response [Table 8.3]
(Butterfield et al., 2006d). Moreover, Pin-1 has been heavily implicated in AD pathogenesis via
its regulation of the phosphorylation state of the microtubule-associated protein tau [see section
2.6] (Lee and Tsai, 2003; Lu et al., 2003), as well as the production of Aβ through binding APP
(Pastorino et al., 2006). In Chapter 7, a significant increase in Pin-1 levels was observed in Tg
PDAPP(J20) mice compared to brain of Non Tg PDAPP littermate controls, which may indicate
an attempt by the brain to reduce Aβ levels and prevent SP formation. In the current study, a
significant decrease in the levels of Pin-1 was observed in brain of Tg PDAPP(M631L) mice
relative to Tg PDAPP(J20) mice. Thus, taken together, results indicate that involvement of Pin-1
in AD pathology may be directly related to Met-35 of Aβ.
8.5.7 Conclusions
The results from the current dissertation study are rather striking, in that all 21 proteins
identified as differentially expressed in brain of Tg PDAPP(M631L) mice are down-regulated
when compared with the brain of Tg PDAPP(J20) mice. The Met35Leu substitution on Aβ
appears not only to lead to a reduction in the levels of oxidative stress levels and AD pathology,
but also lowered levels of proteins involved in energy metabolism and mitochondrial
maintenance pathways. Such global changes in the proteome appear to make the brain of Tg
PDAPP(M631L) mice similar to that of Non Tg M631L controls. Moreover, other affected
pathways include proteins involved in maintenance of neuronal structural integrity, antioxidant
defenses, and cellular signaling likely play key roles in AD pathology as a result of Met-35 redox
status and the overall redox status of the brain. Overall, the current results suggest that in
addition to the role of Met-35-associated oxidative stress and neurotoxicity, this Aβ residue also
causes numerous downstream effects, which lead to differential expression of relevant protein
pathways in AD. Results also suggest that incorporation of Leu at position 35 of Aβ prevents a
global response to oxidative stress, as evidenced by down-regulation of key proteins. Future
studies of Tg PDAPP(M631L) mice (Chapter 9) will involve a continued investigation of the
downstream effects of Aβ(1-42)-induced oxidative stress, accumulation, and plaque deposition,
in an attempt to gain more insight into Aβ(1-42)-associated mechanisms of Met-35-mediated
oxidation via redox proteomics.
Copyright © Miranda Lu Lange, 2010
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CHAPTER 9
REDOX PROTEOMICS ANALYSIS OF AN ALZHEIMER DISEASE TRANSGENIC
MOUSE MODEL CARRYING A MET631LEU SUBSTITUTION ON APP
9.1 Overview
Studies conducted in this dissertation, as well as previous literature reports, have shown
that amyloid-β (Aβ)-induced oxidative stress plays a predominant role in both human and animal
model Alzheimer disease (AD) pathology. Results from Chapters 6 and 7 showed elevated
levels of oxidative stress in vivo in brain of PDAPP transgenic (Tg) mice carrying Swedish and
Indiana mutations in the human amyloid precursor protein (APP) [Tg PDAPP(J20)], as indexed
by protein carbonylation, nitration, and protein-bound 4-hydroxy-2-trans-nonenal (HNE),
compared to non-transgenic (Non Tg PDAPP) littermate controls. Since this oxidative damage
was found to be dependent upon a single methionine residue at position 35 (Met-35) of the Aβ
peptide (residue 631 in human APP numbering) in Chapter 6, the current study compared
genetically and age-matched PDAPP mice carrying a Met to leucine (Leu) substitution at
position 35 (Met35Leu) of Aβ [Tg PDAPP(M631L)] to Tg PDAPP(J20) and Non Tg M631L
littermate mice using a redox proteomics approach. Based on present redox proteomics analyses,
a total of 15 proteins were identified with significantly different levels of protein carbonyls or
protein-resident 3-nitrotyrosine (3-NT), many, of which, have been previously identified as
differentially expressed and/or oxidatively modified in in vitro and in vivo models of Aβ
pathology and subjects with AD. Five proteins were found significantly carbonylated in brain of
Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, while only one protein had
significantly decreased levels of carbonylation; no brain proteins were found to be significantly
carbonylated in Tg PDAPP(M631L) mice relative to Non Tg M631L mice. Redox proteomics 3NT analyses identified three proteins to be significantly nitrated, and two proteins with
significantly reduced levels of protein-resident 3-NT, in Tg PDAPP(M631L) brain relative to
that of Tg PDAPP(J20) mice; four proteins were identified as significantly nitrated in brain of Tg
PDAPP(M631L) mice compared to Non Tg M631L mice. In addition, immunoprecipitation
validation of SEQUEST and PD-Quest image analyses spot identification confirmed the
significant nitration of peptidyl-prolyl cis-trans isomerase 1 (Pin-1) in brain of Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.
9.2 Introduction
Oxidative stress and damage is a hallmark of AD pathology, as many differential
expression and redox proteomics analyses of both human and animal models AD brain have
identified a number of dysfunctional, oxidatively modified proteins consistent with known
biochemical, pathological, and clinical alterations in this devastating dementing disorder [see
section 2.6] (Boyd-Kimball et al., 2005b; Butterfield and Sultana, 2008; Butterfield et al., 2006a;
Reed et al., 2008b; Sultana et al., 2007b; 2006b; 2006c). AD is also marked by the pathological
manifestation of neurofibrillary tangles (NFTs) and senile plaques (SPs), whose main component
is the Aβ(1-42) peptide. In AD brain, it is the soluble, oligomeric form of Aβ(1-42) that is
considered the toxic Aβ species (Demuro et al., 2005; Drake et al., 2003a; Selkoe, 2008; Viola et
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al., 2008), which serves to exacerbate escalating levels of oxidative stress and damage, leading to
loss of learning and memory (Selkoe, 2008; Walsh et al., 2002).
Numerous studies have shown that Aβ(1-42) induces oxidative stress in AD and various
AD model systems, linked to the Met-35 residue of this particular Aβ peptide (Abdul et al.,
2008; Ansari et al., 2006; Boyd-Kimball et al., 2004; 2005b; Butterfield and Boyd-Kimball,
2005; Drake et al., 2003a; Kanski et al., 2002; Mohmmad Abdul et al., 2006; Pappolla et al.,
1999; Resende et al., 2008; Varadarajan et al., 2001; Yatin et al., 1999). It has been proposed
that the oxidative stress properties of Aβ(1-42) are dependent on the formation of a sulfur (S)centered, transient sulfuranyl radical cation on Met-35, that promotes protein oxidation and lipid
peroxidation events within neurons [Figs. 2.54; 2.55] (Kanski et al., 2002; Varadarajan et al.,
2001; Yatin et al., 1999). In support of this notion, results reported in Chapter 6 of this
dissertation demonstrate a significant decrease in three indices of oxidative stress, including
protein carbonyls, protein-resident 3-NT, and protein-bound HNE, in brain of Tg
PDAPP(M631L) mice relative to Tg PDAPP(J20) mice, used as a positive control of Aβ-related
AD pathology. Moreover, the Met35Leu substitution returned oxidative stress levels back to a
baseline amount, similar to that measured in Non Tg M631L littermate control mice.
Therefore, the present dissertation study examined the hypothesis that specific brain
proteins isolated from Tg PDAPP(M631L) mice may have significant differences in oxidative
modification relative to Tg PDAPP(J20) mouse models of Aβ pathology, as well as Non Tg
M631L mice. Post-translational oxidative modification of proteins isolated from brain of Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) and Non Tg M631L mice were identified
following a comparative analysis between proteins separated by 2D-polyacrylamide gel
electrophoresis (2D-PAGE) and identified as oxidatively modified by 2D-Western blotting. A
total of 15 proteins were identified with differential levels of protein carbonyls or proteinresident 3-NT; five proteins were found significantly carbonylated in brain of Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, while only one protein had
significantly decreased levels of carbonylation. No proteins were found to be significantly
carbonylated in Tg PDAPP(M631L) mice relative to Non Tg M631L mice. 3-NT analyses
identified three proteins to be significantly nitrated, and two proteins with significantly reduced
levels of protein-resident 3-NT, in Tg PDAPP(M631L) brain relative to that of Tg PDAPP(J20)
mice; four proteins were identified as significantly nitrated in brain of Tg PDAPP(M631L) mice
compared to Non Tg M631L mice. Results obtained from SEQUEST and PD-Quest image
analyses were validated by Pin-1 immunoprecipitation, which confirmed the significant nitration
of Pin-1 in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice. Findings from
this redox proteomics study serve to enhance understanding of altered pathways in AD as they
pertain to the Aβ peptide and provide potential targets for AD prevention and treatment.
9.3 Experimental Procedures
All materials and methods used in this study are described in Chapter 3 of this
dissertation. Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, and 3.7-3.12.
9.3.1 Statistical Analysis
All data are presented as mean ± standard error of the means (S.E.M.). Statistical
analyses were performed using a two-tailed Student‟s t-test, wherein P<0.05 was considered
significant for differential expression fold-change values and oxidative modification levels.
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Protein and peptide identifications obtained with the SEQUEST search algorithm with a Pvalue<0.01 were considered statistically significant. To further validate PD-Quest and
SEQUEST identifications of significantly different spots, the location of protein spots on the 2Dgels and 2D-Western blots were manually checked to ensure they were near the expected
molecular weight (MW) and isoelectric point (pI) values based on SwissProt database
information.
9.4 Results
PDAPP mice were created in collaboration with Professor Lennart Mucke at the
University of California (San Francisco, CA), while M631L mice were created by our
collaborators at the Buck Institute for Age Research (Novato, CA). Many lines of
PDAPP(M631L) were produced (>10) to derive two with high-level APP expression similar to
that of Tg PDAPP(J20) mice, in order to form an accurate comparison. Therefore, because the
A1058 line of Tg PDAPP(M631L) mice was closest to Tg PDAPP(J20) mice in APP expression,
it was used for all studies reported here. Redox proteomics analyses were performed on proteins
extracted from the brains of Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L mice,
resulting in two comparisons: Tg PDAPP(M631L) mice relative to Tg PDAPP(J20) mice and Tg
PDAPP(M631L) mice relative to Non Tg M631L mice.
9.4.1 Redox Proteomics
Tryptic digestion and MS analysis was completed on excised protein spots according to
PD-Quest analyses of 2D-gels and corresponding 2D-Western blots; Tables 9.1 and 9.2 provide a
list of corresponding protein spot identifications, the number of peptide sequences and spectral
counts (SC; the number of MS/MS events observed that meet SEQUEST filter criteria), MW, pI,
fold-change levels, and P-values associated with each protein identified. Approximately twothirds of proteins listed were identified with more than one single peptide and several SC (Tables
9.1 & 9.2); for proteins identified with only a single peptide, more than one SC was observed
and/or the protein was identified in other MS experiments of that protein spot. I am confident in
the identification of these proteins based on the low P-values associated with the SEQUEST
identifications (i.e., P3.00e-04; the probability of an incorrect identification based on random
identification of a protein). In addition, the location of protein spots visually align with their
anticipated MW and pI values on the 2D-gels (Fig. 9.1) and 2D-Western blots.
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Figure 9.1
A) Non Tg M631L

B) Tg PDAPP(M631L)
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Figure 9.1 (cont.)
C) Tg PDAPP(J20)

Figure 9.1 Representative 2D-gel images of proteins isolated and transferred to 2DWestern blots from Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L mouse
brain. Protein spots identified as significantly carbonylated or nitrated after PD-Quest
and SEQUEST analyses of A) Non Tg M631L, B) Tg PDAPP(M631L), and C) Tg
PDAPP(J20) 2D–Oxyblots are labeled. GFAP, glial fibrillary acidic protein; TCP-1α, Tcomplex protein 1 subunit  A; PK M1/M2, pyruvate kinase isoforms M1/M2; Pin-1,
peptidyl-prolyl cis-trans isomerase 1; AATM, aspartate aminotransferase, mitochondrial;
TPPP, tubulin polymerization-promoting protein; CK, ubiquitous creatine kinase,
mitochondrial; GST μ1, glutathione-S-transferase μ 1; PGA mutase, phosphoglycerate
mutase 1; PEBP-1, phosphatidylethanolamine-binding protein 1.

9.4.1.1 Protein Carbonyls
Utilizing previously established redox proteomics approaches for the detection of protein
carbonyls (Butterfield and Sultana, 2008), six proteins were identified to be significantly affected
by protein carbonylation in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20)
mice as a control (Table 9.1), while no proteins were found to be significantly carbonylated in Tg
PDAPP(M631L) mice relative to Non Tg M631L mice as a control (Table 9.2). Representative
examples of 2D-gel images (corresponding to 2D-Western blots) from these analyses can be
found in Figure 9.1, while two representative examples of carbonyl Western blots can be found
in Figure 9.2. A significant increase in carbonylation was found for five proteins: calmodulin,
isoform 1(*P<0.028), 14-3-3 δ/δ (*P<0.036), phosphatidylethanolamine-binding protein 1
(PEBP-1; *P<0.033), phosphoglycerate mutase 1 (*P<0.049), and PK M1/M2 (*P<0.032; Fig.
9.2a), while a significant decrease in carbonylation was found for aspartate aminotransferase,
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mitochondrial (AATM, *P<0.029; Fig. 9.2b) in brain of Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) mice as a control.
Table 9.1 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) mice.
SwissProt
%
MW
Peptides
b
Protein
Accession
pI
p
Control
P-valued
(kDa)
(SC)a
c
No.
(J20Tg)
Protein Carbonyls:
Calmodulin, isoform 1
P62204 16.83 3.93 2(11)
3.00e-10 17700 ↑ 0.028
14-3-3 protein δ/δ
P63101 27.75 4.57 2(5)
3.00e-10
219 ↑
0.036
PhosphatidylethanolamineP70296 20.82 5.07 2(4)
3.00e-07
323 ↑
0.033
binding protein 1 (PEBP-1)
Phosphoglycerate mutase 1 Q9DBJ1 28.81 6.79 3(7)
4.00e-08
209 ↑
0.049
Pyruvate kinase isozymes
P52480 57.95 6.73 11(37) 4.00e-10 3660 ↑ 0.032
M1/M2 (PK M1/M2)
Aspartate aminotransferase,
P05202 23.56 9.27 2(3)
5.00e-07 1.33 ↓
0.029
mitochondrial (AATM)
3-NT:
Actin (multiple isoforms)
P60710 41.71 5.18 3(5)
6.00e-07 33200 ↑ 0.033
T-complex protein 1,
P11984 60.30 5.7
1(2)
2.00e-07
350 ↑
0.027
subunit α A (TCP-1αA)
Tubulin polymerizationQ7TQD2 23.56 9.87 1(3)
9.00e-13 20.8 ↓
0.026
promoting protein (TPPP)
Aspartate aminotransferase,
P05202 47.38 9.27 2(3)
5.00e-07 1.83 ↓
0.015
mitochondrial (AATM)
Peptidyl-prolyl cis-trans
P17742 18.30 7.97 1(6)
3.00e-04
211 ↑
0.022
isomerase 1 (Pin-1)
a

The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides. The total
number of MS/MS spectral counts (SC) is indicated in ( ).
b
The probability of an incorrect identification associated with each protein identification using the
SEQUEST search alogorithm.
c
Percent oxidation in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice (J20Tg) as a
control (oxidative level arbitrarily set to 100%).
d
The P-value associated with % Control (J20Tg)c calculated using a Student‟s t-test. n=10 for Tg
PDAPP(M631L); n=10 for Tg PDAPP(J20).
pI, isoelectric point; MW, molecular weight.
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Table 9.2 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Non
Tg M631L controls.
SwissProt
%
MW
Peptides
Protein
Accession
pI
pb
Control P-valued
a
(kDa)
(SC)
No.
(NTg)c
3-NT:
Secernin-1
Q9CZC8 46.30 4.52
2(6)
3.00e-08 1110 ↑
0.022
Glial fibrillary acidic protein
P03995 49.87 5.14
2(5)
3.00e-06 154 ↑
0.037
(GFAP)
Glutathione-S-transferase μ1
P10649 25.95 8.11
1(2)
2.00e-07 494 ↑
0.014
(GST μ1)
Creatine kinase, ubiquitous,
P30275 46.98 8.13
1(3)
2.00e-09 3160 ↑
0.038
mitrochondrial (CK)
a

The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides. The
total number of MS/MS spectral counts (SC) is indicated in ( ).
b
The probability of an incorrect identification associated with each protein identification using the
SEQUEST search alogorithm.
c
Percent oxidation in Tg PDAPP(M631L) mice compared to Non Tg M631L (NTg) controls
(oxidative level arbitrarily set to 100%).
d
The P-value associated with % Control (NTg)c calculated using a Student‟s t-test. n=10 for Tg
PDAPP(M631L); n=5 for Non Tg M631L.
pI, isoelectric point; MW, molecular weight.

Figures 9.2
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Figure 9.2 Representative 2D-Western blot images corresponding to carbonylated
pyruvate kinase isoforms M1/M2 (PK M1/M2) and aspartate aminotransferase,
mitochondrial (AATM). A) These images show a clear increase in PK M1/M2 protein
carbonylation in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.
B) These images show a clear increase in AATM protein carbonylation in brain of Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice [images have been zoomed in
to these spots]. Proteins were probed with an anti-dinitrophenylhydrazone (DNP)
antibody, as described in Chapter 3.

9.4.1.2 3-Nitrotyrosine (3-NT) Redox Proteomics
Utilizing previously established redox proteomics approaches for the detection of proteinresident 3-NT (Butterfield and Sultana, 2008; Sultana et al., 2006b), five proteins were identified
to be significantly affected by protein nitration in brain of Tg PDAPP(M631L) mice compared to
Tg PDAPP(J20) mice as a control (Table 9.1), while four proteins were found to be significantly
affected by protein nitration in brain of Tg PDAPP(M631L) mice relative to Non Tg M631L
mice as a control (Table 9.2). Representative examples of 2D-gel images (corresponding to 2DWestern blots) from these analyses can be found in Figure 9.1, while representative examples of
3-NT Western blots are shown in Figures 9.3 and 9.4. A significant increase in nitration was
found for three proteins in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice:
actin (*P<0.033), T-complex protein 1, subunit α A (TCP-1αA; *P<0.027), and peptidyl-prolyl
cis-trans isomerase 1 (Pin-1; *P<0.022; also Fig. 9.3b). Two proteins with a significant decrease
in nitration were the tubulin polymerization-promoting protein (TPPP; *P<0.026), and AATM
(*P<0.015; also Fig. 9.3a). All four proteins found to be significantly affected by nitration in
brain of Tg PDAPP(M631L) mice compared to Non Tg M631L mice as a control showed a
significant increase in 3-NT levels: secernin-1 (*P<0.022), glutathione-S-transferase μ1 (GST
μ1; *P<0.014; also Fig. 9.4a), glial fibrillary acidic protein (GFAP; *P<0.037; also Fig. 9.4b),
and creatine kinase, ubiquitous, mitochondrial (CK; *P<0.038). These results, as well as the
aforementioned protein carbonyl redox proteomics results, will be discussed in detail below
(section 9.5) with respect to protein function(s) and how the detected changes may be implicated
in AD etiology.
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Figure 9.3

Figure 9.3 Representative 2D-Western blot images corresponding to nitrated aspartate
aminotransferase, mitochondrial (AATM) and peptidyl-prolyl cis-trans isomerase 1 (Pin1). A) These images show a clear decrease in AATM nitration in brain of Tg
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice. B) These images show a
clear increase in 3-nitrotyrosine (3-NT)-modified Pin-1 in brain of Tg PDAPP(M631L)
mice compared to Tg PDAPP(J20) mice [images have been zoomed in to these spots].
Proteins were probed with an anti-3-NT antibody, as described in Chapter 3.
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Figure 9.4

Figure 9.4 Representative 2D-Western blot images corresponding to nitrated
glutathione-S-transferase μ1 (GST μ1) and glial fibrillary acidic protein (GFAP). A)
These images show a clear increase in GST μ1 nitration in brain of Tg PDAPP(M631L)
mice compared to Non Tg M631L mice. B) These images show a clear increase in 3nitrotyrosine (3-NT)-modified GFAP in brain of Tg PDAPP(M631L) mice compared to
Non Tg M631L mice [images have been zoomed in to these spots]. Proteins were probed
with an anti-3-NT antibody, as described in Chapter 3.

9.4.2 Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1) Immunoprecipitation
Immunoprecipitation validation was performed for Pin-1 as a representative confirmation
of those brain proteins identified as significantly oxidatively modified by SEQUEST and PDQuest image analyses. Western blot analysis shows that lanes corresponding to Pin-1 (18 kDa)
are indeed nitrated (Fig. 9.5a), while the histogram representing the average lane intensity for
both Tg PDAPP(M631L) and Tg PDAPP(J20) mice shows a significant increase in the level of
nitrated Pin-1 in Tg PDAPP(M631L) brain compared to Tg PDAPP(J20) mice as a control
(*P<0.04; Fig. 9.5b). These results are consistent with redox proteomics analyses described
above, in which Pin-1 was identified as being significantly more nitrated in Tg PDAPP(M631L)
mice relative to Tg PDAPP(J20) mice (211.44%; Table 9.1).
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Figure 9.5

Figure 9.5 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) nitration levels in brain of Tg
PDAPP(M631L) and Tg PDAPP(J20) mice. Following immunoprecipitation, Pin-1
nitration was measured by 1D-polyacrylamide gel electrophoresis (1D-PAGE; 75
μg/lane) and subsequent Western blot analysis of 9 month-old Tg PDAPP(M631L)
[M35L] and Tg PDAPP(J20) [J20] mice. A) Increased band intensity represents an
increase in the amount of 3-nitrotyrosine (3-NT)-modified Pin-1 present. n=5 for both
M35L and J20 groups, however only representative bands from n=3 independent samples
are shown. B) Graphical representation of data shown in A) demonstrates a significant
increase in Pin-1 nitration levels in Tg PDAPP(M631L) mice compared to Tg
PDAPP(J20) mice as a control. Percent control values are presented as mean ± S.E.M.;
*P<0.04.

9.5 Discussion
Indeed, much evidence supports Met-35 as being a major contributor to Aβ(1-42)induced oxidative stress and damage in brain of subjects with AD and mouse models thereof
(Abdul et al., 2008; Ansari et al., 2006; Boyd-Kimball et al., 2004; 2005b; Butterfield and BoydKimball, 2005; Drake et al., 2003a; Kanski et al., 2002; Mohmmad Abdul et al., 2006; Pappolla
et al., 1999; Resende et al., 2008; Varadarajan et al., 2001; Yatin et al., 1999). Results reported
in Chapters 6-8 of this dissertation also support this notion, as replacement of Met-35 with a Leu
was shown to effectively abrogate oxidative stress associated with the native human Aβ(1-42)
188

peptide present in Tg PDAPP(J20) mice and down-regulate a number of proteins identified as
over-expressed in Tg PDAPP(J20) mouse models of Aβ pathology. In the current study, redox
proteomics analyses identified secernin-1, GFAP, GST μ1, and ubiquitous, mitochondrial CK as
being significantly nitrated relative to Non Tg M631L littermate control mice (Table 9.2). The
observed increase in protein-resident 3-NT levels for these proteins in brain of Tg
PDAPP(M631L) mice may reflect a compensatory effect induced by introduction of the APPSw,In
transgene with a Met35Leu substitution, and/or result from toxicity induced by other APP
cleavage products, such as Jcasp, sAPPβ, and C31, or other non-amyloidogenic pathways that
contribute to oxidative stress. Although the primary goal of the current study was to determine
differences in oxidative modification between Tg PDAPP(M631L) and Tg PDAPP(J20) mice,
the effect(s) inherently present in Tg PDAPP(M631L) mice as a result of the M631L transgene
can only be realized through comparison with their Non Tg M631L littermates. Therefore, in
order to gain further insight into the biological pathways altered as a result of the Met35Leu
substitution in normal mice and mouse models of Aβ pathology, differential expression
proteomics analyses of Tg PDAPP(M631L) and Non Tg M631L mice was completed, and
results discussed below with respect to AD pathogenesis.
9.5.1 Oxidative Modification in Brain of Tg PDAPP(M631L) Mice Compared to Non
Tg M631L Mice
GFAP is a glial intermediate filament protein known to maintain the cytoskeletal
structure of mature reactive astrocytes, and is a well-known marker for inflammation (Table 9.3).
GFAP levels are known to increase with age and neurodegeneration, especially in AD (Beach et
al., 1989; Boyd-Kimball et al., 2005c; Eddleston and Mucke, 1993; Gomes et al., 1999; Owen et
al., 2009). Although differential expression studies did not show increased expression of GFAP
in brain of Tg PDAPP(M631L) mice (Chapter 8), the current study identified GFAP to be
significantly more nitrated in Tg PDAPP(M631L) brain compared to Non Tg M631 littermate
mice. This result suggests that the structural integrity of astrocytes may be compromised as a
down-stream effect of the Met35Leu substitution, thereby hindering astrocytic clearance of
cellular debris in brain of Tg PDAPP(M631L) mice and indirectly contributing to the extreme
cognitive deficit of Tg PDAPP(M631L) mice compared to Non Tg M631L and even Tg
PDAPP(J20) mice (Chapter 6). Moreover, it is possible that in brain of Tg PDAPP(M631L)
mice an inflammatory response has been activated, making GFAP more available for oxidative
modification relative to Non Tg M631L mice. This notion is supported by immunohistochemical
results reported in Chapter 6 of this dissertation, where an increase in activated microglia was
observed in Tg PDAPP(M631L) mice. An increased inflammatory response in Tg
PDAPP(M631L) mouse brain could increase the levels and/or activity of inducible nitric oxide
synthase (iNOS; see section 2.4.3), which would increase intracellular levels of nitric oxide
.
(NO ). Such a cascade of events during inflammation may also explain the increase in nitration
observed in brain of Tg PDAPP(M631L) mice, in lieu of carbonylation events.
Like GFAP, the antioxidant defense protein GST μ1was also found to be significantly
nitrated in brain of Tg PDAPP(M631L) mice relative to Non Tg M631L controls. GST normally
catalyzes the S-glutathionylation of reactive oxygen (ROS) and nitrogen species (RNS), as well
as other nucleophilic compounds, such as HNE, which permits efflux of these destructive
compounds out of the cell [see section 2.4.6.1] (Renes et al., 1999). Therefore, Sglutathionylation by GST enzymes not only scavenges ROS and RNS, but also protects redox
sensitive proteins from oxidative modification [Fig. 2.38; see section 2.4.6.1] (Chrestensen et al.,
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2000). Because of its active scavenging role, it is not surprising that GST has previously been
found oxidatively modified in brain of subjects with AD (Perluigi et al., 2009; Sultana and
Butterfield, 2004), as well as in canine models of AD (Opii et al., 2008) and C. elegans treated
with Aβ(1-42) (Boyd-Kimball et al., 2006). Significant nitration of GST μ1 would suggest that a
certain level of non-amyloidogenic oxidative stress is still present in brain of Tg
PDAPP(M631L) mice, albeit significantly less than Tg DAPP(J20) mouse models of Aβ
pathology, and resultant oxidative species are not being scavenged through this particular
antioxidant pathway. This possibility also may indirectly contribute to the significant cognitive
deficit in Tg PDAPP(M631L) mice relative to Non Tg M631L and equal to that of Tg
PDAPP(J20) mice observed in Chapter 6 of this dissertation.
Significant nitration of ubiquitous, mitochondrial CK in this study would seem to imply
an energy deficit in brain of Tg PDAPP(M631L) mice compared to Non Tg M631L controls that
is not directly related to glucose metabolism. CK catalyzes the reversible conversion
phosphocreatine into creatine, which produces adenosine triphosphate (ATP; i.e., energy). In
tissues that rapidly consume ATP, such as skeletal muscle, cardiac smooth muscle, and brain,
phosphocreatine is a key energy reservoir for the rapid buffering and regeneration of ATP,
beyond that produced by glycolysis and the electron transport chain (ETC) [see section 2.3]
(Wallimann and Hemmer, 1994; Wallimann et al., 1992). Ubiquitous, mitochondrial CK, in
particular, is present in non-muscle tissues (i.e., brain), and is located in the mitochondrial
intermembrane space where it produces phosphocreatine from mitochondrially-generated ATP
and cytosolic creatine (Wallimann and Hemmer, 1994). Moreover, previous studies have shown
that CK is oxidatively modified in brain of subjects with AD (Castegna et al., 2002b). Posttranslational oxidative modification of ubiquitous, mitochondrial CK is indicative of a widespread depletion in readily available ATP stores, which would directly contribute to the lack of
learning and memory in Tg PDAPP(M631L) mice.
Interestingly, the cytosolic brain secretory protein, secernin-1, was identified to be
significantly nitrated in brain of Tg PDAPP(M631L) mice relative to Non Tg M631L controls.
To-date there are no studies indicating a link between secernin-1 expression or oxidation and AD
pathology. In fact, the majority of research on this particular protein is related to its function as a
tumor-associated antigen. Secernin-1 typically functions in the regulation of exocytosis in
permeabilized mast cells (Way et al., 2002), which are secretory cells found on mucosal and
serosal surfaces of tissues throughout the body that are involved in the allergic response
(Wedemeyer and Galli, 2000). Upon activation, mast cells secrete a variety of inflammatory
mediators, including histamine and secernin-1 (Griffiths, 1996; Way et al., 2002). Therefore,
significant nitration of sercernin-1 is likely reflective of an impaired immune response in brain of
Tg PDAPP(M631L) mice, possibly activated (as evidenced by secernin-1 secretion) by a
compensatory response induced by the M631L transgene.
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Table 9.3 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to
Tg PDAPP(J20) and Non Tg M631L mice and their cellular functions.
Current
Protein
Cellular Function(s)
Alteration
Tg PDAPP(M631L) vs. Tg PDAPP(J20)
↑ Carbonylation Calmodulin, isoform 1
↑ Carbonylation 14-3-3 δ/δ
↑ Carbonylation

Phosphatidylethanolamine-binding
protein 1 (PEBP-1)

Peptidyl-prolyl cis-trans isomerase 1
(Pin-1)
↑ Carbonylation Phosphoglycerate mutase 1
Pyruvate kinase isozymes M1/M2
↑ Carbonylation
(PK M1/M2)
↑ Nitration

↓ Carbonylation; Aspartate aminotransferase,
↓ Nitration
mitochondrial (AATM)
↑ Nitration

Actin (multiple isoforms)
Tubulin polymerization-promoting
↓ Nitration
protein (TPPP)
T-complex protein 1, subunit α A
↑ Nitration
(TCP-1αA)
Glutathione-S-transferase μ1
↑ Nitration
(GST μ1)
Tg PDAPP(M631L) vs. Non Tg M631L
Creatine kinase, ubiquitous,
↑ Nitration
mitrochondrial (CK)

Ca2+ Signaling & Regulation
Cell Signaling; Protein
trafficking
Cell Signaling, Proliferation,
& Migration; Cholinergic
System
Cell Signaling; Cell-Cycle
Energy Metabolism
Energy Metabolism
Amino Acid Metabolism;
Malate-Aspartate Shuttle
Protein
Structural Protein
Structural Protein
Molecular Chaperone;
Structural Integrity
Antioxidant Defense

Energy Metabolism

↑ Nitration

Glial fibrillary acidic protein (GFAP)

Structural protein;
Inflammatory Marker

↑ Nitration

Glutathione-S-transferase μ1
(GST μ1)

Antioxidant Defense

↑ Nitration

Secernin-1

Secretory System; TumorAssociated Antigen

9.5.2 Oxidative Modification in Brain of Tg PDAPP(M631L) Mice Compared to Tg
PDAPP(J20) Mice
Redox proteomics analyses reported in this study indicate 11 structural, antioxidant, Ca2+
signaling, and energy-related proteins with significant changes in oxidative modifications in Tg
PDAPP(M631L) mice relative to Tg PDAPP(J20) mice. Many of these proteins have also been
previously identified as oxidatively modified in brain of subjects with AD (reviewed in Sultana
et al., 2009). Interestingly, introduction of the Met35Leu substitution on Aβ led to increased
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protein carbonylation and nitration of eight critical glycolytic, cellular signaling, and structural
proteins compared to Tg PDAPP(J20) mice, suggesting the existence of other nonamyloidogenic pathways which contribute to oxidative stress and damage that also affect
learning and memory in these mice. The significant increase in carbonylation and nitration of
proteins detected in Tg PDAPP(M631L) brain compared to that of Tg PDAPP(J20) mice could
be a consequence of proteins produced in low abundance, which might appear to be more
carbonylated or nitrated simply because there are fewer available to oxidize. The downregulation of Pin-1, PEBP-1, phosphoglycerate mutase 1, and PK M1/M2 in Tg PDAPP(M631L)
mice compared to Tg PDAPP(J20) mice (Chapter 8) would seem to support this notion.
However, it seems more likely that other non-amyloidogenic pathways inducing oxidative stress
and/or other APP cleavage products also may contribute to the oxidative modification of these
enzymes.
For example, alternate APP cleavage products, Jcasp, C31, and sAPPβ, have all been
reported to be cytotoxic, inducing activation of internal apoptotic pathways and forming
cytotoxic protein complexes with APP and other proteins (Furukawa et al., 1996; Lu et al., 2000;
Madeira et al., 2005; Park et al., 2009). Chapter 6 of this dissertation showed that Tg
PDAPP(M631L) mice express APP in amounts similar to that of Tg PDAPP(J20) mice, ensuring
the global reduction in indices of oxidative stress in Tg PDAPP(M631L) brain was not a result of
differential expression or production of APP and/or Aβ. Considering both Tg PDAPP(J20) and
Tg PDAPP(M631L) mice express significantly greater amounts of APP than Non Tg mice
(Chapter 6), they are effectively producing copious amounts of APP cleavage products, including
Aβ, C31, Jcasp, and sAPPβ. Although the vast majority of Aβ-related oxidative stress present in
Tg PDAPP(J20) brain was abrogated by the Met35Leu substitution (Chapter 6), neurotoxicity
induced by other cleavage products is still quite probable in brain of Tg PDAPP(M631L) mice,
especially considering the abundance to which they could be produced. The significant cognitive
decline, as measured by Morris water-maze testing, in Tg PDAPP(M631L) mice supports this
possibility (Chapter 6). Moreover, the significant oxidative modification and deactivation of
these proteins, as reported in the current study, would also contribute to the decline in learning
and memory in Tg PDAPP(M631L) mice compared to either Tg PDAPP(J20) or Non Tg M631L
mice.
In addition, present redox proteomics analyses also identified a significant decrease in the
levels of protein carbonyls and protein-resident 3-NT for AATM and a decrease in 3-NT levels
for TPPP in Tg PDAPP(M631L) brain relative to that of Tg PDAPP(J20) mice. AATM is
involved in amino acid metabolism and the malate-aspartate shuttle by catalyzing the reversible
conversion of aspartate and α-ketoglutarate to oxaloacetate and glutamate, key components of
the tricarboxylic acid cycle and neurotransmission (see sections 2.1.3 & 2.3.3). TPPP is a brainspecific protein that interacts with the tubulin/microtubule system, supporting the formation and
elongation of microtubules by promoting polymerization of tubulin, as the name suggests.
Considering the oxidative modification of proteins results in either a toxic “gain-of-function”, or
complete “loss-of-function”, the significant reduction in AATM and TPPP oxidation suggests
that there are antioxidant defense systems still operational in brain of Tg PDAPP(M631L) mice
able to protect proteins from oxidative stress and damage elicited by non-Aβ-related pathways.
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9.5.3 Conclusions
The combined efforts from studies reported in Chapters 6-9 of this dissertation have
provided additional evidence supporting the critical role of Met-35 in Aβ(1-42)-induced
oxidative stress, as well as specific pathways that are altered in AD and mild cognitive
impairment (MCI) brain as a result of this oxidative insult. Although Chapter 6 revealed a
significant decrease in global levels of oxidative stress, these global indices only represent an
ambiguous majority of proteins and lipids in brain tissue being analyzed and can mask the redox
status of individual proteins in a given sample. Therefore, redox proteomics analyses were
utilized to complete an in-depth analysis of specific proteins affected in brain of Tg
PDAPP(J20), Tg PDAPP(M631L), and Non Tg mice. It appears that although the majority of
oxidative stress detected in AD brain is likely the result of Met-35 of Aβ, the observed increases
in protein-resident 3-NT and protein carbonyls in brain of Tg PDAPP(M631L) mice from the
present study are indicative of potential compensatory responses induced by introduction of the
APPSw,In transgene with a Met35Leu substitution, and/or result from toxicity induced by other
APP cleavage products, such as Jcasp, sAPPβ, and C31, or other non-amyloidogenic pathways
that contribute to oxidative stress. Studies to test this notion are now underway.
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CHAPTER 10
CONCLUSIONS & FUTURE STUDIES
10.1 Conclusions
Work presented in this dissertation examined the role of lipid peroxidation, apoptotic
factor expression, and amyloid-β (1-42) [Aβ(1-42)] to the exposure of the aminophospholipid
phosphatidylserine (PtdSer) to the outer-leaflet of the lipid membrane, as well as the role played
by methionine-35 (Met-35) of Aβ in oxidative stress and damage in brain of subjects with
amnestic mild cognitive impairment (aMCI), Alzheimer disease (AD), and mouse models of
familial AD (FAD) Aβ pathology. Chapter 4 of this dissertation demonstrated that within the
inferior parietal lobule (IPL) of subjects with aMCI and AD, a significant collapse in PtdSer
asymmetry was found in association with increased levels of both pro- and anti-apoptotic
proteins, Bax, caspase-3, and Bcl-2. In the same way, results reported in Chapter 5 showed a
significant age-related collapse in PtdSer asymmetry in whole brain of human double-mutant
knock-in mouse models of Aβ pathology (APP/PS-1), together with significantly reduced
Mg2+ATPase activity, representing flippase activity, and increased levels of pro-apoptotic
caspase-3. Moreover, significant PtdSer externalization corresponded to the age at which
significant Aβ(1-42) aggregation occurs in APP/PS-1 mice (9 months), and not of plaque
deposition (12 months), suggesting that elevated levels of Aβ(1-42), together with increasing
oxidative stress and apoptotic pathway activation, may contribute to altered PtdSer membrane
localization. Thus, Chapters 4 and 5 provide evidence that PtdSer asymmetric collapse is an
early indicator of neurodegenerative processes already well underway in AD brain, and may
represent a reliable biomarker of those patients with aMCI that eventually develop full-onset AD.
Analyses of oxidative stress and damage in half brain of APPSw,In (PDAPP) transgenic
mice [Tg PDAPP(J20)] and PDAPP mice carrying a Met35Leu substitution on the Aβ peptide
[Tg PDAPP(M631L)] (i.e., Met-631 in human amyloid precursor protein [APP] numbering) in
Chapter 6-9 revealed that in vivo Aβ-induced oxidative stress requires the presence of Met-35 of
Aβ, as all indices of oxidative damage measured in Chapter 6 (i.e., protein carbonylation,
nitration, and 4-hydroxy-2-trans-nonenal [HNE] modification) in brain of Tg PDAPP(M631L)
mice were completely prevented. While these findings were independent of total Aβ(1-42)
accumulation and deposition, immunohistochemical analyses indicated that the Met35Leu
mutation influences plaque formation, as a clear reduction in Aβ-immunoreactive plaques and
punctate deposition of Aβ(1-42) in Tg PDAPP(M631L) mice was found in conjunction with a
significant increase in microglial activation. In contrast, however, behavioral analyses suggested
that spatial learning and memory was independent of Met-35 of Aβ, as Tg PDAPP(M631L) mice
demonstrated inferior water-maze performance compared to non-transgenic littermates.
Differential expression and redox proteomics analyses in Chapters 7-9 revealed a number
of specific proteins that were significantly altered by the APPSw,In and Met35Leu mutations.
Expression proteomics identified 21 proteins in brain of Tg PDAPP(M631L) mice with
significantly reduced levels of expression compared to Tg PDAPP(J20) mice, used as a positive
control of Aβ-related FAD pathology. In addition, eight proteins were identified with
significantly increased expression levels in brain of Tg PDAPP(J20) mice compared to brain of
Non Tg PDAPP mice as a control, while a total of three proteins (one decreased, two increased)
were found differentially expressed in brain of Tg PDAPP(M631L) mice relative to Non Tg
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M631L littermates. Redox proteomics analyses identified a total of six proteins (five increased,
one decreased) with significantly altered levels of protein carbonylation and a total of five
proteins (three increased, two decreased) with significantly altered levels of protein-bound 3nitrotyrosine (3-NT) in half brain of Tg PDAPP(M631L) mice compared to brain of Tg
PDAPP(J20) mice as a positive control. In brain of Tg PDAPP(J20) mice compared to Non Tg
PDAPP controls only one protein was found significantly carbonylated and two proteins found to
have significantly reduced 3-NT levels. Interestingly, there were no proteins identified as being
significantly carbonylated in brain of Tg PDAPP(M631L) mice compared to Non Tg M631L
littermate control mice, while a total of five proteins were found to have significantly different
levels of protein-resident 3-NT (three increased, two decreased).
Proteins identified as differentially expressed or oxidatively modified as a result of the
APPSw,In and/or Met35Leu mutations play significant roles in the cell-cycle, signaling, structure,
proliferation, migration/trafficking/chaperoning, endocytosis, the cholinergic system, energy and
metabolism of proteins, lipids, and nucleic acids, Ca2+ regulation, inflammation, pH regulation,
detoxification, protein degradation, and mitochondrial permeability. However, the majority of
proteins affected by the Met35Leu substitution are normally involved in energy metabolism and
structural integrity of the cell, suggesting the importance of further investigation into metabolic
and structural alterations in AD brain.
In summary, studies presented in this dissertation demonstrate the considerable toll
oxidative stress and damage, induced by reactive oxygen (ROS) and nitrogen species (RNS), as
well as Aβ, can take on brain integrity in this devastating dementing disorder. Furthermore, these
studies may provide researchers with diagnostic markers of disease pathology and point to
clinical translational possibilities for therapy to potentially treat, slow progression of, or prevent
aMCI, AD, and FAD. Specifically, by blocking oxidative damage dependent on Met-35 of
Aβ(1-42) in brain of subjects with aMCI and AD offers a highly focused therapeutic approach.
10.2 Future Studies
Based on the findings reported in this dissertation, the following are suggested avenues of
future research which may be pursued:
1. A regional analysis of PtdSer asymmetry should be completed in brain of
subjects with aMCI and AD to evaluate any differences in regions highly
implicated in AD pathology (i.e., hippocampus) and those that are not (i.e.,
cerebellum).
2. Considering PtdSer asymmetry could be congruent with loss of other
important membrane contents (i.e., cholesterol, other phospholipids, etc.), a
complete lipid analysis of synaptosomes should be examined. Any change in
the membrane lipid profile could be important to interpretation of PtdSer
asymmetry, especially with age.
3. Because flippase activity is essential to maintenance of PtdSer asymmetry,
derivation and/or acquisition of monoclonal antibodies specific for flippase
should provide researchers with the ability to directly examine its response to
oxidation phenomena apart from Ptdser and other Mg2+ATPases.
4. Since immunohistochemical analyses indicated a clear reduction in Aβimmunoreactive plaques in Tg PDAPP(M631L) mice in conjunction with a
significant increase in microglial activation, and PtdSer externalization is a
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5.

6.

7.

8.

crucial signal for phagocytosis by microglia in the brain, PtdSer asymmetry
studies in tandem with Mg2+ATPase activity assays should be completed in
Tg PDAPP(M631L) mice. If possible, these studies should be conducted as a
function of age.
Because behavioral analyses of Tg PDAPP(M631L) mice demonstrated
inferior performance compared to non-transgenic littermates, an analysis of
apoptotic factor expression (e.g., Bcl-2, Bax, caspase-3, etc.) should be
completed in brain of Tg PDAPP(M631L) and Tg PDAPP(J20) mice. If
possible, these studies should be completed as a function of age, as well as in
parallel with PtdSer asymmetry studies.
A redox proteomics investigation of protein-bound HNE modified proteins in
brain of Tg PDAPP(M631L) and Tg PDAPP(J20) mice should be conducted
in order to indirectly evaluate lipid peroxidation events in brain of these
transgenic mice.
Because behavioral analyses of Tg PDAPP(M631L) mice demonstrated
inferior performance compared to non-transgenic littermates, an analysis of
the levels and toxicity of other non-Aβ, APP cleavage products (e.g., Jcasp,
sAPPβ, C31, etc.) should be assessed, since all have been implicated in
different aspects of the AD phenotype (Galvan et al., 2006; Lu et al., 2000;
Madeira et al., 2005; Nikolaev et al., 2009).
Since Tg PDAPP(M631L) mice have significantly reduced levels of
oxidative stress and punctate plaque staining, but increased microglial
activation and inferior learning and memory, an analysis of the ability to and
properties of the Aβ(1-42)M35L peptide to aggregate should be conducted.
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APPENDIX A
OXYBLOT ANALYSIS OF OXIDATIVE STRESS IN BRAIN OF APPNLh/APPNLh x PS1P264L/PS-1P264L HUMAN DOUBLE KNOCK-IN MICE

A.1 Overview
Results provided in this appendix are supplemental to studies reported in Chapter 5 of
this dissertation. Although an age-related increase in indices of oxidative stress (i.e., protein
carbonyls, protein-resident 3-nitrotyrosine [3-NT], and protein-bound 4-hydroxy-2-trans-nonenal
[HNE]) in brain of APPNLh/APPNLh x PS-1P246L/PS-1P246L human double knock-in (APP/PS-1)
mice has previously been described (Abdul et al., 2008), it is possible that a statistically
significant amount of variation could occur from one sample set to another, which would
drastically alter interpretation of results obtained in Chapter 5. Therefore, these same three
indices of oxidative stress were measured in synaptosomes isolated from whole brain of 1, 6, 9,
and 12 month-old wild-type (WT) and APP/PS-1 mice.
A.2 Experimental Procedures
All materials and methods used in this supplemental study are described in Chapter 3 of
this dissertation. Specifically, sections 3.2.2, 3.3, 3.4.1, 3.5, and 3.13.
A.2.1 Statistical Analysis
All slot-blot (Oxyblot) analyses provided in this supplement are presented as mean ±
standard error of the means (S.E.M.) and analyzed via GraphPad Prism 5.0 software for
Windows (San Diego, CA). In one-variable analyses, one-way ANOVA was used to determine
the effect of WT mouse age on protein carbonylation, nitration, and HNE-modification, followed
by Bonferroni‟s post-hoc analysis to evaluate the significance of differences between group
means. In two-variable analyses, two-way analysis of the variants (ANOVA) was used to
determine the effect of age and WT or APP/PS-1 genotype on the levels of protein carbonylation,
nitration, and HNE-modification, followed by Bonferroni's post-hoc analysis to evaluate the
significance of differences between group means. P<0.05 was considered significant for all
studies.
A.3 Results
A.3.1 Protein Carbonyls
In order to assess the levels of protein oxidation via carbonylation during normal brain
aging, synaptosomes extracted from whole brain of 1 month-old WT mice were used as a control
from which to compare synaptosomes isolated from whole brain of 6, 9, and 12 month-old WT
mice. Results demonstrated a significant age-related increase in protein carbonylation beginning
at 9 months-old (Fig. A.1a, ***P<0.001), an increase that remains significant through 12 months
of age (Fig. A.1a, ***P<0.001). These results are consistent with previous reports of an agerelated increase in protein carbonylation in brain of WT mice (Abdul et al., 2008), as well as
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with the well-known increase in human brain oxidative stress with age that leads to neuronal cell
death (Butterfield and Stadtman, 1997; Harman, 1956).
To assess effects of normal brain aging and mouse genotype, protein carbonyl levels in
synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1 mice were analyzed relative to
that of 1 month-old WT mice as a control (Fig. A.1b). Results demonstrated a significant
increase in protein carbonylation at 9 and 12 months-old in brain of APP/PS-1 mice compared to
1 month-old WT controls (Fig. A.1b, 9 & 12 months-old, ***P<0.001). Additionally, there was
a significant increase in 9 month-old APP/PS-1 protein carbonyl levels compared to respective 9
month-old, age-matched WT mice (Fig. A.1b, §P<0.05), demonstrating that the APP/PS-1 knockin genotype affects levels of oxidative stress, measured by protein carbonylation, significantly
more than normal aging alone at this particular age. These results are consistent with previous
reports of an age-related increase in protein carbonylation in brain of APP/PS-1 mice (Abdul et
al., 2008). Interestingly, both WT and APP/PS-1 mice exhibited an age-related increase in
protein carbonyl levels from 6 to 9 months-old (Fig. A.1a,b, §§§P<0.001), directly correlating
with significant amyloid-β (1-42) [Aβ(1-42)] aggregation reported to begin at 9 months of age in
this particular mouse model of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996;
Siman et al., 2000).
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Figure A.1

Figure A.1 Protein carbonyl (PCO) levels in synaptosomes from brain of wild-type (WT)
and APP/PS-1 mice. A) Protein carbonylation in each WT age-group is presented as a
percentage of 1 month-old WT PCO levels. Results demonstrated a significant increase
in WT mouse carbonylation beginning at 9 months that continues to increase with age.
Percent control values are presented as mean ± S.E.M. and significance assessed by oneway ANOVA followed by Bonferroni‟s post-hoc analysis; §§§,***P<0.001; n=5 for all
age groups. B) PCO levels for each WT and APP/PS-1 age-group is presented as a
percentage of 1 month-old WT PCO levels. Results demonstrated a dramatic agedependent increase in carbonylation in both WT and APP/PS-1 mice from 6 to 9 months
that continues to increase with age. However, this increase is more prominent in
APP/PS-1 mice. Percent control values are presented as mean ± S.E.M. and significance
assessed by two-way ANOVA followed by Bonferroni's post-hoc analysis; §P<0.05,
§§§,
***P<0.001; n=5 for all age groups.
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A.3.2 Protein-Resident 3-Nitrotyrosine (3-NT)
Assessment of protein oxidation via protein nitration in normal brain aging, was also
conducted on synaptosomes extracted from whole brain of 6, 9, and 12 month-old WT mice,
using 1 month-old WT mice as a control. Results demonstrated a significant age-related increase
in protein nitration beginning at 6 months-old that remains significantly increased as mice age to
12 months (Fig. A.2a; 6, 9, & 12 months-old, ***P<0.001). These results are also consistent
with previous reports of an age-related increase in protein nitration in brain of WT mice (Abdul
et al., 2008), as well as with the well-known increase in brain oxidative stress with age that leads
to neuronal cell death (Butterfield and Stadtman, 1997; Harman, 1956).
Effects of normal brain aging and mouse genotype were assessed by measuring the levels
of protein-resident 3-NT in synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1 mice
relative to that of 1 month-old WT mice as a control (Fig. A.2b). These results demonstrated a
significant increase in protein nitration beginning at 6 months-old in APP/PS-1 mice (Fig. A.2b,
**
P<0.01) that remains significant as APP/PS-1 mice age to 12 months of age (Fig. A.2b, 9
months-old, **P<0.01; 12 months-old, ***P<0.001) compared to 1 month-old WT controls.
Additionally, there was a significant increase in 1, 9, and 12 month-old APP/PS-1 3-NT levels
compared to their respective 1, 9, and 12 month-old, age-matched WT mice (Fig. A.2b, 1 & 12
months-old, §§§P<0.001; 9 months-old, §P<0.05), demonstrating that the APP/PS-1 knock-in
genotype affects levels of oxidative stress, as indexed by protein nitration, significantly more
than normal aging alone, as early as 1 month-old. These results are consistent with previous
reports of an age-related increase in protein nitration in brain of APP/PS-1 mice (Abdul et al.,
2008). Interestingly, APP/PS-1 mice exhibited an age-related increase in 3-NT levels from 6 to
9 and 9 to 12 months-old (Fig. A.2b, §§§P<0.001), directly correlating with significant Aβ(1-42)
aggregation reported to begin at 9 months of age in this particular mouse model of Aβ pathology
(Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).
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Figure A.2

Figure A.2 Protein-resident 3-nitrotyrosine (3-NT) levels in synaptosomes from brain of
wild-type (WT) and APP/PS-1 mice. A) Protein nitration in each WT age-group is
presented as a percentage of 1 month-old WT 3-NT levels. Results demonstrated a
significant increase in WT mouse protein nitration beginning at 6 months that continues
to increase with age. Percent control values are presented as mean ± S.E.M. and
significance assessed by one-way ANOVA followed by Bonferroni‟s post-hoc analysis;
***P<0.001; n=5 for all age groups. B) 3-NT levels for each WT and APP/PS-1 agegroup is presented as a percentage of 1 month-old WT 3-NT levels. Results
demonstrated a significant age-dependent increase in protein nitration in both WT and
APP/PS-1 mice beginning at 6 months that continues to increase with age. However, this
increase is more prominent in APP/PS-1 mice. Percent control values are presented as
mean ± S.E.M. and significance assessed by two-way ANOVA followed by Bonferroni's
post-hoc analysis; §P<0.05, **P<0.01, §§§,***P<0.001; n=5 for all age groups.
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A.3.3 Protein-Bound 4-Hydroxy-2-Trans-Nonenal (HNE)
Protein oxidation and lipid peroxidation levels due to normal brain aging were measured
via protein-bound HNE in synaptosomes extracted from whole brain of 6, 9, and 12 month-old
WT mice compared to 1 month-old WT mice as a control. Interestingly, although levels of
protein-bound HNE appear to slightly increase with age, at no age is there a significant increase
compared to 1 month-old WT controls (Fig. A.3a). Moreover, it appears that the levels of
protein-bound HNE drop from 1 to 6 months of age, although not significantly (Fig. A.3a).
Assessment of normal brain aging and mouse genotype was completed by measuring the
levels of protein-bound HNE in synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1
mice relative to that of 1 month-old WT mice as a control (Fig. A.3b). The results showed a
significant increase in protein-bound HNE beginning at 9 months-old in APP/PS-1 mice (Fig.
A.2b, *P<0.05), directly correlating with significant Aβ(1-42) aggregation reported to begin at 9
months of age in this particular mouse model of Aβ pathology (Anantharaman et al., 2006;
Reaume et al., 1996; Siman et al., 2000). This increase was augmented in brain of 12 month-old
APP/PS-1 mice (Fig. A.2b, **P<0.01) relative to 1 month-old WT controls. Additionally, there
was a significant increase in 6 and 12 month-old APP/PS-1 HNE levels compared to their
respective 6 and 12 month-old, age-matched WT mice (Fig. A.2b, 6 & 12 months-old, §P<0.05),
demonstrating that the APP/PS-1 knock-in genotype affects levels of oxidative stress, as indexed
by protein-bound HNE, significantly more than normal aging alone. As with protein carbonyls
and protein-resident 3-NT levels, HNE results are consistent with previous reports of an agerelated increase in protein-bound HNE in brain of APP/PS-1 mice (Abdul et al., 2008).
Additionally, APP/PS-1 mice exhibited an age-related increase in HNE levels from 6 to 12
months-old (Fig. A.3b, §P<0.05).
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Figure A.3

Figure A.3 Protein-bound 4-hydroxy-2-trans-nonenal (HNE) levels in synaptosomes
from brain of wild-type (WT) and APP/PS-1 mice. A) Protein-bound HNE in each WT
age-group is presented as a percentage of 1 month-old WT HNE. Results demonstrated a
slight age-related increase in WT mouse HNE levels that is only significant from 6 to 9
months-old. Percent control values are presented as mean ± S.E.M. and significance
assessed by one-way ANOVA followed by Bonferroni‟s post-hoc analysis; §P<0.05; n=5
for all age groups. B) HNE levels for each WT and APP/PS-1 age-group is presented as
a percentage of 1 month-old WT HNE. Results demonstrated a significant age-dependent
increase in protein-bound HNE in APP/PS-1 mice beginning at 9 months that continues
to increase with age. However, this increase is more prominent in APP/PS-1 mice.
Percent control values are presented as mean ± S.E.M. and significance assessed by twoway ANOVA followed by Bonferroni's post-hoc analysis; §,*P<0.05, §§,**P<0.01; n=5
for all age groups.
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A.4 Conclusions
The three indices of oxidative stress measured in synaptosomes of age-matched WT and
APP/PS-1 mice (i.e., protein carbonyls, protein-resident 3-NT, and protein-bound HNE) confirm
the previously reported age-related increase in protein oxidation and lipid peroxidation (Abdul et
al., 2008) and serve to validate results reported in Chapter 5 of this dissertation. Although both
WT and APP/PS-1 mice follow a similar age-dependent trend of elevated levels of oxidative
stress (Figs. A.1-A.3), it is evident that this increase is more severe in brain of APP/PS-1 mice.
Furthermore, the present results demonstrate a significant increase in oxidative stress from 6 to 9
months-old in all indices of oxidative stress measured (Figs. A.1b-A.3b), corresponding to the
age at which significant Aβ(1-42) aggregation is reported to occur in brain of this mouse model
of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).
Therefore, the current results support the notion that elevated levels of sodium dodecyl sulfate
(SDS)-soluble, oligomeric Aβ(1-42), together with increasing oxidative stress and damage
(Abdul et al., 2008; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; LaFontaine et
al., 2002), in APP/PS-1 brain may contribute to the up-regulation and increased activation of
pro-apoptotic caspase-3, oxidative inactivation of the aminophospholipid translocase flippase,
and alter phosphatidylserine (PtdSer) plasma membrane localization beyond the effects of
normal brain aging, as reported in Chapter 5.
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APPENDIX B
DATA SUPPORTING FIGURES & TABLES
Figure 4.1 NBD-PS assay in inferior parietal lobule (IPL) of subjects with amnestic mild
cognitive impairment (aMCI) and Alzheimer disease (AD).
MCI: Sample ID Well 1 Well 2 Average
Control 1092c 346.636 285.231 315.934
Control 1089c 325.619 316.984 321.302
Control 1103c 314.122 334.489 324.306
Control 1106c 304.455 301.798 303.127
Control 1095c 339.741 320.910 330.326
1029m 195.265 227.985 211.625
MCI
MCI 1083m P 196.007 227.673 211.840
1065m 200.897 194.976 197.937
MCI
1077m 196.155 194.126 195.141
MCI
1087m 213.554 211.565 212.560
MCI

Avg
% Control
% Control
% Control
% Control
% Control
Avg%
StDev%

Control
319.00
-0.961
0.722
1.664
-4.976
3.551
0.00
3.22

T value 18.93358
P-value 6.26E-08
DOF
8
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MCI
205.82
-33.660
-33.592
-37.951
-38.827
-33.367
-35.48
2.68

Figure 4.1 data (cont.)
AD:
Sample ID Well 1 Well 2 Average
234.967 135.567 185.27
Control 1070
198.260 182.433 190.35
Control 1069
1063
179.079 150.883 164.98
Control
178.909 149.138 164.02
Control 1065
189.724 162.905 176.31
Control 1064
1062
128.134 127.017 127.58
AD
1071
145.342 108.232 126.79
AD
1058
124.739 139.589 132.16
AD
1073
163.882 155.939 118.82
AD
1074
146.447 147.934 147.19
AD

Control
Avg 176.19
% Control 5.154
% Control 8.037
% Control -6.360
% Control -6.903
% Control 0.073
Avg % 0.00
StDev % 6.69
T value 6.470900
P-value 0.000194
DOF
8
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AD
130.51
-27.591
-28.038
-24.986
-32.562
-16.458
-25.93
5.95

Figure 4.2 Post-mortem interval (PMI) NBD-PS assay in brain of normal FVB/N mice.
Sample ID Well 1 Well 2 Average
222.863 224.681 223.772
0a
221.716 291.546 256.631
0b
245.133 287.610 266.372
0c
Avg 248.92
StDev 22.32

0hr & 2.8hr
T value
-0.50883
P-value
0.6459
DOF
3

Sample ID Well 1 Well 2 Average
278.868 256.937 267.903
2.8a
207.104 289.736 248.420
2.8b
Avg 258.16
StDev 13.78

0hr & 3.5hr
T value
-0.26979
P-value
0.8007
DOF
4

Sample ID Well 1 Well 2 Average
227.903 262.894 245.399
3.5a
269.376 236.610 252.993
3.5b
255.169 263.450 259.310
3.5c
Avg 252.57
StDev 6.97

2.8hr & 3.5hr
T value
-0.62675
P-value
0.5753
DOF
3
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Figure 4.3 Mg2+ATPase activity assay in brain of normal FVB/N mice.
Column 1 Column 2 Column 3 Column 4
Column 5
(Blank)
Prtn + Buffer + Prtn, Buffer Column 4 Sample ID Buffer Only Buffer Ouabain + Ouabain Column 3
0.131
1.330
0.133
1.098
0.965
0a
0.135
1.369
0.128
1.221
1.093
0b
0.134
1.255
0.130
1.074
0.944
0c
0.136
1.139
0.130
0.940
0.810
2.8a
0.140
1.142
0.142
0.892
0.750
2.8b
0.132
1.332
0.134
1.150
1.016
3.5a
0.132
1.141
0.128
0.804
0.676
3.5b
0.128
1.253
0.125
1.001
0.876
3.5c
0hr & 2.8hr
T value
3.4406
P-value
0.0412
DOF
3
0hr
0.965
1.093
0.944
Avg 1.001
StDev 0.081

2.8hr
0.810
0.750
-0.780
0.042

3.5hr
1.016
0.676
0.876
0.856
0.171

0hr & 3.5hr
T value
1.32608
P-value
0.25547
DoF
4
2.8hr & 3.5hr
T value
-0.58771
P-value
0.59803
DOF
3
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Figure 4.4 Bcl-2 levels in brain from subjects with amnestic mild cognitive impairment (aMCI)
and Alzheimer disease (AD).
Data obtained by my collaborator, visiting Ph.D. student, Giovanna Cenini (University of
Kentucky, Lexington, KY).
Bcl-2 AD Tubulin-Normalized
Sample ID
Values
134
Control 1
161
Control 2
171
Control 3
216
Control 4
213
AD 1
251
AD 2
235
AD 3
q-test out
98
0.75163
AD 4

Bcl-2 MCI Tubulin-Normalized
Sample ID
Values
200
Control 1
190
Control 2
164
Control 3
171
Control 4
244
MCI 1
227
MCI 2
210
MCI 3
225
MCI 4

% Control
% Control
% Control
% Control
Avg %
StDev %
P-value

% Control
% Control
% Control
% Control
Avg %
StDev %
P-value
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Control Avg
170.50
78.59
94.43
100.29
126.69
100.00
20.01
0.0292

AD Avg
233.00
124.93
147.21
137.83
-136.66
11.19

Control Avg MCI Avg
181.25
226.50
110.34
134.62
104.83
125.24
90.48
115.86
94.34
124.14
100.00
124.97
9.18
7.68
0.0059

Figure 4.5 Bax levels in brain from subjects with amnestic mild cognitive impairment (aMCI)
and Alzheimer disease (AD).
Data obtained by my collaborator, visiting Ph.D. student, Giovanna Cenini (University of
Kentucky, Lexington, KY).
Bax AD
Tubulin-Normalized
Sample ID
Values
144
Control 1
163
Control 2
237
Control 3
q-test out
49
0.50532
Control 4
58
AD 1
42
AD 2
39
AD 3
79
AD 4
Bax MCI Tubulin-Normalized
Sample ID
Values
54
Control 1
58
Control 2
81
Control 3
56
Control 4
81
MCI 1
101
MCI 2
103
MCI 3
74
MCI 4

% Control
% Control
% Control
% Control
Avg %
StDev %
P-value

Control Avg
181.33
79.41
89.89
130.70
-100.00
27.10
0.0361

AD Avg
54.50
31.99
23.16
21.51
43.57
30.06
10.11

Control Avg MCI Avg
62.25
89.75
86.75
130.12
% Control
93.17
162.25
% Control
130.12
165.46
% Control
89.96
118.88
% Control
100.00
144.18
Avg %
20.25
23.22
StDev %
P-value
0.0285
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Figure 4.5 Caspase-3 levels in brain from subjects with amnestic mild cognitive impairment
(aMCI) and Alzheimer disease (AD).
Data obtained by my collaborator, visiting Ph.D. student, Giovanna Cenini (University of
Kentucky, Lexington, KY).
Caspase-3 AD
Tubulin-Normalized

Sample ID
Control 1
Control 2
Control 3
Control 4
AD 1
AD 2
AD 3
AD 4

Values
279
322
232
297
425
498
387
298

Control Avg AD Avg
282.50
402.00
98.76
150.44
% Control
176.28
% Control 113.98
82.12
136.99
% Control
105.49
% Control 105.13
142.30
Avg % 100.00
13.45
29.46
StDev %
P-value 0.0400

Caspase-3 MCI
Tubulin-Normalized

Sample ID
Control 1
Control 2
Control 3
Control 4
MCI 1
MCI 2
MCI 3
MCI 4

Values
292
239
307
236
320
326
363
340

Control Avg
268.50
108.75
% Control
89.01
% Control
114.34
% Control
87.90
% Control
100.00
Avg %
13.53
StDev %
P-value
0.0154
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MCI Avg
337.25
119.18
121.42
135.20
126.63
125.61
7.11

Figure 5.1 Soluble amyloid-β (Aβ) load in sodium dodecyl sulfate (SDS)-fractions of aging
APP/PS-1 mouse brain.
(pmol/g) (pmol/g)
(pmol/g) (pmol/g)
Age: Aβ40
Aβ42 Age:
Aβ40
Aβ42
6.81
7.18
1mo 1.21537 1.34043 3 mo
1.14689 1.35563
4.56
2.36
2.03523 1.56419
3.38
3.45
2.21973 1.88059
12.91
3.68
1.91791 2.34759
16.21
2.76
2.10689 1.71798 6 mo
0.72
1.16
1.22665 1.36168
0.92
1.03
1.13288 1.08830
0.00
2.30
2.05539 1.46134
5.17
5.58
1.90115 3.12128
1.59
1.77
1.88439 2.30039 9 mo 21.26
24.96
1.97756 1.92594
219.00 248.17
1.41427 2.45778
54.97
56.24
0.00000 1.10177
25.58
13.49
0.92193 1.46763
1.33
3.55
0.00000 3.10246 12 mo 195.30 121.16
1.29700 2.38094
1951.23 1305.50
0.00000 1.23560
932.64 877.93
2.02453 1.56273
32.72
30.36
0.00000 1.20608
68.83
82.58
0.71109 1.70397
1.29471 1.79449
0.16905 0.13277
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(pmol/g)
(pmol/g)
Age:
Aβ40 Age: Aβ42
1 mo mean 1.25 mean 1.72
s.e.m. 0.16 s.e.m. 0.14
3 mo mean 8.77 mean 3.89
s.e.m. 2.48 s.e.m. 0.86
6 mo mean 1.68 mean 2.37
s.e.m. 0.91 s.e.m. 0.83
9 mo mean 64.43 mean 69.28
s.e.m. 39.58 s.e.m. 45.59
12 mo mean 636.14 mean 483.50
s.e.m. 367.27 s.e.m. 257.74

Figure 5.2 Insoluble amyloid-β (Aβ) load in formic acid (FA)-fractions of aging APP/PS-1
mouse brain.
(pmol/g) (pmol/g)
Age: Aβ40
Aβ42 Age:
0
0
1 mo
3 mo
0
0
0
0
0
0
0
0
0
0
6 mo
0
0
0
0
0
0
0
0
0
0
9 mo
0
0
0
0
0
0
0
0
0
0
12 mo
0
0
0
0
0
0
0
0
0
0
0
0
0
0

(pmol/g)
Aβ40
0.0
0.0
0.0
0.0
0.0
3.452
0.0
0.0
0.0
0.0
0.0
2.958
0.0
0.0
0.0
5.343
145.561
4.976
0.0
0.0

(pmol/g)
Aβ42
0.0
0.0
3.203
2.279
0.0
0.0
1.173
0.0
0.481
0.159
0.113
22.846
4.035
1.864
1.264
26.028
394.731
43.764
5.425
4.505
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Age:
1 mo mean
s.e.m.
3 mo mean
s.e.m.
6 mo mean
s.e.m.
9 mo mean
s.e.m.
12 mo mean
s.e.m.

(pmol/g)
Aβ40
0
0
0
0
0.690
0.690
0.592
0.592
31.176
28.619

mean
s.e.m.
mean
s.e.m.
mean
s.e.m.
mean
s.e.m.
mean
s.e.m.

(pmol/g)
Aβ42
0
0
1.096
0.687
0.362
0.221
6.024
4.253
94.891
75.311

Figure 5.3 Annexin V (AV) binding assay in synaptosomes from wild-type (WT) and APP/PS-1
mice.
1 month Sample ID
2544
wt
2546
wt
2548
wt
2549
wt
2550
wt
AP1
HO
AP2
HO
AP3
HO
2538
HO
2540
HO

Well 1
48.879
56.299
52.431
53.750
48.625
56.099
55.571
48.540
57.684
56.868

Well 2
47.337
51.594
51.106
57.413
50.316
53.664
56.715
47.884
54.835
51.633

Average 6 month Sample ID
48.11
2235
wt
53.95
2236
wt
51.77
2237
wt
55.58
2238
wt
49.47
2292
wt
54.88
1183
wt
56.14
1189
wt
48.21
1218
wt
56.26
2313
HO
54.25
2314
HO
2315
HO
2316
HO
2247
HO
1149
HO
1147
HO
1142
HO

Well 1
53.135
54.166
56.309
56.731
53.899
49.327
51.094
49.448
50.589
58.240
53.907
50.735
52.544
49.528
47.782
58.795

Well 2
55.645
55.176
56.849
57.259
56.660
58.352
61.211
57.227
54.281
58.416
52.351
52.282
53.885
59.803
59.618
61.095

Average
54.39
54.67
56.58
57.00
55.28
53.84
56.15
53.34
52.44
58.33
53.13
51.51
53.21
54.67
53.70
59.95

9 month Sample ID
2030
wt
2032
wt
2154
wt
2155
wt
2156
wt
2002
HO
2003
HO
2195
HO
2196
HO
2197
HO

Well 1
56.006
55.373
59.011
60.249
62.427
63.307
66.495
61.671
66.781
64.721

Well 2
56.193
62.027
59.622
57.647
61.101
62.647
63.904
62.689
64.269
65.069

Average 12 month Sample ID
56.10
1790
wt
58.70
1793
wt
59.32
1800
wt
58.95
1831
wt
61.76
1852
wt
62.98
1817
HO
65.20
1819
HO
62.18
1821
HO
65.53
1856
HO
64.90
1924
HO

Well 1
53.952
57.164
57.813
55.463
56.848
63.865
67.703
61.928
64.717
66.897

Well 2
55.408
56.166
57.507
55.469
57.960
61.693
65.052
62.366
65.355
62.805

Average
54.68
56.67
57.66
55.47
57.40
62.78
66.38
62.15
65.04
64.85
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Figure 5.3 data (cont.)
1 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% Avg
StDev %

Control
92.918
104.195
99.988
107.350
95.550
100.00
6.50

APP/PS-1
106.001
108.437
93.119
108.662
104.782
103.77
6.52

6 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% Avg
StDev %

Control
105.055
105.594
109.279
110.083
106.778
103.988
108.455
103.018
106.53
2.56

APP/PS-1
101.275
112.659
102.616
99.486
102.781
115.780
103.717
105.583
105.49
5.73

9 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% Avg
StDev %

Control
108.353
113.368
114.567
113.855
119.294
113.89
3.89

APP/PS-1
121.637
125.929
120.093
126.558
125.341
123.91
2.87

12 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% Avg
StDev %

Control
105.602
109.445
111.367
107.130
110.873
108.88
2.46

APP/PS-1
121.254
128.205
120.034
125.613
125.256
124.07
3.36
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Figure 5.4 NBD-PS assay in synaptosomes from wild-type (WT) and APP/PS-1 mice.
1 month Sample ID Well 1 Well 2 Average 6 month Sample ID Well 1 Well 2 Average
2549 1020.544 836.678 928.61
2235 1159.214 1188.223 1173.72
wt
wt
2546 1082.930 1143.052 1112.99
2236 1150.728 1115.030 1132.88
wt
wt
2548 1263.832 1045.147 1154.49
2237 1246.071 1100.782 1173.43
wt
wt
2544
1217.608
1132.651
1175.13
2292 1162.174 1170.201 1166.19
wt
wt
2550 1262.349 1069.014 1165.68
2238 1291.406 1097.232 1194.32
wt
wt
2540 1430.835 1278.884 1354.86
1183 1190.820 1189.530 1190.18
HO
wt
2538 1249.006 1083.442 1166.22
1189 1190.057 1161.649 1175.85
HO
wt
AP3
1315.794 1143.848 1229.82
1218 1203.926 1189.204 1196.57
HO
wt
AP2
1431.897 1331.315 1381.61
2313 1116.062 1279.405 1197.73
HO
HO
AP1
1304.520 1325.176 1314.85
2315 1151.949 1201.425 1176.69
HO
HO
2247 1241.221 1184.663 1212.94
HO
2314 1372.741 1051.178 1211.96
HO
2316 1221.478 1208.621 1215.05
HO
1142 1226.663 1231.111 1228.89
HO
1147 1243.001 1235.577 1239.29
HO
1149 1221.682 1216.698 1219.19
HO
9 month Sample ID
2030
wt
2032
wt
2154
wt
2156
wt
2155
wt
2002
HO
2003
HO
2196
HO
2197
HO
2195
HO

Well 1
703.268
633.522
651.827
660.770
700.882
598.696
554.645
578.438
617.726
614.251

Well 2
627.606
661.602
617.525
648.768
645.352
577.096
600.173
581.740
569.970
518.093

Average 12 month Sample ID
665.44
1852
wt
647.56
1790
wt
634.68
1831
wt
654.77
1800
wt
673.12
1793
wt
587.90
1821
HO
577.41
1856
HO
580.09
1817
HO
593.85
1924
HO
566.17
1819
HO
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Well 1
618.798
628.749
684.265
668.327
716.685
585.702
540.114
551.656
537.429
600.517

Well 2
632.694
611.084
690.266
636.730
636.684
539.576
518.679
539.928
592.824
538.175

Average
625.75
619.92
687.27
652.53
676.68
562.64
529.40
545.79
565.13
569.35

Figure 5.4 data (cont.)
1 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% Avg
StDev %

Control
84.085
99.419
104.538
106.407
105.551
100.00
11.19

APP/PS-1
122.681
105.600
107.467
125.103
119.058
116.20
10.17

6 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% Avg
StDev %

9 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% Avg
StDev %

Control APP/PS-1 12 month Control APP/PS-1
60.255 53.233 % 1mo wt 56.661 50.946
58.636 52.284 % 1mo wt 56.133 47.936
57.469 52.526 % 1mo wt 62.231 49.421
59.289 53.772 % 1mo wt 59.086 51.172
60.950 51.266 % 1mo wt 61.273 51.554
59.32
52.62
50.21
% Avg 59.08
1.36
0.96
1.51
StDev % 2.71
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Control
106.279
102.581
106.253
105.597
108.144
107.769
106.472
108.348
106.43
1.85

APP/PS-1
108.454
106.548
109.831
109.742
110.022
111.274
112.216
110.396
109.81
1.72

Figure 5.5 Mg2+ATPase activity in synaptosomes from wild-type (WT) and APP/PS-1 mice.
1 month

wt
wt
wt
wt
wt
HO
HO
HO
HO
HO

Column 1 Column 2 Column 3 Column 4 Column 5
(Blank)
Prtn + Buffer + Prtn, Buffer Prtn, Buffer
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain
0.115
3.673
0.115
1.529
1.520
2235
0.113
3.914
0.116
1.589
1.585
2236
0.102
3.514
0.101
1.416
1.414
2237
0.111
3.846
0.113
1.486
1.455
2238
0.111
3.386
0.115
1.389
1.363
2292
0.119
2.929
0.114
1.290
1.334
2247
0.111
3.776
0.112
1.585
1.535
2313
0.111
3.105
0.112
1.298
1.304
2314
0.111
3.509
0.111
1.420
1.370
2315
0.114
3.662
0.114
1.602
1.393
2316

wt
wt
wt
wt
wt
HO
HO
HO
HO
HO

Avg of
Avg - Column 3
Sample ID Columns 4 & 5
2235
1.525
1.410
2236
1.587
1.471
2237
1.415
1.314
2238
1.471
1.358
2292
1.376
1.261
2247
1.312
1.198
2313
1.560
1.448
2314
1.301
1.189
2315
1.395
1.284
2316
1.498
1.384
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Figure 5.5 data (cont.)
6 month

wt
wt
wt
wt
wt
wt
wt
wt
HO
HO
HO
HO
HO
HO
HO
HO

Column 1 Column 2 Column 3 Column 4 Column 5
(Blank)
Prtn + Buffer + Prtn, Buffer Prtn, Buffer
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain
0.099
3.199
0.101
1.319
1.38
2544
0.101
3.324
0.101
1.321
1.336
2546
0.112
3.401
0.101
1.426
1.614
2548
0.101
3.313
0.101
1.418
1.436
2549
0.101
3.521
0.102
1.450
1.506
2550
1.146
1183
0.098
3.367
0.103
1.277
1189
0.098
3.407
0.099
1.540
1.525
1218
0.101
3.346
0.099
1.488
1.492
0.100
3.652
0.102
1.423
1.551
AP1
0.100
3.516
0.101
1.591
1.679
AP2
0.102
3.339
0.102
1.610
1.508
AP3
0.094
2.790
0.095
1.591
1.546
2538
0.099
3.170
0.099
1.629
1.595
2540
1142
0.099
3.425
0.100
1.583
1.604
1147
0.099
3.355
0.111
1.604
1.635
1149
0.098
3.393
0.100
1.453
1.477

Avg of
Avg - Column 3
Sample ID Columns 4 & 5
2544
1.350
1.249
wt
2546
1.329
1.228
wt
2548
1.426
1.325
wt
2549
1.427
1.326
wt
2550
1.478
1.376
wt
1183
1.212
1.109
wt
1189
1.533
1.434
wt
1218
1.490
1.391
wt
AP1
1.551
1.449
HO
AP2
1.635
1.534
HO
AP3
1.559
1.457
HO
1.569
1.474
2538
HO
1.612
1.513
2540
HO
1.594
1.494
1142
HO
1.620
1.509
1147
HO
1.465
1.365
1149
HO
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Figure 5.5 data (cont.)
9 month

wt
wt
wt
wt
wt
HO
HO
HO
HO
HO

Column 1 Column 2 Column 3 Column 4 Column 5
(Blank)
Prtn + Buffer + Prtn, Buffer Prtn, Buffer
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain
0.097
3.044
0.097
1.220
1.101
2030
0.097
3.008
0.096
1.257
1.246
2032
0.097
3.256
0.096
1.529
1.331
2154
0.093
2.971
0.095
1.408
1.251
2155
0.097
2.526
0.097
1.287
1.213
2156
0.097
3.293
0.098
1.199
1.205
2002
0.098
3.174
0.096
1.274
1.277
2003
0.098
3.181
0.098
1.273
1.307
2195
0.098
3.321
0.100
1.255
1.491
2196
0.099
3.255
0.098
1.106
1.027
2197

Avg of
Avg - Column 3
Sample ID Columns 4 & 5
2030
1.160
1.063
wt
2032
1.251
1.155
wt
2154
1.331
1.235
wt
1.329
1.234
2155
wt
1.250
1.153
2156
wt
1.202
1.104
2002
HO
1.275
1.179
2003
HO
1.290
1.192
2195
HO
1.373
1.273
2196
HO
1.066
0.968
2197
HO
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Figure 5.5 data (cont.)
12 month

wt
wt
wt
wt
wt
HO
HO
HO
HO
HO

Column 1 Column 2 Column 3 Column 4 Column 5
(Blank)
Prtn + Buffer + Prtn, Buffer Prtn, Buffer
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain
0.092
2.903
0.090
1.075
1.232
1793
0.090
2.604
0.091
1.179
1.286
1800
0.091
2.907
0.094
1.189
1.263
1831
0.089
2.832
0.090
1.296
1.326
1852
0.089
2.595
0.090
1.213
1.120
1790
0.090
2.539
0.090
1.040
0.900
1924
0.089
2.649
0.090
1.083
0.993
1817
0.090
2.789
0.090
1.028
0.987
1819
0.087
2.425
0.088
0.921
1.056
1821
0.090
2.486
0.088
1.005
0.906
1856

Avg of
Avg - Column 3
Sample ID Columns 4 & 5
1793
1.154
1.064
wt
1800
1.233
1.142
wt
1831
1.226
1.132
wt
1852
1.311
1.221
wt
1790
1.167
1.077
wt
0.970
0.880
HO 1924
1.038
0.948
HO 1817
1.008
0.918
HO 1819
0.989
0.901
HO 1821
0.956
0.868
HO 1856
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Figure 5.5 data (cont.)
1 month Control APP/PS-1 6 month Control APP/PS-1
% 1mo wt 103.442 87.920 % 1mo wt 91.626 106.341
% 1mo wt 107.955 106.231 % 1mo wt 90.085 112.579
% 1mo wt 96.433 87.260 % 1mo wt 97.241 106.928
% 1mo wt 99.626 94.232 % 1mo wt 97.314 108.139
% 1mo wt 92.544 101.534 % 1mo wt 100.983 111.038
Avg % 100.00 98.23 % 1mo wt 81.352 109.607
9.83 % 1mo wt 105.203 110.707
StDev % 8.92
% 1mo wt 102.084 100.176
Avg % 95.74 108.19
3.87
StDev % 7.73
9 month Control APP/PS-1 12 month Control APP/PS-1
% 1mo wt 78.049 81.022 % 1mo wt 78.049 64.582
% 1mo wt 84.801 86.562 % 1mo wt 83.774 69.573
% 1mo wt 90.636 87.480 % 1mo wt 83.076 67.335
% 1mo wt 90.599 93.424 % 1mo wt 89.608 66.087
% 1mo wt 84.618 71.077 % 1mo wt 79.003 63.665
83.91
66.25
Avg % 85.74
Avg % 82.70
5.22
8.42
4.59
2.33
StDev %
StDev %
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Figure 5.6 Procaspase-3 levels in brain from wild-type (WT) and APP/PS-1 mice.
1 month
wt - 1
56691.3
α-tubulin
procaspase-3 2214.09
HO - 2
45803.40
α-tubulin
procaspase-3 1940.17

wt - 3
57434.67
2308.00
HO - 4
55146.25
2166.64

6 month
wt - 1
60341.08
α-tubulin
procaspase-3 1426.94
HO - 2
61394.67
α-tubulin
procaspase-3 2683.71

wt - 3
wt - 5
wt - 7
wt - 9
70099.09 51354.51 62821.66 63782.40
3837.82 530.54 2626.62 2463.67
HO - 4 HO - 6 HO - 8 HO - 10
53587.43 72781.78 59212.23 65029.00
2942.76 2963.96 1251.33 4151.19

9 month
wt - 1
71717.71
α-tubulin
procaspase-3 1790.00
HO - 2
73900.78
α-tubulin
procaspase-3 2633.50

wt - 3
67338.00
1893.00
HO - 4
67295.00
2761.50

wt - 5
62921.37
2376.40
HO - 6
59684.43
2360.89

wt - 7
69019.17
2811.40
HO - 8
72021.35
2979.06

wt - 9
70733.57
2979.71
HO - 10
66393.16
2106.00

12 month
wt - 1
52970.00
α-tubulin
procaspase-3 1194.00
HO - 2
55305.13
α-tubulin
procaspase-3 1428.82

wt - 3
56917.20
1010.40
HO - 4
54603.08
1133.18

wt - 5
57777.75
1043.00
HO - 6
55924.07
1328.50

wt - 7
58564.63
1578.67
HO - 8
55757.79
1426.67

wt - 9
52010.50
898.80
HO - 10
59621.75
1312.00
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wt - 5
52765.60
2587.28
HO - 6
58594.57
2343.00

wt - 7
51031.82
2242.00
HO - 8
46800.27
1543.40

wt - 9
51544.87
1802.89
HO - 10
48045.71
2120.80

Figure 5.6 data (cont.)
1 month
6 month
procaspase-3 wt
HO procaspase-3 wt
HO
% 1mo wt 94.25 102.22 % 1mo wt 57.07 105.49
% 1mo wt 96.98 94.82
% 1mo wt 132.13 132.53
% 1mo wt 118.33 96.50
% 1mo wt 24.93 98.28
% 1mo wt 106.03 79.59
% 1mo wt 100.90 51.00
% 1mo wt 84.41 106.53 % 1mo wt 93.22 154.06
Avg % 100.00 95.93
Avg % 81.65 108.27
StDev % 12.82 10.25
StDev % 41.45 38.96
9 month
procaspase-3 wt
% 1mo wt 60.23
% 1mo wt 67.84
% 1mo wt 91.15
% 1mo wt 98.30
% 1mo wt 101.66
Avg % 83.84
StDev % 18.66

HO
86.00
99.03
95.46
99.82
76.55
91.37
9.94

12 month
procaspase-3
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg %
StDev %
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wt
54.40
42.84
43.56
65.05
41.70
49.51
10.08

HO
62.35
50.08
57.33
61.75
53.11
56.92
5.34

Figure 5.7 Active p18 fragment caspase-3 levels in brain from wild-type (WT) and APP/PS-1
mice.
1 month
wt - 1
56691.3
α-tubulin
caspase-3 (20kDa) 4968.50
HO - 2
45803.40
α-tubulin
caspase-3 (20kDa) 5623.93

wt - 3
57434.67
5420.21
HO - 4
55146.25
5154.89

wt - 5
52765.60
5184.00
HO - 6
58594.57
8578.60

wt - 7
51031.82
7086.88
HO - 8
46800.27
7499.05

wt - 9
51544.87
6285.95
HO - 10
48045.71
6981.23

6 month
wt - 1
60341.08
α-tubulin
caspase-3 (20kDa) 9651.71
HO - 2
61394.67
α-tubulin
caspase-3 (20kDa) 11448.86

wt - 3
70099.09
11272.00
HO - 4
53587.43
10233.55

wt - 5
51354.51
6630.85
HO - 6
72781.78
11513.34

wt - 7
62821.66
9868.50
HO - 8
59212.23
9944.45

wt - 9
63782.40
9408.52
HO - 10
65029.00
6048.50

9 month
wt - 1
71717.71
α-tubulin
caspase-3 (20kDa) 13271.76
HO - 2
73900.78
α-tubulin
caspase-3 (20kDa) 14333.38

wt - 3
67338.00
11158.42
HO - 4
67295.00
17220.76

wt - 5
62921.37
11282.29
HO - 6
59684.43
13168.20

wt - 7
69019.17
10353.69
HO - 8
72021.35
15434.25

wt - 9
70733.57
12288.00
HO - 10
66393.16
12838.39

12 month
wt - 1
52970.00
α-tubulin
caspase-3 (20kDa) 8349.28
HO - 2
55305.13
α-tubulin
caspase-3 (20kDa) 11651.68

wt - 3
56917.20
8431.57
HO - 4
54603.08
10050.16

wt - 5
57777.75
6822.13
HO - 6
55924.07
11242.65

wt - 7
58564.63
7212.00
HO - 8
55757.79
11981.00

wt - 9
52010.50
10744.79
HO - 10
59621.75
11346.67

225

Figure 5.7 data (cont.)
1 month
caspase-3 (20kDa)
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg %
StDev %
9 month
caspase-3 (20kDa)
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg %
StDev %

wt
80.99
87.21
90.79
128.33
112.69
100.00
19.83

6 month
HO caspase-3 (20kDa) wt
113.46
% 1mo wt 147.81
86.38
% 1mo wt 148.59
135.29
% 1mo wt 119.32
148.07
% 1mo wt 145.16
134.27
% 1mo wt 136.31
123.49
Avg % 139.44
24.17
StDev % 12.26

HO
172.32
176.47
146.18
155.19
85.95
147.22
36.42

wt
171.01
153.13
165.69
138.62
160.53
157.80
12.59

12 month
HO caspase-3 (20kDa) wt
179.23
% 1mo wt 145.66
236.47
% 1mo wt 136.89
203.88
% 1mo wt 109.11
198.03
% 1mo wt 113.80
178.69
% 1mo wt 190.90
199.26
Avg % 139.27
23.62
StDev % 32.68

HO
194.68
170.08
185.77
198.56
175.86
184.99
12.09
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Figure 5.8 Active p12 fragment caspase-3 levels in brain from wild-type (WT) and APP/PS-1
mice.
1 month
wt - 1
56691.3
α-tubulin
caspase-3 (18kDa) 4139.62
HO - 2
45803.40
α-tubulin
caspase-3 (18kDa) 4766.95

wt - 3
57434.67
4168.56
HO - 4
55146.25
3721.40

wt - 5
52765.60
6435.76
HO - 6
58594.57
5976.60

wt - 7
51031.82
5357.30
HO - 8
46800.27
5331.95

wt - 9
51544.87
4657.84
HO - 10
48045.71
6528.27

6 month
wt - 1
wt - 3
60341.08 70099.09
α-tubulin
caspase-3 (18kDa) 3511.82 6865.00
HO - 2 HO - 4
61394.67 53587.43
α-tubulin
caspase-3 (18kDa) 4228.00 6930.88

wt - 5
51354.51
4241.20
HO - 6
72781.78
8632.15

wt - 7
62821.66
6150.73
HO - 8
59212.23
5903.60

wt - 9
63782.40
6363.02
HO - 10
65029.00
2729.25

9 month
wt - 1
wt - 3
71717.71 67338.00
α-tubulin
caspase-3 (18kDa) 13650.28 9932.25
HO - 2 HO - 4
73900.78
67295.00
α-tubulin
caspase-3 (18kDa) 12521.02 12904.67

wt - 5
62921.37
10181.47
HO - 6
59684.43
8979.22

wt - 7
69019.17
10587.57
HO - 8
72021.35
10161.50

wt - 9
70733.57
9406.75
HO - 10
66393.16
6399.26

12 month
wt - 1
wt - 3
52970.00
56917.20
α-tubulin
caspase-3 (18kDa) 2933.10 5713.71
HO - 2 HO - 4
55305.13 54603.08
α-tubulin
caspase-3 (18kDa) 4766.13 5036.00

wt - 5
57777.75
5119.85
HO - 6
55924.07
4962.11

wt - 7
58564.63
4074.15
HO - 8
55757.79
4001.67

wt - 9
52010.50
6031.11
HO - 10
59621.75
4835.33
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Figure 5.8 data (cont.)
1 month
caspase-3 (18kDa)
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg %
StDev %
9 month
caspase-3 (18kDa)
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg %
StDev %

wt
78.87
78.39
131.74
113.39
97.60
100.00
22.94

6 month
HO caspase-3 (18kDa) wt
HO
112.41
% 1mo wt 62.86 74.38
72.89
% 1mo wt 105.78 139.70
110.17
% 1mo wt 89.20 128.11
123.06
% 1mo wt 105.75 107.69
146.76
% 1mo wt 107.75 45.33
113.06
Avg % 94.27 99.04
26.73
StDev % 19.09 38.94

wt
205.58
159.32
174.78
165.69
143.64
169.80
23.00

12 month
HO caspase-3 (18kDa) wt
183.00
% 1mo wt 59.81
207.13
% 1mo wt 108.43
162.50
% 1mo wt 95.71
152.39
% 1mo wt 75.14
104.11
% 1mo wt 125.25
161.83
Avg % 92.87
38.48
StDev % 26.01

228

HO
93.08
99.62
95.84
77.52
87.60
90.73
8.59

Figure 6.1 Oxidative modification of brain in transgenic (Tg) and non-transgenic (Non Tg)
mice: Role of Met-35 of amyloid-β (Aβ). A) Protein oxidation as indexed by protein
carbonylation. B) Lipid peroxidation as indexed by protein-bound 2-hydroxy-2-trans-nonenal
(HNE). C) Protein oxidation as indexed by protein-resident 3-nitrotyrosine (3-NT).
J20 NTg J20 Tg M53L NTg M35L Tg
J20 NTg J20 Tg M35L NTg M35L Tg
184
202
204
151
148
281
321
196
158
242
135
116
75
465
60
219
176
253
116
151
141
724
103
180
149
218
143
162
229
298
219
213
PCO
PCO
252
125
134
441
135
140
Run 1 161
Run 2 267
261
123
388
155
234
138
272
247
216
147
478
260
188
154
149
293
263
132
316
217
140.80
212.00
Avg 165.60 232.90 144.60
Avg 172.00 381.20 167.60
34.73
14.66 StDev 76.19 157.97 103.67
47.00
StDev 14.15 25.88
PCO Combined J20 NTg J20 Tg M53L NTg M35L Tg

% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
Avg %
StDev %

111.11
95.41
106.28
89.98
97.22
86.05
43.60
81.98
133.14
155.23

121.98
146.14
152.78
131.64
152.17
157.61
141.30
130.43
113.53
158.82
163.37
270.35
420.93
173.26
256.40
225.58
158.14
277.91
86.63
183.72
100.00 181.13
30.08 76.40

141.08
93.36
80.22
98.89
86.45
191.53
35.80
61.46
130.67
80.55

100.00
44.24

104.43
80.22
104.43
112.03
92.67
85.06
95.44
101.66
106.50
91.29
116.95
130.67
107.40
127.09
83.53
92.48
147.37
155.13
174.82
129.47
111.93
25.38
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J20NTg vs J20Tg P-value
M35LNTg vs M35LTg P-value
M35LNTg vs J20NTg P-value
M35LTg vs J20Tg P-value

0.00030
0.4446
1.0000
0.0004

Figure 6.1 data (cont.)

J20 NTg J20 Tg M53L NTg M35L Tg
J20 NTg J20 Tg M53L NTg M35L Tg
236
217
196
168
347
651
103
208
201
285
228
209
360
589
75
73
216
271
272
224
280
490
82
141
226
258
238
233
273
463
51
101
HNE
HNE
242
249
194
220
165
Run 1 203
Run 2
252
242
173
119
209
292
318
123
170
228
347
185
257
212
379
64
222
238
321
48
224.00
77.75
122.70
Avg 216.40 238.30 236.60
Avg 315.00 395.10
27.98
32.74 StDev 44.86 153.01
21.44
52.98
StDev 14.94 34.05
HNE Combined J20 NTg J20 Tg M53L NTg M35L Tg

% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
Avg %
StDev %

109.06
92.88
99.82
104.44
93.81
110.16
114.29
88.89
86.67

100.28
131.70
125.23
119.22
111.83
116.45
96.58
78.56
118.76
102.59
233.33
211.11
175.63
165.95
78.85
62.01
113.98
124.37
135.84
115.05
100.00 125.87
10.00 42.46

82.84
96.37
114.96
100.59
105.24
132.48
96.46
105.47
65.59

100.00
18.84

71.01
88.33
94.67
98.48
81.99
102.28
123.42
96.37
89.60
100.59
181.18
63.59
122.82
87.98
143.73
103.66
107.14
161.15
55.75
41.81
100.78
33.75
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0.0170
J20NTg vs J20Tg P-value
M35LNTg vs M35LTg P-value 0.9375
M35LNTg vs J20NTg P-value 1.0000
0.0454
M35LTg vs J20Tg P-value

Figure 6.1 data (cont.)
J20 NTg J20 Tg M35L NTg M35L Tg
J20 NTg J20 Tg M35L NTg M35L Tg
429
567
390
410
374
467
496
268
521
645
385
484
348
457
433
608
492
658
501
438
544
466
388
550
642
408
369
565
400
435
3-NT 435
3-NT 411
463
385
450
619
424
427
Run 1 421
Run 2 321
423
432
789
402
531
358
708
429
531
294
471
342
612
309
503
253
578
383
430
587
459.60
565.00
413.80
392.70
399.60
547.50
428.20
430.10
Avg
Avg
49.66
61.57 StDev 87.29 121.31
41.98
123.32
StDev 44.30 79.05

3-NT Combined J20 NTg J20 Tg M35L NTg M35L Tg

% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
% Control
Avg %
StDev %

93.34
113.36
107.05
94.65
91.60
93.59
87.09
136.14
102.85
80.33

123.37
140.34
143.17
139.69
100.74
92.04
115.54
115.54
133.16
125.76
116.87
114.36
116.62
141.39
154.90
197.45
177.18
117.87
125.88
107.61
100.00 129.97
15.92 25.08

94.25
93.04
121.07
98.60
93.04
115.83
101.12
90.61
93.41
99.02

100.00
10.33

99.08
116.96
105.85
89.17
108.75
104.40
86.52
71.05
74.67
92.56
62.59
141.99
128.44
101.59
99.72
93.88
100.19
79.87
59.08
137.09
97.67
22.49
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0.00049
J20NTg vs J20Tg P-value
M35LNTg vs M35LTg P-value 0.70085
M35LNTg vs J20NTg P-value 1.00000
M35LTg vs J20Tg P-value 0.00012

Figure 6.2 Specificity assay for protein carbonyls.
Data obtained by collaborator Dr. Rukhsana Sultana (University of Kentucky, Lexington, KY).

Figure 6.3 Amyloid precursor protein (APP) expression and amyloid-β (Aβ) production.
Data obtained by our collaborators at the Buck Institute for Age Research (Novato, CA).

Figure 6.4 Immunohistochemical staining of amyloid plaques and microglia.
Data obtained by our collaborators at the Buck Institute for Age Research (Novato, CA).

Figure 6.5 Morris water-maze behavioral assessment of PDAPP mice: Effect of the M631L
mutation. A) Latency index spatial training. B) Floating. C) Probe trial.
Data obtained by our collaborators at the Buck Institute for Age Research (Novato, CA).
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Figure 7.1 Representative 2D-gel images of proteins isolated from Tg PDAPP(J20) and Non Tg
PDAPP mouse brain.
Table 7.1 List of proteins with differential levels in Tg PDAPP(J20) mice relative to Non Tg
PDAPP controls.
Expression
SSP# J20NTg_562 J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524
558.3
563.5
275.8
1047.4
8.9
2
516.1
862.8
1707.2
6.9
8.9
2201
12.1
12
9.3
6.9
8.9
3303
803.6
1217.4
1102.9
1756.1
8.9
4608
12.1
12
9.3
6.9
8.9
4701
12.1
957.3
1333.2
6.9
803.4
7002
488.9
12
9.3
6.9
8.9
7710
SSP# J20Tg_454
J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
1161.9
2262.9
989.4
1345.7
10.3
2
11.6
2399.1
1353.2
2363.1
1016.4
2201
883.7
634.2
652.7
764.5
10.3
3303
3191.9
2212.8
1632.5
1926.4
1208.2
4608
11.6
819.9
520.5
346.2
100.3
4701
2194.3
2329
1845.6
1047.9
2006.4
7002
909.5
1606.1
760.5
1493.6
1980.2
7710
SSP# J20Tg_530
J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
1445.6
1257.4
927.5
1404.9
1329.5
2
2011.2
2413.7
1879.9
1280.7
1537.8
2201
7.3
1045.9
9.4
10.8
864.2
3303
1870.1
1834.4
1059.2
1357.7
2089.5
4608
482.6
968.9
501
397
573.5
4701
1589.8
1965.5
1819.9
2206.1
2243.9
7002
798
1106.2
1526.2
1354.7
1264.2
7710
From Boolean
Normalized intensity values shown
Expression
Fold Change
SSP#
Sample ID
J20NTg Avg J20Tg Avg Tg/NTg P-value
490.78
1213.51
2.47262
2 Calcineurin, subunit B, Type 1
0.0135
620.38
1626.67
2.62205
2201 ρGDP-dissociation inhibitor 1
0.0329
9.84
488.3
49.62398 0.0064
3303 F-actin-capping protein, subunit β
977.78
1838.27
1.88004
4608 α-Enolase
0.0386
9.84
472.15
47.98272 0.0007
4701 T-complex protein 1, subunit α A
622.58
1924.84
3.09172
7002 Peptidyl-prolyl cis-trans isomerase 1
0.0047
ATP
synthase,
subunit
α,
105.2
1279.92
12.16654
7710
5.09e-06
mitochondrial
J20NTg StDev 591.92
502.45
J20Tg StDev
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Figure 7.2 Peptidyl-proyl cis-trans isomerase (Pin-1) expression levels in brain of transgenic
(Tg) and non-transgenic (Non Tg) mice.
NTg - 1
33121.65
actin
12072.42
Pin-1
Normalized 0.36449
Tg - 2
37612.45
actin
14600.10
Pin-1
Normalized 0.38817

NTg - 3
40140.69
13714.17
0.34165
Tg - 4
35244.92
16638.49
0.47208

NTg - 5
37954.74
13363.89
0.35210
Tg - 6
33997.29
13458.34
0.39587

Tot Avg
% NTg
% NTg
% NTg
% NTg
% NTg
Avg %
StDev %

NTg
Tg
0.35590 0.40986
102.41 109.07
96.00
132.64
98.93
111.23
112.00 106.08
90.66
116.79
100.00 115.16
7.97
10.53

P-value

0.0332
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NTg - 7
33752.62
13454.18
0.39861
Tg - 8
29574.00
11165.44
0.37754

NTg - 9
34162.42
11022.26
0.32264
Tg - 10
30400.24
12635.53
0.41564

Figure 7.3 Representative 2D-Western blot image corresponding to carbonylated
dihydropyrimidinase-related protein 2 (Drp-2).
Table 7.2 List of oxidatively modified proteins in Tg PDAPP(J20) mice relative to Non Tg
PDAPP controls.
From Boolean
Normalized intensity values shown
GELS
PCO
SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562
3563.9
6236.7
18167.2
7786.2
4202.3
4702
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
7555
10721
11211.4
17640.9
6380.4
4702
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
6938.1
7190.3
6029.2
111.8
23470.6
4702
BLOTS
PCO
SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562
8.4
64.8
37.7
30.3
57
4702
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
3079.4
48.8
17354.9
9.6
39.5
4702
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
8897.8
3531.9
42.9
50.8
27.8
4702
FOLD CHANGE PER ANIMAL
PCO
J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.01039
0.00208
0.00389
0.01356
4702 0.00236
J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.004552
1.547969
0.000544
0.006191
4702 0.407598
J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
1.282455
0.491203
0.007115
0.454383
0.001184
4702
PCO
Fold ChangeActual %
SSP#
Sample ID
J20Tg Avg J20NTg Avg Tg/NTg Tg/NTg P-value
0.006456
65.110
6510.97 0.0462
4702 Dihydropyrimidinase-related 0.420319
protein 2
0.005
J20NTg StDev
0.566
J20Tg StDev
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Figure 7.4 Representative 2D-Western blot image corresponding to nitrated
phosphatidylethanolamine-binding protein 1 (PEBP-1).
Figure 7.5 Representative 2D-Western blot image corresponding to nitrated peptidyl-prolyl cistrans isomerase 1 (Pin-1).
Table 7.2 List of oxidatively modified proteins in Tg PDAPP(J20) mice relative to Non Tg
PDAPP controls.
From Boolean
Normalized intensity values shown
GELS
3-NT
SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562
6747.6
25746.6
27259.1
32305.6
14233.1
2101
6877.1
23713.3
33630.4
7278.1
7158.7
6101
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
22372.4
31165.8
37589.4
16666.1
2101 28859.2
30480
18198.2
20075.4
19543.1
27219.2
6101
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
31852
14375.3
32730.5
19637.7
2101 21655.7
40687.3
31548.5
24249
44754.9
6101 11188.4
BLOTS
3-NT
SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562
20420.3
37713.3
12902.3
15328.2
2101 11434.3
9324.7
6166.5
16694.1
4033.9
3849.3
6101
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
1563.3
17563.6
14003
2531.2
3198.8
2101
2005.8
4514.4
5331
1795.2
1297.4
6101
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
4679.3
7625.6
4378.3
4225.4
9635.8
2101
53.3
3577.2
4670.2
5498.2
1628.6
6101
FOLD CHANGE PER ANIMAL 3-NT
J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.79313
1.38351
0.39938
1.07694
2101 1.69457
0.26004
0.49640
0.55425
0.53771
6101 1.35591
J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.78506
0.44931
0.06734
0.19193
2101 0.05417
0.24807
0.26555
0.09186
0.04766
6101 0.06581
J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.23941
0.30457
0.12910
0.49068
2101 0.21608
0.08792
0.14803
0.22674
0.03639
6101 0.00476
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Figures 7.4 & 7.5 & Table 7.2 data (cont.)
3-NT
J20
J20
Fold Change Actual %
NTg
Tg
SSP#
Sample ID
Tg Avg NTg Avg
Tg/NTg
Tg/NTg P-value StDev StDev
0.27373
27.37
2101 Phosphatidylethanolamine- 0.29276 1.0695
0.0230 0.504 0.226
binding protein 1
0.12228 0.6409
0.19081
19.08
6101 Peptidyl-prolyl cis-trans
0.0488 0.417 0.094
isomerase 1

237

Figure 7.6 Peptidyl-prolyl cis-trans isomerase (Pin-1) nitration levels in brain of Tg

PDAPP(J20) and Non Tg PDAPP mice.
Tg - 1 Tg - 3 Tg - 6 NTg - 2 NTg - 4 NTg - 5
Pin-1 16115.88 12439.5 11229.45 19655.93 18765 19473.19
NTg
Tg
Tot Avg 19298.04 13261.61
% NTg 101.85 83.51045
% NTg 97.24 64.45991
% NTg 100.91 58.18959
Avg % 100.00 68.72
13.19
StDev % 2.44
P-value 0.015
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Figure 8.1 Representative 2D-gel images of proteins isolated from brain of Tg
PDAPP(M631L) and Non Tg M631L mice.
Table 8.1 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Non
Tg M631L controls.
M35L
SSP#
1903
6201
6902
8002
SSP#
1903
6201
6902
8002
SSP#
1903
6201
6902
8002
M35LNTg
Avg
307.68
541.06
68.44
1434.92

EXPRESSION
M35LNTg 664 M35LNTg 604 M35LNTg 661 M35LNTg 606 M35LNTg 607
16
547.9
6.1
560.3
408.1
422
473.4
740
541.1
528.8
16
259.6
6.1
47.6
12.9
1812.3
1536.1
1680.8
1187.5
957.9
M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
1295.5
7
848.7
781.9
721.7
402.9
284.6
347.3
485.8
13.7
449.8
7
11.6
586.6
1107.4
1403.7
788
946.7
961.5
1095.7
M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
503.9
625.7
643.8
883.8
704.9
370.4
348.3
493.7
514.2
18
496.9
532.6
13.6
501.5
388.9
13.3
13.8
1370.6
12.1
1325.9
M35LNTg
StDev
277.3240
120.9138
108.0478
354.2156

M35LTg Avg
701.69
327.89
409.59
793.13

M35LTg
StDev
324.04929
180.11973
338.09943
573.40273

Fold Change
Tg/NTg
2.28058
0.60601
5.98466
0.55273

From Boolean
Normalized intensity values shown
SSP#
Sample ID
1903 Heat shock protein B1
6201 Proteasome, subunit B, type 1
6902 Dynamin-1
8002 Glutathione-S-transferase μ1
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P-value
0.03579
0.01943
0.01321
0.02044

Figure 8.2 Representative 2D-gel images of proteins isolated from brain of Tg PDAPP(M631L)
and Tg PDAPP(J20) mice.
Table 8.2 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) mice.
From Boolean
Normalized intensity values shown
M35L GELS
SSP#
M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
268.8
369.2
11.6
6
13.7
1104
14.5
328.1
11.6
6
13.7
1105
558.2
409.1
11.6
6
13.7
2008
663.5
7
331
779
13.7
3201
14.5
7
352.8
645.4
13.7
4105
14.5
322.4
11.6
6
13.7
4205
1474.1
575.1
11.6
1802.2
1853.9
4402
14.5
7
11.6
6
645.3
5203
2276.5
1845.8
1919.6
601.4
1096.4
5403
407.9
324.5
163.2
6
13.7
5506
507.8
7
11.6
632
13.7
5702
2028.8
1351.3
1790.2
1696.2
1720.8
6101
14.5
342.4
585.8
797
530.8
6102
14.5
456.8
11.6
6
617.8
6103
1040.9
544.1
568.1
6
657
6203
14.5
910.1
914.4
1231.7
768.5
6301
1262.2
680.5
956.7
1158.8
839.8
6303
1264.4
7
2133.5
1138.9
13.7
6403
723
428.6
536.5
782.6
756.9
6504
904.9
580.9
11.6
6
13.7
6704
14.5
851.3
11.6
6
13.7
7002
405.2
380.1
366.3
373
406.5
7102
2028.4
1751.6
2304.7
2051
2624.1
7402
739.8
954.8
692.8
6
13.7
7710
14.5
7
11.6
6
13.7
8701
1997.8
1080.8
1610.5
2026.3
2114.5
8709
1290.8
616.6
917.2
1127.5
273.5
9001
14.5
7
11.6
70.8
322.4
9204
1123.4
681.1
681.7
1271.5
830.9
9401
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Figure 8.2 & Table 8.2 data (cont.)
M35L GELS Cont.
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
310.8
13.8
13.6
12.1
18
1104
13.3
13.8
13.6
12.1
18
1105
662.3
13.8
700.4
639.6
18
2008
13.3
13.8
489.7
12.1
295.4
3201
13.3
13.8
13.6
12.1
18
4105
301.1
455.9
427.8
12.1
18
4205
456.4
739.7
916.1
12.1
346.7
4402
13.3
13.8
13.6
12.1
18
5203
13.3
722.7
13.6
12.1
18
5403
13.3
13.8
13.6
12.1
18
5506
337.9
13.8
13.6
162.2
18
5702
2120.1
1227.2
1311.5
1019.1
1367.3
6101
13.3
620.8
13.6
12.1
18
6102
13.3
13.8
13.6
12.1
18
6103
555.5
630.1
634.6
839.8
18
6203
314.2
311.8
534
681.8
550.3
6301
549.8
637
604.2
675
516.6
6303
13.3
13.8
13.6
825.3
18
6403
405.3
607.5
658.2
573.8
413.8
6504
1057.6
274.2
307.1
330.7
349.3
6704
1943.2
2139.6
1239.1
1036.9
1315
7002
13.3
13.8
13.6
186.4
18
7102
772.5
1782.1
1971.6
1859.6
1451.1
7402
13.3
13.8
13.6
578
18
7710
13.3
13.8
13.6
12.1
18
8701
852.4
1448.1
1392.2
1220.6
882.3
8709
1549.8
1140.9
1160
1009.6
1163.3
9001
13.3
13.8
13.6
12.1
18
9204
587.6
947
618.5
990.3
663.4
9401

241

Figure 8.2 & Table 8.2 data (cont.)
J20 GELS
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
740.7
447.7
727.2
452.4
211.5
1104
430.3
522.1
432.7
614.7
316.3
1105
584.3
552.6
601.8
806.4
1018.7
2008
687.5
776.4
459.1
631.7
487.3
3201
907.7
927.3
874.5
500.5
1134
4105
551.2
500.1
557.9
465.5
10.3
4205
1980.4
1009.1
1137.2
1627.3
997.7
4402
11.6
672.8
652.9
630.2
482.5
5203
2693.9
2735.9
1893
1828.7
1536.5
5403
11.6
103.8
704
390.3
462.7
5506
11.6
10.7
379.7
896.2
10.3
5702
3059.9
2547
2339.4
1770.2
3513.9
6101
11.6
804.7
787.9
559.8
10.3
6102
485.3
978.6
1113.8
730.6
1026
6103
915.3
1293.4
1283.6
1201.8
819.7
6203
1583.2
1101
1593.7
1060.1
623.5
6301
1139.2
1310.2
1284.7
1339
779.3
6303
2322
2698.7
2177.3
1610.3
2840.7
6403
1344
738.9
906.5
1172.9
561.6
6504
1021.9
1242.8
1073.3
1797.7
1013.1
6704
2194.3
2329
1845.6
1047.9
2006.4
7002
596.1
484.6
329.5
410.5
404.8
7102
3543.2
3377.7
2968.7
2661.6
3301.6
7402
909.5
1606.1
760.5
1493.6
1980.2
7710
700.7
431.6
355.6
1136.3
10.3
8701
4130.1
2457.4
2590.1
3705.7
2263.2
8709
1512.3
1418.6
1358.1
1236.4
2022.7
9001
346.3
433.1
7.7
384
543
9204
1273.8
2639.2
967.2
1080
1003.4
9401
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Figure 8.2 & Table 8.2 data (cont.)
J20 GELS Cont.
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
7.3
413.1
9.4
1113.8
1594.1
1104
7.3
4.3
9.4
10.8
13.8
1105
868.2
969.8
881.8
10.8
13.8
2008
690.2
334.5
408.6
602
551.3
3201
7.3
397.4
504.6
683.2
13.8
4105
7.3
257.1
715.3
368.1
449.7
4205
2389
883.2
2882.1
3270.1
2913.1
4402
563.8
628.2
9.4
10.8
13.8
5203
7.3
1144.4
1490.1
2636.4
1976.4
5403
7.3
710.8
9.4
453.5
947.5
5506
841.3
1596.7
900.3
684.8
1216.8
5702
3417.2
2770.5
2352.7
4752.9
6101 1622.2
922.6
1317.2
1015.9
1071.6
495
6102
7.3
713.1
540.8
1289.9
13.8
6103
995.1
1680.9
1835.5
1528.1
6203 1166.9
1014.4
1485.3
1600
1646.2
6301 1258.5
1242.5
2031
2225.3
1672.8
6303 1291.3
7.3
3421
9.4
2470.5
13.8
6403
809.4
598.3
1167.9
1392.5
1336.3
6504
697.8
1115.7
898.1
10.8
831
6704
1965.5
1819.9
2206.1
2243.9
7002 1589.8
465.6
538.3
390.6
928.7
13.8
7102
2602.4
3013.5
3390.9
2777
7402 1745.6
798
1106.2
1526.2
1354.7
1264.2
7710
578.6
4.3
9.4
875.4
13.8
8701
1728.9
4161.6
5238.6
3819.4
8709 2858.1
1723.5
1871.8
2351.8
2263.4
9001 1554.1
418.9
4.3
266.1
572
13.8
9204
893.6
1546.8
1612.4
1540.6
532.9
9401
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Figure 8.2 & Table 8.2 data (cont.)
J20Tg vs M35L Tg Expression
Fold Change
SSP# J20Tg Avg J20Tg StDev M35LTg Avg M35LTg StDev M35LTg/J20Tg P-value
495.66
103.76
148.59
0.181487
1104 571.72
0.01041
250.68
44.47
99.70
0.188297
1105 236.17
0.03742
363.59
303.27
315.94
0.480755
2008 630.82
0.04536
139.91
261.85
297.92
0.465213
3201 562.86
0.00971
383.54
110.42
216.17
0.185570
4105 595.03
0.00267
233.36
158.31
193.18
0.407753
4205 388.25
0.02742
907.43
818.79
683.10
0.428928
4402 1908.92
0.00712
367.6
311.03
75.52
200.23
0.205441
5203
0.02245
831.59
851.94
888.39
0.474814
5403 1794.26
0.02480
380.09
339.45
98.61
149.93
0.259439
5506
0.02750
545.37
171.76
236.60
0.262293
5702 654.84
0.01929
924.64
1563.25
361.56
0.555409
6101 2814.59
0.00087
434.40
294.83
315.27
0.421390
6102 699.66
0.02828
437.84
117.75
224.37
0.170672
6103 689.92
0.00172
329.20
549.41
321.34
0.431916
6203 1272.03
0.00010
341.34
623.13
355.62
0.480591
6301 1296.59
0.00041
429.31
788.06
259.23
0.550502
6303 1431.53
0.00074
1291.46
544.15
757.84
0.309686
6403 1757.1
0.01962
318.03
588.62
142.17
0.586959
6504 1002.83
0.00143
449.02
383.6
365.84
0.395374
6704 970.22
0.00493
383.51
857.09
821.44
0.445279
7002 1924.84
0.00155
228.83
217.62
185.37
0.476975
7102 456.25
0.01958
2938.22
531.28
1859.67
497.39
0.632924
7402
0.00018
391.35
304.38
386.96
0.237812
7710 1279.92
0.00003
411.6
408.55
12.36
3.54
0.030029
8701
0.00631
1084.04
1462.55
467.81
0.443828
8709 3295.31
0.00011
385.03
1024.92
357.58
0.592005
9001 1731.27
0.00048
218.58
49.71
97.56
0.166299
9204 298.92
0.00405
578.36
839.54
234.50
0.641365
9401 1308.99
0.02865
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Figure 8.2 & Table 8.2 data (cont.)
J20Tg vs M35L Tg Expression
SSP# Sample ID
1104 Phosphatidylethanolamine-binding protein 1
1105 Peroxiredoxin-2
2008 V-type proton ATPase, subunit F
3201 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial
4105 Serum albumin
4205 Proteasome subunit β, type 3
4402 Malate dehydrogenase, cytoplasmic
5203 Triose phosphate isomerase
5403 Acot7, isoform B of cytosolic acyl CoA, thioester 7
5506 Fructose bisphosphate aldolase C
5702 Dihydropyrimidinase-related protein 2
6101 Peptidyl-prolyl cis-trans isomerase 1
6102 Transgelin 3
6103 Peptidyl-prolyl cis-trans isomerase 1
6203 Triose phosphate isomerase
6301 Carbonic anhydrase 2
6303 Phosphoglycerate mutase 1
6403 Glyceraldehyde-3-phosphate dehydrogenase
6504 Fructose bisphosphate aldolase C
6704 Pyruvate kinase M1/M2
7002 Peptidyl-prolyl cis-trans isomerase 1
7102 Superoxide dismutase [Mn], mitochondrial
7402 Glyceraldehyde-3-phosphate dehydrogenase
7710 ATP synthase, subunit α, mitochonodrial
8701 Pyruvate kinase M1/M2
8709 ATP synthase, subunit α, mitochonodrial
9001 Pyruvate kinase M1/M2
9204 Peroxiredoxin-1
9401 Voltage-dependent anion-selective channel protein 1
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Figure 8.3 Pyruvate kinase M2 (PK M2) levels in brain of Tg PDAPP(M631L) mice and Tg
PDAPP(J20) mice.
J20Tg - 1 J20Tg - 3
193182 164524.25
actin
5955.68
8513.4
PK M2
Normalized 0.03083 0.05175

J20Tg - 5
139239.84
10941.13
0.07858

J20Tg - 7 J20Tg - 9 J20Tg - 11
178059.63 163689.3
169476
11907.08 13462.77
15742.5
0.06687
0.08225
0.09289

M35LTg - 2M35LTg - 4M35LTg - 6M35LTg - 8M35LTg - 10M35LTg - 12

176950.5 157933.05 154947.9 162976.68 182230.8
actin
5564
8047.63 7931.52 10506.14 4825.27
PK M2
0.02648
Normalized 0.03144 0.05096 0.05119 0.06446

Tot Avg
% J20Tg
% J20Tg
% J20Tg
% J20Tg
% J20Tg
% J20Tg
Avg %
StDev %

J20Tg
0.06719
45.88
77.01
116.94
99.52
122.40
138.24
100.00
33.79

P-value 0.0604
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M35LTg
0.04409
46.80
75.84
76.18
95.94
39.41
59.50
65.61
21.04

226463.4
9054.75
0.03998

Figure 9.1 Representative 2D-gel images of proteins isolated and transferred to 2D-Western
blots from Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L mouse brain.
Figure 9.2 Representative 2D-Western blot images corresponding to carbonylated pyruvate
kinase isoforms M1/M2 (PK M1/M2) and aspartate aminotransferase, mitochondrial (AATM).
Table 9.1 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) mice.
From Boolean
Normalized intensity values shown
J20 GELS
PCO
SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562
70814.4
114927.9
52535.9
21585.6
0102 26037.7
66
17292.1
65.2
23905.1
95.9
1301
6747.6
25746.6
27259.1
32305.6
14233.1
2101
3743.6
10447.4
7455.2
17573
9127.3
6303
4440.4
19795.3
28569.1
37132.4
12676
7702
8150.9
97.3
34755.2
109.2
95.9
9603
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
51230.3
70661.8
55456.2
20471.3
0102 81226.6
115.9
76.4
2354.2
10858.9
80
1301
22372.4
31165.8
37589.4
16666.1
2101 28859.2
11348
9361.4
11024.4
14781.8
6036.4
6303
10995.2
13778.2
31778.5
10904.8
7702 27453.8
35828.4
42708.1
48827.2
80
9603 44685.8
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
82733.4
84719.9
37751
42713.9
0102 45470.3
50.9
41298.5
111.8
130.2
1301 27105.8
31852
14375.3
32730.5
19637.7
2101 21655.7
8906.7
14794.1
23127.7
22936.4
15752
6303
23546.1
34749.5
31395.7
26015.5
7702 16264.4
50.9
106.9
111.8
130.2
9603 18308.4
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Figures 9.1 & 9.2 & Table 9.1 data (cont.)
J20 BLOTS
PCO
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
41.1
48.8
68.7
9.6
39.5
0102
18664.7
3805.4
5488.6
1237.5
1301 17341.6
5060
8470.2
2932.8
4050.6
6383.8
2101
41.1
48.8
68.7
9.6
39.5
6303
48.8
68.7
9.6
39.5
7702 7898.7
41.1
48.8
68.7
9.6
39.5
9603
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
42.7
53.1
42.9
50.8
27.8
0102
8096.7
7753.2
41618.2
43553.6
1301 7574.7
12543
348.6
6184.6
7297.5
2101 5703.4
42.7
53.1
42.9
50.8
27.8
6303
42.7
53.1
42.9
50.8
27.8
7702
42.7
53.1
42.9
50.8
27.8
9603
J20 FOLD CHANGE PER ANIMAL
J20Tg_454 J20Tg_455 J20Tg_461
SSP# blot/gel
blot/gel
blot/gel
0.00095
0.00097
0102 0.00051
1301 149.62554 244.30236 1.61643
0.37860
0.09410
2101 0.17533
0.00521
0.00623
6303 0.00362
0.00444
0.00499
7702 0.28771
0.00136
0.00161
9603 0.00092
J20Tg_530 J20Tg_560 J20Tg_561
SSP# blot/gel
blot/gel
blot/gel
0.00064
0.00051
0102 0.00094
1301 0.27945 159.07073 0.18774
0.39379
0.02425
2101 0.26337
0.00359
0.00185
6303 0.00479
0.00226
0.00123
7702 0.00263
1.04322
0.40131
9603 0.00233
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PCO
J20Tg_465
blot/gel
0.00017
0.50545
0.10776
0.00065
0.00030
0.00020
J20Tg_565
blot/gel
0.00135
372.25581
0.18896
0.00221
0.00162
0.45438

J20Tg_525
blot/gel
0.00193
15.46875
0.38304
0.00654
0.00362
0.49375
J20Tg_573
blot/gel
0.00065
334.51306
0.37161
0.00176
0.00107
0.21352

Figures 9.1 & 9.2 & Table 9.1 data (cont.)
M35L GELS
PCO
SSP# M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664
21389.8
64614.7
57605.6
6127.5
100.6
0102
75.1
9063.8
127.2
63.4
100.6
1301
13621.3
38835.1
29555.6
7047.3
8919.5
2101
6875.5
11336
8950
12982.1
3108.4
6303
15915.2
19752.1
17895.4
11590.4
7625.4
7702
75.1
41446
30145.8
63.4
100.6
9603
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
58736.2
74459.2
98048.3
31251.3
79448.2
0102
110.3
110.5
133.4
64.4
89.3
1301
12545.4
27049
30129.3
35617.9
15809.5
2101
9613.8
10790.3
11037.9
12375.2
5486.9
6303
24033.3
18319
11459.9
29741.5
20639.3
7702
2228.6
35358.8
30128.1
38273.1
36136.9
9603
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
33045.2
92.2
102.6
91
124.6
0102
86.1
92.2
102.6
91
124.6
1301
10809.6
10356.4
11348.3
12185.8
10544.6
2101
3565.9
4268.5
4554.6
5056.6
3570.3
6303
8503.1
10136.6
8839.8
10446.3
10704.4
7702
9853.7
8939.6
7655
10110.7
4861.8
9603
M35L BLOTS
PCO
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
0.1
43.9
30.7
50.5
51.5
0102
17204.2
22055.3
2757
27442.5
40289.4
1301
3331.7
9557.7
6125.7
6641.5
4857.1
2101
0.1
43.9
30.7
50.5
51.5
6303
81017.8
21202.1
32084.8
50.5
72755.8
7702
0.1
43.9
30.7
50.5
51.5
9603
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
64.5
37.6
42.2
24.4
53.9
0102
9870
43363.6
27224.8
34926.3
39942.7
1301
21324.5
21540
10635.4
11447.4
4691.2
2101
64.5
37.6
42.2
24.4
53.9
6303
64.5
37.6
4307.6
24.4
53.9
7702
64.5
37.6
42.2
24.4
53.9
9603
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Figures 9.1 & 9.2 & Table 9.1 data (cont.)
M35L FOLD CHANGE PER ANIMAL
PCO
M35LTg 591
M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
SSP#
blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.0000017
0.000590
0.000313
0.001616
0.000648
0102
155.97643
199.59548
20.66717
426.12578 451.16909
1301
0.265571
0.353348
0.203314
0.186465
0.307227
2101
0.000010
0.004068
0.002781
0.004081
0.009386
6303
3.371064
1.157383
2.799745
0.001698
3.525110
7702
0.000045
0.001242
0.001019
0.001319
0.001425
9603
M35LTg 605
M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
SSP#
blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.00195
0.40781
0.41131
0.26813
0.43258
0102
114.6341
470.3210
265.3489
383.8055
320.5674
1301
1.97274
2.07987
0.93718
0.93940
0.44489
2101
0.01809
0.00881
0.00927
0.00483
0.01510
6303
0.00759
0.00371
0.48730
0.00234
0.00504
7702
0.00655
0.00421
0.00551
0.00241
0.01109
9603
PCO
Fold Change
SSP# J20Tg Avg J20Tg StDev M35LTg Avg M35LTg StDev M35LTg/J20Tg P-value

0102
1301
2101
6303
7702
9603

0.00086
127.7825
0.23808
0.00365
0.03099
0.26126

0.00050
147.1231
0.13875
0.00202
0.09022
0.34362
SSP#
0102
1301
2101
6303
7702
9603

0.15250
280.8211
0.76900
0.00764
1.13610
0.00348

0.20054
154.9011
0.71713
0.00565
1.50181
0.00341

176.96600
2.197649
3.230002
2.094753
36.66491
0.013326

Sample ID
Calmodulin, isoform 1
14-3-3 δ/δ
Phosphatidylethanolamine-binding protein 1
Phosphoglycerate mutase 1
Pyruvate kinase M1/M2
Aspartate aminotransferase, mitochondrial
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0.0279
0.0360
0.0337
0.0495
0.0321
0.0290

Figure 9.3 Representative 2D-Western blot images corresponding to nitrated aspartate
aminotransferase, mitochondrial (AATM) and peptidyl-prolyl cis-trans isomerase 1 (Pin-1).
Table 9.1 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Tg
PDAPP(J20) mice.
From Boolean
Normalized intensity values shown
J20 GELS
3-NT
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
82132.9
138412.2 125185.2
54236.2
2504 81258.8
5858.5
4466.4
3822.4
777.1
4701 115.9
18198.2
20075.4
19543.1
27219.2
6101 30480
19392.5
29294.7
27923.3
80
9303 23373
35828.4
42708.1
48827.2
80
9603 44685.8
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
83971.4
116217.5
71908.2
118488.8
2504 67332.3
11535.9
5705.2
4092.2
5400.6
4701 3328.6
40687.3
31548.5
24249
44754.9
6101 11188.4
50.3
50.9
106.9
111.8
130.2
9303
50.9
106.9
111.8
130.2
9603 18308.4
J20 BLOTS
3-NT
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
42
79.5
81.9
73.4
74
2504
42
79.5
81.9
73.4
859.9
4701
4514.4
5331
1795.2
1297.4
6101 2005.8
42
79.5
81.9
73.4
74
9303
42
79.5
81.9
73.4
74
9603
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
53.3
77.6
64.8
109.7
91.9
2504
53.3
77.6
64.8
109.7
91.9
4701
53.3
3577.2
4670.2
5498.2
1628.6
6101
53.3
77.6
64.8
109.7
91.9
9303
53.3
77.6
64.8
109.7
91.9
9603
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Figure 9.3 &Table 9.1 data (cont.)
J20 FOLD CHANGE PER ANIMAL 3-NT
J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
2504 0.000517 0.000968 0.000592 0.000586 0.001364
4701 0.362381 0.013570 0.018337 0.019203 1.106550
6101 0.065807 0.248068 0.265549 0.091859 0.047665
0.925
9303 0.001797 0.004100 0.002796 0.002629
0.925
9603 0.000940 0.002219 0.001918 0.001503
J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573
SSP# blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.00092
0.00056
0.00153
0.00078
2504 0.00079
0.01601
0.00673
0.01136
0.02681
0.01702
4701
0.08792
0.14803
0.22674
0.03639
6101 0.00476
1.52456
0.60617
0.98122
0.70584
9303 1.05964
1.52456
0.60617
0.98122
0.70584
9603 0.00291
M35L GELS
3-NT
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
88871.6
135979.1
109628.4
49256.2
69373.7
2504
110.3
2768.6
133.4
64.4
89.3
4701
15453.1
21426.1
20654.8
18115.2
11242.7
6101
110.3
12288.8
17286.8
25551.2
27108.4
9303
2228.6
35358.8
30128.1
38273.1
36136.9
9603
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
38717.2
41253.1
48746.3
56777.8
54357.7
2504
2683.3
92.2
5051.5
1493.7
124.6
4701
13751.3
8223.1
9886.7
7634.8
9448.8
6101
8286.7
12715.5
102.6
15552.1
7710.3
9303
9853.7
8939.6
7655
10110.7
4861.8
9603
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Figure 9.3 &Table 9.1 data (cont.)
M35L BLOTS
3-NT
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
69.4
69574.6
84.2
71.6
37301.4
2504
69.4
2252.4
84.2
71.6
70.7
4701
4240
10717.2
2843.4
2340
1774.5
6101
69.4
88.6
84.2
71.6
70.7
9303
69.4
88.6
84.2
71.6
70.7
9603
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
38614.7
77.8
54.9
83.2
43698.4
2504
47.6
77.8
54.9
83.2
86.5
4701
2060.1
2477.5
1550
3872.2
2562.7
6101
47.6
77.8
54.9
83.2
86.5
9303
47.6
77.8
54.9
83.2
86.5
9603
M35L FOLD CHANGE PER ANIMAL
3-NT
M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
SSP#
blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.00078
0.51166
0.00077
0.00145
0.53769
2504
0.62919
0.81355
0.63118
1.11180
0.79171
4701
0.27438
0.50019
0.13766
0.12917
0.15784
6101
0.62919
0.00721
0.00487
0.00280
0.00261
9303
0.03114
0.00251
0.00279
0.00187
0.00196
9603
M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
SSP#
blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.99735
0.00189
0.00113
0.00147
0.80390
2504
0.01774
0.84382
0.01087
0.05570
0.69422
4701
0.14981
0.30129
0.15678
0.50718
0.27122
6101
0.00574
0.00612
0.53509
0.00535
0.01122
9303
0.00483
0.00870
0.00717
0.00823
0.01779
9603
3-NT

Fold Change
SSP# J20Tg Avg J20Tg StDev M35LTg Avg M35LTg StDev M35LTg/J20Tg P-value

2504
4701
6101
9303
9603

0.00086
0.15980
0.12228
0.58137
0.47523

0.00035
0.35004
0.09427
0.55290
0.55277

0.28581
0.55998
0.25855
0.12102
0.00870
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0.39087
0.39169
0.14381
0.24405
0.00924

332.269
3.50433
2.11444
0.20816
0.01831

0.0332
0.0269
0.0220
0.0269
0.0156

Figure 9.3 &Table 9.1 data (cont.)
SSP# Sample ID
2504 Actin (multiple isoforms)
4701 T-complex protein 1, subunit α A
6101 Peptidyl-prolyl cis-trans isomerase 1
9303 Tubulin polymerization-promoting protein
9603 Aspartate aminotransferase, mitochondrial
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Figure 9.4 Representative 2D-Western blot images corresponding to nitrated glutathione-Stransferase μ 1 (GST μ1) and glial fibrillary acidic protein (GFAP).
Table 9.2 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Non Tg
M631L controls.
From Boolean
Normalized intensity values shown
M35L GELS
3-NT
SSP# M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664
7088.4
11239.4
12790.5
59187
4551.7
1601
75.1
129.5
127.2
63.4
100.6
2603
4904.4
9589.1
8759.1
11020.8
3529.9
8202
18330.5
26573.5
14701.2
19713.6
7580.8
8601
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
110.3
110.5
133.4
21845.7
4235.5
1601
110.3
110.5
133.4
64.4
89.3
2603
3165.1
7168.8
9004.1
6012.8
5250
8202
20809.6
26764.8
14041.9
31282.6
10412.9
8601
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
86.1
92.2
8314.3
91
124.6
1601
86.1
92.2
102.6
91
124.6
2603
3827.9
2628.9
3984.5
4973
2793.3
8202
10715.4
7469.3
14990.1
10640.6
7920.9
8601
M35L BLOTS
3-NT
SSP# M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664
728.4
1527.1
1273.3
5398
11532.9
1601
36.9
29.8
58.8
49.3
47.8
2603
36.9
1091
58.8
1271.3
47.8
8202
36.9
29.8
58.8
49.3
47.8
8601
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596
6964.7
25234.9
8796.3
6292.1
2499.2
1601
69.4
88.6
84.2
71.6
70.7
2603
1681.7
3323.9
1032
1041.7
70.7
8202
4376.4
7944.1
2494.4
71.6
70.7
8601
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663
9948.2
1244.3
2163.4
12279.7
4390.2
1601
47.6
77.8
54.9
83.2
86.5
2603
47.6
1272.7
1443
1742.9
86.5
8202
47.6
77.8
54.9
83.2
2278.9
8601
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Figure 9.4 & Table 9.2 data (cont.)
M35L FOLD CHANGE PER ANIMAL
3-NT
M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664
SSP#
blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
0.102759
0.135870
0.099550
0.091202
2.533757
1601
0.491345
0.230116
0.462264
0.777603
0.475149
2603
0.007524
0.113775
0.006713
0.115355
0.013541
8202
0.002013
0.001121
0.004000
0.002501
0.006305
8601
M35LTg 591
M35LTg 593
M35LTg 594 M35LTg 595 M35LTg 596
SSP#
blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
63.1432
228.3701
65.9393
0.28802
0.59006
1601
0.62919
0.80181
0.63118
1.11180
0.79171
2603
0.53133
0.46366
0.11461
0.17325
0.01347
8202
0.21031
0.29681
0.17764
0.00229
0.00679
8601
M35LTg 605
M35LTg 608
M35LTg 626 M35LTg 662 M35LTg 663
SSP#
blot/gel
blot/gel
blot/gel
blot/gel
blot/gel
115.5424
13.49566
0.26020
134.94176
35.2343
1601
0.55285
0.84382
0.53509
0.91429
0.69422
2603
0.01244
0.48412
0.36215
0.35047
0.03097
8202
0.00444
0.01042
0.00366
0.00782
0.28771
8601

3-NT
Fold Change
M35LTg M35LTg M35LNTg M35LNTg M35LTg/
SSP#
Avg
StDev
Avg
StDev
M35LNTg P-value
1601
2603
8202
8601

65.7805
0.75060
0.25365
0.10079

74.6850
0.17888
0.20729
0.12707

0.59263
0.48730
0.05138
0.00319

1.08526
0.19443
0.05774
0.00203

110.9980
1.54033
4.93652
31.61423

SSP# Sample ID
1601 Secernin 1
2603 Glial fibrillary acidic protein
8202 Glutathione-S-transferase μ1
8601 Creatine kinase, ubiquitous, mitochondrial
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0.0221
0.0366
0.0147
0.0380

Figure 9.5 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) nitration levels in brain of Tg
PDAPP(M631L) and Tg PDAPP(J20) mice.
M35L - 1 M35L - 2 M35L - 3 J20 - 4 J20 - 5 J20 - 6
Pin-1 21488.81 18205.92 18310.87 15485.83 11374.47 15986.08
J20
M35L
Tot Avg 14282.13 19335.2
% J20Tg 108.43 150.4595
% J20Tg 79.64 127.4735
% J20Tg 111.93 128.2083
Avg % 100.00 135.38
13.06
StDev % 17.72
P-value

0.049
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Figure A.1 Protein carbonyl (PCO) levels in synaptosomes from brain of wild-type (WT) and
APP/PS-1 mice.
1 month Sample ID Well 1 Well 2 Average 6 month Sample ID
2544
479
478
478.5
2235
wt
wt
2546
481
488
484.5
2236
wt
wt
2548
455
436
445.5
2237
wt
wt
2549
411
450
430.5
2238
wt
wt
2550
403
429
416.0
2292
wt
wt
AP1
440
456
448.0
2247
HO
HO
AP2
481
493
487.0
2313
HO
HO
AP3
508
507
507.5
2314
HO
HO
2538
522
502
512.0
2315
HO
HO
2540
526
535
530.5
2316
HO
HO

Well 1
386.0
449
417
352
424
444
411
463
454
497

Well 2 Average
378
382.0
448
448.5
383
400.0
355
353.5
410
417.0
437
440.5
441
426.0
488
475.5
487
470.5
505
501.0

9 month Sample ID Well 1 Well 2 Average 12 month Sample ID
2030
1022 1037 1029.5
1852
wt
wt
2032
1006 992
999.0
1790
wt
wt
2154
1000 1053 1026.5
1831
wt
wt
2156
931
964
947.5
1800
wt
wt
2155
889
868
878.5
1793
wt
wt
2002
992
989
990.5
1821
HO
HO
2003
1192 1207 1199.5
1819
HO
HO
2196
1160 1076 1118.0
1817
HO
HO
2197
1052 1070 1061.0
1924
HO
HO
2195
1047 1043 1045.0
HO
1856
HO

Well 1
813
947
1021
968
1021
1166
1148
1025
1095

Well 2 Average
779
796.0
912
929.5
1090 1055.5
943
955.5
972
996.5
1202 1184.0
1214 1181.0
1044 1034.5
1130 1112.5
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NOT
ENOUGH
LEFT!

Figure A.1 data (cont.)
1 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
106.097
107.427
98.7804
95.4545
92.2394
100.00
6.61

HO
99.3348
107.982
112.527
113.525
117.627
110.20
6.98

6 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
84.700
99.445
88.691
78.381
92.461
88.74
7.94

HO
97.671
94.456
105.434
104.323
111.086
102.59
6.59

9 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
228.270
221.507
227.605
210.088
194.789
216.45
14.14

HO
219.623
265.964
247.893
235.255
231.707
240.09
17.63

12 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
176.496
206.097
234.035
211.862
220.953
209.89
21.44

HO
262.527
261.862
229.379
246.674
-250.11
15.64
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Figure A.2 Protein-resident 3-nitrotyrosine (3-NT) levels in synaptosomes from brain of wildtype (WT) and APP/PS-1 mice.
1 month Sample ID Well 1 Well 2 Average
6 month Sample IDWell 1 Well 2 Average
AP2
367 315 341.0
2235
312
275
293.5
wt
wt
AP3
367
362
364.5
2236
398
323
360.5
wt
wt
2540
456 403 429.5
2237
314
292
303.0
wt
wt
2538
284 269 276.5
2238
405
374
389.5
wt
wt
2550
86
106
96.0
2292
315
431
373.0
HO
wt
2544
101 102 101.5
2247
362
378
370.0
HO
HO
2546
98
95
96.5
2313
502
435
468.5
HO
HO
2548
183 120 151.5 q-test out
2314
401
361
381.0
HO
HO
2549
313 315 314.0 0.74541 HO
2315
525
480
502.5
HO
2316
472
408
440.0
HO
AP1
wt
NOT ENOUGH LEFT!
9 month Sample ID Well 1 Well 2 Average12 monthSample ID Well 1 Well 2Average
2030
251 297 274.0
1852
320
330 325.0
wt
wt
2032
296
335
315.5
1790
290
261 275.5
wt
wt
2154
223 232 227.5
1800
280
381 330.5
wt
wt
2156
267 255 261.0
1793
252
204 228.0 q-test out
wt
wt
2155
322 301 311.5
1831
574
671 622.5 0.74018
wt
wt
2002
553 542 547.5
1821
755
982 868.5
HO
HO
2003
389 374 381.5
1817
992
1162 1077.0
HO
HO
2196
394 489 441.5
1924
1041
1164 1102.5
HO
HO
2197
417 374 395.5
1819
651
684 667.5
HO
HO
2195
397 364 380.5
HO
1856
HO
 NOT ENOUGH LEFT!
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Figure A.2 data (cont.)
1 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
86.195
91.134
86.644
136.027
-100.00
24.12

HO 6 month
306.173 % 1mo wt
327.273 % 1mo wt
385.634 % 1mo wt
248.260 % 1mo wt
-- % 1mo wt
316.84
Avg%
56.74
StDev

wt
263.524
323.681
272.054
349.719
334.905
308.78
38.66

HO
332.211
420.651
342.088
451.178
395.062
388.24
50.81

9 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
246.016
283.277
204.265
234.343
279.686
249.52
32.94

HO 12 month
491.582 % 1mo wt
342.536 % 1mo wt
396.409 % 1mo wt
355.107 % 1mo wt
341.639 % 1mo wt
385.45
Avg%
63.38
StDev

wt
291.807
247.363
279.794
296.745
-278.93
22.21

HO
779.798
967.003
989.899
599.327
-834.01
182.58
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Figure A.3 Protein-bound 4-hydroxy-2-trans-nonenal (HNE) levels in synaptosomes from brain
of wild-type (WT) and APP/PS-1 mice
1 month Sample ID Well 1 Well 2 Average 6 month Sample ID Well 1 Well 2 Average
2544
174 159 166.5
2235
166 131 148.5
wt
wt
2546
182 178 180.0
2236
119 100 109.5
wt
wt
2548
195 122 158.5
2237
135
76
105.5
wt
wt
2549
157 171 164.0
2238
136
90
113.0
wt
wt
2550
98
194 146.0
2292
184 130 157.0
wt
wt
AP1
197 196 196.5
2247
239 132 185.5
HO
HO
AP2
159 155 157.0
2313
287 158 222.5
HO
HO
AP3
208 245 226.5
2314
225
69
147.0
HO
HO
2538
267 243 255.0
2315
175 255 215.0
HO
HO
2540
197 180 188.5
2316
118 186 152.0
HO
HO
9 month Sample ID Well 1 Well 2 Average 12 month Sample ID Well 1 Well 2 Average
2030
237 164 200.5
1852
218 199 208.5
wt
wt
2032
179 183 181.0
1790
255 224 239.5
wt
wt
2154
163 213 188.0
1831
139 138 138.5
wt
wt
2156
180 195 187.5
1800
153 145 149.0
wt
wt
2155
221 173 197.0
1793
149 127 138.0
wt
wt
2002
241 202 221.5
1821
238 281 259.5
HO
HO
2003
242 213 227.5
1856
251 212 231.5
HO
HO
2196
215 193 204.0
1817
257 214 235.5 q-test out
HO
HO
2197
209 199 204.0
1924
125 129 127.0 0.788679
HO
HO
2195
224 278 251.0
1819
255 250 252.5
HO
HO
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Figure A.3 data (cont.)

1 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
102.147
110.429
97.239
100.613
89.571
100.00
7.59

HO
120.552
96.319
138.957
156.442
115.644
125.58
22.98

6 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
91.104
67.178
64.724
69.325
96.319
77.73
14.80

HO
113.804
136.503
90.184
131.902
93.252
113.13
21.34

9 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
123.006
111.043
115.337
115.031
120.859
117.06
4.82

HO
135.890
139.571
125.153
125.153
153.988
135.95
11.95

12 month
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
% 1mo wt
Avg%
StDev

wt
127.914
146.933
84.969
91.411
84.663
107.18
28.54

HO
159.202
142.025
144.479
154.908
-150.15
8.22
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APPENDIX C
LIST OF ABBREVIATIONS

A
1o, primary
2o, secondary
A=εlc, Beer-Lambert law; A, absorbance; ε, extinction coefficient or molar absorptivity; l, light
path length; c concentration
AAALAC, Association for Assessment and Accreditation of Laboratory Animal Care
AATM, aspartate aminotransferase, mitochondrial
Aβ, amyloid-β peptide
ABB, Annexin binding buffer
AC buffer, antigen coating buffer
Acetyl CoA, acetyl coenzyme A
AD, Alzheimer disease
ADP, adenosine diphosphate
AIF, apoptosis inducing factor
Akt, a serine/threonine protein kinase (a.k.a., protein kinase B)
ALP, alkaline phosphatase enzyme
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subtype
ANOVA, analysis of the variants
ANT, adenine nucleotide translocase
AOX, antioxidant
Apaf-1, apoptosis protease activating factor-1
APOE, apolipoprotein E
APP, amyloid precursor protein
sAPPβ, a 593 amino acid soluble amyloid precursor protein (sAPP), carboxy (C)-terminal, βsecretase cleavage product, corresponding to amino acids 1 to 593 of APP
APPNLh /APPNLh x PS-1P264L/PS-1P264L mice, amyloid precursor protein (APP) gene carrying a
humanized mouse amyloid-β (Aβ) peptide sequence (NLh), and a presenilin-1 (PS-1)
gene carrying a proline to leucine mutation on codon 264 (P264L).
APP/PS-1 mice, APPNLh /APPNLh x PS-1P264L/PS-1P264L human double mutant knock-in mice
APPSw,In, amyloid precursor protein with Swedish and Indiana mutations
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ATP, adenosine triphosphate
AV, Annexin V

B
BAPTA AM, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA)
acetoxymethyl (AM) ester
Bax, B-cell lymphoma-2 associated X protein
BBB, blood-brain barrier
BCA, Bicinchoninic acid
BCIP, 5-bromo-4-chloro-3-indolyl phosphate dipotassium
Bcl-2, B-cell lymphoma-2 protein
BSA, bovine serum albumin

C
C31, a 31 amino acid amyloid precursor protein (APP) carboxy (C)-terminal cleavage product
corresponding to amino acids 665 to 696 - the last, most C-terminal amino acid of APP
[Ca2+]i, intracellular calcium ion concentration
CA-2, carbonic anhydrase 2
Ca2+ATPase, calcium adenosine triphosphate (ATP) transporting enzyme
CA region, cornu ammonis cell region of brain
Caspase/Cas, aspartate-specific cysteine protease
CD45/64, cluster of differentiation antigens
C. elegans, Caenorhabditis elegans
ChAT, choline acetyltransferase enzyme
CK, creatine kinase
CNS, central nervous system
Complex I, nicotinamide adenine dinucleotide (NADH)-ubiquinone (Q) oxidoreductase
Complex II, succinate-ubiquinone (Q) reductase
Complex III, ubiquinone (Q)-cytochrome c oxidoreductase
Complex IV, cytochrome c oxidase
Complex V, adenosine triphosphate (ATP) synthase
COPD, chronic obstructive pulmonary disease
CoQ10, coenzyme Q10
COX, cyclooxygenase
CREB, cyclic adenosine monophosphate (cAMP)-responsive element binding-protein
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Cu/ZnSOD, copper/zinc superoxide dismutase
CytC, cytochrome c
CypD, cyclophilin D

D
D1-5, dopamine receptors 1-5
DAG, diacyl glycerol
DEA, diethylamine
DHAP, dihydroxyacetone phosphate
DHLA, dihydrolipoic acid
DNA, deoxyribonucleic acid
DNP, 2,4-dinitrophenylhydrazone
DNPH, 2,4-dinitrophenylhydrazine
1D-/2D-PAGE, 1-/2-dimensional-polyacrylamide gel electrophoresis
Drp-2, dihydropyrimidinase protein 2
DTT, dithiothreitol

E
e-, electron
EDTA, ethylenediamine tetraacetic acid
EGTA, ethyleneglycol tetraacetic acid
ELISA, enzyme-linked immunosorbant assay
EndoG, endoprotease G
EPSPs, excitatory post-synaptic potentials
ER, endoplasmic reticulum
ERK 1/2, extracellular signal-regulated kinase 1/2
ESI, electrospray ionization
ETC, electron transport chain
Ex/Em or λex/em, excitation/emission

F
FA, formic acid
FAD, familial Alzheimer disease
FADD, Fas-associated death domain-containing protein
FADH2/FAD, flavin adenine dinucleotide
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FAEE, ferulic acid ethyl ester
FBA-C, fructose bisphosphate aldolase C
FITC, fluorescein isothiocyanate
FT, Fourier transform

G
G-6-P DH, glucose-6-phosphate dehydrogenase
GABA, γ-aminobutyric acid
GAP, glyceraldehyde-3-phosphate
GAPDH, glyceraldehyde-3-phosphate dehydrogenase
sGC, soluble guanylate cyclase
GCEE, γ-glutamylcysteine ethyl ester
GCL, γ-glutamylcysteine ligase
GDP, guanosine diphosphate
GFAP, glial fibrillary acidic protein
cGMP, cyclic guanosine monophosphate
β2GPI, β2 glycoprotein I
GPx, glutathione peroxidase
GSH, glutathione (reduced)
GSSG, glutathione (oxidized)
GST μ1, glutathione-S-transferase μ1
GTP, guanosine triphosphate
GTPase, guanosine triphosphate (GTP) utlizing enzyme

H
H1-3, histamine receptors 1-3
5-HTs, 5-hydroxytryptamine receptor subtypes
HCD, high-energy C-trap dissociation
HCNP, hippocampal neurostimulating peptide
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HK, hexokinase
HLA-DR, human leukocyte antigen-D related
HNE, 4-hydroxy-2-trans-nonenal
HO-1, heme oxygenase-1
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HRP, horseradish peroxidase enzyme
HSP90 B1, heat shock protein 90 B1

I
IA, iodoacetamide
IACUC, Institutional Animal Care and Use Committee
IAP, inhibitor of apoptosis protein
Iba-1, ionized Ca2+ binding-protein-1
IEF, isoelectric focusing
IgG, immunoglobulin G
In, Indiana mutation
V717F, Indiana mutation; valine to phenylalanine substitution on codon 717 of the
human amyloid precursor (APP) minigene.
IP3, inositol trisphosphate
IPG, immobilized pH gradient
IPI, International Protein Index
IPL, inferior parietal lobule
IPSPs, inhibitory post-synaptic potentials

J
Jcasp, short, cytoplasmic domain of the amyloid precursor protein (APP) corresponding to the
16 amino acids most proximal to the membrane, amino acids 649 to 664 of APP695;
generated by ε-secretase cleavage of APP at position 664

K
KD, dissociation constant

L
LA, α-lipoic acid
LOX-1, lectin-like oxidized low-density lipoprotein receptor-1

M
aMCI, amnestic mild cognitive impairment
MDH, malate dehydrogenase
MES, 2-(N-morpholino)ethanesulfonic acid
Mg2+ATPase, magnesium adenosine triphosphate (ATP) utilizing enzyme
MHC, major histocompatibility complex
MMP, mitochondrial membrane permeability
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MMSE, Mini-Mental State Examination
MNDA, methyl-D-aspartate receptor subtypes
MnSOD, manganese superoxide dismutase
MPTP, mitochondrial permeability transition pore
mRNA, messenger ribonucleic acid
MRP-1, multidrug resistance protein-1
MS, mass spectrometer/spectrometry
MW, molecular weight
MWM, molecular weight marker

N
n, sample number
NAC, N-acetyl-L-cysteine
NADH DH, nicotinamide adenine dinucleotide (NADH) dehydrogenase
NADH/NAD+, nicotinamide adenine dinucleotide
NADPH/NADP+, nicotinamide adenine dinucleotide phosphate
Na+/K+ATPase, sodium/potassium adenosine triphosphate (ATP) exchanging enzyme
NBD-PS, 1-palmitoyl-2-[6(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl-sn-glycero-3phosphoserine
NBT, Nitrotetrazolium Blue chloride
NCI, severely aged, but cognitively normal
ND, not determined
NFTs, neurofibrillary tangles
NINCDS-ARDA, National Institute of Neurological and Communicative Disorders and Stroke
and the Alzheimer Disease and Related Disorders Association (also now known as the
Alzheimer Association)
NMDA/NMDAR, N-methyl-D-aspartate receptor subtype
NMR, nuclear magnetic resonance
Non Tg/NTg, non-transgenic
eNOS, endothelial nitric oxide synthase
iNOS, inducible nitric oxide synthase
nNOS, neuronal nitric oxide synthase
Nrf2, NF-E2-related factor-2
3-NT, 3-nitrotyrosine
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O
Omi/HtrA2, Omi stress-regulated endoprotease/high temperature requirement protein A2

P
p, the probability of an incorrect identification associated with each protein identification using
the SEQUEST search alogorithm
P1, pellet 1
P2, pellet 2
p12, 18 kDa active caspase-3
p18, 20 kDa active caspase-3
PBR, peripheral-type benzodiazepine receptor
PBS, phosphate-buffered saline
PCO, protein carbonyls
PDAPP, platelet-derived growth factor (PDGF)-amyloid precursor protein (APP) transgene
PDGF, platelet-derived growth factor
PEBP-1, phosphatidylethanolamine-binding protein 1
PEP, phosphoenolpyruvate
PET, positron emission tomography
PFK, phosphofructokinase
PGA mutase, phosphoglycerate mutase
6-PG DH, 6-phosphogluconate dehydrogenase
PGI, phosphoglucose isomerase
PGM 1, phosphoglycerate mutase 1
pH, hydrogen ion concentration
Pi, inorganic phosphate
pI, isoelectric point
Pin-1, peptidyl-prolyl cis-trans isomerase
PIP2, phosphoinositil-4,5-bisphosphate
pKa, -log10 of the acid dissociation constant (Ka)
PKG, protein kinase G
PK M1/M2, pyruvate kinase mitochondrial 1/2
PLA2, phospholipase A2
PMI, post-mortem interval
PMSF, phenylmethanesulfonyl fluoride
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PP2B, protein phosphatase 2B (i.e., calcineurin, subunit B, Type 1)
PPP, pentose phosphate pathway
PPIases, peptidyl-prolyl isomoerases
PPS, pentose phosphate shunt
PRX-1/-2, peroxiredoxin-1/-2
PS-1/-2, presenilin-1/-2
PSR, phosphatidylserine receptor
PtdEtn, phosphatidylethanolamine
PtdIns, phosphatidylinositol
PtdOH, phosphatidic acid
PtdSer, phosphatidylserine
PUFAs, polyunsaturated fatty acids
PVDF, polyvinylidene difluoride

Q
Q, coenzyme Q/ubiquinone
.

QH , semiquinone
QH2, ubiquinol

R
RBS, reactive bromine species
RCSB protein data bank, Research Collaboratory for Structural Bioinformatics (RCSB) protein
data bank is a repository for the 3D-structural data of large biological molecules
RCS, reactive chlorine species
RIA buffer, radioimmunoassay buffer
RIP, Raf-kinase inhibitor protein
RNS, reactive nitrogen species
ROS, reactive oxygen species
Roto-Vap, rotary evaporator
RT, room temperature

S
S1, supernatant 1
S2, supernatant 2
SC, spectral counts
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S.D., standard deviation
SDS, sodium dodecyl sulfate
S.E.M., standard error of the means
SEQUEST, a tandem mass spectrometry data analysis program used for protein identification
Smac/DIABLO, second mitochondria-derived activator of caspases (Smac)/direct inhibitor of
apoptosis (IAP) binding protein with low pI (DIABLO)
SPs, senile plaques
Sw, Swedish mutation
K670N and M671L, Swedish mutations; lysine to asparagine substitution on codon 670
(K670N) and methionine to leucine mutations on codon 671 (M671L) of human amyloid
precursor (APP) minigene.
Swiss-PDB viewer, Swiss-Protein Data Bank viewer (a.k.a., DeepView) is an application that
provides an interface allowing to visualize and analyze proteins in 3D.

T
TBST, Tris base-sodium chloride-Tween-20 buffer
TCA, trichloroacetic acid
TCA cycle, tricarboxylic acid cycle
TCP-1αA, T-complex protein 1, subunit α A
Tg, transgenic
Tg PDAPP(D664A), platelet-derived growth factor (PDGF)-amyloid precursor protein (APP)
transgenic (Tg) mice carrying the Swedish and Indiana mutations on APP (APPSw,In)
along with an additional aspartate to alanine substitution on codon 664 of APP
Tg PDAPP(J20), platelet-derived growth factor (PDGF)-amyloid precursor protein (APP)
transgenic (Tg) mice carrying the Swedish and Indiana mutations on APP (APPSw,In), line
J20
Tg PDAPP(M631L), platelet-derived growth factor (PDGF)-amyloid precursor protein (APP)
transgenic (Tg) mice carrying the Swedish and Indiana mutations on APP (APPSw,In)
along with an additional methionine to leucine substitution on codon 631 of APP
TGS, Tris/Glycine/Sodium dodecyl sulfate
TMB, tetramethylbenzidine
TNF, tumor necrosis factor
TNFR1, tumor necrosis factor (TNF) receptor 1
TP buffer, Tris-phosphate buffer
TPI, triose phosphate isomerase
TPPP, tubulin polymerization-promoting protein
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U
UK ADC, University of Kentucky Rapid Autopsy Program of the Alzheimer Disease Clinical
Center
UV, ultraviolet

V
VDAC-1, voltage-dependent anion channel-1

W
WT, wild-type

X-Z
XT, extended time

List of Amino Acids
Ala/A, alanine
Arg/R, arginine
Asn/N, asparagine
Asp/D, aspartate/aspartic acid
Cys/C, cysteine
Gln/Q, glutamine
Glu/E, glutamate/glutamic acid
Gly/G, glycine
His/H, histidine
Ile/I, isoleucine
Leu/L, leucine
Lys/K, lysine
Met/M, methionine
Nle, norleucine
Phe/F, phenylalanine
Pro/P, proline
Ser/S, serine
pSer, phosphorylated serine
Thr/T, threonine
pThr, phosphorylated threonine
Trp/W, tryptophan
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Tyr/Y, tyrosine
Val/V, valine

Units of Measure
Concentration:
M, molar
μM, micromolar
mM, millimolar
pM, picomolar
v/v, volume per volume
w/v, weight per volume
Mass/Volume:
g, grams
kDa, kilodaltons
μg, micrograms
mg, milligrams
μl, microliters
ml, milliliters
mol, moles
ng, nanograms
pmol, picomoles
Time:
h/hr, hours
min, minutes
ms, milliseconds
s, seconds
Length/Distance:
cm, centimeters
μm, micrometers
nm, nanometers
Speed:
rpm, revolutions per minute
x g, times gravity
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Temperature:
o

C, degrees Celcius

K, degrees Kelvin
Power:
C, coulombs
F, faradays (C/mol)
J, joules
mV, millivolts
V, volts
W, watts

Chemical Formulas
CaCl2, calcium chloride
C-/COOH-, carboxy-group
-CH2, methyl group
CO2, carbon dioxide
.

CO3 -, carbonate/carbonic acid
H-, hydrogen-atom
HCl, hydrochloric acid
HCO3-, bicarbonate ion
H2O, water
H3O+, hydronium
H2O2, hydrogen peroxide
HPO3, phosphoric acid
H2SO4, sulfuric acid
KCl, potassium chloride
.

L , lipid radical
.

LOO , lipid peroxyl radical
LOOH, lipid hydroperoxide
MgCl2, magnesium chloride
NaBH4, sodium borohydride
NaCl, sodium chloride
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NaHCO3, sodium bicarbonate
Na2HPO4, sodium phosphate
NaN3, sodium azide
Na2S2O4/S2O42-, sodium dithionite/dithionite ion
NH4HCO3, ammonium bicarbonate
(NH4)6Mo7O24 ∙ 4 H2O, ammonium molybdate
N-/NH2-, amino-group
.

NO , nitric oxide radical
.

NO2 , nitrogen dioxide
N2O3, nitrogen trioxide
.

R , alkyl radical
R1/R2, hydrocarbon chains of ambiguous length
ROOH, alkyl hydroperoxide
.

O2 -, superoxide anion
.

OH, hydroxyl radical

OH-, hydroxide ion
ONOO-, peroxynitrite
ONOOCOO-, nitrosoperoxycarbonate
S-, sulfur-atom
.

X , ambiguous molecule/atom radical

276

REFERENCES
Abdul, H. M., Sultana, R., St Clair, D. K., Markesbery, W. R., Butterfield, D. A., 2008.
Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a
function of age. Free Radic. Biol. Med. 45, 1420-5.
Abdul, H. M., Sama, M. A., Furman, J. L., Mathis, D. M., Beckett, T. L., Weidner, A. M., Patel,
E. S., Baig, I., Murphy, M. P., LeVine, H., 3rd, Kraner, S. D., Norris, C. M., 2009.
Cognitive decline in Alzheimer's disease is associated with selective changes in
calcineurin/NFAT signaling. J. Neurosci. 29, 12957-69.
Adam-Vizi, V., 2005. Production of reactive oxygen species in brain mitochondria: Contribution
by electron transport chain and non-electron transport chain sources. Antioxid. Redox
Signal. 7, 1140-9.
Agostinho, P., Lopes, J. P., Velez, Z., Oliveira, C. R., 2008. Overactivation of calcineurin
induced by amyloid- and prion proteins. Neurochem. Int. 52, 1226-33.
Agus, D. B., Gambhir, S. S., Pardridge, W. M., Spielholz, C., Baselga, J., Vera, J. C., Golde, D.
W., 1997. Vitamin C crosses the blood-brain barrier in the oxidized form through the
glucose transporters. J. Clin. Invest. 100, 2842-8.
Aitken, A., Klee, C. B., Cohen, P., 1984. The structure of the B subunit of calcineurin. Eur. J.
Biochem. 139, 663-71.
Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., Geddes, J. W., Markesbery, W. R., 2001.
Protein oxidation in the brain in Alzheimer's disease. Neuroscience. 103, 373-83.
Albrecht, S., Bourdeau, M., Bennett, D., Mufson, E. J., Bhattacharjee, M., LeBlanc, A. C., 2007.
Activation of caspase-6 in aging and mild cognitive impairment. Am. J. Pathol. 170,
1200-9.
Aluise, C. D., St Clair, D., Vore, M., Butterfield, D. A., 2009. In vivo amelioration of
adriamycin-induced oxidative stress in plasma by -glutamylcysteine ethyl ester (GCEE).
Cancer Lett. 282, 25-9.
Alvarez, B., Radi, R., 2003. Peroxynitrite reactivity with amino acids and proteins. Amino
Acids. 25, 295-311.
Alvarez, B., Demicheli, V., Duran, R., Trujillo, M., Cervenansky, C., Freeman, B. A., Radi, R.,
2004. Inactivation of human Cu,Zn superoxide dismutase by peroxynitrite and formation
of histidinyl radical. Free Radic. Biol. Med. 37, 813-22.
Anantharaman, M., Tangpong, J., Keller, J. N., Murphy, M. P., Markesbery, W. R., Kiningham,
K. K., St Clair, D. K., 2006. -Amyloid mediated nitration of manganese superoxide
dismutase: Implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double
knock-in mouse model of Alzheimer's disease. Am. J. Pathol. 168, 1608-18.
Anderson, M. E., Meister, A., 1983. Transport and direct utilization of -glutamylcyst(e)ine for
glutathione synthesis. Proc. Natl. Acad. Sci. U. S. A. 80, 707-11.
Ansari, M. A., Joshi, G., Huang, Q., Opii, W. O., Abdul, H. M., Sultana, R., Butterfield, D. A.,
2006. In vivo administration of D609 leads to protection of subsequently isolated gerbil
brain mitochondria subjected to in vitro oxidative stress induced by amyloid -peptide
and other oxidative stressors: Relevance to Alzheimer's disease and other oxidative
stress-related neurodegenerative disorders. Free Radic. Biol. Med. 41, 1694-703.

277

Anzai, K., Yoshioka, Y., Kirino, Y., 1993. Novel radioactive phospholipid probes as a tool for
measurement of phospholipid translocation across biomembranes. Biochim. Biophys.
Acta. 1151, 69-75.
Arispe, N., Doh, M., 2002. Plasma membrane cholesterol controls the cytotoxicity of
Alzheimer's disease AP(1-40) and (1-42) peptides. FASEB J. 16, 1526-36.
Arivazhagan, P., Ramanathan, K., Panneerselvam, C., 2001. Effect of DL--lipoic acid on
glutathione metabolic enzymes in aged rats. Exp. Gerontol. 37, 81-7.
Aruoma, O. I., Kaur, H., Halliwell, B., 1991. Oxygen free radicals and human diseases. J. R.
Soc. Health. 111, 172-7.
Arur, S., Uche, U. E., Rezaul, K., Fong, M., Scranton, V., Cowan, A. E., Mohler, W., Han, D.
K., 2003. Annexin I is an endogenous ligand that mediates apoptotic cell engulfment.
Dev. Cell. 4, 587-98.
Auland, M. E., Roufogalis, B. D., Devaux, P. F., Zachowski, A., 1994. Reconstitution of ATPdependent aminophospholipid translocation in proteoliposomes. Proc. Natl. Acad. Sci.
U. S. A. 91, 10938-42.
Balasubramanian, K., Schroit, A. J., 2003. Aminophospholipid asymmetry: A matter of life and
death. Annu. Rev. Physiol. 65, 701-34.
Balasubramanian, K., Chandra, J., Schroit, A. J., 1997. Immune clearance of phosphatidylserineexpressing cells by phagocytes. The role of 2-glycoprotein I in macrophage recognition.
J. Biol. Chem. 272, 31113-7.
Balazy, M., Nigam, S., 2003. Aging, lipid modifications and phospholipases -- New concepts.
Ageing Res. Rev. 2, 191-209.
Barnes, J., Godbolt, A. K., Frost, C., Boyes, R. G., Jones, B. F., Scahill, R. I., Rossor, M. N.,
Fox, N. C., 2007. Atrophy rates of the cingulate gyrus and hippocampus in AD and
FTLD. Neurobiol. Aging. 28, 20-8.
Baumeister, R., Leimer, U., Zweckbronner, I., Jakubek, C., Grunberg, J., Haass, C., 1997.
Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate
Caenorhabditis elegans Notch signalling independently of proteolytic processing. Genes
Funct. 1, 149-59.
Beach, T. G., Walker, R., McGeer, E. G., 1989. Patterns of gliosis in Alzheimer's disease and
aging cerebrum. Glia. 2, 420-36.
Beleznay, Z., Zachowski, A., Devaux, P. F., Navazo, M. P., Ott, P., 1993. ATP-dependent
aminophospholipid translocation in erythrocyte vesicles: Stoichiometry of transport.
Biochemistry. 32, 3146-52.
Berg, J. M., Tymoczko, J. L., Stryer, L. (Eds.), 2007. Biochemistry. W. H. Freeman & Co., New
York, NY.
Berman, D. E., Dall'Armi, C., Voronov, S. V., McIntire, L. B., Zhang, H., Moore, A. Z.,
Staniszewski, A., Arancio, O., Kim, T. W., Di Paolo, G., 2008. Oligomeric amyloid-
peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. Nat. Neurosci. 11,
547-54.
Bickford, P. C., Gould, T., Briederick, L., Chadman, K., Pollock, A., Young, D., Shukitt-Hale,
B., Joseph, J., 2000. Antioxidant-rich diets improve cerebellar physiology and motor
learning in aged rats. Brain Res. 866, 211-7.
Biewenga, G. P., Haenen, G. R., Bast, A., 1997. The pharmacology of the antioxidant lipoic acid.
Gen. Pharmacol. 29, 315-31.

278

Binder, L. I., Frankfurter, A., Rebhun, L. I., 1985. The distribution of tau in the mammalian
central nervous system. J. Cell Biol. 101, 1371-8.
Bitan, G., Tarus, B., Vollers, S. S., Lashuel, H. A., Condron, M. M., Straub, J. E., Teplow, D. B.,
2003. A molecular switch in amyloid assembly: Met-35 and amyloid -protein
oligomerization. J. Am. Chem. Soc. 125, 15359-65.
Bitbol, M., Fellmann, P., Zachowski, A., Devaux, P. F., 1987. Ion regulation of
phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human
erythrocytes. Biochim. Biophys. Acta. 904, 268-82.
Blass, J. P., Gibson, G. E., Hoyer, S., 2002. The role of the metabolic lesion in Alzheimer's
disease. J. Alzheimers Dis. 4, 225-32.
Blumenfeld, H. (Ed.) 2002. Neuroanatomy through clinical cases. Sinauer Assocites, Inc.,
Sunderland, MA.
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland,
N. G., Price, D. L., Sisodia, S. S., 1997. Accelerated amyloid deposition in the brains of
transgenic mice coexpressing mutant presenilin-1 and amyloid precursor proteins.
Neuron. 19, 939-45.
Bose-Basu, B., DeRose, E. F., Kirby, T. W., Mueller, G. A., Beard, W. A., Wilson, S. H.,
London, R. E., 2004. Dynamic characterization of a DNA repair enzyme: NMR studies of
[methyl-13C]methionine-labeled DNA polymerase . Biochemistry. 43, 8911-22.
Boyd-Kimball, D., Sultana, R., Mohmmad-Abdul, H., Butterfield, D. A., 2005a. Neurotoxicity
and oxidative stress in D1M-substituted Alzheimer's A(1-42): Relevance to N-terminal
methionine chemistry in small model peptides. Peptides. 26, 665-73.
Boyd-Kimball, D., Mohmmad Abdul, H., Reed, T., Sultana, R., Butterfield, D. A., 2004. Role of
phenylalanine 20 in Alzheimer's amyloid -peptide (1-42)-induced oxidative stress and
neurotoxicity. Chem. Res. Toxicol. 17, 1743-9.
Boyd-Kimball, D., Sultana, R., Poon, H. F., Lynn, B. C., Casamenti, F., Pepeu, G., Klein, J. B.,
Butterfield, D. A., 2005b. Proteomic identification of proteins specifically oxidized by
intracerebral injection of amyloid -peptide (1-42) into rat brain: Implications for
Alzheimer's disease. Neuroscience. 132, 313-24.
Boyd-Kimball, D., Castegna, A., Sultana, R., Poon, H. F., Petroze, R., Lynn, B. C., Klein, J. B.,
Butterfield, D. A., 2005c. Proteomic identification of proteins oxidized by A(1-42) in
synaptosomes: Implications for Alzheimer's disease. Brain Res. 1044, 206-15.
Boyd-Kimball, D., Poon, H. F., Lynn, B. C., Cai, J., Pierce, W. M., Jr., Klein, J. B., Ferguson, J.,
Link, C. D., Butterfield, D. A., 2006. Proteomic identification of proteins specifically
oxidized in Caenorhabditis elegans expressing human A(1-42): Implications for
Alzheimer's disease. Neurobiol. Aging. 27, 1239-49.
Brandt, R., Lee, G., 1993. Functional organization of microtubule-associated protein tau.
Identification of regions which affect microtubule growth, nucleation, and bundle
formation in vitro. J. Biol. Chem. 268, 3414-9.
Bredt, D. S., 1999. Endogenous nitric oxide synthesis: Biological functions and pathophysiology.
Free Radic. Res. 31, 577-96.
Bredt, D. S., Glatt, C. E., Hwang, P. M., Fotuhi, M., Dawson, T. M., Snyder, S. H., 1991. Nitric
oxide synthase protein and mRNA are discretely localized in neuronal populations of the
mammalian CNS together with NADPH diaphorase. Neuron. 7, 615-24.
Bretscher, M. S., 1972. Asymmetrical lipid bilayer structure for biological membranes. Nat.
New Biol. 236, 11-2.
279

Brion, J. P., Guilleminot, J., Couchie, D., Flament-Durand, J., Nunez, J., 1988. Both adult and
juvenile tau microtubule-associated proteins are axon specific in the developing and adult
rat cerebellum. Neuroscience. 25, 139-46.
Broillet, M. C., 1999. S-Nitrosylation of proteins. Cell. Mol. Life Sci. 55, 1036-42.
Brorson, J. R., Schumacker, P. T., Zhang, H., 1999. Nitric oxide acutely inhibits neuronal energy
production. The Committees on Neurobiology and Cell Physiology. J. Neurosci. 19, 14758.
Brown, C. R., Doxsey, S. J., Hong-Brown, L. Q., Martin, R. L., Welch, W. J., 1996. Molecular
chaperones and the centrosome. A role for TCP-1 in microtubule nucleation. J. Biol.
Chem. 271, 824-32.
Brown, L. A., Harris, F. L., Jones, D. P., 1997. Ascorbate deficiency and oxidative stress in the
alveolar type II cell. Am. J. Physiol. 273, L782-8.
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., Gibson, G. E., 2005. Mitochondrial
abnormalities in Alzheimer brain: Mechanistic implications. Ann. Neurol. 57, 695-703.
Burcham, P. C., 1998. Genotoxic lipid peroxidation products: Their DNA damaging properties
and role in formation of endogenous DNA adducts. Mutagenesis. 13, 287-305.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J.,
Cotman, C., Glabe, C., 1992. Assembly and aggregation properties of synthetic
Alzheimer's A4/amyloid peptide analogs. J. Biol. Chem. 267, 546-54.
Bush, A. I., Pettingell, W. H., Multhaup, G., d Paradis, M., Vonsattel, J. P., Gusella, J. F.,
Beyreuther, K., Masters, C. L., Tanzi, R. E., 1994. Rapid induction of Alzheimer A
amyloid formation by zinc. Science. 265, 1464-7.
Butterfield, D., Castegna, A., Pocernich, C., Drake, J., Scapagnini, G., Calabrese, V., 2002a.
Nutritional approaches to combat oxidative stress in Alzheimer's disease. J. Nutr.
Biochem. 13, 444.
Butterfield, D. A., 1997. -Amyloid-associated free radical oxidative stress and neurotoxicity:
Implications for Alzheimer's disease. Chem. Res. Toxicol. 10, 495-506.
Butterfield, D. A., 2002. Amyloid -peptide (1-42)-induced oxidative stress and neurotoxicity:
Implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic.
Res. 36, 1307-13.
Butterfield, D. A., Stadtman, E. R., 1997. Protein oxidation processes in aging brain. Adv. Cell
Aging Gerontol. 2, 161-191.
Butterfield, D. A., Lauderback, C. M., 2002. Lipid peroxidation and protein oxidation in
Alzheimer's disease brain: Potential causes and consequences involving amyloid peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32, 1050-60.
Butterfield, D. A., Kanski, J., 2002. Methionine residue 35 is critical for the oxidative stress and
neurotoxic properties of Alzheimer's amyloid -peptide (1-42). Peptides. 23, 1299-309.
Butterfield, D. A., Boyd-Kimball, D., 2004. Amyloid -peptide (1-42) contributes to the
oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol.
14, 426-32.
Butterfield, D. A., Bush, A. I., 2004. Alzheimer's amyloid -peptide (1-42): Involvement of
methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide.
Neurobiol. Aging. 25, 563-8.
Butterfield, D. A., Boyd-Kimball, D., 2005. The critical role of methionine 35 in Alzheimer's
amyloid -peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim. Biophys.
Acta. 1703, 149-56.
280

Butterfield, D. A., Sultana, R., 2008. Identification of 3-nitrotyrosine-modified brain proteins by
redox proteomics. Methods Enzymol. 440, 295-308.
Butterfield, D. A., Perluigi, M., Sultana, R., 2006a. Oxidative stress in Alzheimer's disease brain:
New insights from redox proteomics. Eur. J. Pharmacol. 545, 39-50.
Butterfield, D. A., Jicha, G., Sultana, R., 2010. Brain oxidative stress in the pathogenesis and
progression of Alzheimer disease. Lancet. Manuscript in Preparation.
Butterfield, D. A., Castegna, A., Lauderback, C. M., Drake, J., 2002b. Evidence that amyloid peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain
contribute to neuronal death. Neurobiol. Aging. 23, 655-64.
Butterfield, D. A., Reed, T., Newman, S. F., Sultana, R., 2007a. Roles of amyloid -peptideassociated oxidative stress and brain protein modifications in the pathogenesis of
Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43, 658-77.
Butterfield, D. A., Poon, H. F., St Clair, D., Keller, J. N., Pierce, W. M., Klein, J. B.,
Markesbery, W. R., 2006b. Redox proteomics identification of oxidatively modified
hippocampal proteins in mild cognitive impairment: Insights into the development of
Alzheimer's disease. Neurobiol. Dis. 22, 223-32.
Butterfield, D. A., Reed, T., Perluigi, M., De Marco, C., Coccia, R., Cini, C., Sultana, R., 2006c.
Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in
brain from persons with mild cognitive impairment. Neurosci. Lett. 397, 170-3.
Butterfield, D. A., Abdul, H. M., Opii, W., Newman, S. F., Joshi, G., Ansari, M. A., Sultana, R.,
2006d. Pin-1 in Alzheimer's disease. J. Neurochem. 98, 1697-706.
Butterfield, D. A., Reed, T. T., Perluigi, M., De Marco, C., Coccia, R., Keller, J. N., Markesbery,
W. R., Sultana, R., 2007b. Elevated levels of 3-nitrotyrosine in brain from subjects with
amnestic mild cognitive impairment: Implications for the role of nitration in the
progression of Alzheimer's disease. Brain Res. 1148, 243-8.
Byun, J., Mueller, D. M., Fabjan, J. S., Heinecke, J. W., 1999. Nitrogen dioxide radical
generated by the myeloperoxidase-hydrogen peroxide-nitrite system promotes lipid
peroxidation of low density lipoprotein. FEBS Lett. 455, 243-6.
Cabiscol, E., Piulats, E., Echave, P., Herrero, E., Ros, J., 2000. Oxidative stress promotes
specific protein damage in Saccharomyces cerevisiae. J. Biol. Chem. 275, 27393-8.
Caceres, A., Kosik, K. S., 1990. Inhibition of neurite polarity by tau antisense oligonucleotides in
primary cerebellar neurons. Nature. 343, 461-3.
Caceres, A., Potrebic, S., Kosik, K. S., 1991. The effect of tau antisense oligonucleotides on
neurite formation of cultured cerebellar macroneurons. J. Neurosci. 11, 1515-23.
Cai, X. D., Golde, T. E., Younkin, S. G., 1993. Release of excess amyloid- protein from a
mutant amyloid- protein precursor. Science. 259, 514-6.
Calabrese, V., Butterfield, D. A., Scapagnini, G., Stella, A. M., Maines, M. D., 2006. Redox
regulation of heat shock protein expression by signaling involving nitric oxide and carbon
monoxide: Relevance to brain aging, neurodegenerative disorders, and longevity.
Antioxid. Redox Signal. 8, 444-77.
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., Stella, A. M., 2007a.
Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity. Nat.
Rev. Neurosci. 8, 766-75.
Calabrese, V., Mancuso, C., Sapienza, M., Puleo, E., Calafato, S., Cornelius, C., Finocchiaro,
M., Mangiameli, A., Di Mauro, M., Stella, A. M., Castellino, P., 2007b. Oxidative stress

281

and cellular stress response in diabetic nephropathy. Cell Stress Chaperones. 12, 299306.
Carlson, N. R. (Ed.) 2008. Foundations of physiological psychology. Allyn & Bacon, Boston,
MA.
Casserly, I., Topol, E., 2004. Convergence of atherosclerosis and Alzheimer's disease:
Inflammation, cholesterol, and misfolded proteins. Lancet. 363, 1139-46.
Castegna, A., Lauderback, C. M., Mohmmad-Abdul, H., Butterfield, D. A., 2004. Modulation of
phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products,
4-hydroxynonenal and acrolein: Implications for Alzheimer's disease. Brain Res. 1004,
193-7.
Castegna, A., Thongboonkerd, V., Klein, J. B., Lynn, B., Markesbery, W. R., Butterfield, D. A.,
2003. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J.
Neurochem. 85, 1394-401.
Castegna, A., Aksenov, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R.,
Markesbery, W. R., Butterfield, D. A., 2002a. Proteomic identification of oxidatively
modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinase-related
protein 2, -enolase, and heat shock cognate 71. J. Neurochem. 82, 1524-32.
Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M.,
Booze, R., Markesbery, W. R., Butterfield, D. A., 2002b. Proteomic identification of
oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB,
glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol.
Med. 33, 562-71.
Castren, E., Ohga, Y., Berzaghi, M. P., Tzimagiorgis, G., Thoenen, H., Lindholm, D., 1994. Bcl2 messenger RNA is localized in neurons of the developing and adult rat brain.
Neuroscience. 61, 165-77.
Celsi, F., Svedberg, M., Unger, C., Cotman, C. W., Carri, M. T., Ottersen, O. P., Nordberg, A.,
Torp, R., 2007. -Amyloid causes downregulation of calcineurin in neurons through
induction of oxidative stress. Neurobiol. Dis. 26, 342-52.
Chalbot, S., Zetterberg, H., Blennow, K., Fladby, T., Grundke-Iqbal, I., Iqbal, K., 2009.
Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in
Alzheimer disease. Clin. Chem. 55, 2171-9.
Chan, A. C., 1993. Partners in defense, vitamin E and vitamin C. Can. J. Physiol. Pharmacol.
71, 725-31.
Chandra, R. K., 2001. Effect of vitamin and trace-element supplementation on cognitive function
in elderly subjects. Nutrition. 17, 709-12.
Chao, C. C., Ma, Y. S., Stadtman, E. R., 1997. Modification of protein surface hydrophobicity
and methionine oxidation by oxidative systems. Proc. Natl. Acad. Sci. U. S. A. 94,
2969-74.
Chatterjee, I. B., Majumder, A. K., Nandi, B. K., Subramanian, N., 1975. Synthesis and some
major functions of vitamin C in animals. Ann. N. Y. Acad. Sci. 258, 24-47.
Chen, Q., Wang, S., Thompson, S. N., Hall, E. D., Guttmann, R. P., 2006. Identification and
characterization of PEBP as a calpain substrate. J. Neurochem. 99, 1133-41.
Chen, X., Sullivan, D. S., Huffaker, T. C., 1994. Two yeast genes with similarity to TCP-1 are
required for microtubule and actin function in vivo. Proc. Natl. Acad. Sci. U. S. A. 91,
9111-5.

282

Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A.,
Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y., Huang, X., Goldstein, L. E., Moir,
R. D., Lim, J. T., Beyreuther, K., Zheng, H., Tanzi, R. E., Masters, C. L., Bush, A. I.,
2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits -amyloid
accumulation in Alzheimer's disease transgenic mice. Neuron. 30, 665-76.
Choi, J., Rees, H. D., Weintraub, S. T., Levey, A. I., Chin, L. S., Li, L., 2005. Oxidative
modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer
and Parkinson diseases. J. Biol. Chem. 280, 11648-55.
Chrestensen, C. A., Starke, D. W., Mieyal, J. J., 2000. Acute cadmium exposure inactivates
thioltransferase (Glutaredoxin), inhibits intracellular reduction of protein-glutathionylmixed disulfides, and initiates apoptosis. J. Biol. Chem. 275, 26556-65.
Christie, L. A., Opii, W. O., Head, E., Araujo, J. A., de Rivera, C., Milgram, N. W., Cotman, C.
W., 2009. Short-term supplementation with acetyl-L-carnitine and lipoic acid alters
plasma protein carbonyl levels but does not improve cognition in aged beagles. Exp.
Gerontol. 44, 752-9.
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey,
C., Lieberburg, I., Selkoe, D. J., 1992. Mutation of the -amyloid precursor protein in
familial Alzheimer's disease increases -protein production. Nature. 360, 672-4.
Clementi, M. E., Pezzotti, M., Orsini, F., Sampaolese, B., Mezzogori, D., Grassi, C., Giardina,
B., Misiti, F., 2006. Alzheimer's amyloid -peptide (1-42) induces cell death in human
neuroblastoma via Bax/Bcl-2 ratio increase: An intriguing role for methionine 35.
Biochem. Biophys. Res. Commun. 342, 206-13.
Cleveland, D. W., Hwo, S. Y., Kirschner, M. W., 1977. Physical and chemical properties of
purified tau factor and the role of tau in microtubule assembly. J. Mol. Biol. 116, 227-47.
Colasanti, M., Persichini, T., Fabrizi, C., Cavalieri, E., Venturini, G., Ascenzi, P., Lauro, G. M.,
Suzuki, H., 1998. Expression of a NOS-III-like protein in human astroglial cell culture.
Biochem. Biophys. Res. Commun. 252, 552-5.
Coleman, P. D., Flood, D. G., 1987. Neuron numbers and dendritic extent in normal aging and
Alzheimer's disease. Neurobiol. Aging. 8, 521-45.
Comfurius, P., Williamson, P., Smeets, E. F., Schlegel, R. A., Bevers, E. M., Zwaal, R. F., 1996.
Reconstitution of phospholipid scramblase activity from human blood platelets.
Biochemistry. 35, 7631-4.
Connor, J., Schroit, A. J., 1988. Transbilayer movement of phosphatidylserine in erythrocytes:
Inhibition of transport and preferential labeling of a 31,000-dalton protein by sulfhydryl
reactive reagents. Biochemistry. 27, 848-51.
Connor, J., Schroit, A. J., 1989. Transbilayer movement of phosphatidylserine in nonhuman
erythrocytes: Evidence that the aminophospholipid transporter is a ubiquitous membrane
protein. Biochemistry. 28, 9680-5.
Connor, J., Schroit, A. J., 1990. Aminophospholipid translocation in erythrocytes: Evidence for
the involvement of a specific transporter and an endofacial protein. Biochemistry. 29,
37-43.
Cotman, C. W., Anderson, A. J., 1995. A potential role for apoptosis in neurodegeneration and
Alzheimer's disease. Mol. Neurobiol. 10, 19-45.
Cras, P., Smith, M. A., Richey, P. L., Siedlak, S. L., Mulvihill, P., Perry, G., 1995. Extracellular
neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive
protein cross-linking in Alzheimer disease. Acta Neuropathol. (Berl.). 89, 291-5.
283

Crouch, P. J., Barnham, K. J., Duce, J. A., Blake, R. E., Masters, C. L., Trounce, I. A., 2006.
Copper-dependent inhibition of cytochrome c oxidase by A(1-42) requires reduced
methionine at residue 35 of the A peptide. J. Neurochem. 99, 226-36.
Cruts, M., van Duijn, C. M., Backhovens, H., Van den Broeck, M., Wehnert, A., Serneels, S.,
Sherrington, R., Hutton, M., Hardy, J., St George-Hyslop, P. H., Hofman, A., Van
Broeckhoven, C., 1998. Estimation of the genetic contribution of presenilin-1 and -2
mutations in a population-based study of presenile Alzheimer disease. Hum. Mol. Genet.
7, 43-51.
Dai, X. L., Sun, Y. X., Jiang, Z. F., 2007. Attenuated cytotoxicity but enhanced fibril of a
mutant amyloid -peptide with a methionine to cysteine substitution. FEBS Lett. 581,
1269-74.
Daleke, D. L., 2003. Regulation of transbilayer plasma membrane phospholipid asymmetry. J.
Lipid Res. 44, 233-42.
Daleke, D. L., Huestis, W. H., 1985. Incorporation and translocation of aminophospholipids in
human erythrocytes. Biochemistry. 24, 5406-16.
Daleke, D. L., Huestis, W. H., 1989. Erythrocyte morphology reflects the transbilayer
distribution of incorporated phospholipids. J. Cell Biol. 108, 1375-85.
Daleke, D. L., Lyles, J. V., 2000. Identification and purification of aminophospholipid flippases.
Biochim. Biophys. Acta. 1486, 108-27.
Daleke, D. L., Lyles, J. V., Nemergut, E., Zimmerman, M. L., 1995. Purification and substrate
specificity of the human erythrocyte aminophospholipid transporter. NATO ASI Series
H. 91, 49-59.
Dalle-Donne, I., Rossi, R., Colombo, G., Giustarini, D., Milzani, A., 2009. Protein Sglutathionylation: A regulatory device from bacteria to humans. Trends Biochem. Sci.
34, 85-96.
Dalle-Donne, I., Aldini, G., Carini, M., Colombo, R., Rossi, R., Milzani, A., 2006. Protein
carbonylation, cellular dysfunction, and disease progression. J. Cell. Mol. Med. 10, 389406.
Dalle-Donne, I., Scaloni, A., Giustarini, D., Cavarra, E., Tell, G., Lungarella, G., Colombo, R.,
Rossi, R., Milzani, A., 2005. Proteins as biomarkers of oxidative/nitrosative stress in
diseases: The contribution of redox proteomics. Mass Spectrom. Rev. 24, 55-99.
Das, P., Howard, V., Loosbrock, N., Dickson, D., Murphy, M. P., Golde, T. E., 2003. Amyloid-
immunization effectively reduces amyloid deposition in FcR-/- knock-out mice. J.
Neurosci. 23, 8532-8.
Dawson, T. M., Snyder, S. H., 1994. Gases as biological messengers: Nitric oxide and carbon
monoxide in the brain. J. Neurosci. 14, 5147-59.
De Giorgio, R., Parodi, J. E., Brecha, N. C., Brunicardi, F. C., Becker, J. M., Go, V. L., Sternini,
C., 1994. Nitric oxide producing neurons in the monkey and human digestive system. J.
Comp. Neurol. 342, 619-27.
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E.
H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., Kopan, R., 1999. A presenilin-1dependent -secretase-like protease mediates release of Notch intracellular domain.
Nature. 398, 518-22.
Debatin, K. M., Krammer, P. H., 2004. Death receptors in chemotherapy and cancer. Oncogene.
23, 2950-66.

284

Dedon, P. C., Tannenbaum, S. R., 2004. Reactive nitrogen species in the chemical biology of
inflammation. Arch. Biochem. Biophys. 423, 12-22.
Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., Glabe, C. G., 2005. Calcium
dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble
amyloid oligomers. J. Biol. Chem. 280, 17294-300.
Desiderio, D. M., Nibbering, N. M., Dalle-Donne, I., Scaloni, A., Butterfield, D. A. (Eds.), 2006.
Redox Proteomics: From protein modifications to cellular dysfunction and disease. John
Wiley & Sons, Inc., Hoboken, NJ.
Devanand, D. P., Pradhaban, G., Liu, X., Khandji, A., De Santi, S., Segal, S., Rusinek, H.,
Pelton, G. H., Honig, L. S., Mayeux, R., Stern, Y., Tabert, M. H., de Leon, M. J., 2007.
Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of
Alzheimer disease. Neurology. 68, 828-36.
Devaux, P. F., 2000. Is lipid translocation involved during endo- and exocytosis? Biochimie. 82,
497-509.
Drake, J., Link, C. D., Butterfield, D. A., 2003a. Oxidative stress precedes fibrillar deposition of
Alzheimer's disease amyloid -peptide (1-42) in a transgenic Caenorhabditis elegans
model. Neurobiol. Aging. 24, 415-20.
Drake, J., Kanski, J., Varadarajan, S., Tsoras, M., Butterfield, D. A., 2002. Elevation of brain
glutathione by -glutamylcysteine ethyl ester protects against peroxynitrite-induced
oxidative stress. J. Neurosci. Res. 68, 776-84.
Drake, J., Sultana, R., Aksenova, M., Calabrese, V., Butterfield, D. A., 2003b. Elevation of
mitochondrial glutathione by -glutamylcysteine ethyl ester protects mitochondria against
peroxynitrite-induced oxidative stress. J. Neurosci. Res. 74, 917-27.
Drummond, D. C., Daleke, D. L., 1995. Synthesis and characterization of N-acylated, pHsensitive 'caged' aminophospholipids. Chem. Phys. Lipids. 75, 27-41.
Du, A. T., Schuff, N., Amend, D., Laakso, M. P., Hsu, Y. Y., Jagust, W. J., Yaffe, K., Kramer, J.
H., Reed, B., Norman, D., Chui, H. C., Weiner, M. W., 2001. Magnetic resonance
imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and
Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 71, 441-7.
Du, A. T., Schuff, N., Kramer, J. H., Ganzer, S., Zhu, X. P., Jagust, W. J., Miller, B. L., Reed, B.
R., Mungas, D., Yaffe, K., Chui, H. C., Weiner, M. W., 2004. Higher atrophy rate of
entorhinal cortex than hippocampus in AD. Neurology. 62, 422-7.
Eckert, G. P., Kirsch, C., Leutz, S., Wood, W. G., Muller, W. E., 2003. Cholesterol modulates
amyloid -peptide's membrane interactions. Pharmacopsychiatry. 36 Suppl 2, S136-43.
Economou, A., Papageorgiou, S. G., Karageorgiou, C., Vassilopoulos, D., 2007. Nonepisodic
memory deficits in amnestic MCI. Cogn. Behav. Neurol. 20, 99-106.
Eddleston, M., Mucke, L., 1993. Molecular profile of reactive astrocytes -- Implications for their
role in neurologic disease. Neuroscience. 54, 15-36.
Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten, J. C., Hofman, A., Witteman, J.
C., Breteler, M. M., 2002. Dietary intake of antioxidants and risk of Alzheimer disease.
JAMA. 287, 3223-9.
Engidawork, E., Gulesserian, T., Seidl, R., Cairns, N., Lubec, G., 2001. Expression of apoptosisrelated proteins in brains of patients with Alzheimer's disease. Neurosci. Lett. 303, 7982.
Esterbauer, H., Zollner, H., 1989. Methods for determination of aldehydic lipid peroxidation
products. Free Radic. Biol. Med. 7, 197-203.
285

Esterbauer, H., Cheeseman, K. H., 1990. Determination of aldehydic lipid peroxidation products:
Malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 186, 407-21.
Esterbauer, H., Schaur, R. J., Zollner, H., 1991. Chemistry and biochemistry of 4hydroxynonenal, malonaldehyde, and related aldehydes. Free Radic. Biol. Med. 11, 81128.
Fabisiak, J. P., Kagan, V. E., Ritov, V. B., Johnson, D. E., Lazo, J. S., 1997. Bcl-2 inhibits
selective oxidation and externalization of phosphatidylserine during paraquat-induced
apoptosis. Am. J. Physiol. 272, C675-84.
Fadok, V. A., de Cathelineau, A., Daleke, D. L., Henson, P. M., Bratton, D. L., 2001. Loss of
phospholipid asymmetry and surface exposure of phosphatidylserine is required for
phagocytosis of apoptotic cells by macrophages and fibroblasts. J. Biol. Chem. 276,
1071-7.
Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., Henson, P. M.,
1992a. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers
specific recognition and removal by macrophages. J. Immunol. 148, 2207-16.
Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A., Henson, P. M., 2000.
A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 405, 8590.
Fadok, V. A., Savill, J. S., Haslett, C., Bratton, D. L., Doherty, D. E., Campbell, P. A., Henson,
P. M., 1992b. Different populations of macrophages use either the vitronectin receptor or
the phosphatidylserine receptor to recognize and remove apoptotic cells. J. Immunol.
149, 4029-35.
Fang, Y. Z., Yang, S., Wu, G., 2002. Free radicals, antioxidants, and nutrition. Nutrition. 18,
872-9.
Farge, E., Ojcius, D. M., Subtil, A., Dautry-Varsat, A., 1999. Enhancement of endocytosis due to
aminophospholipid transport across the plasma membrane of living cells. Am. J. Physiol.
276, C725-33.
Farr, S. A., Poon, H. F., Dogrukol-Ak, D., Drake, J., Banks, W. A., Eyerman, E., Butterfield, D.
A., Morley, J. E., 2003. The antioxidants -lipoic acid and N-acetylcysteine reverse
memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem. 84,
1173-83.
Fay, D. S., Fluet, A., Johnson, C. J., Link, C. D., 1998. In vivo aggregation of -amyloid peptide
variants. J. Neurochem. 71, 1616-25.
Fillenbaum, G. G., Kuchibhatla, M. N., Hanlon, J. T., Artz, M. B., Pieper, C. F., Schmader, K.
E., Dysken, M. W., Gray, S. L., 2005. Dementia and Alzheimer's disease in communitydwelling elders taking vitamin C and/or vitamin E. Ann. Pharmacother. 39, 2009-14.
Flint, D. H., Tuminello, J. F., Emptage, M. H., 1993. The inactivation of Fe-S cluster containing
hydro-lyases by superoxide. J. Biol. Chem. 268, 22369-76.
Flood, D. G., Reaume, A. G., Dorfman, K. S., Lin, Y. G., Lang, D. M., Trusko, S. P., Savage, M.
J., Annaert, W. G., De Strooper, B., Siman, R., Scott, R. W., 2002. FAD mutant PS-1
gene-targeted mice: Increased A42 and A deposition without APP overproduction.
Neurobiol. Aging. 23, 335-48.
Foster, T. C., Sharrow, K. M., Masse, J. R., Norris, C. M., Kumar, A., 2001. Calcineurin links
Ca2+ dysregulation with brain aging. J. Neurosci. 21, 4066-73.
Frei, B., England, L., Ames, B. N., 1989. Ascorbate is an outstanding antioxidant in human
blood plasma. Proc. Natl. Acad. Sci. U. S. A. 86, 6377-81.
286

Frey, K. A., Minoshima, S., Kuhl, D. E., 1998. Neurochemical imaging of Alzheimer's disease
and other degenerative dementias. Q. J. Nucl. Med. 42, 166-78.
Fridovich, I., 1989. Superoxide dismutases. An adaptation to a paramagnetic gas. J. Biol. Chem.
264, 7761-4.
Fuentes-Prior, P., Salvesen, G. S., 2004. The protein structures that shape caspase activity,
specificity, activation and inhibition. Biochem. J. 384, 201-32.
Furukawa, K., Sopher, B. L., Rydel, R. E., Begley, J. G., Pham, D. G., Martin, G. M., Fox, M.,
Mattson, M. P., 1996. Increased activity-regulating and neuroprotective efficacy of secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparinbinding domain. J. Neurochem. 67, 1882-96.
Gabbita, S. P., Aksenov, M. Y., Lovell, M. A., Markesbery, W. R., 1999. Decrease in peptide
methionine sulfoxide reductase in Alzheimer's disease brain. J. Neurochem. 73, 1660-6.
Galli, F., Rovidati, S., Ghibelli, L., Canestrari, F., 1998. S-Nitrosylation of glyceraldehyde-3phosphate dehydrogenase decreases the enzyme affinity to the erythrocyte membrane.
Nitric Oxide. 2, 17-27.
Galvan, V., Zhang, J., Gorostiza, O. F., Banwait, S., Huang, W., Ataie, M., Tang, H., Bredesen,
D. E., 2008. Long-term prevention of Alzheimer's disease-like behavioral deficits in
PDAPP mice carrying a mutation in Asp-664. Behav. Brain Res. 191, 246-55.
Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson,
E., Sagi, S. A., Chevallier, N., Jin, K., Greenberg, D. A., Bredesen, D. E., 2006. Reversal
of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation
of Asp-664. Proc. Natl. Acad. Sci. U. S. A. 103, 7130-5.
Geddes, J. W., Chang-Chui, H., Cooper, S. M., Lott, I. T., Cotman, C. W., 1986. Density and
distribution of NMDA receptors in the human hippocampus in Alzheimer's disease.
Brain Res. 399, 156-61.
Georgakopoulos, A., Marambaud, P., Efthimiopoulos, S., Shioi, J., Cui, W., Li, H. C., Schutte,
M., Gordon, R., Holstein, G. R., Martinelli, G., Mehta, P., Friedrich, V. L., Jr., Robakis,
N. K., 1999. Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion
system and is recruited to intercellular and synaptic contacts. Mol. Cell. 4, 893-902.
George, A. J., Holsinger, R. M., McLean, C. A., Laughton, K. M., Beyreuther, K., Evin, G.,
Masters, C. L., Li, Q. X., 2004. APP intracellular domain is increased and soluble A is
reduced with diet-induced hypercholesterolemia in a transgenic mouse model of
Alzheimer disease. Neurobiol. Dis. 16, 124-32.
Ghassemi, A., Rosenberg, P., 1992. Effects of snake venom phospholipase A2 toxins (bungarotoxin, notexin) and enzymes (Naja naja atra, Naja nigricollis) on
aminophospholipid asymmetry in rat cerebrocortical synaptosomes. Biochem.
Pharmacol. 44, 1073-83.
Giannakopoulos, P., Kovari, E., Savioz, A., de Bilbao, F., Dubois-Dauphin, M., Hof, P. R.,
Bouras, C., 1999. Differential distribution of presenilin-1, Bax, and Bcl-X(L) in
Alzheimer's disease and frontotemporal dementia. Acta Neuropathol. (Berl.). 98, 141-9.
Gilgun-Sherki, Y., Melamed, E., Offen, D., 2001. Oxidative stress induced-neurodegenerative
diseases: The need for antioxidants that penetrate the blood-brain barrier.
Neuropharmacology. 40, 959-75.
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L.,
Haynes, A., Irving, N., James, L., et al., 1991. Segregation of a missense mutation in the
amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349, 704-6.
287

Gomes, F. C., Paulin, D., Moura Neto, V., 1999. Glial fibrillary acidic protein (GFAP):
Modulation by growth factors and its implication in astrocyte differentiation. Braz. J.
Med. Biol. Res. 32, 619-31.
Gomez-Balderas, R., Raffa, D. F., Rickard, G. A., Brunelle, P., Rauk, A., 2005. Computational
studies of Cu(II)/Met and Cu(I)/Met binding motifs relevant for the chemistry of
Alzheimer's disease. J. Phys. Chem. A. 109, 5498-508.
Good, P. F., Werner, P., Hsu, A., Olanow, C. W., Perl, D. P., 1996. Evidence of neuronal
oxidative damage in Alzheimer's disease. Am. J. Pathol. 149, 21-8.
Goto, S., Matsukado, Y., Mihara, Y., Inoue, N., Miyamoto, E., 1986. Calcineurin in human brain
and its relation to extrapyramidal system. Immunohistochemical study on post-mortem
human brains. Acta Neuropathol. 72, 150-6.
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Jr., Younkin, L. H., Suzuki, N.,
Younkin, S. G., 1995. Amyloid- protein (A) in Alzheimer's disease brain. Biochemical
and immunocytochemical analysis with antibodies specific for forms ending at A40 or
A42(43). J. Biol. Chem. 270, 7013-6.
Green, D. R., Kroemer, G., 2004. The pathophysiology of mitochondrial cell death. Science.
305, 626-9.
Greenacre, S. A., Ischiropoulos, H., 2001. Tyrosine nitration: Localisation, quantification,
consequences for protein function and signal transduction. Free Radic. Res. 34, 541-81.
Griffiths, G. M., 1996. Secretory lysosomes - A special mechanism of regulated secretion in
haemopoietic cells. Trends Cell Biol. 6, 329-32.
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., Binder, L. I., 1986a.
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer
cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83, 4913-7.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., Wisniewski, H. M., 1986b.
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
J. Biol. Chem. 261, 6084-9.
Grune, T., Jung, T., Merker, K., Davies, K. J., 2004. Decreased proteolysis caused by protein
aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during
oxidative stress, aging, and disease. Int. J. Biochem. Cell Biol. 36, 2519-30.
Grunewald, R. A., 1993. Ascorbic acid in the brain. Brain Res. Brain Res. Rev. 18, 123-33.
Guix, F. X., Uribesalgo, I., Coma, M., Munoz, F. J., 2005. The physiology and pathophysiology
of nitric oxide in the brain. Prog. Neurobiol. 76, 126-52.
Gupta, R. S., 1995. Evolution of the chaperonin families (Hsp60, Hsp10 and TCP-1) of proteins
and the origin of eukaryotic cells. Mol. Microbiol. 15, 1-11.
Hager, K., Kenklies, M., McAfoose, J., Engel, J., Munch, G., 2007. -Lipoic acid as a new
treatment option for Alzheimer's disease -- A 48 months follow-up analysis. J. Neural.
Transm. Suppl., 189-93.
Hall, M. P., Huestis, W. H., 1994. Phosphatidylserine headgroup diastereomers translocate
equivalently across human erythrocyte membranes. Biochim. Biophys. Acta. 1190, 2437.
Halliwell, B., 1991. Reactive oxygen species in living systems: Source, biochemistry, and role in
human disease. Am. J. Med. 91, 14S-22S.
Halliwell, B., 2006a. Oxidative stress and neurodegeneration: Where are we now? J.
Neurochem. 97, 1634-58.

288

Halliwell, B., 2006b. Proteasomal dysfunction: A common feature of neurodegenerative
diseases? Implications for the environmental origins of neurodegeneration. Antioxid.
Redox Signal. 8, 2007-19.
Halliwell, B., Aruoma, O. I., 1991. DNA damage by oxygen-derived species. Its mechanism and
measurement in mammalian systems. FEBS Lett. 281, 9-19.
Halliwell, B., Whiteman, M., 2004. Measuring reactive species and oxidative damage in vivo and
in cell culture: How should you do it and what do the results mean? Br. J. Pharmacol.
142, 231-55.
Halliwell, B., Zhao, K., Whiteman, M., 1999. Nitric oxide and peroxynitrite. The ugly, the
uglier, and the not so good: A personal view of recent controversies. Free Radic. Res.
31, 651-69.
Hamajima, N., Matsuda, K., Sakata, S., Tamaki, N., Sasaki, M., Nonaka, M., 1996. A novel gene
family defined by human dihydropyrimidinase and three related proteins with differential
tissue distribution. Gene. 180, 157-63.
Hanayama, R., Tanaka, M., Miwa, K., Shinohara, A., Iwamatsu, A., Nagata, S., 2002.
Identification of a factor that links apoptotic cells to phagocytes. Nature. 417, 182-7.
Handelman, G. J., Machlin, L. J., Fitch, K., Weiter, J. J., Dratz, E. A., 1985. Oral -tocopherol
supplements decrease plasma -tocopherol levels in humans. J. Nutr. 115, 807-13.
Harman, D., 1956. Aging: A theory based on free radical and radiation chemistry. J. Gerontol.
11, 298-300.
Hata, R., Masumura, M., Akatsu, H., Li, F., Fujita, H., Nagai, Y., Yamamoto, T., Okada, H.,
Kosaka, K., Sakanaka, M., Sawada, T., 2001. Up-regulation of calcineurin A mRNA in
the Alzheimer's disease brain: Assessment by cDNA microarray. Biochem. Biophys.
Res. Commun. 284, 310-6.
Haugaard, N., Levin, R. M., 2000. Regulation of the activity of choline acetyl transferase by
lipoic acid. Mol. Cell. Biochem. 213, 61-3.
Hayashi, H., Iimuro, M., Matsumoto, Y., Kaneko, M., 1998. Effects of -glutamylcysteine ethyl
ester on heart mitochondrial creatine kinase activity: Involvement of sulfhydryl groups.
Eur. J. Pharmacol. 349, 133-6.
Hemenway, C. S., Heitman, J., 1999. Calcineurin. Structure, function, and inhibition. Cell
Biochem. Biophys. 30, 115-51.
Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M.,
Gabbita, S. P., Wu, J. F., Carney, J. M., et al., 1995. Brain regional correspondence
between Alzheimer's disease histopathology and biomarkers of protein oxidation. J.
Neurochem. 65, 2146-56.
Herrmann, A., Devaux, P. F., 1990. Alteration of the aminophospholipid translocase activity
during in vivo and artificial aging of human erythrocytes. Biochim. Biophys. Acta. 1027,
41-6.
Hertel, C., Terzi, E., Hauser, N., Jakob-Rotne, R., Seelig, J., Kemp, J. A., 1997. Inhibition of the
electrostatic interaction between -amyloid peptide and membranes prevents -amyloidinduced toxicity. Proc. Natl. Acad. Sci. U. S. A. 94, 9412-6.
Higuchi, Y., 2004. Glutathione depletion-induced chromosomal DNA fragmentation associated
with apoptosis and necrosis. J. Cell. Mol. Med. 8, 455-64.
Honig, L. S., Rosenberg, R. N., 2000. Apoptosis and neurologic disease. Am. J. Med. 108, 31730.

289

Hou, L., Kang, I., Marchant, R. E., Zagorski, M. G., 2002. Methionine 35 oxidation reduces
fibril assembly of the amyloid A(1-42) peptide of Alzheimer's disease. J. Biol. Chem.
277, 40173-6.
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G. Q., Tatsuno, G., Hu, K., Kholodenko, D.,
Malenka, R. C., Nicoll, R. A., Mucke, L., 1999. Plaque-independent disruption of neural
circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 96, 322833.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., Cole, G.,
1996. Correlative memory deficits, A elevation, and amyloid plaques in transgenic
mice. Science. 274, 99-102.
Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J. D., Hanson, G. R.,
Stokes, K. C., Leopold, M., Multhaup, G., Goldstein, L. E., Scarpa, R. C., Saunders, A.
J., Lim, J., Moir, R. D., Glabe, C., Bowden, E. F., Masters, C. L., Fairlie, D. P., Tanzi, R.
E., Bush, A. I., 1999. Cu(II) potentiation of Alzheimer A neurotoxicity. Correlation with
cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274, 371116.
Iqbal, K., Alonso, A. D., Gondal, J. A., Gong, C. X., Haque, N., Khatoon, S., Sengupta, A.,
Wang, J. Z., Grundke-Iqbal, I., 2000. Mechanism of neurofibrillary degeneration and
pharmacologic therapeutic approach. J. Neural Transm. Suppl. 59, 213-22.
Ischiropoulos, H., 1998. Biological tyrosine nitration: A pathophysiological function of nitric
oxide and reactive oxygen species. Arch. Biochem. Biophys. 356, 1-11.
Jack, C. R., Jr., Petersen, R. C., Xu, Y. C., O'Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F.,
Waring, S. C., Tangalos, E. G., Kokmen, E., 1999. Prediction of AD with MRI-based
hippocampal volume in mild cognitive impairment. Neurology. 52, 1397-403.
Jackson, R. M., Parish, G., Helton, E. S., 1998. Peroxynitrite modulates MnSOD gene expression
in lung epithelial cells. Free Radic. Biol. Med. 25, 463-72.
Jana, C. K., Das, N., Sohal, R. S., 2002. Specificity of age-related carbonylation of plasma
proteins in the mouse and rat. Arch. Biochem. Biophys. 397, 433-9.
Jarrett, J. T., Berger, E. P., Lansbury, P. T., Jr., 1993. The carboxy terminus of the amyloid
protein is critical for the seeding of amyloid formation: Implications for the pathogenesis
of Alzheimer's disease. Biochemistry. 32, 4693-7.
Jiang, Q., Ames, B. N., 2003. -Tocopherol, but not -tocopherol, decreases proinflammatory
eicosanoids and inflammation damage in rats. FASEB J. 17, 816-22.
Jira, W., Spiteller, G., Schramm, A., 1996. Increase in hydroxy fatty acids in human low density
lipoproteins with age. Chem. Phys. Lipids. 84, 165-73.
Joerchel, S., Raap, M., Bigl, M., Eschrich, K., Schliebs, R., 2008. Oligomeric -amyloid (1-42)
induces the expression of Alzheimer disease-relevant proteins in cholinergic SN56.B5.G4
cells as revealed by proteomic analysis. Int. J. Dev. Neurosci. 26, 301-8.
Johansson, A. S., Bergquist, J., Volbracht, C., Paivio, A., Leist, M., Lannfelt, L., WestlindDanielsson, A., 2007a. Attenuated amyloid- aggregation and neurotoxicity owing to
methionine oxidation. Neuroreport. 18, 559-63.
Johansson, A. S., Garlind, A., Berglind-Dehlin, F., Karlsson, G., Edwards, K., Gellerfors, P.,
Ekholm-Pettersson, F., Palmblad, J., Lannfelt, L., 2007b. Docosahexaenoic acid
stabilizes soluble amyloid- protofibrils and sustains amyloid--induced neurotoxicity in
vitro. FEBS J. 274, 990-1000.

290

Kadlcik, V., Sicard-Roselli, C., Mattioli, T. A., Kodicek, M., Houee-Levin, C., 2004. Oneelectron oxidation of -amyloid peptide: Sequence modulation of reactivity. Free Radic.
Biol. Med. 37, 881-91.
Kagan, V. E., Serbinova, E. A., Forte, T., Scita, G., Packer, L., 1992. Recycling of vitamin E in
human low density lipoproteins. J. Lipid. Res. 33, 385-97.
Kagan, V. E., Fabisiak, J. P., Shvedova, A. A., Tyurina, Y. Y., Tyurin, V. A., Schor, N. F.,
Kawai, K., 2000. Oxidative signaling pathway for externalization of plasma membrane
phosphatidylserine during apoptosis. FEBS Lett. 477, 1-7.
Kagan, V. E., Gleiss, B., Tyurina, Y. Y., Tyurin, V. A., Elenstrom-Magnusson, C., Liu, S. X.,
Serinkan, F. B., Arroyo, A., Chandra, J., Orrenius, S., Fadeel, B., 2002. A role for
oxidative stress in apoptosis: Oxidation and externalization of phosphatidylserine is
required for macrophage clearance of cells undergoing Fas-mediated apoptosis. J.
Immunol. 169, 487-99.
Kagan, V. E., Borisenko, G. G., Serinkan, B. F., Tyurina, Y. Y., Tyurin, V. A., Jiang, J., Liu, S.
X., Shvedova, A. A., Fabisiak, J. P., Uthaisang, W., Fadeel, B., 2003. Appetizing
rancidity of apoptotic cells for macrophages: Oxidation, externalization, and recognition
of phosphatidylserine. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L1-17.
Kahlert, S., Reiser, G., 2000. Requirement of glycolytic and mitochondrial energy supply for
loading of Ca(2+) stores and InsP(3)-mediated Ca(2+) signaling in rat hippocampus
astrocytes. J. Neurosci. Res. 61, 409-20.
Kamata, H., Hirata, H., 1999. Redox regulation of cellular signalling. Cell. Signal. 11, 1-14.
Kanski, J., Aksenova, M., Schoneich, C., Butterfield, D. A., 2002. Substitution of isoleucine 31
by helical-breaking proline abolishes oxidative stress and neurotoxic properties of
Alzheimer's amyloid -peptide. Free Radic. Biol. Med. 32, 1205-11.
Kant, J. A., Steck, T. L., 1973. Specificity in the association of glyceraldehyde-3-phosphate
dehydrogenase with isolated human erythrocyte membranes. J. Biol. Chem. 248, 845764.
Kaplan, P., 2009. Reactive oxygen and nitrogen species and their biological effects. SlideShare.
www.slideshare.net.
Karp, G. (Ed.) 2003. Cell and molecular biology: Concepts and experiments. John Wiley &
Sons, Inc., Hoboken, NJ.
Kato, Y., Hamajima, N., Inagaki, H., Okamura, N., Koji, T., Sasaki, M., Nonaka, M., 1998. Postmeiotic expression of the mouse dihydropyrimidinase-related protein 3 (Drp-3) gene
during spermiogenesis. Mol. Reprod. Dev. 51, 105-11.
Kauppinen, R. A., Enkvist, K., Holopainen, I., Akerman, K. E., 1988. Glucose deprivation
depolarizes plasma membrane of cultured astrocytes and collapses transmembrane
potassium and glutamate gradients. Neuroscience. 26, 283-9.
Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., Glabe, C. G.,
2004. Permeabilization of lipid bilayers is a common conformation-dependent activity of
soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46363-6.
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., Markesbery,
W. R., 2005. Evidence of increased oxidative damage in subjects with mild cognitive
impairment. Neurology. 64, 1152-6.
Kelly, B. L., Vassar, R., Ferreira, A., 2005. -Amyloid-induced dynamin-1 depletion in
hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer
disease. J. Biol. Chem. 280, 31746-53.
291

Keszler, A., Zhang, Y., Hogg, N., 2010. Reaction between nitric oxide, glutathione, and oxygen
in the presence and absence of protein: How are S-nitrosothiols formed? Free Radic.
Biol. Med. 48, 55-64.
Kim, S. H., Fountoulakis, M., Cairns, N., Lubec, G., 2001. Protein levels of human
peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down
syndrome. J. Neural Transm. Suppl., 223-35.
Kitamura, Y., Furukawa, M., Matsuoka, Y., Tooyama, I., Kimura, H., Nomura, Y., Taniguchi,
T., 1998a. In vitro and in vivo induction of heme oxygenase-1 in rat glial cells: Possible
involvement of nitric oxide production from inducible nitric oxide synthase. Glia. 22,
138-48.
Kitamura, Y., Shimohama, S., Kamoshima, W., Ota, T., Matsuoka, Y., Nomura, Y., Smith, M.
A., Perry, G., Whitehouse, P. J., Taniguchi, T., 1998b. Alteration of proteins regulating
apoptosis, Bcl-2, Bcl-X, Bax, Bak, Bad, ICH-1, and CPP32, in Alzheimer's disease.
Brain Res. 780, 260-9.
Klee, C. B., Ren, H., Wang, X., 1998. Regulation of the calmodulin-stimulated protein
phosphatase, calcineurin. J. Biol. Chem. 273, 13367-70.
Klein, W. L., 2006. Synaptic targeting by A oligomers (ADDLS) as a basis for memory loss in
early Alzheimer's disease. Alzheimers Dement. 2, 43-55.
Kontush, A., Mann, U., Arlt, S., Ujeyl, A., Luhrs, C., Muller-Thomsen, T., Beisiegel, U., 2001.
Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with
Alzheimer's disease. Free Radic. Biol. Med. 31, 345-54.
Kowall, N. W., Kosik, K. S., 1987. Axonal disruption and aberrant localization of tau protein
characterize the neuropil pathology of Alzheimer's disease. Ann. Neurol. 22, 639-43.
Krammer, P. H., 2000. CD95's deadly mission in the immune system. Nature. 407, 789-95.
Kroemer, G., Galluzzi, L., Brenner, C., 2007. Mitochondrial membrane permeabilization in cell
death. Physiol Rev. 87, 99-163.
Kuo, Y. M., Kokjohn, T. A., Beach, T. G., Sue, L. I., Brune, D., Lopez, J. C., Kalback, W. M.,
Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., Roher, A. E., 2001. Comparative
analysis of amyloid- chemical structure and amyloid plaque morphology of transgenic
mouse and Alzheimer's disease brains. J. Biol. Chem. 276, 12991-8.
Kuypers, F. A., Lewis, R. A., Hua, M., Schott, M. A., Discher, D., Ernst, J. D., Lubin, B. H.,
1996. Detection of altered membrane phospholipid asymmetry in subpopulations of
human red blood cells using fluorescently labeled Annexin V. Blood. 87, 1179-87.
LaFontaine, M. A., Mattson, M. P., Butterfield, D. A., 2002. Oxidative stress in synaptosomal
proteins from mutant presenilin-1 knock-in mice: Implications for familial Alzheimer's
disease. Neurochem. Res. 27, 417-21.
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.
E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G.
A., Klein, W. L., 1998. Diffusible, nonfibrillar ligands derived from A1-42) are potent
central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95, 6448-53.
Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R.,
Butterfield, D. A., 2001. The glial glutamate transporter, GLT-1, is oxidatively modified
by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of A1-42). J.
Neurochem. 78, 413-6.

292

Laurin, D., Masaki, K. H., Foley, D. J., White, L. R., Launer, L. J., 2004. Midlife dietary intake
of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study.
Am. J. Epidemiol. 159, 959-67.
Ledesma, M. D., Da Silva, J. S., Crassaerts, K., Delacourte, A., De Strooper, B., Dotti, C. G.,
2000. Brain plasmin enhances APP -cleavage and A degradation and is reduced in
Alzheimer's disease brains. EMBO Rep. 1, 530-5.
Lee, M. S., Tsai, L. H., 2003. Cdk5: One of the links between senile plaques and neurofibrillary
tangles? J. Alzheimers Dis. 5, 127-37.
Lee, S. H., Oe, T., Blair, I. A., 2001. Vitamin C-induced decomposition of lipid hydroperoxides
to endogenous genotoxins. Science. 292, 2083-6.
Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., Ashe, K.
H., 2006. A specific amyloid- protein assembly in the brain impairs memory. Nature.
440, 352-7.
Levine, R. L., Garland, D., Oliver, C. N., Amici, A., Climent, I., Lenz, A. G., Ahn, B. W.,
Shaltiel, S., Stadtman, E. R., 1990. Determination of carbonyl content in oxidatively
modified proteins. Methods Enzymol. 186, 464-78.
Levites, Y., Das, P., Price, R. W., Rochette, M. J., Kostura, L. A., McGowan, E. M., Murphy, M.
P., Golde, T. E., 2006. Anti-A42- and anti-A40-specific mAbs attenuate amyloid
deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116, 193-201.
Li, M. O., Sarkisian, M. R., Mehal, W. Z., Rakic, P., Flavell, R. A., 2003. Phosphatidylserine
receptor is required for clearance of apoptotic cells. Science. 302, 1560-3.
Lian, Q., Ladner, C. J., Magnuson, D., Lee, J. M., 2001. Selective changes of calcineurin (protein
phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp. Neurol. 167, 15865.
Liu, J., Mori, A., 1993. Age-associated changes in superoxide dismutase activity, thiobarbituric
acid reactivity, and reduced glutathione level in the brain and liver in senescence
accelerated mice (SAM): A comparison with ddY mice. Mech. Ageing Dev. 71, 23-30.
Liu, J., Head, E., Gharib, A. M., Yuan, W., Ingersoll, R. T., Hagen, T. M., Cotman, C. W.,
Ames, B. N., 2002. Memory loss in old rats is associated with brain mitochondrial decay
and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-lipoic acid. Proc. Natl. Acad. Sci. U. S. A. 99, 2356-61.
Liu, R., Choi, J., 2000. Age-associated decline in -glutamylcysteine synthetase gene expression
in rats. Free Radic. Biol. Med. 28, 566-74.
Lloret, A., Badia, M. C., Mora, N. J., Pallardo, F. V., Alonso, M. D., Vina, J., 2009. Vitamin E
paradox in Alzheimer's disease: It does not prevent loss of cognition and may even be
detrimental. J. Alzheimers Dis. 17, 143-9.
Lodish, H., Berk, A., Zipursky, L. S., Matsudaira, P., Baltimore, D., Darnell, J. (Eds.), 2000.
Molecular cell biology. W. H. Freeman & Co., Ney York, NY.
Loh, R. K., Huestis, W. H., 1993. Human erythrocyte membrane lipid asymmetry: Transbilayer
distribution of rapidly diffusing phosphatidylserines. Biochemistry. 32, 11722-6.
Lopez-Revuelta, A., Sanchez-Gallego, J. I., Hernandez-Hernandez, A., Sanchez-Yague, J.,
Llanillo, M., 2005. Increase in vulnerability to oxidative damage in cholesterol-modified
erythrocytes exposed to t-BuOOH. Biochim. Biophys. Acta. 1734, 74-85.
Lopez-Revuelta, A., Sanchez-Gallego, J. I., Garcia-Montero, A. C., Hernandez-Hernandez, A.,
Sanchez-Yague, J., Llanillo, M., 2007. Membrane cholesterol in the regulation of

293

aminophospholipid asymmetry and phagocytosis in oxidized erythrocytes. Free Radic.
Biol. Med. 42, 1106-18.
Lovell, M. A., Markesbery, W. R., 2007. Oxidative damage in mild cognitive impairment and
early Alzheimer's disease. J. Neurosci. Res. 85, 3036-40.
Lovell, M. A., Xie, C., Markesbery, W. R., 2001. Acrolein is increased in Alzheimer's disease
brain and is toxic to primary hippocampal cultures. Neurobiol. Aging. 22, 187-94.
Lu, D. C., Rabizadeh, S., Chandra, S., Shayya, R. F., Ellerby, L. M., Ye, X., Salvesen, G. S.,
Koo, E. H., Bredesen, D. E., 2000. A second cytotoxic proteolytic peptide derived from
amyloid -protein precursor. Nat. Med. 6, 397-404.
Lu, K. P., Liou, Y. C., Vincent, I., 2003. Proline-directed phosphorylation and isomerization in
mitotic regulation and in Alzheimer's Disease. Bioessays. 25, 174-81.
Lubin, B., Chiu, D., Bastacky, J., Roelofsen, B., Van Deenen, L. L., 1981. Abnormalities in
membrane phospholipid organization in sickled erythrocytes. J. Clin. Invest. 67, 1643-9.
Luchsinger, J. A., Tang, M. X., Shea, S., Mayeux, R., 2003. Antioxidant vitamin intake and risk
of Alzheimer disease. Arch. Neurol. 60, 203-8.
Lyras, L., Cairns, N. J., Jenner, A., Jenner, P., Halliwell, B., 1997. An assessment of oxidative
damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J.
Neurochem. 68, 2061-9.
MacGibbon, G. A., Lawlor, P. A., Sirimanne, E. S., Walton, M. R., Connor, B., Young, D.,
Williams, C., Gluckman, P., Faull, R. L., Hughes, P., Dragunow, M., 1997. Bax
expression in mammalian neurons undergoing apoptosis and in Alzheimer's disease
hippocampus. Brain Res. 750, 223-34.
Madeira, A., Pommet, J. M., Prochiantz, A., Allinquant, B., 2005. SET protein (TAF1, I2PP2A)
is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic
subdomain. FASEB J. 19, 1905-7.
Magee, T., Fuentes, A. M., Garban, H., Rajavashisth, T., Marquez, D., Rodriguez, J. A., Rajfer,
J., Gonzalez-Cadavid, N. F., 1996. Cloning of a novel neuronal nitric oxide synthase
expressed in penis and lower urinary tract. Biochem. Biophys. Res. Commun. 226, 14551.
Maillet, M., Robert, S. J., Cacquevel, M., Gastineau, M., Vivien, D., Bertoglio, J., Zugaza, J. L.,
Fischmeister, R., Lezoualc'h, F., 2003. Crosstalk between Rap1 and Rac regulates
secretion of sAPP. Nat. Cell Biol. 5, 633-9.
Maioli, F., Coveri, M., Pagni, P., Chiandetti, C., Marchetti, C., Ciarrocchi, R., Ruggero, C.,
Nativio, V., Onesti, A., D'Anastasio, C., Pedone, V., 2007. Conversion of mild cognitive
impairment to dementia in elderly subjects: A preliminary study in a memory and
cognitive disorder unit. Arch. Gerontol. Geriatr. 44 Suppl 1, 233-41.
Maiti, P., Lomakin, A., Benedek, G. B., Bitan, G., 2010. Despite its role in assembly, methionine
35 is not necessary for amyloid -protein toxicity. J. Neurochem.
Maki, M., Matsukawa, N., Yuasa, H., Otsuka, Y., Yamamoto, T., Akatsu, H., Okamoto, T.,
Ueda, R., Ojika, K., 2002. Decreased expression of hippocampal cholinergic
neurostimulating peptide precursor protein mRNA in the hippocampus in Alzheimer
disease. J. Neuropathol. Exp. Neurol. 61, 176-85.
Mancuso, C., Bonsignore, A., Di Stasio, E., Mordente, A., Motterlini, R., 2003. Bilirubin and Snitrosothiols interaction: Evidence for a possible role of bilirubin as a scavenger of nitric
oxide. Biochem. Pharmacol. 66, 2355-63.

294

Mandal, D., Moitra, P. K., Saha, S., Basu, J., 2002. Caspase-3 regulates phosphatidylserine
externalization and phagocytosis of oxidatively stressed erythrocytes. FEBS Lett. 513,
184-8.
Mandal, D., Mazumder, A., Das, P., Kundu, M., Basu, J., 2005. Fas-, caspase-8-, and caspase-3dependent signaling regulates the activity of the aminophospholipid translocase and
phosphatidylserine externalization in human erythrocytes. J. Biol. Chem. 280, 39460-7.
Mark, R. J., Lovell, M. A., Markesbery, W. R., Uchida, K., Mattson, M. P., 1997. A role for 4hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion
homeostasis and neuronal death induced by amyloid -peptide. J. Neurochem. 68, 25564.
Markesbery, W. R., 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol.
Med. 23, 134-47.
Markesbery, W. R., 1999. The role of oxidative stress in Alzheimer disease. Arch. Neurol. 56,
1449-52.
Markesbery, W. R., Lovell, M. A., 1998. 4-hydroxynonenal, a product of lipid peroxidation, is
increased in the brain in Alzheimer's disease. Neurobiol. Aging. 19, 33-6.
Markesbery, W. R., Lovell, M. A., 2007. Damage to lipids, proteins, DNA, and RNA in mild
cognitive impairment. Arch. Neurol. 64, 954-6.
Markesbery, W. R., Kryscio, R. J., Lovell, M. A., Morrow, J. D., 2005. Lipid peroxidation is an
early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 58, 730-5.
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., Wekstein, D. R.,
2006. Neuropathologic substrate of mild cognitive impairment. Arch. Neurol. 63, 38-46.
Martin, O. C., Pagano, R. E., 1987. Transbilayer movement of fluorescent analogs of
phosphatidylserine and phosphatidylethanolamine at the plasma membrane of cultured
cells. Evidence for a protein-mediated and ATP-dependent process(es). J. Biol. Chem.
262, 5890-8.
Martin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., Green, D. R., 1996.
Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts
requires ICE/CED-3 protease activity. J. Biol. Chem. 271, 28753-6.
Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., LaFace, D.
M., Green, D. R., 1995. Early redistribution of plasma membrane phosphatidylserine is a
general feature of apoptosis regardless of the initiating stimulus: Inhibition by
overexpression of Bcl-2 and Abl. J. Exp. Med. 182, 1545-56.
Martinon, F., Mayor, A., Tschopp, J., 2009. The inflammasomes: Guardians of the body. Annu.
Rev. Immunol. 27, 229-65.
Martins, I. C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., Van
Gelder, P., Hartmann, D., D'Hooge, R., De Strooper, B., Schymkowitz, J., Rousseau, F.,
2008. Lipids revert inert A amyloid fibrils to neurotoxic protofibrils that affect learning
in mice. EMBO J. 27, 224-33.
Mates, J. M., Perez-Gomez, C., Nunez de Castro, I., 1999. Antioxidant enzymes and human
diseases. Clin. Biochem. 32, 595-603.
Mattson, M. P., 1997. Cellular actions of -amyloid precursor protein and its soluble and
fibrillogenic derivatives. Physiol. Rev. 77, 1081-132.
Mattson, M. P., 2004. Pathways towards and away from Alzheimer's disease. Nature. 430, 6319.

295

Mattson, M. P., Chan, S. L., 2001. Dysregulation of cellular calcium homeostasis in Alzheimer's
disease: Bad genes and bad habits. J. Mol. Neurosci. 17, 205-24.
Mattson, M. P., Fu, W., Waeg, G., Uchida, K., 1997. 4-Hydroxynonenal, a product of lipid
peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau.
Neuroreport. 8, 2275-81.
McCann, S. M., 1997. The nitric oxide hypothesis of brain aging. Exp. Gerontol. 32, 431-40.
McCord, J. M., Fridovich, I., 1969. Superoxide dismutase. An enzymic function for
erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049-55.
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P.,
Beard, J., Das, P., Jansen, K., Delucia, M., Lin, W. L., Dolios, G., Wang, R., Eckman, C.
B., Dickson, D. W., Hutton, M., Hardy, J., Golde, T., 2005. A42 is essential for
parenchymal and vascular amyloid deposition in mice. Neuron. 47, 191-9.
McIntyre, J. C., Sleight, R. G., 1991. Fluorescence assay for phospholipid membrane asymmetry.
Biochemistry. 30, 11819-27.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E. M., 1984. Clinical
diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under
the auspices of Department of Health and Human Services Task Force on Alzheimer's
Disease. Neurology. 34, 939-44.
McLaurin, J., Chakrabartty, A., 1997. Characterization of the interactions of Alzheimer amyloid peptides with phospholipid membranes. Eur. J. Biochem. 245, 355-63.
Merat, D. L., Cheung, W. Y., 1987. Calmodulin-dependent protein phosphatase: Isolation of
subunits and reconstitution to holoenzyme. Methods Enzymol. 139, 79-87.
Mevel, K., Chetelat, G., Desgranges, B., Eustache, F., 2006. [Alzheimer's disease, hippocampus
and neuroimaging]. Encephale. 32 Pt 4, S1149-54.
Mielke, R., Schroder, R., Fink, G. R., Kessler, J., Herholz, K., Heiss, W. D., 1996. Regional
cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta
Neuropathol. 91, 174-9.
Miquel, J., Economos, A. C., Fleming, J., Johnson, J. E., Jr., 1980. Mitochondrial role in cell
aging. Exp. Gerontol. 15, 575-91.
Mishima, K., Tanaka, T., Pu, F., Egashira, N., Iwasaki, K., Hidaka, R., Matsunaga, K., Takata,
J., Karube, Y., Fujiwara, M., 2003. Vitamin E isoforms, -tocotrienol and -tocopherol,
prevent cerebral infarction in mice. Neurosci. Lett. 337, 56-60.
Mohmmad Abdul, H., Butterfield, D. A., 2005. Protection against amyloid -peptide (1-42)induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9xanthogenate (D609) and ferulic acid ethyl ester (FAEE): Implications for Alzheimer's
disease. Biochim. Biophys. Acta. 1741, 140-8.
Mohmmad Abdul, H., Wenk, G. L., Gramling, M., Hauss-Wegrzyniak, B., Butterfield, D. A.,
2004. APP and PS-1 mutations induce brain oxidative stress independent of dietary
cholesterol: Implications for Alzheimer's disease. Neurosci. Lett. 368, 148-50.
Mohmmad Abdul, H., Sultana, R., Keller, J. N., St Clair, D. K., Markesbery, W. R., Butterfield,
D. A., 2006. Mutations in amyloid precursor protein and presenilin-1 genes increase the
basal oxidative stress in murine neuronal cells and lead to increased sensitivity to
oxidative stress mediated by amyloid -peptide (1-42), H2O2 and kainic acid:
implications for Alzheimer's disease. J. Neurochem. 96, 1322-35.
Moldeus, P., 1993. Toxicity induced by nitrogen dioxide in experimental animals and isolated
cell systems. Scand. J. Work Environ. Health. 19 Suppl 2, 28-36.
296

Mori, E., 2005. [Hippocampal atrophy and memory disturbance]. No To Shinkei. 57, 1067-78.
Mori, K., Muto, Y., Kokuzawa, J., Yoshioka, T., Yoshimura, S., Iwama, T., Okano, Y., Sakai,
N., 2004. Neuronal protein NP25 interacts with F-actin. Neurosci. Res. 48, 439-46.
Morris, M. C., Beckett, L. A., Scherr, P. A., Hebert, L. E., Bennett, D. A., Field, T. S., Evans, D.
A., 1998. Vitamin E and vitamin C supplement use and risk of incident Alzheimer
disease. Alzheimer Dis. Assoc. Disord. 12, 121-6.
Morris, M. C., Evans, D. A., Tangney, C. C., Bienias, J. L., Wilson, R. S., Aggarwal, N. T.,
Scherr, P. A., 2005. Relation of the tocopherol forms to incident Alzheimer disease and
to cognitive change. Am. J. Clin. Nutr. 81, 508-14.
Morris, R., 1984. Developments of a water-maze procedure for studying spatial learning in the
rat. J. Neurosci. Methods. 11, 47-60.
Morrot, G., Herve, P., Zachowski, A., Fellmann, P., Devaux, P. F., 1989. Aminophospholipid
translocase of human erythrocytes: Phospholipid substrate specificity and effect of
cholesterol. Biochemistry. 28, 3456-62.
Morrow, J. D., Roberts, L. J., 1997. The isoprostanes: Unique bioactive products of lipid
peroxidation. Prog. Lipid Res. 36, 1-21.
Morton, L. W., Ward, N. C., Croft, K. D., Puddey, I. B., 2002. Evidence for the nitration of tocopherol in vivo: 5-Nitro--tocopherol is elevated in the plasma of subjects with
coronary heart disease. Biochem. J. 364, 625-8.
Moses, G. S., Jensen, M. D., Lue, L. F., Walker, D. G., Sun, A. Y., Simonyi, A., Sun, G. Y.,
2006. Secretory PLA2-IIA: A new inflammatory factor for Alzheimer's disease. J.
Neuroinflammation. 3, 28.
Motterlini, R., Green, C. J., Foresti, R., 2002. Regulation of heme oxygenase-1 by redox signals
involving nitric oxide. Antioxid. Redox Signal. 4, 615-24.
Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K.,
Kholodenko, D., Johnson-Wood, K., McConlogue, L., 2000. High-level neuronal
expression of A(1-42) in wild-type human amyloid protein precursor transgenic mice:
Synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-8.
Muller, W. E., Koch, S., Eckert, A., Hartmann, H., Scheuer, K., 1995. -Amyloid peptide
decreases membrane fluidity. Brain Res. 674, 133-6.
Murphy, M. P., Beckett, T. L., Ding, Q., Patel, E., Markesbery, W. R., St Clair, D. K., LeVine,
H., 3rd, Keller, J. N., 2007. A solubility and deposition during AD progression and in
APPxPS-1 knock-in mice. Neurobiol. Dis. 27, 301-11.
Murray, I. V., Sindoni, M. E., Axelsen, P. H., 2005. Promotion of oxidative lipid membrane
damage by amyloid- proteins. Biochemistry. 44, 12606-13.
Nagy, Z. S., Esiri, M. M., 1997. Apoptosis-related protein expression in the hippocampus in
Alzheimer's disease. Neurobiol. Aging. 18, 565-71.
Naruse, S., Thinakaran, G., Luo, J. J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty,
D. D., Price, D. L., Borchelt, D. R., Wong, P. C., Sisodia, S. S., 1998. Effects of PS-1
deficiency on membrane protein trafficking in neurons. Neuron. 21, 1213-21.
Naslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring,
J., Gandy, S. E., Winblad, B., Greengard, P., et al., 1994. Relative abundance of
Alzheimer A amyloid peptide variants in Alzheimer disease and normal aging. Proc.
Natl. Acad. Sci. U. S. A. 91, 8378-82.
Nicholson, D. W., 1999. Caspase structure, proteolytic substrates, and function during apoptotic
cell death. Cell Death Differ. 6, 1028-42.
297

Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M.,
Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al., 1995. Identification and
inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376,
37-43.
Nikolaev, A., McLaughlin, T., O'Leary, D. D., Tessier-Lavigne, M., 2009. APP binds DR6 to
trigger axon pruning and neuron death via distinct caspases. Nature. 457, 981-9.
Norris, C. M., Kadish, I., Blalock, E. M., Chen, K. C., Thibault, V., Porter, N. M., Landfield, P.
W., Kraner, S. D., 2005. Calcineurin triggers reactive/inflammatory processes in
astrocytes and is up-regulated in aging and Alzheimer's models. J. Neurosci. 25, 464958.
Nourhashemi, F., Gillette-Guyonnet, S., Andrieu, S., Ghisolfi, A., Ousset, P. J., Grandjean, H.,
Grand, A., Pous, J., Vellas, B., Albarede, J. L., 2000. Alzheimer disease: Protective
factors. Am. J. Clin. Nutr. 71, 643S-649S.
Nunomura, A., Moreira, P. I., Lee, H. G., Zhu, X., Castellani, R. J., Smith, M. A., Perry, G.,
2007. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson
diseases. CNS Neurol. Disord. Drug Targets. 6, 411-23.
Ohshima, H., Friesen, M., Brouet, I., Bartsch, H., 1990. Nitrotyrosine as a new marker for
endogenous nitrosation and nitration of proteins. Food Chem. Toxicol. 28, 647-52.
Ojika, K., 1998. [Hippocampal cholinergic neurostimulating peptide]. Seikagaku. 70, 1175-80.
Oltvai, Z. N., Milliman, C. L., Korsmeyer, S. J., 1993. Bcl-2 heterodimerizes in vivo with a
conserved homolog, Bax, that accelerates programmed cell death. Cell. 74, 609-19.
Op den Kamp, J. A., 1979. Lipid asymmetry in membranes. Annu. Rev. Biochem. 48, 47-71.
Opii, W. O., Joshi, G., Head, E., Milgram, N. W., Muggenburg, B. A., Klein, J. B., Pierce, W.
M., Cotman, C. W., Butterfield, D. A., 2008. Proteomic identification of brain proteins in
the canine model of human aging following a long-term treatment with antioxidants and a
program of behavioral enrichment: Relevance to Alzheimer's disease. Neurobiol. Aging.
29, 51-70.
Ott, M., Gogvadze, V., Orrenius, S., Zhivotovsky, B., 2007. Mitochondria, oxidative stress, and
cell death. Apoptosis. 12, 913-22.
Ou, P., Tritschler, H. J., Wolff, S. P., 1995. Thioctic (lipoic) acid: A therapeutic metal-chelating
antioxidant? Biochem. Pharmacol. 50, 123-6.
Owen, J. B., Di Domenico, F., Sultana, R., Perluigi, M., Cini, C., Pierce, W. M., Butterfield, D.
A., 2009. Proteomics-determined differences in the concanavalin-A-fractionated
proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's
disease and mild cognitive impairment: Implications for progression of AD. J. Proteome
Res. 8, 471-82.
Oyama, F., Sawamura, N., Kobayashi, K., Morishima-Kawashima, M., Kuramochi, T., Ito, M.,
Tomita, T., Maruyama, K., Saido, T. C., Iwatsubo, T., Capell, A., Walter, J., Grunberg,
J., Ueyama, Y., Haass, C., Ihara, Y., 1998. Mutant presenilin-2 transgenic mouse: Effect
on an age-dependent increase of amyloid -protein 42 in the brain. J. Neurochem. 71,
313-22.
Packer, L., Tritschler, H. J., Wessel, K., 1997. Neuroprotection by the metabolic antioxidant lipoic acid. Free Radic. Biol. Med. 22, 359-78.
Padh, H., 1990. Cellular functions of ascorbic acid. Biochem. Cell Biol. 68, 1166-73.

298

Pappolla, M. A., Chyan, Y. J., Poeggeler, B., Bozner, P., Ghiso, J., LeDoux, S. P., Wilson, G. L.,
1999. Alzheimer- protein mediated oxidative damage of mitochondrial DNA:
Prevention by melatonin. J. Pineal Res. 27, 226-9.
Park, S. A., Shaked, G. M., Bredesen, D. E., Koo, E. H., 2009. Mechanism of cytotoxicity
mediated by the C31 fragment of the amyloid precursor protein. Biochem. Biophys. Res
Commun. 388, 450-5.
Pastorino, L., Sun, A., Lu, P. J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S. H.,
Li, X., Xia, W., Nicholson, L. K., Lu, K. P., 2006. The prolyl isomerase Pin-1 regulates
amyloid precursor protein processing and amyloid- production. Nature. 440, 528-34.
Paulusma, C. C., Oude Elferink, R. P., 2005. The type 4 subfamily of P-type ATPases, putative
aminophospholipid translocases with a role in human disease. Biochim. Biophys. Acta.
1741, 11-24.
Pellegrini, M., Strasser, A., 1999. A portrait of the Bcl-2 protein family: Life, death, and the
whole picture. J. Clin. Immunol. 19, 365-77.
Perkins, A. J., Hendrie, H. C., Callahan, C. M., Gao, S., Unverzagt, F. W., Xu, Y., Hall, K. S.,
Hui, S. L., 1999. Association of antioxidants with memory in a multiethnic elderly
sample using the Third National Health and Nutrition Examination Survey. Am. J.
Epidemiol. 150, 37-44.
Perluigi, M., Sultana, R., Cenini, G., Di Domenico, F., Memo, M., Pierce, W. M., Coccia, R.,
Butterfield, D. A., 2009. Redox proteomics identification of HNE-modified brain
proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease
pathogenesis. Proteomics Clin. Appl. 3, 682-93.
Persinger, R. L., Poynter, M. E., Ckless, K., Janssen-Heininger, Y. M., 2002. Molecular
mechanisms of nitrogen dioxide induced epithelial injury in the lung. Mol. Cell.
Biochem. 234-235, 71-80.
Peshenko, I. V., Shichi, H., 2001. Oxidation of active center cysteine of bovine 1-Cys
peroxiredoxin to the cysteine sulfenic acid form by peroxide and peroxynitrite. Free
Radic. Biol. Med. 31, 292-303.
Petersen, R. C., 2000. Mild cognitive impairment: Transition between aging and Alzheimer's
disease. Neurologia. 15, 93-101.
Petersen, R. C., 2004. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256,
183-94.
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., Kokmen, E., 1999.
Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 56,
303-8.
Piomelli, D., Astarita, G., Rapaka, R., 2007. A neuroscientist's guide to lipidomics. Nat. Rev.
Neurosci. 8, 743-54.
Podrez, E. A., Schmitt, D., Hoff, H. F., Hazen, S. L., 1999. Myeloperoxidase-generated reactive
nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103,
1547-60.
Pogocki, D., 2004. Mutation of the Phe-20 residue in Alzheimer's amyloid -peptide might
decrease its toxicity due to disruption of the Met-35-cupric site electron transfer pathway.
Chem. Res. Toxicol. 17, 325-9.
Poon, H. F., Calabrese, V., Scapagnini, G., Butterfield, D. A., 2004. Free radicals: Key to brain
aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontol. A.
Biol. Sci. Med. Sci. 59, 478-93.
299

Portet, F., Ousset, P. J., Touchon, J., 2005. [What is a mild cognitive impairment?]. Rev. Prat.
55, 1891-4.
Prasad, M. R., Lovell, M. A., Yatin, M., Dhillon, H., Markesbery, W. R., 1998. Regional
membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23, 81-8.
Price, D. L., Tanzi, R. E., Borchelt, D. R., Sisodia, S. S., 1998. Alzheimer's disease: Genetic
studies and transgenic models. Annu. Rev. Genet. 32, 461-93.
Rajasekaran, M., Mondal, D., Agrawal, K., Chen, I. L., Hellstrom, W., Sikka, S., 1998. Ex vivo
expression of nitric oxide synthase isoforms (eNOS/iNOS) and calmodulin in human
penile cavernosal cells. J. Urol. 160, 2210-5.
Reaume, A. G., Howland, D. S., Trusko, S. P., Savage, M. J., Lang, D. M., Greenberg, B. D.,
Siman, R., Scott, R. W., 1996. Enhanced amyloidogenic processing of the -amyloid
precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease
mutations and a "humanized" A sequence. J. Biol. Chem. 271, 23380-8.
Reed, T., Perluigi, M., Sultana, R., Pierce, W. M., Klein, J. B., Turner, D. M., Coccia, R.,
Markesbery, W. R., Butterfield, D. A., 2008a. Redox proteomic identification of 4hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment:
Insight into the role of lipid peroxidation in the progression and pathogenesis of
Alzheimer's disease. Neurobiol. Dis. 30, 107-20.
Reed, T. T., Pierce, W. M., Jr., Turner, D. M., Markesbery, W. R., Butterfield, D. A., 2008b.
Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior
parietal lobule. J. Cell. Mol. Med.
Reed, T. T., Owen, J., Pierce, W. M., Sebastian, A., Sullivan, P. G., Butterfield, D. A., 2009.
Proteomic identification of nitrated brain proteins in traumatic brain-injured rats treated
postinjury with -glutamylcysteine ethyl ester: Insights into the role of elevation of
glutathione as a potential therapeutic strategy for traumatic brain injury. J. Neurosci.
Res. 87, 408-17.
Renes, J., de Vries, E. G., Nienhuis, E. F., Jansen, P. L., Muller, M., 1999. ATP- and glutathionedependent transport of chemotherapeutic drugs by the multidrug resistance protein, MRP1. Br. J. Pharmacol. 126, 681-8.
Resende, R., Moreira, P. I., Proenca, T., Deshpande, A., Busciglio, J., Pereira, C., Oliveira, C. R.,
2008. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease.
Free Radic. Biol. Med. 44, 2051-7.
Ridnour, L. A., Thomas, D. D., Mancardi, D., Espey, M. G., Miranda, K. M., Paolocci, N.,
Feelisch, M., Fukuto, J., Wink, D. A., 2004. The chemistry of nitrosative stress induced
by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful
biological situations. Biol. Chem. 385, 1-10.
Riek, R., Guntert, P., Dobeli, H., Wipf, B., Wuthrich, K., 2001. NMR studies in aqueous solution
fail to identify significant conformational differences between the monomeric forms of
two Alzheimer peptides with widely different plaque-competence, A(1-40)(ox) and
A(1-42)(ox). Eur. J. Biochem. 268, 5930-6.
Rivier, C., 2001. Role of gaseous neurotransmitters in the hypothalamic-pituitary-adrenal axis.
Ann. N. Y. Acad. Sci. 933, 254-64.
Roder, H. M., Eden, P. A., Ingram, V. M., 1993. Brain protein kinase PK40erk converts tau into
a PHF-like form as found in Alzheimer's disease. Biochem. Biophys. Res. Commun.
193, 639-47.

300

Rodrigo, J., Springall, D. R., Uttenthal, O., Bentura, M. L., Abadia-Molina, F., Riveros-Moreno,
V., Martinez-Murillo, R., Polak, J. M., Moncada, S., 1994. Localization of nitric oxide
synthase in the adult rat brain. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 345, 175-221.
Rogalski, A. A., Steck, T. L., Waseem, A., 1989. Association of glyceraldehyde-3-phosphate
dehydrogenase with the plasma membrane of the intact human red blood cell. J. Biol.
Chem. 264, 6438-46.
Roher, A., Wolfe, D., Palutke, M., KuKuruga, D., 1986. Purification, ultrastructure, and
chemical analysis of Alzheimer disease amyloid plaque core protein. Proc. Natl. Acad.
Sci. U. S. A. 83, 2662-6.
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M.,
Zurcher-Neely, H. A., Heinrikson, R. L., Ball, M. J., et al., 1993. Structural alterations in
the peptide backbone of -amyloid core protein may account for its deposition and
stability in Alzheimer's disease. J. Biol. Chem. 268, 3072-83.
Rose, R. C., Bode, A. M., 1993. Biology of free radical scavengers: An evaluation of ascorbate.
FASEB J. 7, 1135-42.
Rothman, J. E., Lenard, J., 1977. Membrane asymmetry. Science. 195, 743-53.
Rozzini, L., Chilovi, B. V., Conti, M., Bertoletti, E., Delrio, I., Trabucchi, M., Padovani, A.,
2007. Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type
is independent to memory deterioration. Int. J. Geriatr. Psychiatry. 22, 1217-22.
Sadava, D., Heller, H. C., Orians, G. H., Purves, W. K., Hillis, D. M. (Eds.), 2007. Life: The
science of biology. Sinauer Associates, Sunderland, MA.
Sadrzadeh, S. M., Vincenzi, F. F., Hinds, T. R., 1993. Simultaneous measurement of multiple
membrane ATPases in microtiter plates. J. Pharmacol. Toxicol. Methods. 30, 103-10.
Sagai, M., Ichinose, T., Kubota, K., 1984. Studies on the biochemical effects of nitrogen dioxide.
IV. Relation between the change of lipid peroxidation and the antioxidative protective
system in rat lungs upon life span exposure to low levels of NO2. Toxicol. Appl.
Pharmacol. 73, 444-56.
Saganich, M. J., Schroeder, B. E., Galvan, V., Bredesen, D. E., Koo, E. H., Heinemann, S. F.,
2006. Deficits in synaptic transmission and learning in amyloid precursor protein (APP)
transgenic mice require C-terminal cleavage of APP. J. Neurosci. . 26, 13428-36.
Sambrano, G. R., Steinberg, D., 1995. Recognition of oxidatively damaged and apoptotic cells
by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: Role
of membrane phosphatidylserine. Proc. Natl. Acad. Sci. U. S. A. 92, 1396-400.
Santos, C. X., Tanaka, L. Y., Wosniak, J., Laurindo, F. R., 2009. Mechanisms and implications
of reactive oxygen species generation during the unfolded protein response: Roles of
endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH
oxidase. Antioxid. Redox Signal. 11, 2409-27.
Sastre, J., Pallardo, F. V., Garcia de la Asuncion, J., Vina, J., 2000. Mitochondria, oxidative
stress, and aging. Free Radic. Res. 32, 189-98.
Satou, T., Cummings, B. J., Cotman, C. W., 1995. Immunoreactivity for Bcl-2 protein within
neurons in the Alzheimer's disease brain increases with disease severity. Brain Res. 697,
35-43.
Savill, J., Dransfield, I., Hogg, N., Haslett, C., 1990. Vitronectin receptor-mediated phagocytosis
of cells undergoing apoptosis. Nature. 343, 170-3.

301

Sayre, L. M., Zelasko, D. A., Harris, P. L., Perry, G., Salomon, R. G., Smith, M. A., 1997. 4Hydroxynonenal-derived advanced lipid peroxidation end products are increased in
Alzheimer's disease. J. Neurochem. 68, 2092-7.
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M.,
Krammer, P. H., Peter, M. E., 1998. Two CD95 (APO-1/Fas) signaling pathways.
EMBO J. 17, 1675-87.
Schagger, H., Ohm, T. G., 1995. Human diseases with defects in oxidative phosphorylation. 2.
F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide
gel electrophoresis. Eur. J. Biochem. 227, 916-21.
Schaur, R. J., 2003. Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol.
Aspects Med. 24, 149-59.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J.,
Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj,
P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., Younkin, S., 1996.
Secreted amyloid -protein similar to that in the senile plaques of Alzheimer's disease is
increased in vivo by the presenilin-1 and -2 and APP mutations linked to familial
Alzheimer's disease. Nat. Med. 2, 864-70.
Schlegel, R. A., McEvoy, L., Williamson, P., 1985. Membrane phospholipid asymmetry and the
adherence of loaded red blood cells. Bibl. Haematol., 150-6.
Schoneich, C., 2002. Redox processes of methionine relevant to -amyloid oxidation and
Alzheimer's disease. Arch. Biochem. Biophys. 397, 370-6.
Schreiber, M., Trojan, S., 1991. Ascorbic acid in the brain. Physiol. Res. 40, 413-8.
Schroit, A. J., Madsen, J. W., Tanaka, Y., 1985. In vivo recognition and clearance of red blood
cells containing phosphatidylserine in their plasma membranes. J. Biol. Chem. 260,
5131-8.
Schubert, D., Behl, C., Lesley, R., Brack, A., Dargusch, R., Sagara, Y., Kimura, H., 1995.
Amyloid peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci.
U. S. A. 92, 1989-93.
Schuller, E., Gulesserian, T., Seidl, R., Cairns, N., Lube, G., 2001. Brain T-complex polypeptide
1 (TCP- 1) related to its natural substrate 1 tubulin is decreased in Alzheimer's disease.
Life Sci. 69, 263-70.
Schwab, C., Bondada, V., Sparks, D. L., Cahan, L. D., Geddes, J. W., 1994. Postmortem changes
in the levels and localization of microtubule-associated proteins (tau, MAP2, and
MAP1B) in the rat and human hippocampus. Hippocampus. 4, 210-25.
Scott, R. S., McMahon, E. J., Pop, S. M., Reap, E. A., Caricchio, R., Cohen, P. L., Earp, H. S.,
Matsushima, G. K., 2001. Phagocytosis and clearance of apoptotic cells is mediated by
MER. Nature. 411, 207-11.
Seaton, T. A., Jenner, P., Marsden, C. D., 1996. The isomers of thioctic acid alter Cdeoxyglucose incorporation in rat basal ganglia. Biochem. Pharmacol. 51, 983-6.
Seigneuret, M., Devaux, P. F., 1984. ATP-dependent asymmetric distribution of spin-labeled
phospholipids in the erythrocyte membrane: Relation to shape changes. Proc. Natl.
Acad. Sci. U. S. A. 81, 3751-5.
Selkoe, D. J., 1996. Amyloid -protein and the genetics of Alzheimer's disease. J. Biol. Chem.
271, 18295-8.
Selkoe, D. J., 2001a. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 74166.
302

Selkoe, D. J., 2001b. Alzheimer's disease results from the cerebral accumulation and cytotoxicity
of amyloid -protein. J. Alzheimers Dis. 3, 75-80.
Selkoe, D. J., 2008. Soluble oligomers of the amyloid -protein impair synaptic plasticity and
behavior. Behav. Brain Res. 192, 106-13.
Selkoe, D. J., Yamazaki, T., Citron, M., Podlisny, M. B., Koo, E. H., Teplow, D. B., Haass, C.,
1996. The role of APP processing and trafficking pathways in the formation of amyloid
-protein. Ann. N. Y. Acad. Sci. 777, 57-64.
Sen, C. K., Roy, S., Han, D., Packer, L., 1997. Regulation of cellular thiols in human
lymphocytes by -lipoic acid: A flow cytometric analysis. Free Radic. Biol. Med. 22,
1241-57.
Shankar, G. M., Leissring, M. A., Adame, A., Sun, X., Spooner, E., Masliah, E., Selkoe, D. J.,
Lemere, C. A., Walsh, D. M., 2009. Biochemical and immunohistochemical analysis of
an Alzheimer's disease mouse model reveals the presence of multiple cerebral A
assembly forms throughout life. Neurobiol. Dis. 36, 293-302.
Siegel, G. J., Albers, R. W., Brady, S. T., Price, D. L. (Eds.), 2006. Basic Neurochemistry:
Molecular, cellular, and medical aspects. Elsevier Academic Press, Burlington, MA.
Siems, W., Grune, T., 2003. Intracellular metabolism of 4-hydroxynonenal. Mol. Aspects Med.
24, 167-75.
Siman, R., Reaume, A. G., Savage, M. J., Trusko, S., Lin, Y. G., Scott, R. W., Flood, D. G.,
2000. Presenilin-1 P264L knock-in mutation: Differential effects on A production,
amyloid deposition, and neuronal vulnerability. J. Neurosci. 20, 8717-26.
Simard, M., Arcuino, G., Takano, T., Liu, Q. S., Nedergaard, M., 2003. Signaling at the
gliovascular interface. J. Neurosci. 23, 9254-62.
Sinjoanu, R. C., Kleinschmidt, S., Bitner, R. S., Brioni, J. D., Moeller, A., Ferreira, A., 2008.
The novel calpain inhibitor A-705253 potently inhibits oligomeric -amyloid-induced
dynamin-1 and tau cleavage in hippocampal neurons. Neurochem. Int. 53, 79-88.
Sly, W. S., Hu, P. Y., 1995. Human carbonic anhydrases and carbonic anhydrase deficiencies.
Annu. Rev. Biochem. 64, 375-401.
Smale, G., Nichols, N. R., Brady, D. R., Finch, C. E., Horton, W. E., Jr., 1995. Evidence for
apoptotic cell death in Alzheimer's disease. Exp. Neurol. 133, 225-30.
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., Perry, G., 1997. Widespread
peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17, 2653-7.
Smith, M. A., Richey, P. L., Taneda, S., Kutty, R. K., Sayre, L. M., Monnier, V. M., Perry, G.,
1994. Advanced Maillard reaction end products, free radicals, and protein oxidation in
Alzheimer's disease. Ann. N. Y. Acad. Sci. 738, 447-54.
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D.,
Fujimoto, E. K., Goeke, N. M., Olson, B. J., Klenk, D. C., 1985. Measurement of protein
using bicinchoninic acid. Anal. Biochem. 150, 76-85.
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter,
M. W., Lombroso, P. J., Gouras, G. K., Greengard, P., 2005. Regulation of NMDA
receptor trafficking by amyloid-. Nat. Neurosci. 8, 1051-8.
Sokolov, Y., Kozak, J. A., Kayed, R., Chanturiya, A., Glabe, C., Hall, J. E., 2006. Soluble
amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen.
Physiol. 128, 637-47.

303

Soriano, S., Lu, D. C., Chandra, S., Pietrzik, C. U., Koo, E. H., 2001. The amyloidogenic
pathway of amyloid precursor protein (APP) is independent of its cleavage by caspases.
J. Biol. Chem. 276, 29045-50.
Spiteller, G., 2001. Lipid peroxidation in aging and age-dependent diseases. Exp. Gerontol. 36,
1425-57.
Sprong, H., van der Sluijs, P., van Meer, G., 2001. How proteins move lipids and lipids move
proteins. Nat. Rev. Mol. Cell Biol. 2, 504-13.
Stadtman, E. R., 1990. Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and
biological consequences. Free Radic. Biol. Med. 9, 315-25.
Stadtman, E. R., 2004. Cyclic oxidation and reduction of methionine residues of proteins in
antioxidant defense and cellular regulation. Arch. Biochem. Biophys. 423, 2-5.
Stadtman, E. R., 2006. Protein oxidation and aging. Free Radic. Res. 40, 1250-8.
Struhl, G., Greenwald, I., 1999. Presenilin is required for activity and nuclear access of Notch in
Drosophila. Nature. 398, 522-5.
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S.,
Ledermann, B., Burki, K., Frey, P., Paganetti, P. A., Waridel, C., Calhoun, M. E., Jucker,
M., Probst, A., Staufenbiel, M., Sommer, B., 1997. Two amyloid precursor protein
transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci.
U. S. A. 94, 13287-92.
Su, J. H., Anderson, A. J., Cummings, B. J., Cotman, C. W., 1994. Immunohistochemical
evidence for apoptosis in Alzheimer's disease. NeuroReport. 5, 2529-33.
Su, J. H., Satou, T., Anderson, A. J., Cotman, C. W., 1996. Up-regulation of Bcl-2 is associated
with neuronal DNA damage in Alzheimer's disease. NeuroReport. 7, 437-40.
Su, J. H., Zhao, M., Anderson, A. J., Srinivasan, A., Cotman, C. W., 2001. Activated caspase-3
expression in Alzheimer's and aged control brain: Correlation with Alzheimer pathology.
Brain Res. 898, 350-7.
Subramaniam, R., Roediger, F., Jordan, B., Mattson, M. P., Keller, J. N., Waeg, G., Butterfield,
D. A., 1997. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the
conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69, 1161-9.
Suh, J. H., Wang, H., Liu, R. M., Liu, J., Hagen, T. M., 2004. (R)--Lipoic acid reverses the agerelated loss in GSH redox status in post-mitotic tissues: Evidence for increased cysteine
requirement for GSH synthesis. Arch. Biochem. Biophys. 423, 126-35.
Sultana, R., Butterfield, D. A., 2004. Oxidatively modified GST and MRP-1 in Alzheimer's
disease brain: Implications for accumulation of reactive lipid peroxidation products.
Neurochem. Res. 29, 2215-20.
Sultana, R., Perluigi, M., Butterfield, D. A., 2009. Oxidatively modified proteins in Alzheimer's
disease (AD), mild cognitive impairment and animal models of AD: Role of A in
pathogenesis. Acta Neuropathol. 118, 131-50.
Sultana, R., Newman, S., Mohmmad-Abdul, H., Keller, J. N., Butterfield, D. A., 2004. Protective
effect of the xanthate, D609, on Alzheimer's amyloid -peptide (1-42)-induced oxidative
stress in primary neuronal cells. Free Radic. Res. 38, 449-58.
Sultana, R., Ravagna, A., Mohmmad-Abdul, H., Calabrese, V., Butterfield, D. A., 2005. Ferulic
acid ethyl ester protects neurons against amyloid -peptide (1-42)-induced oxidative
stress and neurotoxicity: Relationship to antioxidant activity. J. Neurochem. 92, 749-58.

304

Sultana, R., Reed, T., Perluigi, M., Coccia, R., Pierce, W. M., Butterfield, D. A., 2007a.
Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment:
A regional study. J. Cell. Mol. Med. 11, 839-51.
Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M., Butterfield, D.
A., 2007b. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J.
Alzheimers Dis. 11, 153-64.
Sultana, R., Poon, H. F., Cai, J., Pierce, W. M., Merchant, M., Klein, J. B., Markesbery, W. R.,
Butterfield, D. A., 2006a. Identification of nitrated proteins in Alzheimer's disease brain
using a redox proteomics approach. Neurobiol. Dis. 22, 76-87.
Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M.,
Markesbery, W. R., Butterfield, D. A., 2006b. Redox proteomics identification of
oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to
understand pathological and biochemical alterations in AD. Neurobiol. Aging. 27, 156476.
Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Markesbery, W.
R., Zhou, X. Z., Lu, K. P., Butterfield, D. A., 2006c. Oxidative modification and downregulation of Pin-1 in Alzheimer's disease hippocampus: A redox proteomics analysis.
Neurobiol. Aging. 27, 918-25.
Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos, L., Jr., Eckman, C., Golde, T. E.,
Younkin, S. G., 1994. An increased percentage of long amyloid- protein secreted by
familial amyloid- protein precursor (APP717) mutants. Science. 264, 1336-40.
Thinakaran, G., Regard, J. B., Bouton, C. M., Harris, C. L., Price, D. L., Borchelt, D. R., Sisodia,
S. S., 1998. Stable association of presenilin derivatives and absence of presenilin
interactions with APP. Neurobiol. Dis. 4, 438-53.
Thomas, C. E., Aust, S. D., 1986. Free radicals and environmental toxins. Ann. Emerg. Med.
15, 1075-83.
Thongboonkerd, V., Luengpailin, J., Cao, J., Pierce, W. M., Cai, J., Klein, J. B., Doyle, R. J.,
2002. Fluoride exposure attenuates expression of Streptococcus pyogenes virulence
factors. J. Biol. Chem. 277, 16599-605.
Tilley, L., Cribier, S., Roelofsen, B., Op den Kamp, J. A., van Deenen, L. L., 1986. ATPdependent translocation of amino phospholipids across the human erythrocyte membrane.
FEBS Lett. 194, 21-7.
Toda, N., Ayajiki, K., Okamura, T., 2005. Nitric oxide and penile erectile function. Pharmacol.
Ther. 106, 233-66.
Topinka, J., Binkova, B., Sram, R. J., Erin, A. N., 1989. The influence of -tocopherol and
pyritinol on oxidative DNA damage and lipid peroxidation in human lymphocytes.
Mutat. Res. 225, 131-6.
Tortosa, A., Lopez, E., Ferrer, I., 1998. Bcl-2 and Bax protein expression in Alzheimer's disease.
Acta Neuropathol. (Berl.). 95, 407-12.
Trojanowski, J. Q., Schuck, T., Schmidt, M. L., Lee, V. M., 1989. Distribution of tau proteins in
the normal human central and peripheral nervous system. J. Histochem. Cytochem. 37,
209-15.
Tsai, I. H., Murthy, S. N., Steck, T. L., 1982. Effect of red cell membrane binding on the
catalytic activity of glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 257,
1438-42.

305

Tucker, H. M., Kihiko-Ehmann, M., Wright, S., Rydel, R. E., Estus, S., 2000a. Tissue
plasminogen activator requires plasminogen to modulate amyloid- neurotoxicity and
deposition. J. Neurochem. 75, 2172-7.
Tucker, H. M., Kihiko, M., Caldwell, J. N., Wright, S., Kawarabayashi, T., Price, D., Walker, D.,
Scheff, S., McGillis, J. P., Rydel, R. E., Estus, S., 2000b. The plasmin system is induced
by and degrades amyloid- aggregates. J. Neurosci. 20, 3937-46.
Turner, P. R., O'Connor, K., Tate, W. P., Abraham, W. C., 2003. Roles of amyloid precursor
protein and its fragments in regulating neural activity, plasticity, and memory. Prog.
Neurobiol. 70, 1-32.
Tyurina, Y. Y., Tyurin, V. A., Zhao, Q., Djukic, M., Quinn, P. J., Pitt, B. R., Kagan, V. E.,
2004a. Oxidation of phosphatidylserine: A mechanism for plasma membrane
phospholipid scrambling during apoptosis? Biochem. Biophys. Res. Commun. 324,
1059-64.
Tyurina, Y. Y., Serinkan, F. B., Tyurin, V. A., Kini, V., Yalowich, J. C., Schroit, A. J., Fadeel,
B., Kagan, V. E., 2004b. Lipid antioxidant, etoposide, inhibits phosphatidylserine
externalization and macrophage clearance of apoptotic cells by preventing
phosphatidylserine oxidation. J. Biol. Chem. 279, 6056-64.
Ursic, D., Sedbrook, J. C., Himmel, K. L., Culbertson, M. R., 1994. The essential yeast TCP-1
protein affects actin and microtubules. Mol. Biol. Cell. 5, 1065-80.
Van Nostrand, W. E., Porter, M., 1999. Plasmin cleavage of the amyloid -protein: Alteration of
secondary structure and stimulation of tissue plasminogen activator activity.
Biochemistry. 38, 11570-6.
Vanags, D. M., Porn-Ares, M. I., Coppola, S., Burgess, D. H., Orrenius, S., 1996. Protease
involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol.
Chem. 271, 31075-85.
Varadarajan, S., Yatin, S., Aksenova, M., Butterfield, D. A., 2000. Review: Alzheimer's amyloid
-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130,
184-208.
Varadarajan, S., Kanski, J., Aksenova, M., Lauderback, C., Butterfield, D. A., 2001. Different
mechanisms of oxidative stress and neurotoxicity for Alzheimer's A(1-42) and A(2535). J. Am. Chem. Soc. 123, 5625-31.
Verkleij, A. J., Post, J. A., 2000. Membrane phospholipid asymmetry and signal transduction. J.
Membr. Biol. 178, 1-10.
Vincent, S. R., Kimura, H., 1992. Histochemical mapping of nitric oxide synthase in the rat
brain. Neuroscience. 46, 755-84.
Viola, K. L., Velasco, P. T., Klein, W. L., 2008. Why Alzheimer's is a disease of memory: The
attack on synapses by A oligomers (ADDLs). J. Nutr. Health Aging. 12, 51S-7S.
Vogt, W., 1995. Oxidation of methionyl residues in proteins: Tools, targets, and reversal. Free
Radic. Biol. Med. 18, 93-105.
Waeg, G., Dimsity, G., Esterbauer, H., 1996. Monoclonal antibodies for detection of 4hydroxynonenal modified proteins. Free Radic. Res. 25, 149-59.
Wali, R. K., Jaffe, S., Kumar, D., Sorgente, N., Kalra, V. K., 1987. Increased adherence of
oxidant-treated human and bovine erythrocytes to cultured endothelial cells. J. Cell.
Physiol. 133, 25-36.
Wallimann, T., Hemmer, W., 1994. Creatine kinase in non-muscle tissues and cells. Mol. Cell.
Biochem. 133-134, 193-220.
306

Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., Eppenberger, H. M., 1992. Intracellular
compartmentation, structure and function of creatine kinase isoenzymes in tissues with
high and fluctuating energy demands: The 'phosphocreatine circuit' for cellular energy
homeostasis. Biochem. J. 281 ( Pt 1), 21-40.
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J.,
Selkoe, D. J., 2002. Naturally secreted oligomers of amyloid- protein potently inhibit
hippocampal long-term potentiation in vivo. Nature. 416, 535-9.
Wang, J. H., Duddle, J., Devalia, J. L., Davies, R. J., 1995a. Nitrogen dioxide increases
eosinophil activation in the early-phase response to nasal allergen provocation. Int. Arch.
Allergy Immunol. 107, 103-5.
Wang, Z., Ciabattoni, G., Creminon, C., Lawson, J., Fitzgerald, G. A., Patrono, C., Maclouf, J.,
1995b. Immunological characterization of urinary 8-epi-prostaglandin F2 excretion in
man. J. Pharmacol. Exp. Ther. 275, 94-100.
Watson, G. S., Craft, S., 2004. Modulation of memory by insulin and glucose:
Neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 490, 97113.
Way, G., Morrice, N., Smythe, C., O'Sullivan, A. J., 2002. Purification and identification of
secernin, a novel cytosolic protein that regulates exocytosis in mast cells. Mol. Biol. Cell.
13, 3344-54.
Wedemeyer, J., Galli, S. J., 2000. Mast cells and basophils in acquired immunity. Br. Med. Bull.
56, 936-55.
Weeds, A., Maciver, S., 1993. F-actin capping proteins. Curr. Opin. Cell Biol. 5, 63-9.
Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J. M., Masters, C. L., Beyreuther,
K., 1989. Identification, biogenesis, and localization of precursors of Alzheimer's disease
A4 amyloid protein. Cell. 57, 115-26.
Weisiger, R. A., Fridovich, I., 1973. Mitochondrial superoxide simutase. Site of synthesis and
intramitochondrial localization. J. Biol. Chem. 248, 4793-6.
Weiss, J. N., Lamp, S. T., 1989. Cardiac ATP-sensitive K+ channels. Evidence for preferential
regulation by glycolysis. J. Gen. Physiol. 94, 911-35.
Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T.,
Younkin, L. H., Carlson, G. A., Younkin, S. G., Ashe, K. H., 2002. The relationship
between A and memory in the Tg2576 mouse model of Alzheimer's disease. J.
Neurosci. 22, 1858-67.
Whittaker, V. P., 1959. The isolation and characterization of acetylcholine-containing particles
from brain. Biochem. J. 72, 694-706.
Whittaker, V. P., 1968. The morphology of fractions of rat forebrain synaptosomes separated on
continuous sucrose density gradients. Biochem. J. 106, 412-7.
Whittaker, V. P., 1993. Thirty years of synaptosome research. J. Neurocytol. 22, 735-42.
Wiechelman, K. J., Braun, R. D., Fitzpatrick, J. D., 1988. Investigation of the bicinchoninic acid
protein assay: Identification of the groups responsible for color formation. Anal.
Biochem. 175, 231-7.
Williams, T. I., Lynn, B. C., Markesbery, W. R., Lovell, M. A., 2006. Increased levels of 4hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in
mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging. 27, 1094-9.

307

Williamson, K. S., Gabbita, S. P., Mou, S., West, M., Pye, Q. N., Markesbery, W. R., Cooney, R.
V., Grammas, P., Reimann-Philipp, U., Floyd, R. A., Hensley, K., 2002. The nitration
product 5-nitro--tocopherol is increased in the Alzheimer brain. Nitric Oxide. 6, 221-7.
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., Nordberg, A.,
Backman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., Blennow, K., de Leon, M.,
DeCarli, C., Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J., Jack, C., Jorm, A.,
Ritchie, K., van Duijn, C., Visser, P., Petersen, R. C., 2004. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group
on Mild Cognitive Impairment. J. Intern. Med. 256, 240-6.
Wirths, O., Weis, J., Szczygielski, J., Multhaup, G., Bayer, T. A., 2006. Axonopathy in an
APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol. 111, 3129.
Wisniewski, T., Dowjat, W. K., Buxbaum, J. D., Khorkova, O., Efthimiopoulos, S., Kulczycki,
J., Lojkowska, W., Wegiel, J., Wisniewski, H. M., Frangione, B., 1998. A novel Polish
presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads
to death as early as the age of 28 years. Neuroreport. 9, 217-21.
Wolf, B. B., Green, D. R., 1999. Suicidal tendencies: Apoptotic cell death by caspase family
proteinases. J. Biol. Chem. 274, 20049-52.
Wolfe, M. S., Citron, M., Diehl, T. S., Xia, W., Donkor, I. O., Selkoe, D. J., 1998. A substratebased difluoro ketone selectively inhibits Alzheimer's -secretase activity. J. Med.
Chem. 41, 6-9.
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., Selkoe, D. J., 1999a.
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and
-secretase activity. Nature. 398, 513-7.
Wolfe, M. S., Xia, W., Moore, C. L., Leatherwood, D. D., Ostaszewski, B., Rahmati, T., Donkor,
I. O., Selkoe, D. J., 1999b. Peptidomimetic probes and molecular modeling suggest that
Alzheimer's -secretase is an intramembrane-cleaving aspartyl protease. Biochemistry.
38, 4720-7.
Wood, W. G., Eckert, G. P., Igbavboa, U., Muller, W. E., 2003. Amyloid -protein interactions
with membranes and cholesterol: Causes or casualties of Alzheimer's disease. Biochim.
Biophys. Acta. 1610, 281-290.
Wood, W. G., Schroeder, F., Igbavboa, U., Avdulov, N. A., Chochina, S. V., 2002. Brain
membrane cholesterol domains, aging, and amyloid -peptides. Neurobiol. Aging. 23,
685-94.
Wu, S. K., Zeng, K., Wilson, I. A., Balch, W. E., 1996. Structural insights into the function of
the Rab GDI superfamily. Trends Biochem. Sci. 21, 472-6.
Xia, W., Zhang, J., Perez, R., Koo, E. H., Selkoe, D. J., 1997. Interaction between amyloid
precursor protein and presenilins in mammalian cells: Implications for the pathogenesis
of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94, 8208-13.
Xia, W., Zhang, J., Ostaszewski, B. L., Kimberly, W. T., Seubert, P., Koo, E. H., Shen, J.,
Selkoe, D. J., 1998. Presenilin-1 regulates the processing of -amyloid precursor protein
C-terminal fragments and the generation of amyloid -protein in endoplasmic reticulum
and Golgi. Biochemistry. 37, 16465-71.
Xu, K. Y., Becker, L. C., 1998. Ultrastructural localization of glycolytic enzymes on
sarcoplasmic reticulum vesticles. J. Histochem. Cytochem. 46, 419-27.

308

Xu, K. Y., Zweier, J. L., Becker, L. C., 1995. Functional coupling between glycolysis and
sarcoplasmic reticulum Ca2+ transport. Circ. Res. 77, 88-97.
Yao, P. J., Zhu, M., Pyun, E. I., Brooks, A. I., Therianos, S., Meyers, V. E., Coleman, P. D.,
2003. Defects in expression of genes related to synaptic vesicle trafficking in frontal
cortex of Alzheimer's disease. Neurobiol. Dis. 12, 97-109.
Yatin, S. M., Varadarajan, S., Link, C. D., Butterfield, D. A., 1999. In vitro and in vivo oxidative
stress associated with Alzheimer's amyloid -peptide (1-42). Neurobiol. Aging. 20, 32530; discussion 339-42.
Yau, P., 2009. Apoptosis. The Science Creative Quarterly. www.scq.ubc.ca.
Yoo, B. C., Kim, S. H., Cairns, N., Fountoulakis, M., Lubec, G., 2001. Deranged expression of
molecular chaperones in brains of patients with Alzheimer's disease. Biochem. Biophys.
Res. Commun. 280, 249-58.
Yu, G., Chen, F., Levesque, G., Nishimura, M., Zhang, D. M., Levesque, L., Rogaeva, E., Xu,
D., Liang, Y., Duthie, M., St George-Hyslop, P. H., Fraser, P. E., 1998. The presenilin-1
protein is a component of a high molecular weight intracellular complex that contains catenin. J. Biol. Chem. 273, 16470-5.
Zachowski, A., Gaudry-Talarmain, Y. M., 1990. Phospholipid transverse diffusion in
synaptosomes: Evidence for the involvement of the aminophospholipid translocase. J.
Neurochem. 55, 1352-6.
Zandi, P. P., Anthony, J. C., Khachaturian, A. S., Stone, S. V., Gustafson, D., Tschanz, J. T.,
Norton, M. C., Welsh-Bohmer, K. A., Breitner, J. C., 2004. Reduced risk of Alzheimer
disease in users of antioxidant vitamin supplements: The Cache County Study. Arch.
Neurol. 61, 82-8.
Zhang, R., Brennan, M. L., Shen, Z., MacPherson, J. C., Schmitt, D., Molenda, C. E., Hazen, S.
L., 2002. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid
peroxidation at sites of inflammation. J. Biol. Chem. 277, 46116-22.
Zhou, J., Liyanage, U., Medina, M., Ho, C., Simmons, A. D., Lovett, M., Kosik, K. S., 1997.
Presenilin-1 interaction in the brain with a novel member of the Armadillo family.
Neuroreport. 8, 2085-90.
Zhu, M., Gu, F., Shi, J., Hu, J., Hu, Y., Zhao, Z., 2008. Increased oxidative stress and astrogliosis
responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and
presenilin-2. Free Radic. Biol. Med. 45, 1493-9.
Zwaal, R. F., Schroit, A. J., 1997. Pathophysiologic implications of membrane phospholipid
asymmetry in blood cells. Blood. 89, 1121-32.
Zwaal, R. F., Comfurius, P., Bevers, E. M., 1998. Lipid-protein interactions in blood
coagulation. Biochim. Biophys. Acta. 1376, 433-53.

309

VITA
Miranda Lu Lange was born August 4, 1982 in Cuba City, Wisconsin and raised in
Platteville, Wisconsin. She completed her secondary education at Platteville High School in
Platteville, Wisconsin in May 2000 and graduated with a Bachelors of Science in Biochemistry
and Molecular Biology from the University of Wisconsin-Eau Claire, in Eau Claire, Wisconsin
in May 2005. Prior to entering the Chemistry graduate program at the University of Kentucky,
in Lexington, Kentucky in August 2005, she began her research under Professor David Allan
Butterfield, Ph.D. in June 2005. During her time at the University of Kentucky, she was
awarded the “Fast Start” graduate student award in May 2006, the “Outstanding General
Chemistry Teaching Assistant” award in May 2008, and chosen as a Research Challenge Trust
Fund (RCTF) fellowship recipient from August 2008 to August 2009. Miranda completed her
graduate research under the superior guidance and mentorship of Professor D. A. Butterfield,
Ph.D. in May 2010.

Scientific publications stemming from this dissertation research:
1. Bader Lange M. L., Cenini G., Pirrodi M., Mohmmad Abdul H., Sultana R., Galli F.,
Memo M., and Butterfield D. A. (2008). Loss of phospholipid asymmetry and elevated
brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and
Alzheimer disease. Neurobiol Dis 29, 456-64.
2. Butterfield D.A. and Bader Lange M.L. (2009). The multifunctional role of enolase in
Alzheimer disease: Beyond altered glucose metabolism. J Neurochem 111, 915-33.
3. Butterfield D.A., Galvan V., Bader Lange M.L., Tang H., Sowell R.A., Fombonne J.,
Gorostiza O., Zhang J., Sultana R., and Bredesen D.E. (2010). In vivo oxidative stress in
Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β-peptide
of APP. Free Radic Biol Med 48, 136-44.
4. Bader Lange M.L., St. Clair, D., Markesbery, W.R., Studzinski, C.M., Murphy, M.P.,
and Butterfield, D.A. (2010). Age-related loss of phospholipid asymmetry in
APPNLh/APPNLh x PS-1P264L/PS-1P264L human double knock-in mice: Relevance to
Alzheimer disease. Neurobiol Dis 38, 104-115.
5. Butterfield D.A., Hardas S., and Bader Lange M.L. (2010). Oxidatively modified
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer disease: Many
pathways to neurodegeneration. J Alzheimers Dis, in press.
6. Sultana R., Bader Lange M.L., and Butterfield D.A. (2010). Involvements of the lipid
peroxidation product, HNE, in the pathogenesis and progression of Alzheimer‟s disease.
Biochim Biophys Acta, in press.
7. Sowell Robinson R.A., Bader Lange M.L., Sultana R., Galvan V., Tang H., Fombonne
J., Gorostiza O., Zhang J., Cai J., Pierce W.M., Bredesen D.E., and Butterfield D.A.
(2010). Differential expression and redox proteomics of an Alzheimer disease transgenic
mouse model: Effects of the amyloid-β peptide of APP. (Submitted for publication to J
Alzheimers Dis).

310

8. Pocernich C.B., Bader Lange M.L., Sultana R., and Butterfield D.A. (2010). Nutritional
approaches to modulate oxidative stress in Alzheimer‟s disease. (Submitted for publication
to Curr Alzheimer Res).
9. Sowell Robinson R.A., Bader Lange M.L., Galvan V., Fombonne J., Gorostiza O.,
Zhang J., Pierce W.M., Bredesen D.E., and Butterfield D.A. (2010). In vivo effects on
the proteome of an Alzheimer disease human mutant transgenic mouse model with an
additional Met631Leu substitution on APP. (To be submitted for publication to Mol Cell
Proteomics).
10. Bader Lange M.L., Sowell Robinson R.A., Galvan V., Fombonne J., Gorostiza O.,
Zhang J., Pierce W.M., Bredesen D.E., and Butterfield D.A. (2010). R edox proteomics
analysis of an Alzheimer disease transgenic mouse model carrying a Met631Leu substitution
on APP. (Manuscript in preparation).

311

